



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


<p>(51) International Patent Classification ⁶ : C12N 15/12, 15/15, 15/18, 15/20, 15/57, 15/86, 7/01, 9/64, C07K 14/56, 14/61, 14/705, 14/745, 14/755, 14/81, A61K 38/17</p>	<p>A3</p>	<p>(11) International Publication Number: WO 98/00541</p> <p>(43) International Publication Date: 8 January 1998 (08.01.98)</p>									
<p>(21) International Application Number: PCT/US97/11784</p> <p>(22) International Filing Date: 2 July 1997 (02.07.97)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>08/645,601</td> <td>3 July 1996 (03.07.96)</td> <td>US</td> </tr> <tr> <td>08/696,381</td> <td>13 August 1996 (13.08.96)</td> <td>US</td> </tr> <tr> <td>08/869,309</td> <td>4 June 1997 (04.06.97)</td> <td>US</td> </tr> </table> <p>(71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).</p> <p>(72) Inventors: JOLLY, Douglas, J.; 277 Hillcrest Drive, Leucadia, CA 92024 (US). BARBER, Jack, R.; 1168 Carlotta Street, San Diego, CA 92129 (US). CHANG, Stephen, M., W.; 12912 Camino del Valle, Poway, CA 92064 (US). RESPESS, James, G.; 4966 Lamont Street, San Diego, CA 92109 (US). ALLEN, John, R.; 8998 Adobe Buffs Drive, San Diego, CA 92129 (US). BODER, Mordechai; 3480 Juniper Street, San Diego, CA 92104 (US). CHONG, Kimberly; 12014 Dappie Way, San Diego, CA 92128 (US). DE LA VEGA, Dan, Jr.; 4220 Ampudia Street, San Diego, CA 92103 (US). DePOLO, Nicholas, J.; 964 Santa Estella,</p>		08/645,601	3 July 1996 (03.07.96)	US	08/696,381	13 August 1996 (13.08.96)	US	08/869,309	4 June 1997 (04.06.97)	US	<p>Solano Beach, CA 92075 (US). HSU, David, Chi-Tang; 7387 Mannix Court, San Diego, CA 92122 (US). IBANEZ, Carlos, E.; 13592 Millpond Way, San Diego, CA 92129 (US). MITTELSTAEDT, Denise, M.; 13687 Quinton Road, San Diego, CA 92129 (US). PRUSSAK, Charles, E.; 5121 Camino Playa Malaya, San Diego, CA 92124 (US). GREENGARD, Judith; 9053 Mesa Woods Avenue, San Diego, CA 92126 (US). LEE, Robert; 7961 Calle Posada, Carlsbad, CA 92009 (US).</p> <p>(74) Agents: KRUSE, Norman, J. et al.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).</p> <p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 19 March 1998 (19.03.98)</p>
08/645,601	3 July 1996 (03.07.96)	US									
08/696,381	13 August 1996 (13.08.96)	US									
08/869,309	4 June 1997 (04.06.97)	US									

(54) Title: METHODS FOR ADMINISTRATION OF RECOMBINANT GENE DELIVERY VEHICLES FOR TREATMENT OF HUMAN DISEASE


(57) Abstract

Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 10⁵ cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.

RETROVIRAL BACKBONE (N2-derived)



CROSS-LESS RETROVIRAL BACKBONE: pBA-5



135

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	JP	Japan	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	KE	Kenya	NL	Netherlands	VN	Viet Nam
CG	Congo	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CH	Switzerland	KP	Democratic People's Republic of Korea	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KR	Republic of Korea	PL	Poland		
CM	Cameroon	KZ	Kazakstan	PT	Portugal		
CN	China	LC	Saint Lucia	RO	Romania		
CU	Cuba	LI	Liechtenstein	RU	Russian Federation		
CZ	Czech Republic	LK	Sri Lanka	SD	Sudan		
DE	Germany	LR	Liberia	SE	Sweden		
DK	Denmark			SG	Singapore		
EE	Estonia						

CORRECTED
VERSION*

CORRECTED
VERSION**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

C12N 15/12, 15/15, 15/18, 15/20, 15/57,
15/86, 7/01, 9/64, C07K 14/56, 14/61, 14/705,
14/745, 14/755, 14/81, A61K 38/17

A3

(11) International Publication Number:

WO 98/00541

(43) International Publication Date:

8 January 1998 (08.01.98)

(21) International Application Number: PCT/US97/11784

(22) International Filing Date: 2 July 1997 (02.07.97)

(30) Priority Data:

08/645,601	3 July 1996 (03.07.96)	US
08/696,381	13 August 1996 (13.08.96)	US
08/869,309	4 June 1997 (04.06.97)	US

(71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).

(72) Inventors: JOLLY, Douglas, J.; 277 Hillcrest Drive, Leucadia, CA 92024 (US). BARBER, Jack, R.; 1168 Carlotta Street, San Diego, CA 92129 (US). CHANG, Stephen, M., W.; 12912 Camino del Valle, Poway, CA 92064 (US). RESPESS, James, G.; 4966 Lamont Street, San Diego, CA 92109 (US). ALLEN, John, R.; 8998 Adobe Buffs Drive, San Diego, CA 92129 (US). BODER, Mordechai; 3480 Juniper Street, San Diego, CA 92104 (US). CHONG, Kimberly; 12014 Dappie Way, San Diego, CA 92128 (US). DE LA VEGA, Dan, Jr.; 4220 Ampudia Street, San Diego, CA 92103 (US). DePOLO, Nicholas, J.; 964 Santa Estella,

Solano Beach, CA 92075 (US). HSU, David, Chi-Tang; 7387 Mannix Court, San Diego, CA 92122 (US). IBANEZ, Carlos, E.; 13592 Millpond Way, San Diego, CA 92129 (US). MITTELSTAEDT, Denise, M.; 13687 Quinton Road, San Diego, CA 92129 (US). PRUSSAK, Charles, E.; 5121 Camino Playa Malaya, San Diego, CA 92124 (US). GREENGARD, Judith; 9053 Mesa Woods Avenue, San Diego, CA 92126 (US). LEE, Robert; 7961 Calle Posada, Carlsbad, CA 92009 (US).

(74) Agents: KRUSE, Norman, J. et al.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.


(88) Date of publication of the international search report:

19 March 1998 (19.03.98)


(54) Title: METHODS FOR ADMINISTRATION OF RECOMBINANT GENE DELIVERY VEHICLES FOR TREATMENT OF HUMAN DISEASE

(57) Abstract

Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 10^5 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.



CROSS-LESS RETROVIRAL BACKBONE: pBA-5



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR ADMINISTRATION OF RECOMBINANT GENE DELIVERY VEHICLES FOR TREATMENT OF HUMAN DISEASE

Field of the Invention

5 The present invention relates to methods of administration of recombinant gene transfer vehicles for the treatment of hemophilia, thrombosis, and other diseases. The present invention also relates generally to recombinant retroviruses, and more specifically, to high titer recombinant retroviral particle preparations suitable for a variety of applications.

10 Background of the Invention

 A variety of human disorders can be treated by the methods described herein. For example, hemophilia is a genetic disease characterized by a severe blood clotting deficiency. As such, it will be amenable to treatment by gene therapy. In hemophilia A, an X-chromosome linked genetic defect disrupts the gene encoding factor VIII, a trace
15 plasma glycoprotein which acts as a cofactor in conjunction with factor IXa in the activation of factor X. In humans, the factor VIII gene codes for 2,351 amino acids. The protein has six domains, designated from amino to carboxy terminus as A1, A2, B, A3, C1, and C2, respectively (Wood *et al.*, 1984, *Nature* 312:330; Vehar *et al.*, 1984, *Nature* 312:337, and Loole *et al.*, 1984, *Nature* 312:342) with a deduced molecular weight of
20 about 280 kilo Daltons (kD). The 980 amino acid B domain is deleted in the activated procoagulant form of the protein. Additionally, in the native protein two polypeptide chains, the heavy and light chain, flanking the B domain, are bound to a divalent calcium cation.

 The genetic defect causing hemophilia A affects about one in every 10,000 males.
25 Due to the resultant clotting deficiency, those afflicted with the disease suffer severe bleeding episodes due to small injuries, internal bleeding, and joint hemorrhage, which lead to arthropathy, the major cause of morbidity in hemophilia. Normal levels of factor VIII are between 50 to 200 ng/ml of blood plasma (Mannucci, P.M. in *Practical Laboratory Hematology*, ed. Koepke, J.A., Churchill Livingstone, N.Y., pp:347-371,
30 1990), however, patients suffering from mild to moderate hemophilia A typically have

plasma levels well below 2 - 60 ng/ml, while levels below about 2 ng/mL result in severe hemophilia.

Previously, therapy for hemophilia A involved repeated administration of human factor VIII purified from blood products pooled in lots from over 1000 donors. However, because of the low levels of circulating factor VIII, resulting pharmaceutical products using the natural protein typically were highly impure, with an estimated purity by weight (factor VIII to total protein) of approximately 0.04%. Due to the frequency of administration and inability to remove various human pathogens from such preparations, more than 90% of those suffering from hemophilia A were infected in the 1980s with the human immunodeficiency virus (HIV) as a result of their therapy. Many of these HIV infected patients and other HIV negative hemophiliacs have also been infected by Hepatitis B in the same way. Fortunately, recent advances in genetic engineering have lead to the commercial availability of a recombinant form of the protein free from contamination with human pathogens, except for those potentially derived from tissue culture origin of the proteins, or from human serum albumin used in formulation of the recombinant protein. However, this form of therapy is expensive and chronic, and a large proportion of hemophiliacs continue to rely on plasma-derived products due to expense and or shortages of the recombinant product. In addition, most hemophilia A patients in the United States do not presently receive factor VIII maintenance therapy, but instead only receive the polypeptide prior to activities or events which might cause bleeding, such as surgery, or to treat spontaneous bleeding. Interestingly, this is despite evidence showing that hemophilic arthropathy can be prevented by administering from an early age prophylactic amounts of factor VIII, typically 24 - 40 IU per kilogram bodyweight, three times a week. Such therapy kept factor VIII concentrations from falling below 1% of normal (Nillson, *et al.*, *J. Internal Med.* 232:23, 1992). For these reasons, a genetic therapy affording continuous, long term therapeutically effective expression levels or amounts of factor VIII, *i.e.*, to decrease the severity of or eliminate the clotting disorder associated with hemophilia A, would be of great benefit.

A condition clinically indistinguishable from Hemophilia A is Hemophilia B, resulting from the deficiency of clotting factor IX. The incidence of this condition is about 5-fold lower than that of hemophilia A, and presents many of the same therapeutic

challenges and difficulties. For similar reasons, it would be of great benefit to provide a gene therapy to these patients.

Factor X deficiency results in a rare but serious bleeding disorder affecting 1 in 500,000 known as Stuart disease. Le *et al.*, 1997, *Blood* 89:1254-9, describes therapeutic levels of functional human factor X in rats after retroviral mediated hepatic gene therapy. As in the case of hemophilia A and B, a genetic therapy affording continuous, long term therapeutically effective expression levels or amounts of factor X, *i.e.*, to decrease the severity of or eliminate the clotting disorder associated with hemophilia B, would be of great benefit.

The present invention also provides for gene therapy delivery of other clotting factors for treatment or prophylaxis of thrombosis. Venous thromboembolism has an annual incidence of 1/1000 in the general population (Dahlback, 1995, *Blood* 85:607). Precipitating factors can include hemostatic challenges such as surgery, fractures, inflammation, immobilization, pregnancy, oral contraceptive use, trauma, cancer, etc. Thrombosis is often familial, and a number of genetic risk factors have been identified. The clinical condition in which recurrent thrombosis occurs has been dubbed thrombophilia. The natural defenses against thrombosis involve two major systems: serpin inhibitors of thrombin, *e.g.*, antithrombin III, the major pathway by which heparin exerts its clinical antithrombin effect, and the protein C system. Gene therapy for thrombosis disorders is needed and is addressed by the instant invention.

The present invention also provides methods for treatment of diseases such as viral hepatitis. Currently, the only approved treatment for chronic hepatitis B, C and D infections is the use of alpha interferon 2a and 2b. However, for patients with hepatitis B infections only about 35% of patients infected as adults responded to such treatment, and in perinatal infectees only about 10% responded to treatment (Perrillo *et al.*, 1990, *New Eng. J. Med.* 323:295-301). For hepatitis C infections, despite apparent short term success utilizing such therapy, six months after termination of treatment half of the patients who responded to therapy had relapsed. (Davis *et al.*, *New Eng. J. Med.* 321:1501-1506). In pilot studies for hepatitis D infections, 25 - 60% of patients responded to alpha interferon therapy. Sustained responses were rare; 85-90% of patients who responded had relapsed. (di Bisceglie, A. M. D., *Viral Hepatitis A to F: An Update*, 1994). In addition, a further

difficulty with alpha interferon therapy is that the composition frequently has toxic side effects which require reduced dosages for sensitive patients. Thus, improved methods for treatment of viral hepatitis are needed and are addressed by the present invention.

The instant invention also relates to the production and use of high titer recombinant retroviruses. Since the discovery of DNA in the 1940s and continuing through the most recent era of recombinant DNA technology, substantial research has been undertaken in order to realize the possibility that the course of disease may be affected through interaction with the nucleic acids of living organisms. Most recently, a wide variety of methods have been described for altering or affecting genes, including for example, viral vectors derived from retroviruses, adenoviruses, vaccinia viruses, herpes viruses, and adeno-associated viruses (see Jolly, 1994, *Cancer Gene Therapy* 1(1):51-64), as well as direct transfer techniques such as lipofection (Felgner *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 84:7413-7417), direct DNA injection (Acsadi *et al.*, 1991, *Nature* 352:815-818), microprojectile bombardment (Williams *et al.*, 1991, *PNAS* 88:2726-2730), liposomes of several types (see, e.g., Wang *et al.*, 1987, *PNAS* 84:7851-7855) and administration of nucleic acids alone (PCT Patent Publication No. WO 90/11092).

Of these techniques, recombinant retroviral gene delivery methods have been most extensively utilized, in part due to: (1) the efficient entry of genetic material (the vector genome) into cells; (2) an active, efficient process of entry into the target cell nucleus; (3) relatively high levels of gene expression; (4) the potential to target particular cellular subtypes through control of the vector-target cell binding and the tissue-specific control of gene expression; (5) a general lack of pre-existing host immunity; and (6) substantial knowledge and clinical experience which has been gained with such vectors.

Briefly, retroviruses are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate. In particular, upon infection by the RNA virus, the retroviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each retrovirus. The viral DNA is then integrated pseudo-randomly into the host cell genome of the infecting cell, forming a "provirus" which is inherited by daughter cells.

Wild type retroviral genomes (and their proviral copies) contain three genes (the *gag*, *pol*, and *env* genes), which are preceded by a packaging signal (ψ), and two long

terminal repeat (LTR) sequences which flank both ends. Briefly, the *gag* gene encodes the internal structural (nucleocapsid) proteins. The *pol* gene codes for the RNA-dependent DNA polymerase which reverse transcribes the RNA genome, and the *env* gene encodes the retroviral envelope glycoproteins. The 5' and 3' LTRs contain *cis*-acting elements
5 necessary to promote transcription and polyadenylation of retroviral RNA.

Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsidation of retroviral RNA into particles (the ψ sequence). Removal of the packaging signal prevents encapsidation (packaging of retroviral RNA into infectious virions) of genomic RNA, although the
10 resulting mutant can still direct synthesis of all proteins encoded in the viral genome.

Recombinant retroviruses and various uses thereof have been described in numerous references including, for example, Mann *et al.*, 1983, *Cell* 33:153; Cane and Mulligan, 1984, *Proc. Natl. Acad. Sci. USA* 81:6349; Miller *et al.*, 1990, *Human Gene Therapy* 1:5-14; U.S. Patent Nos. 4,405,712; 4,861,719; 4,980,289 and PCT Patent
15 Publication Nos. WO 89/02468; WO 89/05349 and WO 90/02806. Briefly, a foreign gene of interest may be incorporated into the retrovirus in place of the normal retroviral RNA. When the retrovirus injects its RNA into a cell, the foreign gene is also introduced into the cell, and may then be integrated into the host's cellular DNA as if it were the retrovirus itself. Expression of this foreign gene within the host results in expression of the foreign
20 protein by the host cell.

One disadvantage, however, of recombinant retroviruses is that they principally infect only replicating cells, thereby making efficient direct gene transfer difficult. Indeed, some scientists have suggested that other, more efficient methods of gene transfer, such as direct administration of pure plasmid DNA, be utilized (Davis *et al.*, 1993, *Human Gene
25 Therapy* 4:733-740).

In order to increase the efficacy of recombinant retroviruses, methods which have been suggested for increasing the efficacy of recombinant retroviruses have principally been aimed at inducing the desired target cells to replicate, thereby allowing the retroviruses to infect the cells. Such methods have included, for example chemical
30 treatment with 10% carbon tetrachloride in mineral oil (Kaleko *et al.*, 1991, *Human Gene Therapy* 2:27-32). Alternatively, others have suggested excising large portions of the liver

(e.g., 70% in Rettinger *et al.*, 1994, *PNAS* 91:1460-1464; 70% in Moscioni *et al.*, 1993, *Surgery* 113:304-311) in order to stimulate the rapid division of hepatocytes and thereby increase the infection of such cells.

One further disadvantage of recombinant retroviruses, is that serum from primates
5 (e.g., humans) is known to cause inactivation by an antibody independent complement
lysis method. In particular retroviruses of avian, murine, feline, and simian origin are all
inactivated and lysed by normal human serum. (Welsh *et al.*, 1975, *Nature* 257:612-614;
Welsh *et al.*, 1976, *Virology* 74:432-440; Banapour *et al.*, 1986, *Virology* 152:268-271;
and Cooper *et al.*, Immunology of the Complement System, Pub., American Press, Inc.,
10 pp. 139-162, 1986). The scientific literature has also reported that replication competent
murine amphotropic retroviruses injected intravenously into primates are cleared within 15
minutes and that the disappearance is mediated, wholly or in part, by primate complement.
(Cornetta *et al.*, 1991, *Human Gene Therapy* 2:5-14; Cornetta *et al.*, 1990, *Human Gene*
Therapy 1:15-30; and Banapour *et al.*, 1986, *Virology* 152:268-271)

15 In order to increase the affect of recombinant retroviruses that are delivered *in vivo*,
the present invention provides recombinant retrovirus compositions which are capable of
surviving inactivation in human serum. In addition, the present invention provides high
titer recombinant retrovirus compositions which allow delivery of therapeutics or
palliatives by routes not previously deemed possible, and without the need to induce
20 replication of cells by chemical treatment or by excision of a target organ such as the liver.
The present invention provides these, as well as other related advantages.

Summary of the Invention

This invention provides for preparations of replication defective recombinant
retrovirus expressing human factor VIII protein, wherein the recombinant retrovirus is
25 capable of infecting human cells and is resistant to degradation by human complement.
The invention also provides for preparations of replication defective recombinant
retrovirus expressing human factor VIII protein in which the recombinant retrovirus
preparation is resistant to degradation by human complement and is capable of inducing
long term systemic expression of human factor VIII when administered intravenously to a
30 human afflicted with hemophilia A. The wherein said long term systemic expression

results in a measurable level of recombinant human factor VIII protein being produced in the blood of said human for a period of at least 30 days after the administration of said recombinant retroviral vector preparation and more preferably for at least six months after injection, and yet more preferably for longer periods of time as described herein.

5 Pharmaceutical compositions and therapeutic methods of the above-described retroviral vectors expressing factor VIII protein are also provided herein as are therapeutic methods for treatment of hemophilia A by intravenous injection of these retroviral vectors. The retroviral vectors of the invention can express a B domain-deleted form of factor VIII, which in one embodiment can be the SQN mutation of factor VIII. The retroviral
10 vectors of the invention can have a titer on HT1080 cells of greater than 10^6 , more preferably 10^7 cfu/ml and more preferably at least 10^8 cfu/ml, more preferably 10^9 cfu/ml, more preferably at least 10^{10} cfu/ml, and most preferably 10^{11} cfu/ml.

 In addition, the present invention provides high titer compositions comprising recombinant retroviruses, as well as methods for utilizing these compositions. Within one
15 aspect of the present invention, methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 10^5 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid
20 molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of said human. Within certain embodiments, the titer may be greater than 10^6 cfu/ml, 10^7 cfu/ml, 10^8 cfu/ml, 10^9 cfu/ml, 10^{10} cfu/ml, or 10^{11} cfu/ml.

 Within other aspects of the invention, methods are provided for obtaining
25 measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the steps of administering to a human a recombinant retroviral preparation having a titer in human serum and on HT1080 cells equivalent to its titer in heat-inactivated serum and on HT1080 cells, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or
30 enzyme which generates an enzymatic product, such that measurable levels of the protein,

nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of said human.

As utilized within the context of the present invention, "measurable levels" of a protein, nucleic acid molecule, or enzymatic product refers to a statistically significant level of detection over background, utilizing any suitable technique (e.g., antibody-mediated detection of a protein, PCR analysis for the presence of a nucleic acid molecule, or visualization of enzymatic products). Further, as utilized within the context of the present invention, "equivalent" titers are deemed to be those which are substantially the same within a given assay, generally, within about three-fold of each other.

Within certain embodiments of the invention, the recombinant retrovirus is administered to a site such as the cerebral spinal fluid, bone marrow, joints, arterial endothelial cells, rectum, buccal/sublingual, vagina, the lymph system, to an organ selected from the group consisting of lung, liver, spleen, skin, blood and brain, or to a site selected from the group consisting of tumors and interstitial spaces. Within other embodiments, the recombinant retrovirus may be administered intraocularly, intranasally, sublingually, orally, topically, intravesically, intrathecally, topically, intravenously, intraperitoneally, intracranially, intramuscularly, or subcutaneously.

Within yet other embodiments of the present invention, the protein is a viral antigen obtained from a virus such as influenza virus, respiratory syncytial virus, HPV, HBV, HCV, EBV, HIV, HSV, FeLV, FIV, Hantavirus, HTLV I, HTLV II and CMV. Within other embodiments, the protein is a cytokine such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, γ -IFN, G-CSF and GM-CSF, or a receptor for any of these cytokines.

Within another embodiment, the nucleic acid molecule may be an antisense sequence, a non-coding non-heterologous sense sequence, and a ribozyme sequence. Within yet another aspect, the protein is a toxin.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth below which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety as if each were individually noted for incorporation.

Brief Description of the Drawings

Figure 1 is a schematic illustration of p31N2R5(+).

Figure 2 is a schematic illustration of pN2R3(-).

Figure 3 is a schematic illustration of p31N25 (+).

5 Figure 4 is a schematic illustration of pN2R3(+).

Figure 5 is a schematic illustration of pN2R5(-).

Figure 6 is a schematic illustration of p31N25 (+).

Figure 7 is a schematic illustration of pTK A.

Figure 8 is a schematic illustration of pPrTK A.

10 Figure 9 is a schematic illustration of pTK-1 and pTK-3.

Figure 10 is a bar graph which illustrates the effect of Ganciclovir on CT26, CT26 bgal and CT26TK Neo cells.

Figure 11 is a graph which illustrates the effect of tumor volume over time in a Ganciclovir dose study of mice injected with CT26TK Neo.

15 Figure 12 is a graph illustrating the effect of Ganciclovir in CT26 versus CT26TK Neo cells.

Figure 13 is a graph demonstrating retention of viral activity upon reconstitution of a representative recombinant retrovirus lyophilized in a formulation buffer containing mannitol.

20 Figure 14 is a graph demonstrating retention of viral activity upon reconstitution of a representative recombinant retrovirus lyophilized in a formulation buffer containing lactose.

Figure 15 is a graph demonstrating retention of viral activity upon reconstitution of a representative recombinant retrovirus lyophilized in a formulation buffer containing
25 trehalose.

Figures 16A-16D are representative graphs comparing stability of liquid non-lyophilized recombinant retrovirus stored at -80°C versus lyophilized formulated recombinant retrovirus stored at -20°C, using various saccharides.

Figure 17 is a bar graph which depicts the results of a reverse transcriptase assay on samples sliced from a gel. Slice 1 is from the lowest part of the gel, and slice 8 from the highest.

Figure 18 depicts a 8% to 25% gradient polyacrylamide gel. Lane 1 is DA/ β gal S-500 purified; Lane 2 is DA/ β gal crude supernatant; Lane 3 is HIV-IT crude supernatant; lane 4 is DAC 6A3 crude supernatant; Lane 5 is HBC/SA2 crude supernatant; and Lane 5 is molecular weight markers.

Figure 19 is a schematic illustration of pDHF811.

Figures 20A-D are graphs which indicate the total quantity of lactate in low seed and high seed cultures (Figures 20A and 20B, respectively) and the level of lactate production per day in low seed and high seed cultures (Figures 22C and 22D, respectively).

Figure 21 is a bar graph which depicts the titer of the cell line 2X- β -gal under different initial seeding conditions.

Figure 22: Factor VIII antigen was determined in citrated blood samples drawn on the indicated days. Antigen determined by a standard curve obtained using normal pooled human plasma is plotted on the left y axis; the per cent of normal human levels is indicated on the right y axis.

Figure 23: Factor VIII expression in rabbits. Juvenile rabbits were injected with a total of 10^9 cfu of the factor VIII vector B-del-1 in a total of 9 injections over days 0, 1, and 2. Citrated plasma samples were obtained at the indicated times and human factor VIII antigen levels determined by ELISA. Rabbits 93 and 95 (controls) received formulation buffer in lieu of vector.

Figure 24: Serum samples were obtained from rabbits on indicated days, and human growth hormone antigen was measured using ELISA.

Figure 25: Serum samples were obtained from mice on indicated days and human growth hormone antigen was determined by ELISA. Since the animals were too small on Day 14 to yield sufficient sample for the ELISA measurement, sera from test animals 1-5, test animals 6-10, and control animals 11 and 12 were respectively pooled prior to measurement. Data from subsequent days were obtained from individual animals.

Figure 26: Sera were obtained from adult mice on the indicated days. Human growth hormone antigen was measured by ELISA. Each point represents an individual animal. Negative controls had been injected with formulation buffer; positive controls with 1E7 cfu retroviral vector; "600 ug CsA" with both vector and cyclosporin A as described in the text.

Figure 27: PCR localization of vector in B-del-1 treated rabbits. Rabbits #82 and 95 shown in figure 22, herein were sacrificed on Day 511. DNA was extracted from indicated organs, subjected to 40 cycles of PCR, and dot blotted, and hybridized to 32-P labeled probe as described in text. Several replicate PCR reactions were run. Lanes indicated "spike" had 5 copies of amplicon added to the template.

Figure 28: Quantitative PCR of beta-galactosidase vector in organs of transduced mice. Juvenile mice, transduced as described in the text, were sacrificed on Day 59. DNA was obtained from indicated organs and subjected to quantitative PCR as described.

Figure 29: Human growth hormone antigen in organs of transduced mice. Indicated organs were lysed and analyzed by ELISA as described in the text. Results are shown normalized to the amount of total protein recovered from the organ.

Figure 30: Expression of human factor VIII antigen in transduced normal dogs. Juvenile dogs (#47 and #55) were injected with a total of 4E9 cfu of factor VIII vector B-del-1 in a total of 9 injections over days 0,1, and 2. Control dog #39 received formulation buffer on the same schedule. Dog #47 was boosted with the same amount of vector on days 90, 91, and 92. At indicated times, cuitrated plasma was obtained and analyzed by ELISA for human factor VIII antigen. Percent human level is calculated based on a level of 200 ng/ml factor VIII in pooled in normal human plasma.

Figure 31: Transfer of expression of human growth hormone following adoptive transfer of splenocytes from transduced donor mice to lethally irradiated syngeneic recipients. Juvenile mice were transduced with growth hormone retroviral vector as described in the text. On day 59, Donors #1-5 were sacrificed, and splenocytes from each were injected into two lethally irradiated recipients (A and B, numbered according to donor number). Every 14 days subsequent to reconstitution, serum from the recipients was monitored for growth hormone levels.

Figure 32: Whole blood clotting times in hemophiliac dogs treated with factor VIII vector. Two hemophiliac dogs (#28 and #33) were injected with B-del-1 as described in the text. At indicated times, citrated whole blood samples were obtained and clotting times were determined following recalcification. Clotting times of two untreated normal littermates are included for reference.

Figure 33 is a schematic illustration of pKT1.

Figure 34 is a description of all modifications carried out on retroviral vector as shown in A), resulting in the cross-less retroviral vector shown in B). The cross-less retroviral backbone cloned into a prokaryotic vector is called pBA-5.

Figure 35: Schematic representation of pKm201-80L.

Figure 36: Schematic representation of pKm201-90-H.

Figure 37: Schematic representation of pSVF8-t β 2.

Figure 38: Nucleotide and predicted amino acid sequence linking the light and heavy chains of Factor VIII in pSVF8-t β 2.

Figure 39: Linker sequences for pSVF8-500 and pc1/1 AG α F8-500.

Figure 40: Schematic representation of pSVF8500 and pc1/1 AG α F8-500.

Figure 41: Linker sequence for pSVF8-500B.

Detailed Description of the Invention

Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms that will be used hereinafter.

"Vector construct", "retroviral vector", "recombinant vector", and "recombinant retroviral vector" refers to a nucleic acid construct which carries, and within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest. The retroviral vector must include at least one transcriptional promoter/enhancer or locus defining element(s), or other elements which control gene expression by other means such as alternate splicing, nuclear RNA export, post-translational modification of messenger, or post-transcriptional modification of protein. Such vector constructs must also include a packaging signal, long terminal repeats (LTRs) or portion thereof, and positive and negative strand primer binding sites appropriate to the retrovirus used (if these are not already present in the retroviral vector). Optionally, the recombinant retroviral vector may

also include a signal which directs polyadenylation, selectable markers such as Neomycin resistance, TK, hygromycin resistance, phleomycin resistance histidinol resistance, or DHFR, as well as one or more restriction sites and a translation termination sequence. By way of example, such vectors typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3' LTR or a portion thereof.

"Recombinant retrovirus", "retroviral gene delivery vehicle" and "retroviral vector particle" as utilized within the present invention refers to a retrovirus which carries at least one gene of interest. The retrovirus may also contain a selectable marker. The recombinant retrovirus is capable of reverse transcribing its genetic material into DNA and incorporating this genetic material into a host cell's DNA upon infection.

"Factor VIII" is a nonenzymatic cofactor found in blood in an inactive precursor form. Precursor factor VIII is converted to the active cofactor, factor VIIIa, through limited proteolysis at specific sites by plasma proteases, notably thrombin and factor IXa. The majority of factor VIII circulates as a two-chain heterodimer most likely due to intracellular or pericellular processing of the single chain gene product. The two chains are noncovalently associated in a metal ion dependent manner.

The "biological activity" of factor VIII refers to a function or set of functions performed by the polypeptide or fragments thereof in a biological system or in an *in vitro* facsimile thereof. The biological activity of factor VIIIa is characterized by its ability to form a membrane binding site for factors IXa and X in a conformation suitable for activation of the latter by the former. This includes standard assays of factor IX or X activation, binding to phospholipids, von Willebrand factor, or specific cell surface molecules, and susceptibility to thrombin, factor IXa, activated protein C, or other specific proteases under appropriate conditions. More particularly biologically active factor VIII corrects the coagulation defect in plasma derived from individuals afflicted with hemophilia A.

"Factor VIII cDNA molecule" is one encoding a full-length factor VIII polypeptide, a B domain deleted factor VIII protein, or other forms of factor VIII protein with biological activity. The human full-length factor VIII coding region is 7,056 nucleotides.

"Biologically active factor IX" encompasses those forms of factor IX which are capable of correcting the coagulation defect in plasma derived from individuals afflicted with hemophilia B as measured in a standard *in vitro* clotting assay.

As noted above, the present invention provides for methods of administration of recombinant gene delivery vehicles for treatment of hemophilia and a variety of other disorders by gene therapy techniques. The present invention provides high titer complement resistant recombinant retroviral preparations which are suitable for administration to humans. Such preparations provide the unexpected result of providing efficacious gene therapy for a variety of diseases (and by a variety of routes) that were previously not amenable for gene therapy. In addition, the present invention provides recombinant retroviruses which are capable of surviving inactivation in human serum, thereby allowing more efficient gene transfer over prolonged periods of time.

5 A. PREPARATION OF RECOMBINANT GENE DELIVERY VEHICLES:
GENE DELIVERY VEHICLES

The therapeutic proteins of the present invention may be utilized in a wide variety of gene delivery vehicles. The gene delivery vehicle may be of either viral or non-viral origin (See generally, Jolly, 1994, *Cancer Gene Therapy* 1:51-64; Kimura, 1994, *Human Gene Therapy* 5:845-852; Connelly, 1995, *Human Gene Therapy* 6:185-193; and Kapliff, 10 1994, *Nature Genetics* 6:148-153). Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using 15 endogenous mammalian or heterologous promoters. Expression of the coding sequence *in vivo* can be either constitutive or regulated as is described in detail below.

1. Retroviral vectors

As noted above, the present invention provides recombinant retroviruses which are constructed to carry or express a selected nucleic acid molecule of interest. Briefly, 20 numerous retroviral gene delivery vehicles may be utilized within the context of the present invention, including for example those described in EP 0,415,731; WO 90/07936;

WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 9311230; WO 9310218; Vile and Hart, 1993, *Cancer Res.* 53:3860-3864; Vile and Hart, 1993, *Cancer Res.* 53:962-967; Ram *et al.*, 1993, *Cancer Res.* 53:83-88; Takamiya *et al.*, 1992, *J. Neurosci. Res.* 33:493-503; Baba *et al.*, 1993, *J. Neurosurg.* 79:729-735 (U.S. Patent No. 4,777,127, GB 2,200,651, EP 0,345,242 and WO 91/02805). Particularly preferred recombinant retroviruses include those described in WO 91/02805.

Retroviral gene delivery vehicles of the present invention may be readily constructed from a wide variety of retroviruses, including for example, B, C, and D type retroviruses as well as spumaviruses and lentiviruses (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Preferred retroviruses for the preparation or construction of retroviral gene delivery vehicles of the present invention include retroviruses selected from the group consisting of Avian Leukosis Virus, Bovine Leukemia Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe, 1976, *J. Virol.* 19:19-25), Abelson (ATCC No. VR-999), Friend ATCC No. VR-245), Graffi, Gross (ATCC No. VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998), and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such retroviruses may be readily obtained from depositories or collections such as the American Type Culture Collection ("ATCC"; Rockville, Maryland), or isolated from known sources using commonly available techniques.

Any of the above retroviruses may be readily utilized in order to assemble or construct retroviral gene delivery vehicles given the disclosure provided herein, and standard recombinant techniques (*e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, 1985, *PNAS* 82:488). In addition, within certain embodiments of the invention, portions of the retroviral gene delivery vehicles may be derived from different retroviruses. For example, within one embodiment of the invention, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

Within preferred aspects of the present invention, recombinant retroviruses may be made by introducing a vector construct as discussed above, into a cell (termed a "packaging cell") which contains those elements necessary for production of infectious recombinant retrovirus which are lacking in the vector construct. A wide variety of retrovector constructs may be utilized within the present invention in order to prepare recombinant retroviruses. For example, within one aspect of the present invention retrovector constructs are provided comprising a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein the vector construct lacks gag/pol or env coding sequences. Briefly, Long Terminal Repeats ("LTRs") are subdivided into three elements, designated U5, U3, and U3. These elements contain a variety of signals which are responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements which are located within U3. LTRs may be readily identified in the provirus due to their precise duplication at either end of the genome. As utilized herein, a 5' LTR should be understood to include a 5' promoter element and sufficient LTR sequence to allow reverse transcription and integration of the DNA form of the vector. The 3' LTR should be understood to include a polyadenylation signal, and sufficient LTR sequence to allow reverse transcription and integration of the DNA form of the vector.

The tRNA binding site and origin of second strand DNA synthesis are also important for a retrovirus to be biologically active, and may be readily identified by one of skill in the art. For example, retroviral tRNA binds to a tRNA binding site by Watson-Crick base pairing, and is carried with the retrovirus genome into a viral particle. The tRNA is then utilized as a primer for DNA synthesis by reverse transcriptase. The tRNA binding site may be readily identified based upon its location just downstream from the 5' LTR. Similarly, the origin of second strand DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus. This region, which is also referred to as the poly-purine tract, is located just upstream of the 3' LTR.

In addition to a 5' and 3' LTR, tRNA binding site, and origin of second strand DNA synthesis, certain preferred retrovector constructs which are provided herein also comprise a packaging signal, as well as one or more nucleic acid molecules (e.g., heterologous sequences), each of which is discussed in more detail below.

Within one aspect of the invention, retrovector constructs are provided which lack both *gag/pol* and *env* coding sequences. As utilized herein, the phrase "lacks *gag/pol* or *env* coding sequences" should be understood to mean that the retrovector does not contain at least 20, preferably at least 15, more preferably at least 10, and most preferably at least 8 consecutive nucleotides which are found in *gag/pol* or *env* genes, and in particular, within *gag/pol* or *env* expression cassettes that are used to construct packaging cell lines for the retrovector construct.

Packaging cell lines suitable for use with the above-described retrovector constructs may be readily prepared (see PCT Patent Publication No. WO 95/30763; see also WO 92/05266), and utilized to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles. Within particularly preferred embodiments of the present invention packaging cell lines are made from human (e.g., HT1080 cells) or mink parent cell lines, thereby allowing production of recombinant retroviruses that are capable of surviving inactivation in human serum.

Utilizing the methods of the present invention as disclosed herein, packaging cell lines that produce greater than recombinant retroviral particles at titers greater than 10^6 or 10^7 cfu/ml (in crude supernatant) may readily be obtained. In addition, it should be noted that such titers are generally obtained from titer assays on HT1080 cells, which produce a three-fold lower titer than titers obtained on murine 3T3 cells.

2. Alphavirus and eucaryotic layered vector gene delivery vehicles

The present invention also provides a variety of alphavirus-based vectors which can function as gene delivery vehicles. Such vectors can be constructed from a wide variety of alphaviruses, including for example, Sindbis viruses vectors, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532).

As an example, the Sindbis virus, which is the prototype member of the alphavirus genus of the togavirus family is an unsegmented genomic RNA (49S RNA) of virus of approximately 11,703 nucleotides in length. This virus contains a 5' cap and a 3' polyadenylated tail, and displays positive polarity. Infectious enveloped Sindbis virus is

produced by assembly of the viral nucleocapsid proteins onto the viral genomic RNA in the cytoplasm and budding through the cell membrane embedded with viral encoded glycoproteins. Entry of virus into cells is by endocytosis through clatharin coated pits, fusion of the viral membrane with the endosome, release of the nucleocapsid, and
5 uncoating of the viral genome. During viral replication the genomic 49S RNA serves as template for synthesis of the complementary negative strand. This negative strand in turn serves as template for genomic RNA and an internally initiated 26S subgenomic RNA. The Sindbis viral nonstructural proteins are translated from the genomic RNA while structural proteins are translated from the subgenomic 26S RNA. All viral genes are
10 expressed as a polyprotein and processed into individual proteins by post translational proteolytic cleavage. The packaging sequence resides within the nonstructural coding region, therefore only the genomic 49S RNA is packaged into virions.

A variety of different alphavirus vector systems may be constructed and utilized within the present invention. Representative examples of such systems include those
15 described in U.S. Patent application Nos. 08/198,450, 08/405,627 and 08/679,640, U.S. Patent Nos. 5,091,309; 5,217,879 and 5,185,440, PCT Publication Nos. WO 92/10578, WO/94/21792, WO 95/27069, WO 95/27044 and WO 95/07994.

Particularly preferred alphavirus vectors for use within the present invention include those which are described within U.S. Application No. 08/198,450. Briefly,
20 within one embodiment, alphavirus vector constructs are provided comprising a 5' sequence which is capable of initiating *in vitro* transcription of a alphavirus RNA, a nucleotide sequence encoding alphavirus non-structural proteins, a viral junction region which is active, modified to reduce viral transcription of the subgenomic fragment, or inactivated such that viral transcription of the subgenomic fragment is prevented, and a
25 alphavirus RNA polymerase recognition sequence.

In still further embodiments, the vector constructs described above contain no alphavirus structural proteins in the vector constructs. The selected heterologous sequence may be located downstream from the viral junction region; in the vector constructs having a second viral junction, the selected heterologous sequence may be located downstream
30 from the second viral junction region, where the heterologous sequence is located downstream, the vector construct may comprise a polylinker located between the viral

junction region and said heterologous sequence, and preferably the polylinker does not contain a wild-type Sindbis virus restriction endonuclease recognition sequence.

In addition, within one embodiment of the invention the gene delivery vehicles is a eukaryotic layered expression systems (ELVS) (see PCT Patent Publication Nos. WO 95/07994 and WO 96/17072 for a detailed description of eukaryotic layered expression systems). Although initially developed for alphavirus vectors, ELVS vectors may also be developed using other viral and non-viral nucleotide sequences (see PCT Patent Publication Nos. WO 95/07994 and WO 96/17072.

3. Adeno-associated viral vectors

Gene delivery vehicles of the present invention also include parvovirus such as adenovirus associated virus (AAV) vectors. Representative examples of such vectors include the AAV vectors disclosed by Srivastava in WO 93/09239, Samulski *et al.*, 1989, *J. Vir.* 63:3822-3828; Mendelson *et al.*, 1988, *Viol.* 166:154-165; Flotte *et al.*, 1993, *PNAS* 90(22):10613-10617. Particularly preferred AAV vectors comprise the two AAV inverted terminal repeats in which the native D-sequences are modified by substitution of nucleotides, such that at least 5 native nucleotides and up to 18 native nucleotides, preferably at least 10 native nucleotides up to 18 native nucleotides, most preferably 10 native nucleotides are retained and the remaining nucleotides of the D-sequence are deleted or replaced with non-native nucleotides. The native D-sequences of the AAV inverted terminal repeats are sequences of 20 consecutive nucleotides in each AAV inverted terminal repeat (*i.e.*, there is one sequence at each end) which are not involved in HP formation. The non-native replacement nucleotide may be any nucleotide other than the nucleotide found in the native D-sequence in the same position. Other employable exemplary AAV vectors are pWP-19, pWN-1, both of which are disclosed in Nahreini, 1993, *Gene* 124:257-262. Another example of such an AAV vector is psub201. See Samulski, 1987, *J. Virol.* 61:3096. Another exemplary AAV vector is the Double-D ITR vector. How to make the Double D ITR vector is disclosed in U.S. Patent No. 5,478,745. Still other vectors are those disclosed in Carter, U.S. Patent No. 4,797,368 and Muzyczka, U.S. Patent No. 5,139,941; Chartejee, U.S. Patent No. 5,474,935; and Kotin, PCT Patent Publication WO 94/288157. Yet a further example of an AAV vector employable in this

invention is SSV9AFABTKneo, which contains the AFP enhancer and albumin promoter and directs expression predominantly in the liver. Its structure and how to make it are disclosed in Su, *Human Gene Therapy* 7:463-470, 1996. Additional AAV gene therapy vectors are described in U.S. Patent Nos. 5,354,678; 5,173,414; 5,139,941; and 5,252,479.

5 4. Other Viral Vector Delivery Systems

In addition to retroviral vectors and alphavirus-based vectors, numerous other viral vectors systems may also be utilized as a gene delivery vehicle. For example, within one embodiment of the invention adenoviral vectors may be employed as a gene delivery vehicle. Representative examples of such vectors include those described by, for example,
10 Berkner, 1988, *Biotechniques* 6:616-627; Rosenfeld *et al.*, 1991, *Science* 252:431-434; WO 93/9191; Kolls *et al.*, 1994, *PNAS* 91(1):215-219; Kass-Eisler *et al.*, 1993, *PNAS* 90(24):11498-502; Guzman *et al.*, 1993, *Circulation* 88(6):2838-48; Guzman *et al.*, 1993, *Cir. Res.* 73(6):1202-1207; Zabner *et al.*, 1993, *Cell* 75(2):207-216; Li *et al.*, 1993, *Hum. Gene Ther.* 4(4):403-409; Caillaud *et al.*, 1993, *Eur. J. Neurosci.* 5(10):1287-1291;
15 Vincent *et al.*, 1993, *Nat. Genet.* 5(2):130-134; Jaffe *et al.*, 1992, *Nat. Genet.* 1(5):372-378; and Levrero *et al.*, 1991, *Gene* 101(2):195-202; and WO 93/07283; WO 93/06223; and WO 93/07282. Exemplary known adenoviral gene therapy vectors employable in this invention include those described in the above referenced documents and in PCT Patent Publication No. WO 94/12649, WO 93/03769, WO 93/19191, WO 94/28938, WO
20 95/11984, WO 95/00655, WO 95/27071, WO 95/29993, WO 95/34671, WO 96/05320, WO 94/08026, WO 94/11506, WO 93/06223, WO 94/24299, WO 95/14102, WO 95/24297, WO 95/02697, WO 94/28152, WO 94/24299, WO 95/09241, WO 95/25807, WO 95/05835, WO 94/18922 and WO 95/09654. Alternatively, administration of DNA linked to killed adenovirus as described in Curiel, 1992, *Hum. Gene Ther.* 3:147-154, may
25 be employed.

Gene delivery vehicles of the present invention also include herpes vectors. Representative examples of such vectors include those disclosed by Kit in *Adv. Exp. Med. Biol.* 215:219-236, 1989; and those disclosed in U.S. Patent No. 5,288,641 and EP 0176170 (Roizman). Additional exemplary herpes simplex virus vectors include
30 HFEM/ICP6-LacZ disclosed in WO 95/04139 (Wistar Institute), pHSVlac described in

Geller, 1988, *Science* 241:1667-1669, and in WO 90/09441 and WO 92/07945; HSV Us3::pgC-lacZ described in Fink, 1992, *Human Gene Therapy* 3:11-19; and HSV 7134, 2 RH 105 and GAL4 described in EP 0453242 (Breakefield), and those deposited with the ATCC as accession numbers ATCC VR-977 and ATCC VR-260.

5 Gene delivery vehicles may also be generated from a wide variety of other viruses, including for example, poliovirus (Evans *et al.*, 1989, *Nature* 339:385-388; and Sabin, 1973, *J. Biol. Standardization* 1:115-118); rhinovirus; pox viruses, such as canary pox virus or vaccinia virus (Fisher-Hoch *et al.*, 1989, *PNAS* 86:317-321; Flexner *et al.*, 1989, *Ann. N.Y. Acad. Sci.* 569:86-103; Flexner *et al.*, 1990, *Vaccine* 8:17-21; U.S. Patent Nos. 10 4,603,112, 4,769,330 and 5,017,487; WO 89/01973); SV40 (Mulligan *et al.*, 1979, *Nature* 277:108-114); influenza virus (Luytjes *et al.*, 1989, *Cell* 59:1107-1113; McMichael *et al.*, 1983, *N. Eng. J. Med.* 309:13-17; and Yap *et al.*, 1978, *Nature* 273:238-239); SV40; HIV (Poznansky, 1991, *J. Virol.* 65:532-536); measles (EP 0 440,219); astrovirus (Munroe *et al.*, 1993, *J. Vir.* 67:3611-3614); and coronavirus, as well as other viral systems (*e.g.*, EP 15 0,440,219; WO 92/06693; U.S. Patent No. 5,166,057). In addition, viral carriers may be homologous, non-pathogenic(defective), replication competent virus (*e.g.*, Overbaugh *et al.*, 1988, *Science* 239:906-910), and nevertheless induce cellular immune responses, including CTL.

4. Non-viral gene delivery vehicles

20 Other gene delivery vehicles and methods that may be employed such as, for example, nucleic acid expression vectors; polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see U.S. Serial No. 08/366,787, filed December 30, 1994, and Curiel, 1992, *Hum Gene Ther* 3:147-154; ligand linked DNA, for example see Wu, 1989, *J Biol Chem* 264:16985-16987; eucaryotic cell delivery vehicles cells, for example 25 see U.S. Serial No. 08/240,030, filed May 9, 1994, and U.S. Serial No. 08/404,796; deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun, as described in US Patent No. 5,149,655; ionizing radiation as described in U.S. 5,206,152 and in WO 92/11033; nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip, 1994, *Mol Cell Biol* 14:2411-2418, and in 30 Woffendin, 1994, *Proc. Natl. Acad. Sci.* 91:1581-1585.

Particle mediated gene transfer may be employed, for example, see U.S. provisional application No. 60/023,867. Briefly, the sequence of interest can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as

5 polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomuroid, as described in Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432, insulin as described in Hucked, 1990, *Biochem Pharmacol* 40:253-263, galactose as described in Plank, 1992, *Bioconjugate Chem* 3:533-539, lactose or transferrin.

10 Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Patent No. 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby

15 facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Liposomes that can act as gene delivery vehicles are described in U.S. Patent No. 5,422,120, PCT Patent Publication Nos. WO 95/13796, WO 94/23697, and WO 91/144445, and European Patent Publication No. 524,968. As described in U.S. provisional application No. 60/023,867, nucleic acid sequences can be inserted into

20 conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomuroid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the

25 control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods

30 for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Patent No.

5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Patent No. 5,206,152 and PCT Patent Publication No. WO 92/11033.

Exemplary liposome and polycationic gene delivery vehicles are those described in U.S. Patent Nos. 5,422,120 and 4,762,915, in PCT Patent Publication Nos. WO 95/13796,
5 WO 94/23697, and WO 91/14445, in European Patent Publication No. 524,968 and in Starrier, Biochemistry, pages 236-240 (1975) W.H. Freeman, San Francisco; Shokai, *Biochem Biophys Acct* 600:1, 1980; Bayer, 1979, *Biochem Biophys Acct* 550:464; Rivet, 1987, *Meth Enzyme* 149:119; Wang, 1987, *Proc Natl Acad Sci* 84:7851; Plant, 1989, *Anal Biochem* 176:420.

10 B. Construction of Recombinant Gene Delivery Vehicles Expressing Therapeutic Proteins

The gene delivery vehicles of the invention can be administered by intravenous delivery or by other methods described herein in order to induce long term *in vivo*
15 expression of a variety of therapeutic proteins. As is demonstrated in Examples 18-24 herein, administration of a retroviral vector intravenously results in sustained, long-term systemic expression of therapeutic genes expressed by the retroviral vector. Thus, methods for obtaining long-term systemic expression *in vivo* of a variety of proteins known to one of skill in the art are encompassed by the instant invention. Preferably,
20 long-term *in vivo* systemic expression is obtained by intravenous delivery methods as is described in detail below (see Section H of this application). For long term expression from a retroviral vector *in vivo*, the action of human complement on the retroviral vector is suppressed. This can be done by a variety of techniques known to one of skill in the art. Preferably, human packaging cell lines are used in order to inhibit the action of human
25 complement on the retroviral vector particles (see PCT publication number US 91/06852, entitled "Packaging Cells"). The terms "human complement resistant" or "resistance to human complement" when applied to a gene delivery vehicle such as a retroviral vector means that the vectors is at least 70% resistant, more preferably 80% resistant and most preferably at least 90% resistant to inactivation by human complement when tested in a
30 standard serum inactivation assay as described in Example 11 herein.

The production of high titer preparations of recombinant retroviral vectors is described in detail herein. The term "high titer retroviral vector preparation" as used herein refers to a retroviral vector preparation that has a titer greater than 10^6 cfu/ml, more preferably greater than 10^7 cfu/ml, still more preferably greater than 10^8 cfu/ml, more preferably greater than 10^9 cfu/ml, yet more preferably greater than 10^{10} cfu/ml, and most preferably greater than 10^{11} cfu/ml when tested on HT1080 cells in the assay for colony forming units on HT1080 cells as is described herein. This assay depends on the expression a marker protein to determine cfu/ml. The term "cfu" refers to "colony forming units" when vectors contain a selectable marker. The term refers to identifiable colonies when a phenotypically observable marker is used, such as blue colonies when the marker is beta -galactosidase. In some cases, for example for factor VIII vectors, when no marker gene is present, "cfu" refers to units measured by a PCR-based titer. Briefly, HT1080 cells are transduced with the markerless vector and number of proviral DNA copies are measured by quantitative PCR; HT1080 cells transduced with a retroviral vector containing the neomycin resistance gene are used as a standard (see Section F of the Detailed Description, herein).

The terms "long term systemic expression" or "sustained systemic expression" as used herein in reference to *in vivo* expression of protein encoded by a retroviral vector mean measurable or biologically active expression into the bloodstream for 30 days, more preferably for 60 days, yet more preferably for 90 days, and more preferably for six months, still for preferably for 1 year, more preferably for at least 5 years after administration of the retroviral vector particle to a host. Most preferably, the expression would be for the life of the patient such that the retroviral vector would only need to be administered to the patient once, or that "booster" injections would have to be delivered to the patient only a few times during the lifetime of the patient. The term "measurable expression" as used herein in reference to *in vivo* expression of a protein encoded by a retroviral vector means that the protein is produced in sufficient amounts so as to be detectable in biological fluids such as serum by an assay specific for the expressed protein. The term "systemic expression" as used herein means that the proteins are expressed into the circulation and are thus useful for treatment of certain diseases. A variety of diseases discussed in detail below are amenable to treatment by this type of gene therapy.

For example, measurement of human growth hormone can be determined by an ELISA assay specific for human growth hormone protein as described in Example 19 herein. The term "biologically active expression" or "protein expression in biologically or therapeutically active amounts" when used herein in reference to *in vivo* expression of a protein encoded by a retroviral vector means that protein is produced in sufficient amounts so as to be detectable in a functional assay. For example, expression of factor VIII can be measured in a clotting assay as described in Example 18, herein. Similarly other expressed proteins can be measured by specific assays for each particular protein that are known to those of skill in the art.

Long-term *in vivo* expression of a variety of proteins can be effected by the methods of the invention, preferably by *in vivo* administration of high titer retroviral vectors as described herein. A large variety of different proteins can be expressed for therapeutic applications in a number of different disease states. Preferred proteins include, cytokines and immune system modulators, hormones, growth factors, vaccine antigens, and proteins for treatment of inherited diseases.

1 Gene Delivery Vehicles Expressing Human Factor VIII and Factor IX for Treatment of Hemophilia

Preparation of retroviral vectors expressing a B-domain deleted factor VIII protein are described in detail in the Example section of this application (see Examples 1, 2, 27 and 28 herein). In particular, these examples demonstrate the insertion of a particular factor VIII deletion called the SQN deletion the construction of which is described in Example 2 herein, and which is further described in detail in PCT WO 91/09122.

The B domain separates the second and third A domains of factor FVIII in the newly synthesized single-chain molecule. The B domain extends from amino acids 712 to 1648 according to Wood *et al.*, 1984, *Nature* 312:330-337. Proteolytic activation of factor VIII involves cleavage at specific Arg residues located at positions 372, 740, and 1689. Cleavages of plasma factor VIII by thrombin or Factor Xa at Arg 372 and Arg 1689 are essential for factor VIII to participate in coagulation. Therefore, activated factor VIII consists of a heterodimer comprising amino acids residues 1-372 (containing the A1 domain) and residues 373-740 (containing the A2 domain), and residues 1690-2332

(containing the A3-C1-C2 domain). An important advantage in using the B domain deleted FVIII molecule is that the reduced size appears to be less prone to proteolytic degradation and therefore, no addition of plasma-derived albumin is necessary for stabilization of the final product. The term "B domain deletion" as used herein with respect to factor VIII protein refers to a factor VIII protein in which some or all removal of some or all of the amino acids between residues 711 and 1694 have been deleted, and which still preserves a biologically active FVIII molecule.

A range of B domain deletions can exist depending on which amino acid residues are in the B domain is deleted and whereby the biological activity of the FVIII molecule is still preserved. A specific B domain deletion called the SQN exists which is created by fusing Ser 743 to Gln 1638 (Lind *et al.*, 1995, *Eur J. Biochem* 323:19-27, and PCT WO 91/09122) This deletes amino acid residues 744 to 1637 from the B domain creating a Ser-Glu-Asn (SQN) link between the A2 and A3 FVIII domains. When compared to plasma-derived FVIII, the SQN deletion of the B domain of FVIII did not influence its *in vivo* pharmacokinetics (Fijnvandraat, et. al., *P.R.Schattauer Verlagsgesellschaft mbH (Stuttgart)* 77:298-302, 1997). The terms "Factor VIII SQN deletion" or "SQN deletion" as used herein refer to this deletion and to other deletions which preserve the single S-Q-N tripeptide sequence and which result in the deletion of the amino acids between the two B-domain SQN sequences (See PCT WO 91/09122 for a description of this amino acid sequence).

There are number of other B-domain deleted forms of factor VIII. cDNA's encoding all of these B-domain deleted factor VIII proteins can be inserted into retroviral vectors by using standard molecular biology techniques similar to those described in Examples 1, 2, 27 and 28 herein. For example cDNA molecules encoding the following B-domain factor VIII deletions can be constructed as described below:

Eaton (1986) <i>Biochemistry</i> 25:8343	des 797-1562 deletion
Toole (1986) <i>PNAS</i> 83:5939	des 760-1639 (LA-FVIII)
Meutien (1988) <i>Prot Eng</i> 2:301	des 771-1666 (FVIII del II: missing one thrombin site)
Sarver (1987) <i>DNA</i> 6:553	des 747-1560

Mertens (1993) Br J Haematol 85:133	des 868-1562 des 713-1637 (thrombin resistant)
Esmon (1990) Blood 76:1593	des 797-1562
Donath (1995) Biochem J 312:49	des 741-1668
Webb (1993) BBRC 190:536	PCR cloned from mRNA
Lind (1995) Eur J Biochem 232:19	des 748-1648 (partially processed) des 753-1648 (partially processed) des 777-1648 (partially processed) des 744-1637 (FVIII-SQ) des 748-1645 (FVIII-RH) des B-domain + 0, 1, 2 Arg (partially processed) desB, +3Arg (FVIIIIR4) desB, +4Arg (FVIIIIR5)
Langner (1988) Behring Inst Mitt 16-25	des 741-1689 des 816-1598
Cheung (1996) Blood 88:325a	des 746-1639
Pipes (1996) Blood 88:441a	des 795-1688 (thrombin sites mutated)

A B domain deletion in which an IgG hinge region has been inserted can also be used. For instance, a deletion of this type can be obtained from plasmid PSVF8-t β 2. PSVF8-t β 2 is a plasmid, which was designed to link the heavy and light chains with a short hinge region from immunoglobulin A (see Figure 37). To obtain cleavage at the end of the heavy chain and to release the light chain, some residues of the β domain were included on either side of the hinge sequence. The 5' untranslated leader and signal peptide are from the human Factor VIII:C cDNA, with the Kozak consensus sequence at the initiation codon as in pSVF8-302. A description of this vector is included in Chapman *et al.*, U.S. Patent No. 5,595,886. The 3' untranslated region is the same fused Factor VIII and tPA sequence as found in pSVF8-80K.

The construction was completed in two steps: an oligomer with cohesive ends for EcoRI and BclI (117 bp) was cloned into a transfer vector, pF8GM7, the DNA sequence of the oligomer was checked by m13 subcloning and Sanger sequencing.

Next, the final plasmid was assembled by ligation of the following three fragments:

- 5 (a) FspI-EcoRI fragment from pSVF8-92S;
- (b) EcoRI-NdeI fragment of the transfer vector pF8GM7 with oligomer; and
- (c) FspI-NdeI fragment of pSVF8-80K.

Descriptions of pSVF8-92S and pSVF8-80K are included in Chapman *et al.*, U.S. Patent No. 5,595,886. The sequence linking the heavy and light chains is shown in Figure 38.

10 Three additional B domain-deleted factor VIII constructs of particular interest for inclusion in the gene delivery vehicles of the invention can be prepared as follows.

Plasmid pSVF8-500 encodes a factor VIII protein with amino acids 770 to 1656 of the full length Factor VIII deleted, according to the nomenclature used in Seq ID No. 45. In addition the threonine at position 1672 of the full-length factor VIII sequence of Seq ID 15 No. 45 was also deleted. The following is a description of the construction of the vector.

The pSVF8-500 plasmid is a derivative of pSVF8-302 in which the regions coding for the 92K and 80K domains are fused with a small connecting β -region of 21 amino acids, retaining the natural proteolytic processing sites. This plasmid was constructed in the following manner:

20 (1) A SalI-KpnI fragment of 1984 bp containing the region coding for the 92K protein (except for the carboxyl terminal end) and BstXI-SalI fragment of 2186 bp containing the region coding for the carboxyl end of the 80K protein with 3' end untranslated region were isolated by gel electrophoresis after digestion of pSVF8-302 with restriction enzymes.

25 (2) A BclI-BstXI fragment of 1705 bp containing most of the region coding for the 80K protein was isolated after gel electrophoresis of the BamHI-XbaI fragment of pUC1215. pUCF812 is prepared from pF8-102 which is described in U.S. Patent No. 5,045,455. pF8-102 is digested with Bam-XbaI and ligated into vector pUC12 by *in vitro* mutagenesis at a BclI site using the following primer: 5' ACT ACT CTT CAA TCT GAT 30 CAA GAG GAA 3' (Seq ID No. 52).

(3) A KpnI-EcoRI fragment containing the carboxyl end of the 92K protein and part of the β region (4 amino acids) was obtained by digestion of the SalI cassette from pSVF8-302 with KpnI and EcoRI.

(4) Ligation of four pieces of synthetic DNA (shown in Figure 39) to the fragments of steps (2) and (3) and digestion with KpnI.

(5) Final ligation of fragments from steps (1) and (4); digestion with SalI and gel purification of the 6428 bp SalI cassette.

(6) Ligation of the SalI cassette into pSV7d vector; transformation of HB101 and colony hybridization to isolate pSVF8-500 (Figure 40). The sequence of the junction region coding for 92K- β -80K was verified by DNA sequence after cloning in M13.

Note that the sequence in the linker shown in Figure 39 is different from wild type human Factor VIII. The sequence was changed to incorporate unique NruI and MluI restriction sites without changing the amino acid sequence. These sites were also used to construct other two additional B-domain deleted vectors which are described below.

pSV500B Δ Thr was constructed from pSVF8-500. The threonine deletion at position 1672 was maintained. The synthetic linker shown in Figure 41 was used to construct pSV500B Δ Thr. The linker extends from a unique NruI site at Ser(765) to a unique MluI site at Ile(1659) in the pSVF8-500 vector. This linker was substituted for the corresponding region of pSVF8-500.

A third vector pSVF8-500B was constructed from pSV500B Δ Thr. This vector is identical to pSVF8-500B except that the codon for threonine 1672 was re-inserted using standard mutagenesis methods. The relationship between, pSVF8-500B, pSVF8-500B, is further illustrated in the table below. Amino acid sequence numbers in the table were determined by reference to full-length factor VIII sequence depicted in Seq. ID No. 45.

Name	Amino Acids Deleted	Thr at 1672 Deletion
pSVF8-500	770 to 1656	Yes
pSVF8-500B Δ Thr	779 to 1658	Yes
pSVF80-500B	779 to 1658	No

In all cases, the BglII-PflI 1.35 kb fragments of each modified cDNA listed above can be inserted into the retroviral vectors described herein using standard molecular

biology procedures known to those of skill in the art and described herein. For instance, cDNA clones containing the B domain-deleted factor VIII proteins can be excised and used to replace the BglII to PflI fragment in the retroviral vectors described in examples 27 and 28 herein. A similar procedure can be used to construct other retroviral vectors ,
5 including those described in section A, above.

The full-length factor VIII cDNA can also be inserted into the retroviral vectors of the invention as described in Example 2 herein and in WO 96/21035 which is hereby incorporated by reference in its entirety. In addition, the full-length human factor VIII cDNA can be derived from the construct pSV7dF8-200 or pSV7dF8-300 described in
10 Example 28, herein. This can be constructed similarly to the retroviral vector expressing the B-domain deleted factor VIII described in Example 28 where the cDNA fragment is cloned into the BglII/PflI linearized vector. For instance, an AccI to XbaI 5.9 kb fragment can replace the 3.15 kb AccI to XbaI fragment of the modified cDNA in F8:4213. The construction of the retroviral vector can then essentially follow the steps described in
15 Example 28. A variety of Factor VIII deletions, mutations, and polypeptide analogs of Factor VIII can also be introduced into the gene delivery vehicles of the invention including retroviral vectors by modifications of the procedures described herein. These analogs include, for instance, those described in PCT Patent Publication Nos. WO 97/03193, WO 97/03194, WO 97/03195, and WO 97/03191, all of which are hereby
20 incorporated by reference.

Other vectors expressing B domain deleted factor VIII or full-length factor VIII can be constructed using techniques known to those of skill in the art or described herein. For instance, adenoviral vectors expressing B-domain deleted factor VIII molecules can be constructed as described in WO 94/29471. Gene delivery vehicles derived from
25 adenovirus are also provided, in which the factor VIII gene, or its various derivatives as described herein, is inserted into a variety of adenovirus-derived vectors, and subsequently recombinant vector particles are generated as described. The adenovirus vectors of the invention also include the following vectors constructed to express factor VIII proteins.

The prototype recombinant adenovirus vectors were deleted in the early region one, [E1a/E1b, (E1)] region, rendering them replication defective. Following insertion of a
30 gene of interest into the deleted region, propagation of the recombinant E1-deleted

adenovirus vector is accomplished in 293 cells, a complementing human embryonic kidney cell line stably transformed with the Ad E1 region, which provide these Ad gene products in *trans*. Recombinant Ad vectors generated in this fashion can yield preparations with titers between 10^{11} to 10^{13} particles/ml (Reviewed in Berkner, 1988, *Biotechniques* 6:616-629). However there are several drawbacks to this prototype Ad vector system, including: (1) restriction of heterologous genetic material to approximately 4.5 to 5.0 kb, and (2) partial replication competence of the E1-deleted Ad vectors (Rich, 1993, *Hum. Gen. Ther.* 4:461-476). This later point arises in part to a complementing "E1-like activity" that is expressed in human cells, and results in the expression of other viral gene products present in these vectors, including the highly immunogenic, "late", or structural gene products (e.g. penton protein). As a result of immune responses of the recipient to Ad-specific proteins expressed by the E1-deleted vectors, expression of the heterologous gene, or transgene is transient and associated with the development of pathology at the site of gene transfer.

Thus, second generation Ad vectors have sought to further "cripple" the capacity of the vector to replicate, and express viral-specific gene products, and to increase the capacity of heterologous genetic material. Such vectors have been of three types: (1) E1 and E3 genes deleted [Bett, *PNAS*, 91:8802-8806, 1994], (2) E1 and E4 genes deleted (Wang, 1995, *Gene Ther.* 2:775-783, and PCT Patent Publication Nos. WO 96/22378 and WO 95/02697), and (3) deletion of all Ad viral genes, or "gutless" (Fisher, 1996, *Virology*, 217:11-22; Hardy, *J. Virol*, 71:1842-1849, and Kochanek, 1996, *PNAS*, 93:5731-5736). The duration of transgene expression in animals inoculated with these second generation recombinant adenovirus vectors has been dramatically increased, as a result of the mitigation of the recipient's immune response.

As expected, increased deletion of viral-specific genes in the second generation Ad vectors has also resulted in an increased capacity for heterologous genetic material, thus extending the usefulness of this system for application to human gene transfer. This capacity for heterologous genetic material is approximately 8 kb in the E1/E3 and E1/E4 vectors, and is greater than 30 kb for the "gutless" Ad vectors, permitting the insertion of entire genes, including relevant gene expression control regions.

Generation of recombinant Ad vectors, including the E1/E3, E1/E4, and "gutless" vectors, harboring the full-length factor VIII gene, or its B-domain derived derivatives, can be accomplished according to methods well-known to those skilled in the art. For example: (1) the full-length factor VIII gene, or its B-domain derived derivatives can be
5 inserted into plasmid pBHG11 (Bett, 1994, *PNAS* 91:8802-8806), and recombinant E1/E3-deleted Ad vectors are generated after transfection of 293 cells and subsequent intracellular homologous recombination, (2) the full-length factor VIII gene, or its B-domain derived derivatives can be first substituted into the E1 region of any of a variety of E1-deleted Ad vectors and co-transfected with Cla I digested H5dl1014, and recombinant
10 E1/E4-deleted Ad vectors are generated after transfection of 293-E4 cells [Wang Gene Ther., 2:775-783, (1995)], and subsequent intracellular homologous recombination, (3) the full-length factor VIII gene, or its B-domain derived derivatives is first inserted into the Δ Ad plasmid" [Fisher, 1996, *Virology*, 217:11-22), along with appropriate amounts of "stuffer" sequence derived from, for example, bacteriophage lambda DNA, to permit
15 efficient packaging of recombinant "gutless" adenovirus vector genomes, transfected onto 293 cells and infected with H5.CBALP helper virus (Yang, 1995, *Virol.* 69:2004-2015). Purification of recombinant "gutless" adenovirus vector particles from helper virus can be accomplished, for example, by centrifugation over a cesium gradient, as a result of a buoyant density lower than that of helper virus.

20 In the case of adeno-associated viral vectors, preferably a factor VIII heavy chain and light chain are inserted into separate vectors, as is demonstrated in Examples 29 and 30 herein. Other adenoviral vectors including those described above and in co-owned U.S. serial number 60/025649 can be constructed to express factor VIII light chain and heavy chain using the techniques described in Examples 29 and 30. Heavy and light chain
25 constructs for inclusion into the AAV vectors of the invention can be prepared for instance as described in Chapman *et al.*, U.S. Patent No. 5,595,886.

Hemophilia B can also be treated with systemically administered factor IX-expressing gene delivery vehicles including retroviral vectors. Human factor IX deficiency (Christmas disease or Hemophilia B) affects primarily males because it is transmitted as
30 sex-linked recessive trait. It affects about 2000 people in the US. The human factor gene codes a 416 amino acids of mature protein.

The human factor IX cDNA can be obtained for instance by constructing plasmid pHfIX1, as described by Kurachi and Davie, 1982, *PNAS* 79(21):6461-6464. The cDNA sequence can be excised as a PstI fragment of about 1.5 kb, blunt ended using T4 DNA polymerase. The factor cDNA fragment can be readily inserted, for example into a SrfI site introduced into a retroviral vector. For instance the cDNA fragment can be inserted into the SrfI site of a linearized pMBA retroviral vector using the procedure described in Examples 27 and 28 herein. In this case, the resulting retroviral vector: pMB-F9 will be produced from HAI cells and its expression will be determined using HT1080 fibroblasts as target cells.

Similarly, the full-length factor IX cDNA fragment can be introduced into other gene delivery vehicles described herein, such as adenoviral vectors and AAV vectors. In the case of adenoviral vectors, vectors expressing factor IX can be produced, for instance, as described in. For instance, adenoviral vectors expressing B-domain deleted factor VIII molecules can be constructed as described in WO 94/29471. Adenoviral vectors expressing factor IX protein can be produced by methods similar to those described above for factor VIII protein.

In the case of AAV vectors, a factor IX cDNA can be inserted into vectors using, for instance, procedures similar to those described in Examples 29 and 30 herein for factor VIII heavy and light chains. Other adenoviral vectors including those described above and in co-owned U.S. provisional application No. 60/025,649 can be constructed to express factor VIII light chain and heavy chain using the techniques similar to those of Examples 29 and 30.

2. Gene delivery vehicles expressing other clotting factors:

(a) Factor V Vectors For Treatment or Prophylaxis of Thrombosis Due to APC Resistance

The present invention provides for needed therapy and prophylaxis of these and other disorders of thrombosis and hypercoagulation by delivery of gene delivery vehicles expressing factor V. Blood coagulation consists of a series of sequential activations of circulating serine protease zymogens, culminating the activation of prothrombin to form thrombin and the subsequent generation of fibrin, the substance of the clot. Two of these

reactions, the activation of prothrombin and factor X, require the participation of the large proteinaceous cofactors, factors Va and VIIIa, respectively. The serine protease zymogen, Protein C, exerts its anticoagulant effect when it is cleaved by thrombin to form activated protein C. Activated protein C (APC) destroys the activity of factors Va and VIIIa through cleavage at specific arginine residues. Genetic deficiencies of protein C or its cofactor, protein S, account for ~5-10% of cases of familial thrombophilia. In 1993, Dahlback, 1993, *PNAS* 90:1004, described a new form of thrombophilia, called activated protein C resistance (APC resistance) in which added APC failed to prolong the clotting times of patients' plasmas. This was subsequently shown to account for up to 40% of cases of familial thrombophilia, making it the most common form of inherited disposition to thrombosis (Sun *et al.*, 1994, *Blood* 83:3120). >95% of APC resistance cases result from a single point mutation in factor V, R506Q (Bertina *et al.*, 1994, *Nature* 369:64, and Greengard *et al.*, 1994, *Lancet* 343:1361). This mutation was subsequently found to be present in various healthy European populations at a level of 1-10% (Svensson *et al.*, 1994, *New Engl J Med* 300:517; Griffin *et al.*, 1993, *Blood* 82:1989; Koster *et al.*, *Lancet* 342:1503), and presence/absence of symptoms can vary considerably in a family with numerous homozygotes (Greengard *et al.*, 1995, *New Engl J Med* 331:1559), underscoring the multifactorial nature of thrombotic disease. Rosendaal *et al.*, 1995, *Blood* 85:1504, estimated the relative risk of thrombosis in a heterozygote for APC resistance as seven-fold, and for homozygotes as 80-fold.

Greengard *et al.* described (*Thromb Haemostas* (1995) 73:1361 (abs)) carrying both a null allele for factor V deficiency and APC resistance. Since these two factor V defects assorted independently, they represented two different factor V alleles. The compound heterozygotes had circulating factor V derived only from the APC resistant factor V allele, and two of the three symptomatic family members had this "pseudohomozygous" genotype. Other family members with only factor V deficiency had no thrombosis. While not wishing to be bound by theory, the risk factor of an APC resistance allele can be compensated in some cases by the mere presence of some normal (APC responsive) factor V. Thus, delivery of factor V by the gene delivery vehicles and the therapeutic methods of the invention to provide normal factor V can be of therapeutic

benefit even in the presence of the same amount of resistant factor V, perhaps due to this mechanism.

Gene delivery vehicles, including retroviral vectors can be constructed using molecular biology techniques known to those of skill in the art. For instance, Factor V cDNA is obtained from pMT2-V (Jenny, 1987, *Proc. Natl. Acad. Sci. USA* 84:4846; ATCC deposit #40515) by digestion with Sall. The 7 kb cDNA band is excised from agarose gels and cloned into retroviral vectors, using standard molecular biology techniques. For example, the factor V cDNA insert can be cloned into the Sall site of Sall digested pBA9 vector as described for insertion of a factor VIII fragment in Example 28 herein.,

Either a full-length or a B-domain deletion or substitution of the factor V cDNA can be expressed by the gene therapy vectors of the invention. Factor V B-domain deletions such as those reported by Marquette, 1995, *Blood* 86:3026, and Kane, 1990, *Biochemistry* 29:6762, can be made as described by these authors.

(b) Antithrombin III Vectors for Treatment or Prophylaxis of Deficiency or Other Hypercoagulable States

The central enzyme of the coagulation pathways, thrombin, acts directly through cleavage of fibrinogen to form fibrin, the substance of the clot, or indirectly through positive feedback mechanisms involving activation of other clotting factors. The most commonly used acute-phase anticoagulant used is heparin, most of whose effects are mediated through augmentation of the inhibition of thrombin. The major thrombin inhibitor in plasma is antithrombin III (ATIII). The frequency of ATIII deficiency is as high as 1:500 (Tait, 1990, *Br J Haematol* 75:141). Although most cases are clinically silent, deficiency may pose a risk factor synergistic with others. Most patients are treated with oral anticoagulants, supplemented by ATIII concentrates for surgery or other major trauma (Winter, 1981, *Br J Haematol* 49:449-457). Oral anticoagulation is considered an inconvenient and inadequate treatment for hypercoagulable states, while plasma-derived proteins carry the risk of transmittal of infectious agents and other problems. Acquired deficiencies of ATIII are more frequent, such as in premature infants, L-asparaginase therapy for leukemia, DIC, sepsis, nephrotic syndromes, traumatic bleeding, severe burns,

malignancies, ARDS, DVT/PE, and enteropathies. Concentrates have been used for animal models of some of these conditions (Emerson, 1994, *Blood Coag Fibrinol* 5:37). The use of gene therapy to deliver ATIII using the methods described herein can provide useful therapy, particularly in ATIII deficiency states.

5 Gene delivery vehicles including retroviral vectors capable of expressing ATIII cDNA can be readily constructed using standard molecular biology techniques known to those of skill in the art. For instance a retroviral vector expressing AT III can be constructed from the vector pKT218 (Prochownik, 1983, *J. Biol. Chem.* 258:8389; ATCC number 57224/57225) by excision with PstI. The 1.6 kb cDNA insert can be recovered
10 from agarose gels and cloned into the PstI site of vector SK-. The insert can be recovered by restriction enzyme digestion and cloned into retroviral vectors described herein by the restriction enzymes. For instance, the AT III insert can be excised by XhoI/NotI digestion and cloned into the XhoI/NotI digested pMBA vector described in Example 27 herein to form pMBA-AT3.

15

(c) Protein C Vectors for Treatment or Prophylaxis of Deficiency or Other Hypercoagulable States

As described above, protein C is a serine protease zymogen that acts to downregulate the coagulation cascade. Its deficiency is associated with increased risk of
20 recurrent thrombosis, purpura fulminans, and warfarin-induced skin necrosis (Bauer, in Disorders of Hemostasis, Ratnoff & Forbes (Eds), WB Saunders, Philadelphia (1996)). The incidence of heterozygosity is as high as 1/200 (Miletich, 1987, *New Engl J. Med.* 317:991). Although most cases are clinically silent, deficiency may pose a risk factor synergistic with others. Recombinant protein C is administered on a compassionate basis
25 to severely affected homozygotes (Minford, 1996, *Br J Haematol* 93:215). Homozygotes and symptomatic heterozygotes could be treated more effectively by retroviral-mediated gene delivery. In addition, there is evidence to suggest that augmenting levels of activated protein C (APC) could play a major role in prevention of thrombosis in patients with other causes (genetic or acquired) of hypercoagulability. Gruber (*Blood* 79:2340(1992)) showed
30 that low levels of APC circulate in the plasma of normals, and speculated that basal levels of APC serve to downregulate coagulation in response to low-level prothrombotic signals.

The ratio of circulating endogenous APC level to protein C zymogen level was lower in protein C-deficient individuals with history of thrombosis than in their thrombosis-free relatives, but in general APC levels overall are proportional to the zymogen protein C levels (España, 1996, *Thrombos Haemostas* 75:56-61). While not wishing to be bound by theory, it may be that gene therapy vectors which express protein C in non-deficient individuals at risk for thrombosis from other causes will have a protective effect in individuals with normal levels of protein C due to this mechanism. An artificial variant of protein C, HPC-FLINQ (Richardson, 1992, *Nature* 360:261; Kurz, 1997, *Blood* 89:534) was recently described with an enhanced activation profile in the presence of thrombin without the normally required cofactor, thrombomodulin (see below), so that APC was generated in the presence of thrombin levels attained during the clotting of plasma. In addition, HPC-S460A, a second artificial variant of human protein C, has a normal activation profile but a much lowered propensity for subsequent inhibition by plasma serpins. While not wishing to be bound by theory, since binding to serpins is the major mechanism for removal of APC from the circulation, the nonenzymatic anticoagulant activity demonstrated for this variant (Gale, 1997, *Prot. Sci.* 6:132) may be preferred due to have a significantly prolonged plasma half-life upon activation. Yet another approach was taken by Ehrlich, 1989, *J. Biol. Chem.* 264:14298, who made a variant of protein C that would become activated during the process of secretion, resulting in secretion of the activated enzyme. In particular, delivery of these variants by the means of gene therapy vectors and the gene therapy methods described herein are useful in reducing thrombosis in individuals at risk.

The gene delivery vehicles of the invention, including retroviral vectors, capable of expressing Protein C can be made using techniques known to those of skill in the art. For instance, protein C cDNA will be obtained by restriction enzyme digestion of published vector (Foster, 1984, *Proc. Natl. Acad. Sci. USA* 81:4766; Beckmann, 1985, *Nucleic Acids Res* 13:5233). The 1.6 kb cDNA insert can be recovered from agarose gels and cloned into the multiple cloning site of vector SK- under standard conditions. The insert can be recovered by restriction enzyme digestion and cloned into a retroviral vector; for example, excision by XhoI/NotI digestion followed by cloning into XhoI/NotI digested retroviral vector. For instance, the protein C DNA fragment can be cloned into the XhoI/NotI

digested pMBA vector described in Example 27 herein to form pMBA-PC. In some cases, variants of protein C will be constructed prior to cloning into the vector backbone, as described in Ehrlich, Richardson, Kurz, Gale publications cited above.

(d) Prothrombin Vectors for Treatment or Prophylaxis of Hypercoagulable States

5 As described above, the normal protein C anticoagulant pathway requires activation by the enzyme thrombin. Thrombin is normally a procoagulant enzyme which cleaves fibrinogen to form fibrin, activates platelets, and performs positive feedback reactions upon components of the coagulation cascade. Its action in the anticoagulant pathway under physiological conditions is dependent upon binding to an endothelial cell
10 surface-bound cofactor, thrombomodulin. Upon binding to this protein, thrombin undergoes a conformational change that greatly reduces its ability to perform the procoagulant reactions mentioned above while greatly increasing the rate of activation of protein C zymogen, thus changing its specificity from a procoagulant to an anticoagulant enzyme. In accordance with this model, infusion of low levels of thrombin has been shown
15 to be antithrombotic (Gruber, 1990, *Circ.* 82:578; Hanson, 1993, *J. Clin. Invest.* 92:2003; McBane, 1995, *Thromb Haemostas* 74:879). Thrombin variants with similar changes in specificity in the absence of thrombomodulin have been developed (Dang, 1997, *Nature Biotech* 15:146; Gibbs, 1995, *Nature* 378:413; (1991) *PNAS* 88:7371; Wu, 1991, *PNAS*, 88:6775; Guinto, 1995, *PNAS* 92:11185). Delivery of these variants by the means of gene
20 delivery vehicles and the therapeutic methods of the invention would be useful in reducing thrombosis in individuals at risk.

Gene delivery vehicles expressing prothrombin and its variants can be constructed by methods known to those of skill in the art, by using variations on the methods described herein. For instance, prothrombin cDNA can be obtained by restriction enzyme digestion
25 of a published vector (Degen (1983) *Biochemistry* 22:2087). The 1.9 kb cDNA insert can be recovered from agarose gels and cloned into the multiple cloning site of vector SK-. The insert can be recovered by restriction enzyme digestion and cloned into a retroviral vector using restriction enzyme digestion. For instance, excision by *Cla*I/*Not*I digestion and cloning into *Cla*I/*Not*I digested pBA-9 vector to form pBA9-FII can be performed by
30 using a modification of the procedure similar to that described in Example 28 herein for

factor VIII b-domain deletion fragments. In some cases, variants of prothrombin are constructed prior to cloning into the vector backbone, as described in the Dang, Wu, Gibbs, and Guinto publications cited above.

(c) Thrombomodulin Vector for Treatment or Prophylaxis of Hypercoagulable States

As described above, the endothelial cell surface protein, thrombomodulin, is a necessary cofactor for the normal activation of protein C by thrombin. A soluble recombinant form has been described (Parkinson, 1990, *J. Biol. Chem.* 265:12602), which was proposed for use as a clinical therapeutic anticoagulant acting by means of the protein C pathway. Delivery of this and other variants by the gene delivery vehicles and the gene therapy methods of the invention is useful in reducing thrombosis in individuals at risk.

Gene delivery vehicles, including retroviral vectors, expressing thrombomodulin and its variants can be constructed using techniques known to those of skill in the art. For instance, thrombomodulin cDNA can be obtained from the vector puc19TM15 (Jackman, 1987, *Proc. Natl. Acad. Sci. USA* 84:6425; Shirai, 1988, *J. Biochem.* 103:281; Wen, 1987, *Biochemistry* 26:4350; Suzuki, 1987, *EMBO J* 6:1891; ATCC number 61348, 61349) by excision with Sall. The 3.7 kb cDNA insert will be recovered from agarose gels and cloned into the Sall site of retroviral vector. For instance, the thrombomodulin fragment can be cloned into the Sall site of Sall-digested pBA-9 vector to form pBA9-TM, using a modification of the procedure described in Example 28 herein. Variants of thrombomodulin lacking the cytoplasmic and transmembrane domains can be constructed prior to cloning into the vector backbone, as described by Parkinson.

Gene delivery vehicles expressing therapeutic agents for treatment of viral hepatitis

Gene delivery vehicles including retroviral vectors and the methods of administration described are useful for treatment of viral hepatitis, including hepatitis B and hepatitis C. For instance, the gene delivery vehicles of the invention can be used to express interferon-alpha for treatment of viral hepatitis. While not wishing to be bound by theory, it is shown in Example 24 herein that retroviral vectors injected intravenously preferentially transduce liver cells. Thus, the methods of intravenous delivery described

herein for gene delivery vehicles can be used for treatment of liver diseases such as hepatitis and in particular viral hepatitis, in which therapeutic proteins expressed by the gene delivery vehicles such as retroviral vectors can be delivered preferentially to the liver.

Currently, the only approved treatment for chronic hepatitis B, C and D infections is the use of alpha interferon 2a and 2b. Alpha-interferon is a secreted protein induced in B lymphocytes, macrophages and null lymphocytes by foreign cells, virus-infected cells, tumor cells, bacterial cells and products and viral envelopes. The mechanism of antiviral action of interferon is by inducing the synthesis of effector proteins: two of the most important are 2', 5'-oligo-adenylate synthetase (OAS) and dsRNA-dependent protein kinase (RDPK). OAS synthesizes adenylyate oligomers that activate RNAaseL, which degrades viral single stranded RNA. RDPK phosphorylates initiation factor eIF-2a which results in the inhibition of viral protein translation. In addition to the direct antiviral effect, alpha interferon has immunomodulatory effects that are important against viral infections. These immunomodulatory effects are: enhancement of the expression of both Class I and class II major histocompatibility complex (MHC) molecules, modulation of the expression of the interleukin-2 receptor, TNF- α receptor, transferrin receptor, enhancement of spontaneous natural killer (NK) cell cytotoxicity and modulation of antibody production by B cells. In chronic hepatitis B infection, the beneficial effect of interferon alpha appears to be from the immunomodulatory effects, while in chronic hepatitis C infection, the beneficial effect is dependent on its antiviral activity. (Bresters, D., in *Hepatitis C Virus*, pp121-136, Reesink HW (ed), 1994). The mechanism of action in interferon alpha for treatment of chronic hepatitis D is poorly understood (Rizzetto, M. and Rosina, F. in *Viral Hepatitis*, pp. 363-369, Zuckerman, A. J. and Thomas H. C. (ed), 1993).

Localized expression of interferon alpha in the liver from a gene delivery vehicle such as a retroviral vector can be an effective treatment for hepatitis. While not wishing to bound by theory, delivery of alpha interferon at the site of infection by the gene therapy vectors of the invention, including retroviral vectors, results in high local concentration of the cytokine thereby focusing the antiviral and immunological effects to the adjacent infected hepatocytes. A further advantage of this treatment is that the current systemic mode of systemic alpha interferon therapy may either be unnecessary or be reduced in dose and frequency of treatment. This reduction can reduce the adverse side effects

associated with the systemic delivery of alpha interferon. Thus, the gene therapy approaches described herein may be used in combination with administration of alpha-interferon protein formulations.

5 The construction of a number of different retroviral vectors expressing interferon-alpha is described in detail in Example 33, herein. Other retroviral vectors not specifically listed in Example 33 can also be readily constructed to express interferon-alpha using similar procedures. There are at least 24 different human alpha interferon genes or pseudogenes. There are two distinct families (I and II); mature human alpha interferon (I) are 166 amino acids long (one is 165 amino acids) whereas alpha interferon (II) have 172
10 amino acids. Eighteen genes are in the alpha interferon I family, including at least four pseudogenes. Six genes are in the alpha interferon II family, including five pseudogenes (Callard, R., and Gearing, A., *Cytokine Facts Book*, Academic Press, 1994 pp. 148-154). In Example 33 herein, we use alpha interferon 2a, 2b, 2c, 54 and 76, all members of the alpha interferon (I) family. Similar techniques can be used for inserting other members of
15 the alpha interferon I family (such as alpha interferon F and N) into retroviral vectors. Thus other biologically active forms of alpha-interferon in addition to 2a, 2b, 2c, 54 and 76 as described herein can also be expressed by the gene delivery vehicles of the invention and used for treatment of viral hepatitis.

Patients with viral hepatitis can be treated a combination gene therapy approach. A
20 gene delivery vehicle expressing a protein drug such as alpha-interferon can be administered intravenously or directly to the liver by methods described herein. This therapeutic approach can be combined with intramuscular delivery of a gene delivery vehicle expressing a hepatitis B or hepatitis C antigen for inducing a immune response against the hepatitis virus. Specific hepatitis B and C antigens useful in this type of
25 therapy and the construction of retroviral vectors expressing such antigens are described herein and in PCT Patent Publication No. WO 93/15207. In addition, molecularly cloned genomes which encode the hepatitis B virus may be obtained from a variety of sources including, for example, the American Type Culture Collection (ATCC, Rockville, Maryland). For example, ATCC No. 45020 contains the total genomic DNA of hepatitis
30 B (extracted from purified Dane particles) (see Figure 3 of Blum *et al.*, 1989, *TIG* 5(5):154-158) in the Bam HI site of pBR322 (Moriarty *et al.*, 1981, *Proc. Natl. Acad. Sci.*

USA 78:2606-2610). (Note that correctable errors occur in the sequence of ATCC No. 45020.)

4. Gene delivery vehicles expressing cytokines and immunomodulatory factors:

Genes encoding any of the cytokine and immunomodulatory proteins described herein can be expressed in a retroviral vector to achieve long term *in vivo* expression. Other forms of these cytokines which are known to those of skill in the art can also be used. For instance, nucleic acid sequences encoding native IL-2 and gamma-interferon can be obtained as described in US Patent Nos. 4,738,927 and 5,326,859, respectively, while useful muteins of these proteins can be obtained as described in U.S. Patent No. 4,853,332. As an additional example, nucleic acid sequences encoding the short and long forms of mCSF can be obtained as described in US Patent Nos. 4, 847,201 and 4,879,227, respectively. Retroviral vectors expressing cytokine or immunomodulatory genes can be produced as described herein and in PCT publication number US 94/02951 entitled "Compositions and Methods for Cancer Immunotherapy".

Additional examples of such factors include cytokines, such as IL-1, IL-2 (Karupiah *et al.*, 1990, *J. Immunology* 144:290-298; Weber *et al.*, 1987, *J. Exp. Med.* 166:1716-1733; Gansbacher *et al.*, 1990, *J. Exp. Med.* 172:1217-1224; U.S. Patent No. 4,738,927), IL-3, IL-4 (Tepper *et al.*, 1989, *Cell* 57:503-512; Golumbek *et al.*, 1991, *Science* 254:713-716; U.S. Patent No. 5,017,691), IL-5, IL-6 (Brakenhof *et al.*, 1987, *J. Immunol.* 139:4116-4121; WO 90/06370), IL-7 (U.S. Patent No. 4,965,195), IL-8, IL-9, IL-10, IL-11, IL-12, IL-13 (*Cytokine Bulletin*, Summer 1994), IL-14 and IL-15, particularly IL-2, IL-4, IL-6, IL-12, and IL-13, alpha interferon (Finter *et al.*, 1991, *Drugs* 42(5):749-765; U.S. Patent No. 4,892,743; U.S. Patent No. 4,966,843; WO 85/02862; Nagata *et al.*, 1980, *Nature* 284:316-320; Familletti *et al.*, 1981, *Methods in Enz.* 78:387-394; Twu *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:2046-2050; Faktor *et al.*, 1990, *Oncogene* 5:867-872), beta interferon (Seif *et al.*, 1991, *J. Virol.* 65:664-671), gamma interferons (Radford *et al.*, *The American Society of Hepatology* 20082015, 1991; Watanabe *et al.*, 1989, *PNAS* 86:9456-9460; Gansbacher *et al.*, 1990, *Cancer Research* 50:7820-7825; Maio *et al.*, 1989, *Can. Immunol. Immunother.* 30:34-42; U.S. Patent No. 4,762,791; U.S. Patent No. 4,727,138), G-CSF (U.S. Patent Nos. 4,999,291 and

4,810,643), GM-CSF (WO 85/04188), tumor necrosis factors (TNFs) (Jayaraman *et al.*, 1990, *J. Immunology* 144:942-951), CD3 (Krissanen *et al.*, 1987, *Immunogenetics* 26:258-266), ICAM-1 (Altman *et al.*, 1989, *Nature* 338:512-514; Simmons *et al.*, 1988, *Nature* 331:624-627), ICAM-2, LFA-1, LFA-3 (Wallner *et al.*, 1987, *J. Exp. Med.* 166(4):923-932), MHC class I molecules, MHC class II molecules, B7.1-.3, β_2 -microglobulin (Parnes *et al.*, 1981, *PNAS* 78:2253-2257), chaperones such as calnexin, MHC linked transporter proteins or analogs thereof (Powis *et al.*, 1991, *Nature* 354:528-531). Within one preferred embodiment, the gene encodes gamma-interferon. Immunomodulatory factors may also be agonists, antagonists, or ligands for these molecules. For example soluble forms of receptors can often behave as antagonists for these types of factors, as can mutated forms of the factors themselves.

Nucleic acid molecules that encode the above-described substances, as well as other nucleic acid molecules that are advantageous for use within the present invention, may be readily obtained from a variety of sources, including for example depositories such as the American Type Culture Collection (ATCC, Rockville, Maryland), or from commercial sources such as British Bio-Technology Limited (Cowley, Oxford England). Representative examples include BBG 12 (containing the GM-CSF gene coding for the mature protein of 127 amino acids), BBG 6 (which contains sequences encoding gamma interferon), ATCC No. 39656 (which contains sequences encoding TNF), ATCC No. 20663 (which contains sequences encoding alpha interferon), ATCC Nos. 31902, 31902 and 39517 (which contains sequences encoding beta interferon), ATCC No 67024 (which contains a sequence which encodes Interleukin-1b), ATCC Nos. 39405, 39452, 39516, 39626 and 39673 (which contains sequences encoding Interleukin-2), ATCC Nos. 59399, 59398, and 67326 (which contain sequences encoding Interleukin-3), ATCC No. 57592 (which contains sequences encoding Interleukin-4), ATCC Nos. 59394 and 59395 (which contain sequences encoding Interleukin-5), and ATCC No. 67153 (which contains sequences encoding Interleukin-6).

Plasmids containing cytokine genes or immunomodulatory genes can be digested with appropriate restriction enzymes, and DNA fragments containing the particular gene of interest can be inserted into the gene delivery vector using standard molecular biology techniques. (See Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition,

Vols. 1-3, Cold Spring Harbor Laboratory (1989) or Ausbel, et al. ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley -Interscience, New York (1987). In particular, retroviral vectors expressing cytokine and immunomodulatory molecules can be constructed as described in PCT publication number WO 94/02951 and PCT publication
5 number WO 96/21015, both of which are incorporated by reference in their entirety.

4. Gene delivery vehicles expressing polypeptide hormones and growth factors:

Retroviral vectors producing a variety of known polypeptide hormones and growth factors can be used in the methods of the invention to produce therapeutic long-term
10 expression of these proteins. A large variety of hormones, growth factors and other proteins which are useful for long term expression by the retroviral vectors of the invention are described, for instance, in EP publication number 0437478B1, entitled "Cyclodextrin-Peptide Complexes". Nucleic acid sequences encoding a variety of hormones can be used, including human growth hormone, insulin, calcitonin, prolactin,
15 follicle stimulating hormone, leutinizing hormone, human chorionic gonadotropin, thyroid stimulating hormone. Retroviral vectors expressing polypeptide hormones and growth factors can be prepared by methods known to those of skill in the art and as described herein. For instance, a retroviral vector expressing human growth hormone can be prepared as described in Example 8, herein. As an additional example, nucleic acid
20 sequences encoding different forms of human insulin can be isolated as described in European Patent Publications EP 026598 or 070632, and incorporated into retroviral vectors as described herein.

Any of the polypeptide growth factors described below in section C of this application can also be administered therapeutically by long-term expression *in vivo* with
25 a retroviral vector. For instance, a variety of different forms of IGF-1 and IGF-2 growth factor polypeptides are also well known the art and can be incorporated into retroviral vectors for long term expression *in vivo*. See e. g. European Patent No. 0123228B1, grant published on Sept. 19, 1993, entitled "Hybrid DNA Synthesis of Mature Insulin-like Growth Factors". As an additional example, the long term *in vivo* expression of different
30 forms of fibroblast growth factor can also be effected by the methods of invention. See,

eg. U.S. Patent No. 5,464,774, issued November 7, 1995, U.S. Patent No. 5,155,214, and U. S. Patent No. 4,994,559, for a description of different fibroblast growth factors.

Plasmids containing cytokine genes or immunodulatory genes can be digested with appropriate restriction enzymes, and DNA fragments containing the particular gene of interest can be inserted into the gene delivery vector using standard molecular biology techniques. (See Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, Vols. 1-3, Cold Spring Harbor Laboratory (1989) or Ausbel, et al. ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley -Interscience, New York (1987). In particular, retroviral vectors expressing polypeptide hormones and growth factors can be constructed using procedures similar to those described herein for human growth hormone.

5. Gene delivery vehicles expressing proteins for treatment of hereditary disorders:

There are a number of proteins useful for treatment of hereditary disorders that can be expressed *in vivo* by the methods of invention. Many genetic diseases caused by inheritance of defective genes result in the failure to produce normal gene products, for example, thalassemia, phenylketonuria, Lesch-Nyhan syndrome, severe combined immunodeficiency (SCID), hemophilia, A and B, cystic fibrosis, Duchenne's Muscular Dystrophy, inherited emphysema and familial hypercholesterolemia (Mulligan *et al.*, 1993, *Science* 260:926; Anderson *et al.*, 1992, *Science* 256:808; Friedman *et al.*, 1989, *Science* 244:1275). Although genetic diseases may result in the absence of a gene product, endocrine disorders, such as diabetes and hypopituitarism, are caused by the inability of the gene to produce adequate levels of the appropriate hormone insulin and human growth hormone respectively.

Gene therapy by the methods of the invention is a powerful approach for treating these types of disorders. This therapy involves the introduction of normal recombinant genes into somatic cells so that new or missing proteins are produced inside the cells of a patient. A number of genetic diseases have been selected for treatment with gene therapy, including adenine deaminase deficiency, cystic fibrosis, α_1 -antitrypsin deficiency, Gaucher's syndrome, as well as non-genetic diseases. As an example of the present invention, a retroviral vector can be used to treat Gaucher disease. Gaucher disease is a

genetic disorder that is characterized by the deficiency of the enzyme glucocerebrosidase. This enzyme deficiency leads to the accumulation of glucocerebroside in the lysosomes of all cells in the body. For a review see *Science* 256:794, 1992 and *The Metabolic Basis of Inherited Disease*, 6th ed., Scriver, et al., vol. 2, p. 1677).

5 As described in detail above, long term expression of Factor VIII or Factor IX is useful for treatment of blood clotting disorders, such as hemophilia. Different forms of Factor VIII, such as the B domain deleted Factor VIII construct described in Example 2 herein can be used to produce retroviral vectors expressing Factor VIII for use in the methods of the invention. In addition to clotting factors, there are a number of proteins
10 which can be expressed in the retroviral vectors of the invention and which are useful for treatment of hereditary diseases. These include lactase for treatment of hereditary lactose intolerance, AD for treatment of ADA deficiency, and alpha-1 antitrypsin for treatment of alpha-1 antitrypsin deficiency. See F.D. Ledley, 1987, *J. Pediatrics* 110:157-174; I. Verma, *Scientific American* (Nov., 1987) pp. 68-84; and PCT Patent Publication WO
15 95/27512 entitled "Gene Therapy Treatment for a Variety of Diseases and Disorders" for a description of gene therapy treatment of genetic diseases.

One such disorder is familial hypercholesterolemia is a disease characterized clinically by a lifelong elevation of low density lipoprotein (LDL), the major cholesterol-transport lipoprotein in human plasma; Pathologically by the deposition of LDL-derived
20 cholesterol in tendons, skin and arteries leading to premature coronary heart disease; and genetically by autosomal dominant inherited trait. Hetrozygotes number about 1 in 500 persons worldwide. Their cells are able to bind cholesterol at about half the rate of normal cells. Their plasma cholesterol levels show two fold elevation starting at birth. Homozygotes number 1 in 1 million persons. They have severe cholesterolemia with
25 death occurring usually before age 20. The disease (Arteriosclerosis) depends on geography. It affects 15.5 per 100,000 individuals in the U.S. (20,000 total) and 3.3 per 100,000 individuals in Japan. Gene delivery vehicles expressing the LDL receptor for treatment of disorders manifesting with elevated serum LDL can be constructed by techniques known to those of skill in the art. An example of a retroviral vector expressing
30 LDS receptor is shown in example 32 herein. Other retroviral vectors such as those

described herein can readily be constructed using PCR amplification and restriction enzyme treatment methods similar to those described in Example 31.

Similarly, retroviral vectors expressing alpha-1 antitrypsin for treatment of alpha-1 antitrypsin deficiency can be constructed by variations of the procedure demonstrated in Example 32, herein.

6. Gene delivery vehicles expressing other therapeutic proteins:

There are a variety of other proteins of therapeutic interest that can be expressed *in vivo* by retroviral vectors using the methods of the invention. For instance sustained *in vivo* expression of tissue factor inhibitory protein (TFPI) is useful for treatment of conditions including sepsis and DIC and in preventing reperfusion injury. (See PCT Patent Publications Nos. WO 93/24143, WO 93/25230 and WO 96/06637. Nucleic acid sequences encoding various forms of TFPI can be obtained, for example, as described in US Patent Nos. 4,966,852; 5,106,833; and 5,466,783, and can be incorporated in retroviral vectors as is described herein.

Other proteins of therapeutic interest such as erythropoietin (EPO) and leptin can also be expressed *in vivo* by retroviral vectors according to the methods of the invention. For instance EPO is useful in gene therapy treatment of a variety of disorders including anemia (see PCT publication number WO 95/13376 entitled "Gene Therapy for Treatment of Anemia".) Sustained gene therapy delivery of leptin by the methods of the invention is useful in treatment of obesity. (See WO 96/05309 entitled "Obesity Polypeptides able to modulate body weight" for a description of the leptin gene and its use in the treatment of obesity. Retroviral vector expressing EPO or leptin can readily be produced using the methods described herein and the constructs described in these two patent publications.

A variety of other disorders can also be treated by the methods of the invention. For example, sustained *in vivo* systemic production of apolipoprotein E or apolipoprotein A by the retroviral vectors of the invention can be used for treatment of hyperlipidemia. (See Breslow, J. et al. Biotechnology 12, 365 (1994).) In addition, sustained production of angiotensin receptor inhibitor (T.L. Goodfriend, et al., 1996, *N. Engl. J. Med.* 334:1469) can be effected by the gene therapy methods described herein. As yet an additional example, the long term *in vivo* systemic production of angiotensin by the recombinant retroviruses of

the invention is useful in the treatment of a variety of tumors. (See O'Reilly *et al.*, 1996, *Nature Med.* 2:689.

Sequences which encode the above-described nucleic acid molecules may be obtained from a variety of sources. For example, plasmids which contain sequences that
5 encode altered cellular products may be obtained from a depository such as the American Type Culture Collection (ATCC, Rockville, Maryland), or from commercial sources such as Advanced Biotechnologies (Columbia, Maryland). Plasmids containing cytokine genes or immunodulatory genes can be digested with appropriate restriction enzymes, and DNA
10 fragments containing the particular gene of interest can be inserted into the gene delivery vector using standard molecular biology techniques. (See Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, Vols. 1-3, Cold Spring Harbor Laboratory (1989) or Ausbel, et al. ed. *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (1987).

Alternatively, cDNA sequences for use with the present invention may be obtained
15 from cells which express or contain the sequences. Briefly, within one embodiment mRNA from a cell which expresses the gene of interest is reverse transcribed with reverse transcriptase using oligo dT or random primers. The single-stranded cDNA may then be amplified by PCR (see U.S. Patent Nos. 4,683,202, 4,683,195 and 4,800,159. See also *PCR Technology: Principles and Applications for DNA Amplification*, Erlich (ed.),
20 Stockton Press, 1989) utilizing oligonucleotide primers complementary to sequences on either side of desired sequences. In particular, a double-stranded DNA is denatured by heating in the presence of heat stable Taq polymerase, sequence-specific DNA primers, ATP, CTP, GTP and TTP. Double-stranded DNA is produced when synthesis is
25 complete. This cycle may be repeated many times, resulting in a factorial amplification of the desired DNA.

Nucleic acid molecules which are carried and/or expressed by the recombinant retroviruses described herein may also be synthesized, for example, on an Applied Biosystems Inc. DNA synthesizer (e.g., APB DNA synthesizer model 392 (Foster City, California).

30 7. Recombinant retroviruses of expressing therapeutic genes:

A wide variety of nucleic acid molecules may be carried and/or expressed by the recombinant retroviruses of the present invention. Generally, the nucleic acid molecules which are described herein do not occur naturally in the recombinant retrovirus that carries it, and provides some desirable benefit, typically an ability to fight a disease, or other pathogenic agent or condition. As used herein, "pathogenic agent" refers to a cell that is responsible for a disease state. Representative examples of pathogenic agents include tumor cells, autoreactive immune cells, hormone secreting cells, cells which lack a function that they would normally have, cells that have an additional inappropriate gene expression which does not normally occur in that cell type, and cells infected with bacteria, viruses, or other intracellular parasites. In addition, as used herein "pathogenic agent" may also refer to a cell that over-expresses or inappropriately expresses a recombinant retrovirus (*e.g.*, in the wrong cell type), or that has become tumorigenic due to inappropriate insertion into a host cell's genome.

Examples of nucleic acid molecules which may be carried and/or expressed by the recombinant retroviruses of the present invention include genes and other nucleic acid molecules which encode a substance, as well as biologically active nucleic acid molecules such as inactivating sequences that incorporate into a specified intracellular nucleic acid molecule and inactivate that molecule. A nucleic acid molecule is considered to be biologically active when the molecule itself provides the desired benefit without requiring the expression of a substance. For example, the biologically active nucleic acid molecule may be an inactivating sequence that incorporates into a specified intracellular nucleic acid molecule and inactivates that molecule, or the molecule may be a tRNA, rRNA or mRNA that has a configuration that provides a binding capability.

Substances which may be encoded by the nucleic acid molecules described herein include proteins (*e.g.*, antibodies including single chain molecules), immunostimulatory molecules (such as antigens) immunosuppressive molecules, blocking agents, palliatives (such as toxins, antisense ribonucleic acids, ribozymes, enzymes, and other material capable of inhibiting a function of a pathogenic agent) cytokines, various polypeptides or peptide hormones, their agonists or antagonists, where these hormones can be derived from tissues such as the pituitary, hypothalamus, kidney, endothelial cells, liver, pancreas, bone, hemopoetic marrow, and adrenal. Such polypeptides can be used for induction of

growth, regression of tissue, suppression of immune responses, apoptosis, gene expression, blocking receptor-ligand interaction, immune responses and can be treatment for certain anemias, diabetes, infections, high blood pressure, abnormal blood chemistry or chemistries (*e.g.*, elevated blood cholesterol, deficiency of blood clotting factors, elevated LDL with lowered HDL), levels of Alzheimer associated amyloid protein, bone erosion/calcium deposition, and controlling levels of various metabolites such as steroid hormones, purines, and pyrimidines.

For palliatives, when "capable of inhibiting a function" is utilized within the context of the present invention, it should be understood that the palliative either directly inhibits the function or indirectly does so, for example, by converting an agent present in the cells from one which would not normally inhibit a function of the pathogenic agent to one which does. Examples of such functions for viral diseases include adsorption, replication, gene expression, assembly, and exit of the virus from infected cells. Examples of such functions for cancerous diseases include cell replication, susceptibility to external signals (*e.g.*, contact inhibition), and lack of production of anti-oncogene proteins. Examples of such functions for cardiovascular disease include inappropriate growth or accumulation of material in blood vessels, high blood pressure, undesirable blood levels of factors such as cholesterol or low density lipoprotein that predispose to disease, localized hypoxia, and inappropriately high and tissue-damaging levels of free radicals. Examples of such functions for neurological conditions include pain, lack of dopamine production, inability to replace damaged cells, deficiencies in motor control of physical activity, inappropriately low levels of various peptide hormones derived from neurological tissue such as the pituitary or hypothalamus, accumulation of Alzheimer's Disease associated amyloid plaque protein, and inability to regenerate damaged nerve junctions. Examples of such functions for autoimmune or inflammatory disease include inappropriate production of cytokines and lymphokines, inappropriate production and existence of autoimmune antibodies and cellular immune responses, inappropriate disruption of tissues by proteases and collagenases, inhibition of the normal action of proteases, lack of production of factors normally supplied by destroyed cells, and excessive or aberrant regrowth of tissues under autoimmune attack.

Within one aspect of the present invention, methods are provided for administration of a recombinant retrovirus which directs the expression of a palliative. Within various embodiments, the palliative may be a DNA molecule, an RNA molecule, or some combination of the two.

5 Representative examples of palliatives that act directly to inhibit the growth of cells include toxins such as ricin (Lamb *et al.*, 1985, *Eur. J. Biochem.* 148:265-270), abrin (Wood *et al.*, 1991, *Eur. J. Biochem.* 198:723-732; Evensen *et al.*, 1991, *J. of Biol. Chem.* 266:6848-6852; Collins *et al.*, 1990, *J. of Biol. Chem.* 265:8665-8669; Chen *et al.*, 1992, *Fed. of Eur. Biochem Soc.* 309:115-118), diphtheria toxin (Tweten *et al.*, 1985, *J. Biol.*
10 *Chem.* 260:10392-10394), cholera toxin (Mekalanos *et al.*, 1983, *Nature* 306:551-557; Sanchez and Holmgren, 1989, *PNAS* 86:481-485), gelonin (Stirpe *et al.*, 1980, *J. Biol. Chem.* 255:6947-6953), pokeweed (Irvin, 1983, *Pharmac. Ther.* 21:371-387), antiviral protein (Barbieri *et al.*, 1982, *Biochem. J.* 203:55-59; Irvin *et al.*, 1980, *Arch. Biochem. & Biophys.* 200:418-425; Irvin, 1975, *Arch. Biochem. & Biophys.* 169:522-528), tritin,
15 *Shigella* toxin (Calderwood *et al.*, 1987, *PNAS* 84:4364-4368; Jackson *et al.*, 1987, *Microb. Path.* 2:147-153), and *Pseudomonas* exotoxin A (Carroll and Collier, 1987, *J. Biol. Chem.* 262:8707-8711). A detailed description of recombinant retroviruses which express Russell's Viper Venom is provided in PCT Patent Publication No. WO 96/21416.

 Within other aspects of the invention, the recombinant retrovirus carries a gene
20 specifying a product which is not in itself toxic, but when processed or modified by a protein, such as a protease specific to a viral or other pathogen, is converted into a toxic form. For example, the recombinant retrovirus could carry a gene encoding a proprotein chain which becomes toxic upon processing by the HIV protease. More specifically, a synthetic inactive proprotein form of the toxic ricin or diphtheria A chains could be
25 cleaved to the active form by arranging for the HIV virally encoded protease to recognize and cleave at an appropriate "pro" element.

 Within yet another aspect of the invention, the recombinant retrovirus directs the expression of a substance capable of activating an otherwise inactive precursor into an active inhibitor of a pathogenic agent, or a conditional toxic palliative, which are
30 palliatives that are toxic for the cell expressing the pathogenic condition. As should be evident given the disclosure provided herein, a wide variety of inactive precursors may be

converted into active inhibitors of a pathogenic agent. For example, antiviral nucleoside analogues such as AZT or ddI are metabolized by cellular mechanisms to the nucleotide triphosphate form in order to specifically inhibit retroviral reverse transcriptase, and thus viral replication (Furman *et al.*, 1986, *Proc. Natl. Acad. Sci. USA* 83:8333-8337).

5 Recombinant retroviruses which direct the expression of a gene product (*e.g.*, a protein) such as Herpes Simplex Virus Thymidine Kinase (HSVTK) or Varicella Zoster Virus Thymidine Kinase (VZVTK) which assists in metabolizing antiviral nucleoside analogues to their active form are therefore useful in activating nucleoside analogue precursors (*e.g.*, AZT or ddC) into their active form. AZT or ddI therapy will thereby be more effective,
10 allowing lower doses, less generalized toxicity, and higher potency against productive infection. Additional nucleoside analogues whose nucleotide triphosphate forms show selectivity for retroviral reverse transcriptase but, as a result of the substrate specificity of cellular nucleoside and nucleotide kinases are not phosphorylated, will be made more efficacious.

15 Within one embodiment of the invention, the HSVTK gene may be expressed under the control of a constitutive macrophage or T-cell-specific promoter, and introduced into macrophage or T-cells. Constitutive expression of HSVTK results in more effective metabolism of nucleotide analogues such as AZT or ddI to their biologically active nucleotide triphosphate form, and thereby provides greater efficacy, delivery of lower
20 doses, less generalized toxicity, and higher potency against productive infection. Additional nucleoside analogues whose nucleotide triphosphate forms show selectivity for retroviral reverse transcriptase but, as a result of the substrate specificity of cellular nucleoside and nucleotide kinases are not phosphorylated, may also be utilized within the context of the present invention.

25 Within a related aspect of the present invention, recombinant retroviruses are provided which direct the expression of a substance that activates another compound with little or no cytotoxicity into a toxic product in the presence of a pathogenic agent, thereby effecting localized therapy to the pathogenic agent. In this case, expression of the gene product from the recombinant retrovirus is limited to situations wherein an entity
30 associated with the pathogenic agent, such as an intracellular signal identifying the pathogenic state, is present, thereby avoiding destruction of nonpathogenic cells. This

cell-type specificity may also be conferred at the level of infection, by targeting the recombinant retrovirus to cells having or being susceptible to the pathogenic condition.

Within a related aspect of the present invention, recombinant retroviruses are provided which direct the expression of a gene product(s) that activates a compound with little or no cytotoxicity into a toxic product. Briefly, a wide variety of gene products which either directly or indirectly activate a compound with little or no cytotoxicity into a toxic product may be utilized within the context of the present invention. Representative examples of such gene products include HSVTK and VZVTk which selectively monophosphorylate certain purine arabinosides and substituted pyrimidine compounds, converting them to cytotoxic or cytostatic metabolites. More specifically, exposure of the drugs ganciclovir, acyclovir, or any of their analogues (*e.g.*, FIAC, DHPG) to HSVTK, phosphorylates the drug into its corresponding active nucleotide triphosphate form.

For example, within one embodiment of the invention, the recombinant retrovirus directs the expression of the herpes simplex virus thymidine kinase ("HSVTK") gene downstream, and under the transcriptional control of an HIV promoter (which is known to be transcriptionally silent except when activated by HIV tat protein). Briefly, expression of the tat gene product in human cells infected with HIV and carrying the recombinant retrovirus causes increased production of HSVTK. The cells (either *in vitro* or *in vivo*) are then exposed to a drug such as ganciclovir, acyclovir or its analogues (FIAC, DHPG). As noted above, these drugs are known to be phosphorylated by HSVTK (but not by cellular thymidine kinase) to their corresponding active nucleotide triphosphate forms. Acyclovir triphosphates inhibit cellular polymerases in general, leading to the specific destruction of cells expressing HSVTK in transgenic mice (see Borrelli *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:7572). Those cells containing the recombinant retrovirus and expressing HIV tat protein are selectively killed by the presence of a specific dose of these drugs.

Within one embodiment of the invention, expression of a conditionally lethal HSVTK gene may be made even more HIV-specific by including cis-acting elements in the transcript ("CRS/CAR"), which require an additional HIV gene product, rev, for optimal activity (Rosen *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:2071). More generally, cis elements present in mRNAs have been shown in some cases to regulate mRNA stability or translatability. Sequences of this type (*i.e.*, post-transcriptional regulation of

gene expression) may be used for event- or tissue-specific regulation of vector gene expression. In addition, multimerization of these sequences (*i.e.*, rev-responsive "CRS/CAR" or tat-responsive "TAR" elements for HIV) may be utilized in order to generate even greater specificity.

5 In a manner similar to the preceding embodiment, recombinant retroviruses may be generated which carry a gene for phosphorylation, phosphoribosylation, ribosylation, or other metabolism of a purine- or pyrimidine-based drug. Such genes may have no equivalent in mammalian cells, and might come from organisms such as a virus, bacterium, fungus, or protozoan. Representative examples include: *E. coli* guanine
10 phosphoribosyl transferase ("gpt") gene product, which converts thioxanthine into thioxanthine monophosphate (see Besnard *et al.*, 1987, *Mol. Cell. Biol.* 7:4139-4141); alkaline phosphatase, which will convert inactive phosphorylated compounds such as mitomycin phosphate and doxorubicin-phosphate to toxic dephosphorylated compounds; fungal (*e.g.*, *Fusarium oxysporum*) or bacterial cytosine deaminase which will convert 5-
15 fluorocytosine to the toxic compound 5-fluorouracil (Mullen, 1992, *PNAS* 89:33); carboxypeptidase G2 which will cleave the glutamic acid from para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid, thereby creating a toxic benzoic acid mustard; and Penicillin-V amidase, which will convert phenoxyacetamide derivatives of doxorubicin and melphalan to toxic compounds. Conditionally lethal gene products of this type have
20 application to many presently known purine- or pyrimidine-based anticancer drugs, which often require intracellular ribosylation or phosphorylation in order to become effective cytotoxic agents. The conditionally lethal gene product could also metabolize a nontoxic drug, which is not a purine or pyrimidine analogue, to a cytotoxic form (see Searle *et al.*, 1986, *Br. J. Cancer* 53:377-384).

25 Additionally, in the instance where the target pathogen is a mammalian virus, recombinant retroviruses vectors may be constructed to take advantage of the fact that mammalian viruses in general tend to have "immediate early" genes, which are necessary for subsequent transcriptional activation of other viral promoter elements. Gene products of this nature are excellent candidates for intracellular signals (or "identifying agents") of
30 viral infection. Thus, conditionally lethal genes transcribed from transcriptional promoter elements that are responsive to such viral "immediate early" gene products could

specifically kill cells infected with any particular virus. Additionally, since the human α and β interferon promoter elements are transcriptionally activated in response to infection by a wide variety of nonrelated viruses, the introduction of vectors expressing a conditionally lethal gene product like HSVTK, for example, from these viral-responsive elements (VREs) could result in the destruction of cells infected with a variety of different viruses.

In another embodiment of the invention, recombinant retroviruses are provided that produce substances such as inhibitor palliatives, that inhibit viral assembly. In this context, the recombinant retrovirus codes for defective *gag*, *pol*, *env* or other viral particle proteins or peptides which inhibit in a dominant fashion the assembly of viral particles. Such inhibition occurs because the interaction of normal subunits of the viral particle is disturbed by interaction with the defective subunits.

One way of increasing the effectiveness of inhibitory palliatives is to express inhibitory genes, such as viral inhibitory genes, in conjunction with the expression of genes which increase the probability of infection of the resistant cell by the virus in question. The result is a nonproductive "dead-end" event which would compete for productive infection events. In the specific case of HIV, a recombinant retrovirus may be administered that inhibits HIV replication (by expressing anti-sense tat, etc., as described above) and also overexpress proteins required for infection, such as CD4. In this way, a relatively small number of vector-infected HIV-resistant cells act as a "sink" or "magnet" for multiple nonproductive fusion events with free virus or virally infected cells.

In another embodiment of the invention, recombinant retroviruses are provided for the expression substances such as inhibiting peptides or proteins specific for viral protease. Viral protease cleaves the viral *gag* and *gag/pol* proteins into a number of smaller peptides. Failure of this cleavage in all cases leads to complete inhibition of production of infectious retroviral particles. The HIV protease is known to be an aspartyl protease, and these are known to be inhibited by peptides made from amino acids from protein or analogues. Recombinant retroviruses that inhibit HIV will express one or multiple fused copies of such peptide inhibitors.

Administration of the recombinant retroviruses discussed above should be effective against many virally linked diseases, cancers, or other pathogenic agents.

Within still other embodiments of the invention, recombinant retroviruses are provided that express a palliative, wherein the palliative has a membrane anchor and acts as an anti-tumor agent(s). Such a palliative may be constructed, for example, as an anti-tumor agent - membrane anchor fusion protein. Briefly, the membrane anchor aspect of the fusion protein may be selected from a variety of sequences, including, for example, the transmembrane domain of well known molecules. Generally, membrane anchor sequences are regions of a protein that bind the protein to a membrane. Customarily, there are two types of anchor sequences that attach a protein to the outer surface of a cell membrane: (1) transmembrane regions that span the lipid bilayer of the cell membrane, and interact with the hydrophobic center region (proteins containing such regions are referred to integral membrane proteins), and (2) domains which interact with an integral membrane protein or with the polar surface of the membrane (such proteins are referred to as peripheral, or extrinsic, proteins).

Membrane anchors for use within the present invention may contain transmembrane domains which span the membrane one or more times. For example, in glycophorin and guanylyl cyclase, the membrane binding region spans the membrane once, whereas the transmembrane domain of rhodopsin spans the membrane seven times, and that of the photosynthetic reaction center of *Rhodospseudomonas viridis* spans the membrane eleven times (see Ross *et al.*, 1982, *J. Biol. Chem.* 257:4152; Garbers, 1991, *Pharmac. Ther.* 50:337-345; Engelman *et al.*, 1980, *Proc. Natl. Acad. Sci. USA* 77:2023; Heijne and Manoil, 1990, *Prot. Eng.* 4:109-112). Membrane anchors for use in the present invention can also include, for example, phosphoinositol anchors. Regardless of the number of times the protein crosses the membrane, the membrane spanning regions typically have a similar structure. More specifically, the 20 to 25 amino-acid residue portion of the domain that is located inside the membrane generally consists almost entirely of hydrophobic residues (see Eisenberg *et al.*, 1984, *Ann. Rev. Biochem.* 53:595-623). For example, 28 of the 34 residues in the membrane spanning region of glycophorin are hydrophobic (see Ross *et al.*, *supra*; Tomita *et al.*, 1978, *Biochemistry* 17:4756-4770). In addition, although structures such as beta sheets and barrels do occur, the membrane spanning regions typically have an alpha helical structure, as determined by X-ray diffraction, crystallography and cross-linking studies (see Eisenberg *et al.*, *supra*; Heijne

and Manoil, *supra*). The location of these transmembrane helices within a given sequence can often be predicted based on hydrophobicity plots. Stryer *et al.*, *Biochemistry*, 3rd. ed. 304, 1988. Particularly preferred membrane anchors for use within the present invention include naturally occurring cellular proteins (that are non-immunogenic) which have been demonstrated to function as membrane signal anchors (such as glycophorin).

Within a preferred embodiment of the present invention, a DNA sequence is provided which encodes a membrane anchor - gamma interferon fusion protein. Within one embodiment, this fusion protein may be constructed by genetically fusing the sequence which encodes the membrane anchor of the gamma-chain of the Fc receptor, to a sequence which encodes gamma-interferon.

In yet another aspect, recombinant retroviruses are provided which have a therapeutic effect by encoding one or more ribozymes (RNA enzymes) (Haseloff and Gerlach, 1989, *Nature* 334:585) which will cleave, and hence inactivate, RNA molecules corresponding to a pathogenic function. Since ribozymes function by recognizing a specific sequence in the target RNA and this sequence is normally 12 to 17 bp, this allows specific recognition of a particular RNA sequence corresponding to a pathogenic state, such as HIV tat, and toxicity is specific to such pathogenic state. Additional specificity may be achieved in some cases by making this a conditional toxic palliative, as discussed above.

In still another aspect, recombinant retroviruses are provided comprising a biologically active nucleic acid molecule that is an antisense sequence (an antisense sequence may also be encoded by a nucleic acid sequence and then produced within a host cell via transcription). In preferred embodiments, the antisense sequence is selected from the group consisting of sequences which encode influenza virus, HIV, HSV, HPV, CMV, and HBV. The antisense sequence may also be an antisense RNA complementary to RNA sequences necessary for pathogenicity. Alternatively, the biologically active nucleic acid molecule may be a sense RNA (or DNA) complementary to RNA sequences necessary for pathogenicity.

More particularly, the biologically active nucleic acid molecule may be an antisense sequence. Briefly, antisense sequences are designed to bind to RNA transcripts, and thereby prevent cellular synthesis of a particular protein, or prevent use of that RNA

sequence by the cell. Representative examples of such sequences include antisense thymidine kinase, antisense dihydrofolate reductase (Maher and Dolnick, 1987, *Arch. Biochem. & Biophys.* 253:214-220; Bzik *et al.*, 1987, *PNAS* 84:8360-8364), antisense HER2 (Coussens *et al.*, 1985, *Science* 230:1132-1139), antisense ABL (Fainstein *et al.*, 1989, *Oncogene* 4:1477-1481), antisense Myc (Stanton *et al.*, 1984, *Nature* 310:423-425) and antisense *ras*, as well as antisense sequences which block any of the enzymes in the nucleotide biosynthetic pathway.

In addition, within a further embodiment of the invention antisense RNA may be utilized as an anti-tumor agent in order to induce a potent Class I restricted response.

Briefly, in addition to binding RNA and thereby preventing translation of a specific mRNA, high levels of specific antisense sequences are believed to induce the increased expression of interferons (including gamma-interferon), due to the formation of large quantities of double-stranded RNA. The increased expression of gamma interferon, in turn, boosts the expression of MHC Class I antigens. Preferred antisense sequences for use in this regard include actin RNA, myosin RNA, and histone RNA. Antisense RNA which forms a mismatch with actin RNA is particularly preferred.

In another embodiment, the substances of the invention include a surface protein that is itself therapeutically beneficial. For example, in the particular case of HIV, expression of the human CD4 protein specifically in HIV-infected cells may be beneficial in two ways:

1. Binding of CD4 to HIV env intracellularly could inhibit the formation of viable viral particles much as soluble CD4 has been shown to do for free virus, but without the problem of systematic clearance and possible immunogenicity, since the protein will remain membrane bound and is structurally identical to endogenous CD4 (to which the patient should be immunologically tolerant).

2. Since the CD4/HIV env complex has been implicated as a cause of cell death, additional expression of CD4 (in the presence of excess HIV-env present in HIV-infected cells) leads to more rapid cell death and thus inhibits viral dissemination. This may be particularly applicable to monocytes and macrophages, which act as a reservoir for virus production as

a result of their relative refractility to HIV-induced cytotoxicity (which, in turn, is apparently due to the relative lack of CD4 on their cell surfaces).

Still further aspects of the present invention relate to recombinant retroviruses capable of immunostimulation. Briefly, the ability to recognize and defend against foreign pathogens is essential to the function of the immune system. In particular, the immune system must be capable of distinguishing "self" from "nonself" (*i.e.*, foreign), so that the defensive mechanisms of the host are directed toward invading entities instead of against host tissues. Cytolytic T lymphocytes (CTLs) are typically induced, or stimulated, by the display of a cell surface recognition structure, such as a processed, pathogen-specific peptide, in conjunction with a MHC class I or class II cell surface protein.

Diseases suitable to treatment include viral infections such as influenza virus, respiratory syncytial virus, HPV, HBV, HCV, EBV, HIV, HSV, FeLV, FIV, Hantavirus, HTLV I, HTLV II and CMV, cancers such as melanomas, renal carcinoma, breast cancer, ovarian cancer and other cancers, and heart disease.

In one embodiment, the invention provides methods for stimulating a specific immune response and inhibiting viral spread by using recombinant retroviruses that direct the expression of an antigen or modified form thereof in susceptible target cells, wherein the antigen is capable of either (1) initiating an immune response to the viral antigen or (2) preventing the viral spread by occupying cellular receptors required for viral interactions. Expression of the protein may be transient or stable with time. Where an immune response is to be stimulated to a pathogenic antigen, the recombinant retrovirus is preferably designed to express a modified form of the antigen which will stimulate an immune response and which has reduced pathogenicity relative to the native antigen. This immune response is achieved when cells present antigens in the correct manner, *i.e.*, in the context of the MHC class I and/or II molecules along with accessory molecules such as CD3, ICAM-1, ICAM-2, LFA-1, or analogs thereof (*e.g.*, Altmann *et al.*, 1989, *Nature* 338:512).

An immune response can also be achieved by transferring to an appropriate immune cell (such as a T lymphocyte) (a) the gene for the specific T-cell receptor that recognizes the antigen of interest (in the context of an appropriate MHC molecule if necessary), (b) the gene for an immunoglobulin which recognizes the antigen of interest,

or (c) the gene for a hybrid of the two which provides a CTL response in the absence of the MHC context. Thus, recombinant retroviruses may also be used as an immunostimulant, immunomodulator, or vaccine, etc.

In the particular case of disease caused by HIV infection, where
5 immunostimulation is desired, the antigen generated from a recombinant retrovirus may be in a form which will elicit either or both an HLA class I- or class II-restricted immune response. In the case of HIV envelope antigen, for example, the antigen is preferably selected from gp 160, gp 120, and gp 41, which have been modified to reduce their pathogenicity. In particular, the selected antigen is modified to reduce the possibility of
10 syncytia, to avoid expression of epitopes leading to a disease enhancing immune response, to remove immunodominant, but haplotype-specific epitopes or to present several haplotype-specific epitopes, and allow a response capable of eliminating cells infected with most or all strains of HIV. The haplotype-specific epitopes can be further selected to promote the stimulation of an immune response within an animal which is cross-reactive
15 against other strains of HIV. Antigens from other HIV genes or combinations of genes, such as gag, pol, rev, vif, nef, prot, gag/pol, gag prot, etc., may also provide protection in particular cases.

HIV is only one example. This approach should be effective against many virally linked diseases or cancers where a characteristic antigen (which does not need to be a
20 membrane protein) is expressed, such as in HPV and cervical carcinoma, HTLV-I-induced leukemias, prostate-specific antigen (PSA) and prostate cancer, mutated p53 and colon carcinoma and melanoma, melanoma specific antigens (MAGEs), and melanoma, mucin and breast cancer.

In accordance with the immunostimulation aspects of the invention, substances
25 which are carried and/or expressed by the recombinant retroviruses of the present invention may also include "immunomodulatory factors," many of which are set forth above. Immunomodulatory factors refer to factors that, when manufactured by one or more of the cells involved in an immune response, or, which when added exogenously to the cells, causes the immune response to be different in quality or potency from that which
30 would have occurred in the absence of the factor. The factor may also be expressed from a non-recombinant retrovirus derived gene, but the expression is driven or controlled by the

recombinant retrovirus. The quality or potency of a response may be measured by a variety of assays known to one of skill in the art including, for example, *in vitro* assays which measure cellular proliferation (e.g., ^3H thymidine uptake), and *in vitro* cytotoxic assays (e.g., which measure ^{51}Cr release) (see, Warner *et al.*, 1991, *AIDS Res. and Human Retroviruses* 7:645-655). Immunomodulatory factors may be active both *in vivo* and *ex vivo*.

Representative examples of such factors include cytokines, such as IL-1, IL-2 (Karupiah *et al.*, 1990, *J. Immunology* 144:290-298; Weber *et al.*, 1987, *J. Exp. Med.* 166:1716-1733; Gansbacher *et al.*, 1990, *J. Exp. Med.* 172:1217-1224; U.S. Patent No. 4,738,927), IL-3, IL-4 (Tepper *et al.*, *Cell* 57:503-512, 1989; Golumbek *et al.*, 1991, *Science* 254:713-716; U.S. Patent No. 5,017,691), IL-5, IL-6 (Brakenhof *et al.*, 1987, *J. Immunol.* 139:4116-4121; WO 90/06370), IL-7 (U.S. Patent No. 4,965,195), IL-8, IL-9, IL-10, IL-11, IL-12, IL-13 (*Cytokine Bulletin*, Summer 1994), IL-14 and IL-15, particularly IL-2, IL-4, IL-6, IL-12, and IL-13, alpha interferon (Finter *et al.*, 1991, *Drugs* 42(5):749-765; U.S. Patent No. 4,892,743; U.S. Patent No. 4,966,843; WO 85/02862; Nagata *et al.*, *Nature* 284:316-320, 1980; Familletti *et al.*, 1981, *Methods in Enz.* 78:387-394; Twu *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:2046-2050, 1989; Faktor *et al.*, 1990, *Oncogene* 5:867-872), beta interferon (Seif *et al.*, 1991, *J. Virol.* 65:664-671), gamma interferons (Radford *et al.*, *The American Society of Hepatology* 20082015, 1991; Watanabe *et al.*, 1989, *PNAS* 86:9456-9460; Gansbacher *et al.*, 1990, *Cancer Research* 50:7820-7825; Maio *et al.*, 1989, *Can. Immunol. Immunother.* 30:34-42; U.S. Patent No. 4,762,791; U.S. Patent No. 4,727,138), G-CSF (U.S. Patent Nos. 4,999,291 and 4,810,643), GM-CSF (WO 85/04188), tumor necrosis factors (TNFs) (Jayaraman *et al.*, *J. Immunology* 144:942-951, 1990), CD3 (Krissanen *et al.*, 1987, *Immunogenetics* 26:258-266), ICAM-1 (Altman *et al.*, 1989, *Nature* 338:512-514; Simmons *et al.*, 1988, *Nature* 331:624-627), ICAM-2, LFA-1, LFA-3 (Wallner *et al.*, 1987, *J. Exp. Med.* 166(4):923-932), MHC class I molecules, MHC class II molecules, B7.1-3, β_2 -microglobulin (Parnes *et al.*, *PNAS* 78:2253-2257, 1981), chaperones such as calnexin, MHC linked transporter proteins or analogs thereof (Powis *et al.*, *Nature* 354:528-531, 1991). Within one preferred embodiment, the gene encodes gamma-interferon. Immunomodulatory factors may also be agonists, antagonists, or ligands for these molecules. For example soluble

forms of receptors can often behave as antagonists for these types of factors, as can mutated forms of the factors themselves.

An example of an immunomodulatory factor cited above is a member of the B7 family of molecules (e.g., B7.1-.3 costimulatory factor). Briefly, activation of the full functional activity of T cells requires two signals. One signal is provided by interaction of the antigen-specific T cell receptor with peptides which are bound to major histocompatibility complex (MHC) molecules, and the second signal, referred to as costimulation, is delivered to the T cell by antigen presenting cells. The second signal is required for interleukin-2 (IL-2) production by T cells, and appears to involve interaction of the B7.1-.3 molecule on antigen-presenting cells with CD28 and CTLA-4 receptors on T lymphocytes (Linsley et al., *J. Exp. Med.*, 173:721-730, 1991a and *J. Exp. Med.*, 174:561-570, 1991). Within one embodiment of the invention, B7.1-.3 may be introduced into tumor cells in order to cause costimulation of CD8⁺ T cells, such that the CD8⁺ T cells produce enough IL-2 to expand and become fully activated. These CD8⁺ T cells can kill tumor cells that are not expressing B7 because costimulation is no longer required for further CTL function. Vectors that express both the costimulatory B7.1-.3 factor, and, for example, an immunogenic HBV core protein, may be made utilizing methods which are described herein. Cells transduced with these vectors will become more effective antigen presenting cells. The HBV core-specific CTL response will be augmented from the fully activated CD8⁺ T cell via the costimulatory ligand B7.1-.3.

The choice of which immunomodulatory factor to include within a recombinant retrovirus may be based upon known therapeutic effects of the factor, or, experimentally determined. For example, a known therapeutic effector in chronic hepatitis B infections is alpha interferon. This has been found to be efficacious in compensating a patient's immunological deficit, and thereby assisting recovery from the disease. Alternatively, a suitable immunomodulatory factor may be experimentally determined. Briefly, blood samples are first taken from patients with a hepatic disease. Peripheral blood lymphocytes (PBLs) are restimulated *in vitro* with autologous or HLA matched cells (e.g., EBV transformed cells) that have been transduced with a recombinant retrovirus which directs the expression of an immunogenic portion of a hepatitis antigen and the immunomodulatory factor. These stimulated PBLs are then used as effectors in a CTL

assay with the HLA matched transduced cells as targets. An increase in CTL response over that seen in the same assay performed using HLA matched stimulator and target cells transduced with a vector encoding the antigen alone, indicates a useful immunomodulatory factor. Within one embodiment of the invention, the immunomodulatory factor gamma
5 interferon is particularly preferred.

The present invention also includes recombinant retroviruses which encode immunogenic portions of desired antigens including, for example, viral, bacterial or parasite antigens. For example, various immunogenic portions of the HBV S antigens may be combined in order to present an immune response when administered by one of the
10 recombinant retroviruses described herein. In addition, due to the large immunological variability that is found in different geographic regions for the S antigen open reading frame of HBV, particular combinations of antigens may be preferred for administration in particular geographic regions. Briefly, epitopes that are found in all human hepatitis B virus S samples are defined as determinant "a". Mutually exclusive subtype determinants
15 however have also been identified by two-dimensional double immunodiffusion (Ouchterlony, 1958, *Progr. Allergy* 5:1). These determinants have been designated "d" or "y" and "w" or "r" (LeBouvier, 1971, *J. Infect.* 123:671; Bancroft *et al.*, 1972, *J. Immunol.* 109 842; Courouce *et al.*, 1976, *Bibl. Haematol.* 42:1-158). The immunological variability is due to single nucleotide substitutions in two areas of the hepatitis B virus S
20 antigen open reading frame resulting in the following amino acid changes: (1) exchange of lysine-122 to arginine in the hepatitis B virus S antigen open reading frame causes a subtype shift from d to y, and (2) exchange of arginine-160 to lysine causes the shift from subtype d to w. In black Africa, subtype ayw is predominant, whereas in the U.S. and northern Europe the subtype adw₂ is more abundant (*Molecular Biology of the Hepatitis B Virus*, M. H. Van Man (ed.), CRC Press, 1991). As will be evident to one of ordinary skill in the art, it is generally preferred to construct a vector for administration which is appropriate to the particular hepatitis B virus subtype which is prevalent in the
25 geographical region of administration. Subtypes of a particular region may be determined by two dimensional double immunodiffusion or, preferably, by sequencing the S antigen
30 open reading frame of HBV virus isolated from individuals within that region.

Also presented by HBV are pol ("HBV pol"), ORF 5, and ORF 6 antigens. Briefly, the polymerase open reading frame of HBV encodes reverse transcriptase activity found in virions and core-like particles in infected liver tissue. The polymerase protein consists of at least two domains: the amino terminal domain encodes the protein that
5 primes reverse transcription, and the carboxyl terminal domain which encodes reverse transcriptase and RNase H activity. Immunogenic portions of HBV pol may be administered to a warm-blooded animal by introducing into the animal a recombinant retrovirus which expresses the antigen of interest in order to generate an immune response within the animal. Similarly, other HBV antigens such as ORF 5 and ORF 6, (Miller *et*
10 *al.*, 1989, *Hepatology* 9:322-327), may be expressed utilizing recombinant retroviruses as described herein.

As noted above, at least one immunogenic portion of a hepatitis B antigen can be incorporated into a recombinant retrovirus. The immunogenic portion(s) which are incorporated into the recombinant retrovirus may be of varying length, although it is
15 generally preferred that the portions be at least 9 amino acids long, and may include the entire antigen. Immunogenicity of a particular sequence is often difficult to predict, although T cell epitopes may be predicted utilizing the HLA A2.1 motif described by Falk *et al.*, 1991, *Nature* 351:290. From this analysis, peptides may be synthesized and used as targets in an *in vitro* cytotoxic assay. Other assays, however, may also be utilized,
20 including, for example, ELISA which detects the presence of antibodies against the newly introduced vector, as well as assays which test for T helper cells, such as gamma-interferon assays, IL-2 production assays, and proliferation assays.

Within one embodiment of the present invention, at least one immunogenic portion of a hepatitis C antigen can be incorporated into a recombinant retrovirus. Preferred
25 immunogenic portion(s) of hepatitis C may be found in the C and NS3-NS4 regions since these regions are the most conserved among various types of hepatitis C virus (Houghton *et al.*, 1991, *Hepatology* 14:381-388). Particularly preferred immunogenic portions may be determined by a variety of methods. For example, as noted above for the hepatitis B virus, identification of immunogenic portions of the polypeptide may be predicted based
30 upon amino acid sequence. Briefly, various computer programs which are known to those of ordinary skill in the art may be utilized to predict CTL epitopes. For example, CTL

epitopes for the HLA A2.1 haplotype may be predicted utilizing the HLA A2.1 motif described by Falk et al. (*Nature* 351:290, 1991). From this analysis, peptides are synthesized and used as targets in an *in vitro* cytotoxic assay.

Within another aspect of the present invention, methods are provided for
5 destroying hepatitis B carcinoma cells comprising the step of administering to a warm-blooded animal a recombinant retrovirus which directs the expression of an immunogenic portion of antigen X, such that an immune response is generated. Sequences which encode the HBxAg may readily be obtained by one of skill in the art given the disclosure provided herein. Briefly, within one embodiment of the present invention, a 642 bp Nco I-
10 Taq I is recovered from ATCC 45020, and inserted into recombinant retroviruses as described above for other hepatitis B antigens.

The X antigen, however, is a known transactivator which may function in a manner similar to other potential oncogenes (*e.g.*, E1A). Thus, it is generally preferable to first alter the X antigen such that the gene product is non-tumorigenic before inserting it into
15 recombinant retrovirus. Various methods may be utilized to render the X antigen non-tumorigenic including, for example, by truncation, point mutation, addition of premature stop codons, or phosphorylation site alteration. Within one embodiment, the sequence or gene of interest which encodes the X antigen is truncated. Truncation may produce a variety of fragments, although it is generally preferable to retain greater than or equal to
20 50% of the encoding gene sequence. In addition, it is necessary that any truncation leave intact some of the immunogenic sequences of the gene product. Alternatively, within another embodiment of the invention, multiple translational termination codons may be introduced into the gene. Insertion of termination codons prematurely terminates protein expression, thus preventing expression of the transforming portion of the protein.

25 The X gene or modified versions thereof may be tested for tumorigenicity in a variety of ways. Representative assays include tumor formation in nude mice, colony formation in soft agar, and preparation of transgenic animals, such as transgenic mice.

Within another aspect of the present invention, methods are provided for
30 destroying hepatitis C carcinoma cells comprising the step of administering to a warm-blooded animal a recombinant retrovirus which directs the expression of an immunogenic portion of a hepatitis C antigen. Preferred immunogenic portion(s) of a hepatitis C antigen

may be found in the polypeptide which contains the Core antigen and the NS1-NS5 regions (Choo *et al.*, 1991, *Proc. Natl. Acad. Sci. USA* 88:2451-2455). Particularly preferred immunogenic portions may be determined by a variety of methods. For example, as noted above preferred immunogenic portions may be predicted based upon amino acid sequence. Briefly, various computer programs which are known to those of ordinary skill in the art may be utilized to predict CTL epitopes. For example, CTL epitopes for the HLA A2.1 haplotype may be predicted utilizing the HLA A2.1 motif described by Falk *et al.* (*Nature* 351:290, 1991). Another method that may also be utilized to predict immunogenic portions is to determine which portion has the property of CTL induction in mice utilizing retroviruses (*see*, Warner *et al.*, 1991, *AIDS Res. and Human Retroviruses* 7:645-655). As noted within Warner *et al.*, CTL induction in mice may be utilized to predict cellular immunogenicity in humans. Preferred immunogenic portions may also be deduced by determining which fragments of the polypeptide antigen or peptides are capable of inducing lysis by autologous patient lymphocytes of target cells (e.g., autologous EBV-transformed lymphocytes) expressing the fragments after vector transduction of the corresponding genes.

Preferred immunogenic portions may also be selected in the following manner. Briefly, blood samples from a patient with a target disease, such as HCV, are analyzed with antibodies to individual HCV polypeptide regions (e.g., HCV core, E1, E2/SN1 and NS2-NS3 regions), in order to determine which antigenic fragments are present in the patient's serum. In patients treated with alpha interferon to give temporary remission, some antigenic determinants will disappear and be supplanted by endogenous antibodies to the antigen. Such antigens are useful as immunogenic portions within the context of the present invention (Hayata *et al.*, 1991, *Hepatology* 13:1022-1028; Davis *et al.*, 1989, *N. Engl. J. Med.* 321:1501-1506).

Additional immunogenic portions of a chosen antigen, such as those from the hepatitis C virus, may be obtained by truncating the coding sequence. For example, with HCV the following sites may be truncated: Bst UI, Ssp I, Ppu M1, and Msp I (Valenzuela *et al.*, 1979, *Nature* 280:815-19; Valenzuela *et al.*, *Animal Virus Genetics: ICN 10th Symp. Mol. Cell Biol.*, 1980, B. N. Fields and R. Jaenisch (eds.), pp. 57-70,

New York: Academic). Further methods for determining suitable immunogenic portions as well as methods are also described below in the context of hepatitis C.

With respect to the treatment of HBV, particularly preferred immunogenic portions for incorporation into recombinant retroviruses include HBeAg, HBcAg, and HBsAg.

- 5 Further, more than one immunogenic portion (as well as immunomodulatory factors, if desired) may be incorporated into the recombinant retrovirus. For example, within one embodiment a recombinant retrovirus may be prepared which directs the co-expression of both an immunogenic portion of the hepatitis B antigen, as well as an immunogenic portion of the hepatitis C polypeptide. Such constructs may be administered in order to
- 10 prevent or treat acute and chronic hepatitis infections of either type B or C. Similarly, within other embodiments, a recombinant retrovirus may be prepared which directs the co-expression of both an immunogenic portion of the hepatitis B X antigen, as well as an immunogenic portion of the hepatitis C polypeptide. Such a construct may similarly be administered in order to treat hepatocellular carcinoma that is associated with either
- 15 hepatitis B or C. In addition, because those individuals chronically infected with hepatitis B and C are at higher risk for developing hepatocellular carcinoma, such a vector may also be utilized as a prophylactic treatment for the disease.

- Immunogenic portions may also be selected by other methods. For example, the HLA A2.1/K^b transgenic mouse has been shown to be useful as a model for human T-cell
- 20 recognition of viral antigens. Briefly, in the influenza and hepatitis B viral systems, the murine T-cell receptor repertoire recognizes the same antigenic determinants recognized by human T-cells. In both systems, the CTL response generated in the HLA A2.1/K^b transgenic mouse is directed toward virtually the same epitope as those recognized by human CTLs of the HLA A2.1 haplotype (Vitiello *et al.*, 1991, *J. Exp. Med.* 173:1007-
- 25 1015; Vitiello *et al.*, *Abstract of Molecular Biology of Hepatitis B Virus Symposia*, 1992).

- Immunogenic proteins of the present invention may also be manipulated by a variety of methods known in the art, in order to render them more immunogenic. Representative examples of such methods include: adding amino acid sequences that correspond to T helper epitopes; promoting cellular uptake by adding hydrophobic
- 30 residues; by forming particulate structures; or any combination of these (*see generally*,

Hart, op. cit., Milich *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:1610-1614; Willis, *Nature* 340:323-324, 1989; Griffiths *et al.*, 1991, *J. Virol.* 65:450-456).

The present invention also provides recombinant retroviruses capable of immune down-regulation. Briefly, specific down-regulation of inappropriate or unwanted immune responses, such as in autoimmune or pseudo-autoimmune diseases such as chronic hepatitis, diabetes, rheumatoid arthritis, graft vs. host disease and Alzheimer's, or in transplants of heterologous tissue such as bone marrow, can be engineered using immune-suppressive viral gene products, or active portion thereof, which suppress surface expression of transplantation (MHC) antigen. Within the present invention, an "active portion" of a gene product is that fragment of the gene product which must be retained for biological activity. Such fragments or active domains can be readily identified by systematically removing nucleotide sequences from the protein sequence, transforming target cells with the resulting recombinant retrovirus, and determining MHC class I presentation on the surface of cells using FACS analysis or other immunological assays, such as a CTL assay. These fragments are particularly useful when the size of the sequence encoding the entire protein exceeds the capacity of the viral carrier. Alternatively, the active domain of the MHC antigen presentation inhibitor protein can be enzymatically digested and the active portion purified by biochemical methods. For example, a monoclonal antibody that blocks the active portion of the protein can be used to isolate and purify the active portion of the cleaved protein (Harlow *et al.*, *Antibodies: A Laboratory Manual*, Cold Springs Harbor, 1988).

Within one embodiment, the suppression is effected by specifically inhibiting the activation of display of processed peptides in the context of self MHC molecules along with accessory molecules such as CD8, intercellular adhesion molecule -1 (ICAM-1), ICAM-2, ICAM-3, leukocyte functional antigen-1 (LFA-1) (Altmann *et al.*, 1989, *Nature* 338:521), the B7.1-3 molecule (Freeman *et al.*, 1989, *J. Immunol.* 143:2714), LFA-3 (Singer, 1992, *Science* 255:1671; Rao, 1991, *Crit. Rev. Immunol.* 10:495), or other cell adhesion molecules. Antigenic peptide presentation in association with MHC class I molecules leads to CTL activation. Transfer and stable integration of specific sequences capable of expressing products expected to inhibit MHC antigen presentation block activation of T-cells, such as CD8⁺ CTL, and therefore suppress graft rejection. A

standard CTL assay may be utilized in order to detect this response. Components of the antigen presentation pathway include the 45 Kd MHC class I heavy chain, β_2 -microglobulin, processing enzymes such as proteases, accessory molecules, chaperones such as calnexin (Gaczynska *et al.*, 1993, *Nature*, 365:264-282), and transporter proteins such as PSF1, TAP1 and TAP 2 (Driscoll *et al.*, 1993, *Nature* 365:262-263).

In an alternative example, recombinant retroviruses are provided which direct the expression of a gene product or an active portion of a gene product capable of binding β_2 -microglobulin. Briefly, transport of MHC class I molecules to the cell surface for antigen presentation requires association with β_2 -microglobulin. Thus, proteins that bind β_2 -microglobulin and inhibit its association with MHC class I indirectly inhibit MHC class I antigen presentation. Suitable proteins include the H301 gene product. Briefly, the H301 gene, obtained from the human cytomegalovirus (CMV) encodes a glycoprotein with sequence homology to the β_2 -microglobulin binding site on the heavy chain of the MHC class I molecule (Browne *et al.*, 1990, *Nature* 347:770). H301 binds β_2 -microglobulin, thereby preventing the maturation of MHC class I molecules, and renders transformed cells unrecognizable by cytotoxic T-cells, thus evading MHC class I restricted immune surveillance.

Within another embodiment, recombinant retroviruses are provided which direct the expression of a protein or active portion of a protein that binds to newly synthesized MHC class I molecules intracellularly. This binding prevents migration of the MHC class I molecule from the endoplasmic reticulum, resulting in the inhibition of terminal glycosylation. This blocks transport of these molecules to the cell surface and prevents cell recognition and lysis by CTL. For instance, one of the products of the E3 gene may be used to inhibit transport of MHC class I molecules to the surface of the transformed cell. More specifically, E3 encodes a 19 kD transmembrane glycoprotein, E3/19K, transcribed from the E3 region of the adenovirus 2 genome. Within the context of the present invention, tissue cells are transformed with a recombinant retrovirus containing the E3/19K sequence, which upon expression produces the E3/19K protein. The E3/19K protein inhibits the surface expression of MHC class I surface molecules, and cells transformed by the recombinant retrovirus evade an immune response. Consequently, donor cells can be transplanted with reduced risk of graft rejection and may require only a

minimal immunosuppressive regimen for the transplant patient. This allows an acceptable donor-recipient chimeric state to exist with fewer complications. Similar treatments may be used to treat the range of so-called autoimmune diseases, including systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis or chronic hepatitis B infection.

5 Another alternative method of immunosuppression involves the use of antisense message, ribozyme, or other gene expression inhibitor specific for T-cell clones which are autoreactive in nature. These block the expression of the T-cell receptor of particular unwanted clones responsible for an autoimmune response. The anti-sense, ribozyme, or other gene may be introduced using a viral vector delivery system.

10 Other proteins, not discussed above, that function to inhibit, suppress or down-regulate MHC class I antigen presentation may also be identified and utilized within the context of the present invention. In order to identify such proteins, in particular those derived from mammalian pathogens (and, in turn, active portions thereof), a recombinant retrovirus that expresses a protein or an active portion thereof suspected of being capable
15 of inhibiting MHC class I antigen presentation is transformed into a tester cell line, such as BC. The tester cell lines with and without the sequence encoding the candidate protein are compared to stimulators and/or targets in the CTL assay. A decrease in cell lysis corresponding to the transformed tester cell indicates that the candidate protein is capable of inhibiting MHC presentation.

20 Many infectious diseases, cancers, autoimmune diseases, and other diseases involve the interaction of viral particles with cells, cells with cells, or cells with factors. In viral infections, viruses commonly enter cells via receptors on the surface of susceptible cells. In cancers, cells may respond inappropriately or not at all to signals from other cells or factors. In autoimmune disease, there is inappropriate recognition of "self" markers.
25 Within the present invention, such interactions may be blocked by utilizing recombinant retroviruses that produce, *in vivo*, an analogue to either of the partners in an interaction. Such an analogue is known as a blocking agent.

This blocking action may occur intracellularly, on the cell membrane, or extracellularly. The blocking action of a viral or, in particular, a recombinant retrovirus
30 carrying a gene for a blocking agent, can be mediated either from inside a susceptible cell

or by secreting a version of the blocking protein to locally block the pathogenic interaction.

For example, in the case of HIV, the two agents of interaction are the gp 120/gp 41 envelope protein and the CD4 receptor molecule. Thus, an appropriate blocker would be a recombinant retrovirus expressing either an HIV env analogue that blocks HIV entry without causing pathogenic effects, or a CD4 receptor analogue. The CD4 analogue would be secreted and would function to protect neighboring cells, while the gp 120/gp 41 is secreted or produced only intracellularly so as to protect only the vector-containing cell. It may be advantageous to add human immunoglobulin heavy chains or other components to CD4 in order to enhance stability or complement lysis. Delivery of a recombinant retrovirus encoding such a hybrid-soluble CD4 to a host results in a continuous supply of a stable hybrid molecule.

Vector particles leading to expression of HIV env may also be constructed. It will be evident to one skilled in the art which portions are capable of blocking virus adsorption without overt pathogenic side effects (Willey *et al.*, 1988, *J. Virol.* 62:139; Fisher *et al.*, 1986, *Science* 233:655).

C. Tissue-specific promoters

Although not an absolute requirement for the practice of the invention, in a further embodiment, the gene delivery vehicles of the invention can contain a liver specific promoter to maximize the potential for liver specific expression of the exogenous DNA sequence contained in the vectors. Preferred liver specific promoters include the hepatitis B X-gene promoter and the hepatitis B core protein promoter. These liver specific promoters are preferably employed with their respective enhancers. The enhancer element can be linked at either the 5' or the 3' end of the nucleic acid encoding the therapeutic molecule. The hepatitis B X gene promoter and its enhancer can be obtained from the viral genome as a 332 base pair EcoRV-NcoI DNA fragment employing the methods described in Twu, 1987, *J. Virol.* 61:3448-3453. The hepatitis B core protein promoter can be obtained from the viral genome as a 584 base pair BamHI-BglII DNA fragment employing the methods described in Gerlach, 1992, *Virol* 189:59-66. It may be necessary to remove the negative regulatory sequence in the BamHI-BglII fragment prior to inserting

it. Other liver specific promoters include the AFP (alpha fetal protein) gene promoter and the albumin gene promoter, as disclosed in EP Patent Publication 0 415 731, the -1 antitrypsin gene promoter, as disclosed in Rettenger, 1994, *Proc. Natl. Acad. Sci.* 91:1460-1464, the fibrinogen gene promoter, the APO-A1 (Apolipoprotein A1) gene promoter, and the promoter genes for liver transference enzymes such as, for example, SGOT, SGPT and -glutamyle transferase. See also PCT Patent Publications WO 90/07936 and WO 91/02805 for a description of the use of liver specific promoters in retroviral vectors.

For the retroviral vectors described herein, such as those described in Examples 1 and 27 herein, a liver specific promoter as described in this section can be introduced into the vector to operably linked to gene of interest (for example factor VIII) in order to induce more liver specific expression of the protein. In the case of AAV vectors, the promoter is operably linked to the nucleic acid encoding the therapeutic molecule upstream from the latter and between the AAV vector sequences (for example between the inverted terminal repeats in psub201 or downstream of the Double D ITR sequence).

Examples of the construction of retroviral vectors expressing α interferon under the control of liver-specific promoters is shown in Example 33 herein. Similar techniques can be used to construct retroviral vectors expressing other proteins under control of liver-specific promoters.

D. Use of gene delivery vectors co-expressing therapeutic protein and a prodrug-converting

enzyme:

The gene delivery vehicles and the therapeutic methods of delivery are useful for the long term expression of therapeutic proteins for treatment of a variety of disorders described herein. Particularly, because of the long term treatment made possible by the present invention, it can be desirable for the gene delivery vehicles of the invention to co-express a prodrug converting enzyme which converts a non-cytotoxic compound into its cytotoxic counterpart. The prototype of such enzymes is herpes simplex thymidine kinase (HSVTK) which converts the prodrug gancyclovir into a toxic compound.

Techniques for introducing HSVTK or other prodrug converting enzymes into gene delivery vehicles, particularly retroviral vectors are well known to those of skill in the art. (See eg. WO 91/02805, WO 90/07936, and WO 95/14091). Procedures for preparing gene delivery vehicles, particularly retroviral vectors which co-express a therapeutic protein and HSVTK or other prodrug converting enzymes are described herein and are also described in number of publications (See, eg. WO 93/10218.) These procedures can readily be used by those of skill in the art to introduce the HSVTK gene or a gene encoding another prodrug converting enzyme into the gene delivery vehicles of the invention. In addition, the pro-drug converting enzyme can be introduced into a second vector particle which is then co-administered with the gene delivery vehicle expressing the therapeutic protein. An example of this approach is described in WO 96/21015.

E. Pretreatment of target tissues:

Retroviral vectors are known to preferentially infect dividing cells. (See Miller *et al.*, 1990, *Molecular Cell Biol.* 10:4239.) There are variety of techniques that may be used to increase the number of dividing cells in target tissues and thereby enhance the efficiency of target cell infection by the retroviral vectors of the invention. For example, growth factors may be used to stimulate target tissues to enter the portion of the cell cycle in which retroviral vector integration can take place. Such growth factors and their target tissues include, but are not limited to, the following:

Protein S and Gas6 acting on nervous system cells and smooth muscle cells; thrombin acting on smooth muscle cells, gastrointestinal epithelium, liver fat storage cells, dental pulp cells, fibroblasts, endothelial cells, mesangial cells, and astrocytes; coagulation Factor Xa acting on smooth muscle cells; nerve growth factor acting on nervous system cells; CSF-1 acting on placenta and endometrium; IGF-1 acting on kidney, bone, skin, adipose tissue, airway smooth muscle cells, gastrointestinal epithelium, neural tissue, muscle, and follicular cells; insulin acting on gastrointestinal epithelium, skin, and adipose tissue; KGF acting on urothelium, mammary epithelium, skin, liver, and gastrointestinal epithelium; TGF acting on gastrointestinal epithelium, dental pulp, neural tissue, fibroblasts, connective tissue, inner ear sensory epithelium, colon, bone, pneumocyte type

II cells, cornea, and smooth muscle cells; endothelin acting on kidney, smooth muscle cells, melanocytes, cardiac muscle, and astrocytes; PDGF acting on kidney, airway smooth muscle cells, gastrointestinal epithelium, neural tissue, and connective tissue; EGF acting on kidney, skin, neural tissue, inner ear sensory epithelium, connective tissue, fibroblasts, endometrium, liver, and intestine; HGF acting on liver, kidney, mammary epithelium, gastrointestinal epithelium, alveolar epithelium, melanocytes, placenta, and alveolar type II cells; PSA acting on prostate, breast, lung, colon, ovary, liver, and kidney; injurin and HGF-activators acting on liver, kidney, and mammary epithelium; FGF acting on neural cells, kidney, endothelium, fibroblasts, skin, skeletal muscle, connective tissue, melanocytes, cornea, bone marrow, dental pulp cells, liver, melanocytes, smooth muscle cells, and thyroid follicular cells; VEGF acting on endothelial cells; Arg-vasopressin acting on liver, kidney, and fibroblasts; thyroid hormones acting on bone; azoxymethane acting on the colon; prostaglandins acting on liver and dental pulp; IL1 acting on fibroblasts; IL2 acting on T cells; IL15 acting on muscle; triiodothyronine acting on liver; LIF acting on muscle and bone; amphiregulin acting on the skin; soluble thrombomodulin acting on fibroblasts; stem cell factor acting on erythroid progenitors; osteogenic protein 1 acting on chondrocytes, and bone; bone morphogenic protein acting on liver; MGF acting on melanocytes; MGSA acting on melanocytes; heregulins acting on mammary epithelium, keratinocytes, and Schwann cells; and melanotropin acting on melanocytes.

Growth factors can also be used in combination, particularly but not limited to mixtures consisting of one or several of EGF, IGF, PDGF, FGF, or KGF. In particular, multiple growth factors known to stimulate cell division of a particular target tissue can be used in combination to increase the proportion of dividing cells in the tissue. The actions of the above and other growth factors can also be potentiated with substances including but not limited to dextran sulfate, heparin, and other sulfated glycosaminoglycans, FBP, leukotrienes, prostaglandins, oleic acid, HGF activators, androgens, estrogens, ethanol, PF4, and TGF beta antagonists. Treatment with growth factors or the other substances described above can occur by administering the substances *in vivo* or can also be used in other treatment modalities such as *ex vivo* treatment.

The polypeptide growth factors described herein can be administered in a variety of forms including full-length growth factors, growth factor fragments, truncated growth

factors, growth factor fusion proteins and growth factor analogues. Growth factor fusion proteins include fusion proteins with the full-length growth factor, truncated growth factor, growth factor analogue, and growth factor fragment. As used herein the term "growth factor fragment" refers to any growth factor polypeptide that contains less than a full-length sequence, and which retains sufficient biological activity to be used in the methods of the invention. The term "growth factor analogue" as used herein refers to growth factors, truncated growth factors and growth factor fragments with amino acid substitutions, deletions, additions, and modifications; and retaining the biological activity of the growth factor. Thus, the term "growth factor analogue" as used herein includes splice variants, truncations, variants, alleles and derivatives of the mature protein. Analogues possess one or more of the bioactivities of the full length protein. Thus, polypeptides that are identical or contain at least 60%, preferably 70%, more preferably 80%, and most preferably 90% amino acid sequence homology to the amino acid sequence of the mature protein wherever derived, from human or nonhuman sources, are included within this definition.

Growth factor analogues include variants of the growth factors described herein. Growth factor variants contain amino acid substitutions, deletions, or insertions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acid residues such as to alter a glycosylation site, a phosphorylation site, an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/hydrophilicity and/or steric bulk of the amino acid substituted, for example, substitutions between the members of the following groups are conservative substitutions: Gly/Ala, Val/Ile/Leu, Asp/Glu, Lys/Arg, Asn/Gln, Ser/Thr/Cys and Phe/Tyr. The analogs herein further include peptides having one or more peptide mimics, also known as peptoids, that possess the bioactivity of the protein. Included within the definition are also polypeptides containing one or more analog amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages as well as other modifications known in the art, both naturally occurring and non-naturally occurring. The term polypeptide also does not exclude post-expression

modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like.

A large variety of different forms of the various growth factors described above are known to those of skill in the art and can be used in the methods of the invention. For example, a variety of PDGF polypeptides are known in the art. For instance, nucleic acid vectors encoding naturally occurring PDGF and the production of recombinant PDGF are described in U.S. Patent No. 5,219,759, issued June 15, 1993, entitled "Recombinant DNA encoding PDGF A-chain Polypeptide Expression Vectors". In addition to the naturally occurring PDGF polypeptides, a variety of PDGF analogues are known in the art and can be used in the methods described herein. (See eg. U.S. Patent No. 5,149,792, issued September 22, 1992, entitled "Platelet-Derived Growth Factor B Chain Analogues"; U.S. Patent No. 5,128,321, issued July 7, 1992, entitled "PDGF Analogues and Methods of Use"; and U.S. Patent No. 4,849,407, issued July 18, 1989, and entitled "Biologically Active Mosaic Proteins".

Different forms of IGF-1 and IGF-2 growth factor polypeptides are also well known the art. For example, recombinant human, as well as specific DNA sequences and expression vectors for the production of human IGF-1 are described in European Patent No. 0123228B1, grant published on September 19, 1993, entitled "Hybrid DNA Synthesis of Mature Insulin-like Growth Factors". A variety of other forms of IGF-1 polypeptides, are known in the art and can readily be produced for use in the methods of the invention. See eg. U.S. Patent No. 5,019,500, entitled "59 Valine Insulin-Like Growth Factor I and Process for Production Thereof"; PCT Patent Publication No. WO 93/23067 entitled "IGF-1 Analogues"; European Patent No. EP0128733B1, entitled " Human Insulin-Like Growth Factor (IGF) Produced from a Human Host, Process, Expression Vector and Recombinant Host Therefor., and IGF-containing Pharmaceutical Composition".

FGF growth factors encompass two families of growth factors found in a variety of different tissues and which are mitogenic factors for a number of different tissues. These two families of polypeptides have been termed acidic FGF and basic FGF. A large variety of different FGF polypeptides, analogues and fragments are known in the art and can be used in the methods of the present invention. See, eg. U. S. Patent No. 5,464,774, issued Nov. 7, 1995, entitled "Bovine Basic Fibroblast Growth Factor"; U.S. Patent No.

5,155,214, entitled Basic Fibroblast Growth Factor, and U.S. Patent No. 4,994,559, entitled "Human Fibroblast Growth Factor".

Different forms of keratinocyte growth factor that are useful in the methods of the invention are also known to those of skill in the art. See, for example, a preferred truncated form of KGF which is described in PCT Patent Publication No. 95/10434, published January 12, 1995, and entitled "A Truncated Form of KGF Having Increased Biological Activity". Similarly, different forms of EGF polypeptides are known in the art. See *eg.* PCT publication No. WO 90/08771 and U.S. Patent No. 5,096,825, issued March 17, 1992, entitled Gene for Human Epidermal Growth Factor and Synthesis of Expression Thereof.

The growth factor polypeptides, fragments and analogues used in the instant invention can be produced in a variety of ways, including isolation of PDGF polypeptide from naturally occurring sources, polypeptide chain synthesis by peptide synthesis methods and production of recombinant proteins. These methods are well known to those of skill in the art and are further described herein. For examples of the production of recombinant PDGF polypeptides and analogues, see U.S. Patent No. 5,045,633, issued Sept. 3, 1991, entitled "Expression of Biologically Active PDGF Analogues in Eucaryotic Cells"; U.S. Patent No. 4,769,328, issued Sept. 6, 1988, entitled "Expression of Biologically Active PDGF Analogues in Yeast"; and U.S. Patent No. 4,801,542, issued Jan. 31, 1989, entitled "Expression of Biologically Active PDGF Analogues in Eucaryotic Cells". For examples of the production of FGF polypeptides see *eg.* U.S. Patent No. 5,229,501, entitled "Expression and Production of Human Fibroblast Growth Factor Receptor", U.S. Patent No. 5,331,095, entitled "Process for Purification and Production of Basic Fibroblast Growth Factor"; and U.S. Patent No. 5,143,829, entitled High Level Expression of Basic FGF Having a Homogeneous N-terminus".

Liver is an attractive organ for gene therapy because it is easily accessible via the circulation and is the source of a variety of proteins involved in genetic disorders, including factor VIII. Gene therapy targeting the liver using the retroviral vectors of the invention can be performed with or without pretreatment to include benign hyperplasia of the liver. Pretreatment to induce benign liver hyperplasia can be effected, for example, by

treatment with hepatocyte growth factor (HGF) and/or transforming growth factor alpha. (See eg. Liu, et al. (1994) *Hepatology* 19:1521.)

A variety of different forms of HGF useful to induce liver cell proliferation are known in the art. See eg. European Patent Publication No. EP 461560, published December 12, 1991, and entitled "Recombinant Human Leukocyte Derived Hepatocyte Growth Factor- with DNA encoding it, Recombinant Expression Vectors, and Transformant Cells Expressing it." HGF can also be produced and administered to induce liver proliferation in vivo as is described in Joplin *et al.*, 1992, *J. Clin. Invest.* 90:1284.

Liver cells can also be stimulated by administration of agents that mediate or potentiate the activation of endogenous HGF. HGF is produced as a single chain protein that is inactive as a growth factor. Single chain HGF is subsequently cleaved into a two-chain form which is the biologically active growth factor. Enzymes which are shown to convert single-chain HGF to its biologically active form are useful for inducing liver cell proliferation. Therefore, these enzymes can be administered either alone or in combination with exogenous HGF to enhance liver proliferation. Examples of such enzymes are coagulation factor XIIa (see Shiomura *et al.*, 1995, *European J. of Biochem* 229:257), HGF activator (see Shiomura *et al.*, 1992, *Cytotechnology* 8:219); HGF converting enzyme (Mizuno *et al.*, 1994, *Biochem. Biophys. Res. Comm.* 198:1161); and urokinase and tissue plasminogen activators (Mars *et al.*, 1993, *Am J. Pathol.* 143:949). For example, urokinase can be co-administered with HGF. HGF and urokinase could be either be co-formulated or mixed immediately prior to injection. If HGF and urokinase were co-formulated, they could, for example, be stored at low pH in order to minimize the activity of urokinase.

The effects of either HGF or TGFalpha on liver stimulation have also been shown to be enhanced by prior administration of collagenase (Liu, 1994, *Hepatology* 19:1521). Agents that stimulate release of collagenase-like materials from monocytic cell types, such as LPS or endotoxin-like substances (Beauchamp, 1994, *Surgery* 116:637) may also be used. Nonenzymatic adjuncts and costimulants of growth factors may also be used, including cations with HGF (Ni, 1994, *Hepatology* 19:183), heparin or other sulfated glycosaminoglycans with HGF (Yamakazi, 1996, *Cytokine* 8:178; Matsumoto, 1996,

Biochem Biophys Res Commun 227:455), spermine or spermidine with HGF (Higaki, 1994, *Gastroenterology* 106:1024), nicotinamide with EGF (Wu (1994) *Cancer Res* 54:5964), or choline (Tessitore, 1997, *Biochem J.* 322:151). The phosphofetuin/phospho-alpha-2-HS glycoprotein pathway downregulates liver regeneration. Inhibitors of this pathway may be used to upregulate liver proliferation. Such inhibitors include IL6, IL1alpha, or anti-fetuin antibodies (Ohnishi, 1997, *Eur. J. Biochem.* 243:753). Combinations of these agents can also be applied along with the various growth factors described above.

In addition to growth factor therapy, liver cell growth can also be stimulated by nutritional manipulation. A variety of different nutritional regimens can be used. For instance, a period of protein deprivation followed by consumption of a high protein meal can be used to stimulate DNA synthesis and cell division. (See Mead *et al.*, 1990, *Cancer Res.* 50:7023-7030.)

Another example of stimulation of cell division in a particular tissue is the use of cyclooxygenase inhibitors, such as indomethacin, to induce hyperplasia in the gastric mucosa. In particular, indomethacin is known to increase DNA synthesis and cell clearance in duodenal and jejunal mucosa (see Uribe *et al.*, 1992, *Dig. Dis. Sci.* 37:403-408). Thus, pretreatment with indomethacin or other non-steroidal anti inflammatory drugs can be used to increase cell proliferation in the gastric mucosa. In addition, prostaglandins, in particular, prostaglandin E2 can be used after introduction of the gene therapy vehicle in order to increase the retention of the transduced intestinal cells.

Yet another example of a method to increase the number of dividing cells in gastric mucosa is the administration omeprazole. Omeprazole can be obtained and administered as described in Kakei *et al.*, 1995, *Biochem. Biophys. Res. Comm.* 214:861-867.

An additional class of drugs that is known to induce liver proliferation is the peroxisome proliferators. These are a set of structurally diverse drugs that cause an increase in the number of peroxisomes present in hepatocytes, but which also lead to hepatocyte mitosis mimicking regeneration through unknown mechanism(s). Some of these have found clinical utility as hypolipidemic drugs, particularly clofibrate (Reddy and Lalwai, 1983, *CRC Crit Rev Toxicol* 12:1-58), and act through activation of members of the superfamily of nuclear steroid receptors known as PPAR (peroxisome proliferator-

activated receptors) and subsequent increased transcription of peroxisomal beta-oxidative enzymes (Isseman and Green, 1990, *Nature* 347:645-650), and possibly through down-regulation of the endoplasmic reticulum protein, BiP (Motojima & Goto, 1992, *FEBS Lett* 308:207-210). These drugs include clofibrate (Sigma Chemical Compan, St. Louis, MO, USA), WY 16463 (Chem Syn, Lenexa, KS, USA), DEHP (Aldrich, Milwaukee WI, USA), DHEA (Sigma), PFDA (Aldrich), PFOA (Aldrich), fenofibrate (Laboratories Fournier, Daix, France), gemfibrozil (Lopid, Warner-Lambert , Ann Arbor MI), (Sigma), clofibric acid (Sigma), bezafibrate (Sigma), methyl clofenapate, tibric acid, BR 931(4-chloro-6(2,3-xylidino)2-pyrimidinylthio-(N-beta-hydroxy-ethyl)acetamide), DEHA
10 (di(2ethylhexyl)adipate), nafenopin, clinofibrate.

Other classes of nonproteinaceous substances known to stimulate liver proliferation may be employed. These include 9-cis-retinoic acid (Ohmura, 1996, *Life Sciences* 58:PL211), the glycolipid, hepatopoietin B, (Michalopoulos, 1990, *FASEB J* 4:176), cyclosporine A (Masuhara, 1993, *Carcinogenesis* 14:1579), phosphatidylethanolamine N-methyltransferase inhibitors such as 3-deazaadenosine or other methylation inhibitors
15 (Chiang, 1979, *Biochem Pharmacol* 28:1897), nonsteroidal antiinflammatory drugs that activate PPAR such as flufenamic acid, fenoprofen, and ibuprofen (Lehmann, 1997, *J. Biol. Chem.* 272:3406); or apoptosis-inducing molecules (Busch, 1984, *Carcinogenesis* 5:453; Colambano, 1985, *Lab Invest* 52:670) such as anti-Fas antibody, dexamethasone, etoposide, camptothecin, staurosporin, hypericin, S-nitrosoglutathione, taxol, 4-
20 hydroxyphenyl retinamide, prostaglandin A2, delta-12-PGJ2, sulindac sulfone, actinomycin D, beta-lapachone, TPEN, vinblastine, vincristine, and A23187. Triiodothrone can also be administered as a stimulatory compound. Combinations of these substances can also be applied along with the peptide growth factors described
25 herein.

D. CELL CULTURE

As noted above, the present invention provides high titer recombinant retroviral preparation suitable for administration to humans. In order to produce such high titer preparations, cell culture methods as described below are provided in order to enable the
30 production of high titer recombinant retroviruses. Briefly, a wide variety of methods may

be utilized, including for example, the use of fermenters or bioreactors, roller bottles, cell hotels or cell factories, and hollow fiber culture.

In particular, for bioreactors or fermenters, cells are preferably grown on microcarriers (*i.e.*, Cytodex 1 or Cytodex 2; Pharmacia, Piscataway, N.J. at concentrations ranging from 3 to 15 g/L microcarrier. Suitable media, and growth conditions are described by way of a representative illustration in Example 17.

For roller bottles, suitable conditions include those described above for bioreactors, with the exception that microcarrier beads are not utilized. Generally, cells are grown in 850 cm² roller bottles ("FALCON" Corning, Corning New York) containing DMEM media, along with 15%-20% FBS. Preferably, the bottles are sealed to avoid contamination, although "open" bottles may also be utilized under appropriate conditions (*e.g.*, 5% CO₂). Generally, the roller bottles are incubated at a temperature of 37°C, with a rotation speed of 0.5 rpm/minute.

Cell factories may also be utilized for the large scale cell culture and production of recombinant retroviruses. Briefly, cell factories (also termed "cell hotels") typically contain 2, 10, or 40 trays, are molded from virgin polystyrene, treated to provide a Nuclon D surface, and assembled by sonic welding one to another. Generally, these factories have two port tubes which allow access to the chambers for adding reagents or removing culture fluid. A 10-layer factory provides 6000cm² of surface area for growing cells, roughly the equivalent of 27 T-225 flasks. Cell factories are available from a variety of manufacturers, including for example Nunc.

Most cell types are capable of producing high titer vector into the media for 3-6 days, allowing for multiple harvests. Each cell type is tested to determine the optimal harvest time after seeding the culture and optimal number of harvest days. Cells are typically initially grown in DMEM supplemented with 2-20% FBS in roller bottles until the required number of cells for seeding a cell factory is obtained. Cells are then seeded into the factories and 2 liters of culture supernatant containing vector is harvested from each day for four days. Fresh DMEM/FBS is used to replenish the cultures.

Within other aspects of the present invention, hollow fiber culture methods are provided for the production of recombinant retroviruses. Briefly, high titer retroviral production using hollow fiber cultures is based on increasing viral concentration as the

cells are being cultured to a high density in a reduced volume of media. Cells are fed nutrients and waste products are diluted using a larger volume of fresh media which circulates through the lumen of numerous capillary fibers. The cells are cultured on the exterior spaces of the capillary fibers in a bioreactor chamber where cell waste products are exchanged for nutrients by diffusion through 30,000 Dalton pores in the capillary fibers. Retroviruses which are produced from the cell lines are too large to pass through the 30,000 Dalton pore membrane, and thus concentrate in the hollow fiber bioreactor along side of the cells. The volume of media being cultured on the cell side is approximately 10 to 100 fold lower then volumes required for equivalent cell densities cultured in tissue culture dishes or flasks. This decrease fold in volume inversely correlates with the fold induction of titer when hollow fiber retroviral titers are compared to tissue culture dishes or flasks. This 10-100 fold induction in titer is seen when an individual retroviral producer cell line is amiable to hollow fiber growth conditions. To achieve maximum cell density, the individual cells must be able to grow in very close proximity and on top of each other. Many cell lines will not grow in this fashion and retroviral packaging cell lines based on these types of cell lines may not achieve 10 fold increases in titer. Cell lines which would grow very well would be non-adherent cell line and it is believed that a retroviral producer line based on a non-adherent cell line may reach 100 fold increases in titer compared to tissue culture dishes and flasks.

The harvest procedure, in its original design, is a procedure which uses syringes to evacuate and replace culture sups to harvest the produced vector. This syringe procedure has an associated high risk of possible contamination, which requires a significant number manual connections and disconnection's of media flow paths. However a convenient procedure has been devised which will reduce the risk of contaminating the cultures, increase the daily volumes which can harvested and reduce the time required to handle the culture system. The harvesting procedure is now performed using a batch peristaltic pump drive to deliver precise volumes of fresh media to replace equal volumes of harvest material which is then delivered through thin line tubing into a collection bottle stored at 4⁰C. The pump batch sequence is activated by a timer which can be set at specific time points and the pump can be adjusted to harvest any set volume of harvest material, twenty-four hours a day. The collected supernatant can then be frozen, pooled with earlier

harvests, or processed as described elsewhere. This collection procedure can be used for any hollow fiber system including the Cellco (Rockville, Maryland), Unisyn (Tustin, CA), or Cellex (Coon Rapids, MN) systems including ceramic matrix high density culture systems.

5

E. CONCENTRATION AND PURIFICATION OF RECOMBINANT RETROVIRAL PARTICLES

As noted above, the present invention provides methods for concentrating and purifying recombinant retroviruses, in order to increase the purity of therapeutic preparation, as well as to increase the titer of recombinant retrovirus that may be given. A wide variety of methods may be utilized for increasing viral concentration and purity, including for example, precipitation of recombinant retroviruses with ammonium sulfate, polyethylene glycol ("PEG") concentration, concentration by centrifugation (either with or without gradients such as PERCOLL, or "cushions" such as sucrose, use of concentration filters (e.g., Amicon filtration), and 2-phase separations. Each of these methods will be discussed in more detail below.

15

Briefly, in order to accomplish concentration by precipitation of recombinant retroviruses with ammonium sulfate, ammonium sulfate is added slowly to an appropriate concentration, followed by centrifugation and removal of the ammonium sulfate either by dialysis or by separation on a hydrophobic column. One difficulty with this method however, is that in addition to concentration of recombinant retroviruses, other proteinaceous debris may also be concentrated.

20

Alternatively, recombinant retroviruses may be concentrated from culture medium with PEG (Green *et al.*, 1970, *PNAS* 67:385-393; Syrewicz *et al.*, 1972, *Appl. Micro.* 24:488-494). Such methods are rapid, simple, and inexpensive. However, like ammonium sulfate precipitation, use of PEG also concentrates other proteins from solution.

25

Within other embodiments, recombinant retroviruses may be concentrated by centrifugation, and more particularly, low speed centrifugation. Briefly, low speed centrifugation allows concentration of recombinant retroviruses, while avoiding the difficulties associated with pelleting that accompanies high speed centrifugation (e.g.,

30

virus destruction or inactivation). Particularly preferred methods for concentrating viruses by low-speed centrifugation are described below in more detail in Example 15.

Within yet other aspects of the invention, recombinant retroviruses may be concentrated by an aqueous two-phase separation method. Briefly, polymeric aqueous two-phase systems may be prepared by dissolving two different non-compatible polymers in water. Many pairs of water-soluble polymers may be utilized in the construction of such two-phase systems, including for example polyethylene glycol ("PEG") or methylcellulose, and dextran or dextran sulfate (see Walter and Johansson, 1986, *Anal. Biochem.* 155:215-242; Albertsson, "Partition of Cell Particles and Macromolecules" Wiley, New York, 1960). As described in more detail below in Example 13, utilizing PEG at concentrations ranging from 5% to 8% (preferably 6.5%), and dextran sulfate at concentrations ranging from 0.4% to 1% (preferably 0.4%), an aqueous two-phase system may be established suitable for purifying recombinant retroviruses. Utilizing such procedures, approximately 1.4 liters of crude research grade supernatant may be reduced to a 10 mL volume, while recovering approximately 50% of the total starting retrovirus.

For purposes of illustration, one representative concentration process which combines several concentration steps is set forth below. Briefly, recombinant retroviruses may be prepared either from roller bottles, cell factories, or bioreactors prior to concentration. Preferably, daily harvests of recombinant retroviruses from producer cells is preferred, followed by addition of fresh media. Removed media containing the recombinant retrovirus may be frozen at -70°C, or more preferably, stored at 2°C to 8°C in large pooled batches prior to processing.

For material obtained from a bioreactor, the recombinant retrovirus pool is first clarified through a 0.8 um filter (1.2 um glass fiber pre-filter, 0.8 um cellulose acetate) connected in series with a 0.65 um filter (Sartorius). This filter arrangement provides approximately 2 square feet of filter, and allows processing of about 15-20 liters of pooled material before clogging. For material obtained from roller bottles or cell factories, a single 0.65um cartridge (2 sq. ft.) normally suffices for volumes up to 40 liters. For 80 liter cell factory processes, a 5 sq. ft. filter may be required.

Preferably, after clarification, the filter is rinsed with buffer (150 mM NaCl, 25 mM Tris, pH 7.2-7.5). This step has allowed recoveries of recombinant retrovirus ranging from 80% to 120%.

Following clarification, recombinant retroviruses are concentrated by tangential
5 flow ultrafiltration utilizing Filtron units and Sigma Screen cassettes with a 300,000 mw cut off. For bioreactor material (containing 12% to 16% FBS), 4 to 5 liters of material may be concentrated per cassette. For roller bottles or cell factories at 12-16% FBS, 5-6 liters of material may be concentrated per cassette. Finally, for cell factories containing 10% FBS, 8 to 9 liters of material may be concentrated per cassette. Utilizing a pressure
10 differential of 2 psi between filtrate (8 psi) and retentate (10 psi), up to 80 liters of material may be concentrated to a volume of less than 500 ml in under two hours. This process also provides a yield of about 80%.

Following the ultrafiltration step, DNase is added to a concentration of 50 U/ml, and recirculated at a lower pump speed with the filtrate line closed for 30 minutes. If
15 retroviruses have been trapped within a gel layer formed during the ultrafiltration, this step will break down trapped retrovirus, and improve recovery.

Discontinuous diafiltration is then accomplished by addition of 4 liters of additional buffer, and utilizing the same cross differential pressure set forth above. Generally, recovery after this step is approximately 70%.

20 Concentrated material is then subjected to column chromatography on a Pharmacia S-500 HG size exclusion gel, utilizing 50 mM NaCl and 25 mM Tris pH 7.2-7.5 as minimum salt and ionic strength concentrations. Generally, recombinant retroviruses elute off in the first peak.

Tangential flow filtration may once again be utilized in order to further reduce the
25 volume to under 200 ml. Finally, the concentrated material is sterilized by filtration through a 0.2 um Millipore filter (PVDF, or Sterivex).

F. ASSAYS

Within other aspects of the present invention, methods are provided for
30 quantitating retroviral particles utilizing non-denaturing gels (e.g., 4-15% gradient polyacrylamide gels), along with methods for estimating or quantitating the resultant

products such as, for example, staining with coomassie blue or silver stain, followed by densitometry scanning. Such methods, while not capable of discriminating between viable and non-viable vector particles, are advantageous because they are relatively simple and quick. One representative example of such methods is set forth below in Example 10 in more detail.

Within other aspects of the present invention, assays are provided for titering recombinant retrovirus in a sample. Typically, such assays may be based upon presence of a selectable marker, or formation of blue colonies. However, within certain embodiments recombinant retroviruses are provided which do not include a gene coding for a selectable marker. Therefore, antibody and PCR assays, the latter of which is described below, may be employed in order to determine retrovirus titer. To use PCR to amplify sequences unique to the recombinant retroviruses described herein, various primers are required. Such primers can readily be designed by those skilled in the art and will depend on the retroviral vector backbone employed and the components thereof, the particular region(s) desired to be amplified, *etc.* Representative examples of particular primer pairs include those specific for LTR sequences, packaging signal sequences or other regions of the retroviral backbone, include primers specific for the nucleic acid molecule (*i.e.*, non-heterologous sequence) of interest.

Briefly, within one embodiment of the invention a PCR titering assay is performed by growing a known number of cells, transduced with a recombinant retrovirus on 6-well plates for at least 16 hr. before harvest. One well per plate is sacrificed for counting. Cells from the other wells are lysed and their contents isolated. DNA is prepared using a QUIAmp DNA isolation kit (QUIAgen, Inc., Chatsworth, CA). DNAs are resuspended in 5×10^6 cell equivalents/ μ l per sample.

To calculate titer, a standard curve is generated using DNA isolated from 5×10^6 untransduced HT1080 cells (negative control) and 5×10^6 HT1080 cells transduced with a known vector and having one copy of that vector per cell genome (positive control), such as may be prepared from packaging cell lines transduced with a recombinant retrovirus encoding a selectable marker, *e.g.*, neomycin resistance. The standard curve is generated by combining different amounts of the positive and negative control DNA and amplifying specific sequences therefrom by PCR using primers specific to a particular region of the

recombinant retrovirus. A representative group of mixtures for generating a standard curve is:

<u>Tube</u>	<u>100%</u>	<u>75%</u>	<u>50%</u>	<u>25%</u>	<u>10%</u>	<u>5%</u>	<u>0%</u>	<u>Blank</u>
5 Positive Control (μl)	50	37.5	25	12.5	5	2.5	0	0
Negative Control (μl) 0	12.5	25	37.5	45	47.5	50	0	
Distilled water (μl)	0	0	0	0	0	0	0	50

Five microliters from each tube is placed into one of eight reaction tubes (duplicates are also prepared), with the remainder being stored at -20°C. Five microliters from each sample DNA preparations are placed into their own reaction tubes in duplicate. PCR reactions (50 μl total volume) are then initiated by adding 45.0 μl of a reaction mix containing the following components per tube to be tested: 24.5 μl water, 5 μl 10X reaction PCR buffer, 4 μl of 25 mM MgCl₂, 4 μl dNTPs (containing 2.5 mM of each of dATP, dGTP, dCTP, and dTTP), 5 μl of primer mix (100 ng of each primer), 0.25 μl TaqStart monoclonal antibody (Clontech Laboratories, Inc., Palo Alto, CA), 1.00 μl TaqStart buffer (Clontech Labs, Inc.), and 0.25 μl AmpliTaq DNA polymerase (Perkin-Elmer, Inc., Norwalk, CN). Just prior to aliquoting the reaction mix to the reaction tubes, 1 μl of γ-³²P dCTP (250 μCi; 3000 C/mmol, 10 mCi/mL, Amersham Corp., Arlington Heights, IL) is added into the reaction mix. After aliquoting 45.0 μL the reaction mix into each of the reaction tubes, the tubes are capped and placed into a thermocycler. The particular denaturation, annealing, elongation times and temperatures, and number of thermocycles will vary depending on size and nucleotide composition of the primer pair used. 25-30 amplification thermocycles are then performed. 5 μL of each reaction is then spotted on DE81 ion exchange chromatography paper (Whatman, Maidstone, England) and dried for 10 min. The filter is then washed five times, 100 mL per wash, in 50 mM Na₂HPO₄, pH 7, 200 mM NaCl, after which it is air dried and then sandwiched in Saran Wrap. Quantitation is performed on a PhosphorImager SI (Molecular Dynamics, Sunnyvale, CA). Filters are typically exposed to a phosphor screen, which stores energy from ionizing radiation, for a suitable period, typically about 120 min. After exposure, the phosphor screen is scanned, whereby light is emitted in proportion to the radioactivity on

the original filter. The scanning results are then downloaded and plotted on a log scale as cpm (ordinate) versus percent positive control DNA (abscissa). Titers (infectious units/mL) for each sample are calculated by multiplying the number of cells from which DNA was isolated by the percentage (converted to decimal form) determined from the standard curve based on the detected radioactivity, divided by the volume of recombinant retrovirus used to transduce the cells. As will be appreciated by those in the art, other methods of detection, such as colorimetric methods, may also be employed to label the amplified products.

10 G. FORMULATION

Within other aspects of the present invention, methods are provided for preserving an infectious recombinant retrovirus, such that the recombinant retrovirus is capable of infecting mammalian cells upon reconstitution (see U.S. Serial No. 08/153,342). Briefly, recombinant retrovirus which has been purified or concentrated as described above may be preserved by first adding a sufficient amount of a formulation buffer to the media containing the recombinant retrovirus, in order to form an aqueous suspension. The formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering component in water. As utilized within the context of the present invention, a "buffering compound" or "buffering component" should be understood to refer to a substance that functions to maintain the aqueous suspension at a desired pH. The aqueous solution may also contain one or more amino acids.

The recombinant retrovirus can also be preserved in a purified form. More specifically, prior to the addition of the formulation buffer, the crude recombinant retrovirus described above may be clarified by passing it through a filter, and then concentrated, such as by a cross flow concentrating system (Filtron Technology Corp., Northborough, MA). Within one embodiment, DNase is added to the concentrate to digest exogenous DNA. The digest is then diafiltrated to remove excess media components and establish the recombinant retrovirus in a more desirable buffered solution. The diafiltrate is then passed over a Sephadex S-500 gel column and a purified recombinant retrovirus is eluted. A sufficient amount of formulation buffer is added to this eluate to reach a desired

final concentration of the constituents (see, *e.g.*, Example 9) and to minimally dilute the recombinant retrovirus, and the aqueous suspension is then stored, preferably at -70°C or immediately dried. As noted above, the formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering
5 component in water. The aqueous solution may also contain one or more amino acids.

The crude recombinant retrovirus can also be purified by ion exchange column chromatography. This method is described in more detail in U.S. Patent Application Serial No. 08/093,436. In general, the crude recombinant retrovirus is clarified by passing it through a filter, and the filtrate loaded onto a column containing a highly sulfonated
10 cellulose matrix. The recombinant retrovirus is eluted from the column in purified form by using a high salt buffer. The high salt buffer is then exchanged for a more desirable buffer by passing the eluate over a molecular exclusion column. A sufficient amount of formulation buffer is then added, as discussed above, to the purified recombinant retrovirus and the aqueous suspension is either dried immediately or stored, preferably at
15 -70°C.

The aqueous suspension in crude or purified form can be dried by lyophilization or evaporation at ambient temperature. Specifically, lyophilization involves the steps of cooling the aqueous suspension below the glass transition temperature or below the eutectic point temperature of the aqueous suspension, and removing water from the cooled
20 suspension by sublimation to form a lyophilized retrovirus. Briefly, aliquots of the formulated recombinant retrovirus are placed into an Edwards Refrigerated Chamber (3 shelf RC3S unit) attached to a freeze dryer (Supermodulyo 12K). A multistep freeze drying procedure as described by Phillips et al. (Cryobiology 18:414, 1981) is used to lyophilize the formulated recombinant retrovirus, preferably from a temperature of -40°C
25 to -45°C. The resulting composition contains less than 10% water by weight of the lyophilized retrovirus. Once lyophilized, the recombinant retrovirus is stable and may be stored at -20°C to 25°C, as discussed in more detail below.

Within the evaporative method, water is removed from the aqueous suspension at ambient temperature by evaporation. Within one embodiment, water is removed through
30 spray drying (EP 520,748). Within the spray drying process, the aqueous suspension is delivered into a flow of preheated gas, usually air, whereupon water rapidly evaporates

from droplets of the suspension. Spray drying apparatus are available from a number of manufacturers (e.g., Drytec, Ltd., Tonbridge, England; Lab-Plant, Ltd., Huddersfield, England). Once dehydrated, the recombinant retrovirus is stable and may be stored at -20°C to 25°C. Within the methods described herein, the resulting moisture content of the dried or lyophilized retrovirus may be determined through use of a Karl-Fischer apparatus (EM Science Aquastar™ VIB volumetric titrator, Cherry Hill, NJ), or through a gravimetric method.

The aqueous solutions used for formulation, as previously described, are composed of a saccharide, high molecular weight structural additive, a buffering component, and water. The solution may also include one or more amino acids. The combination of these components act to preserve the activity of the recombinant retrovirus upon freezing and lyophilization, or drying through evaporation. Although a preferred saccharide is lactose, other saccharides may be used, such as sucrose, mannitol, glucose, trehalose, inositol, fructose, maltose or galactose. In addition, combinations of saccharides can be used, for example, lactose and mannitol, or sucrose and mannitol. A particularly preferred concentration of lactose is 3%-4% by weight. Preferably, the concentration of the saccharide ranges from 1% to 12% by weight.

The high molecular weight structural additive aids in preventing viral aggregation during freezing and provides structural support in the lyophilized or dried state. Within the context of the present invention, structural additives are considered to be of "high molecular weight" if they are greater than 5000 m.w. A preferred high molecular weight structural additive is human serum albumin. However, other substances may also be used, such as hydroxyethyl-cellulose, hydroxymethyl-cellulose, dextran, cellulose, gelatin, or povidone. A particularly preferred concentration of human serum albumin is 0.1% by weight. Preferably, the concentration of the high molecular weight structural additive ranges from 0.1% to 10% by weight.

The amino acids, if present, function to further preserve viral infectivity upon cooling, and thawing of the aqueous suspension. In addition, amino acids function to further preserve viral infectivity during sublimation of the cooled aqueous suspension and while in the lyophilized state. A preferred amino acid is arginine, but other amino acids such as lysine, ornithine, serine, glycine, glutamine, asparagine, glutamic acid or aspartic

acid can also be used. A particularly preferred arginine concentration is 0.1% by weight. Preferably, the amino acid concentration ranges from 0.1% to 10% by weight.

The buffering component acts to buffer the solution by maintaining a relatively constant pH. A variety of buffers may be used, depending on the pH range desired, preferably between 7.0 and 7.8. Suitable buffers include phosphate buffer and citrate buffer. A particularly preferred pH of the recombinant retrovirus formulation is 7.4, and a preferred buffer is tromethamine.

In addition, it is preferable that the aqueous solution contain a neutral salt which is used to adjust the final formulated recombinant retrovirus to an appropriate iso-osmotic salt concentration. Suitable neutral salts include sodium chloride, potassium chloride or magnesium chloride. A preferred salt is sodium chloride.

Aqueous solutions containing the desired concentration of the components described above may be prepared as concentrated stock solutions.

A particularly preferred method of preserving recombinant retroviruses in a lyophilized state for subsequent reconstitution comprises the steps of (a) combining an infectious recombinant retrovirus with an aqueous solution to form an aqueous suspension, the aqueous suspension including 4% by weight of lactose, 0.1% by weight of human serum albumin, 0.03% or less by weight of NaCl, 0.1% by weight of arginine, and an amount of tromethamine buffer effective to provide a pH of the aqueous suspension of approximately 7.4, thereby stabilizing the infectious recombinant retrovirus; (b) cooling the suspension to a temperature of from -40°C to -45°C to form a frozen suspension; and (c) removing water from the frozen suspension by sublimation to form a lyophilized composition having less than 2% water by weight of the lyophilized composition, the composition being capable of infecting mammalian cells upon reconstitution. It is preferred that the recombinant retrovirus be replication defective and suitable for administration into humans upon reconstitution.

As illustrated in Figures 1 and 2, mannitol and lactose lyophilized recombinant retrovirus formulations were assayed for preservation of viral activity under various storage temperatures as a function of time. Similarly, Figure 3 illustrates the results of assays of trehalose recombinant retrovirus formulations for preservation of viral activity under various storage temperatures as a function of time. Figure 4 depicts a comparison of

the viral infectivity of frozen formulated recombinant retrovirus (-80°C) as a liquid and the viral infectivity of lyophilized recombinant retrovirus stored at -20°C. Mannitol formulations may lose considerable activity upon lyophilization (5-6 fold), but appear to remain stable subsequent to the lyophilization event. Although not preferable, such a loss is acceptable assuming sufficient amounts of retrovirus are present in the aqueous solution.

It will be evident to those skilled in the art given the disclosure provided herein that it may be preferable to utilize certain saccharides within the aqueous solution when the lyophilized retrovirus is intended for storage at room temperature. More specifically, it is preferable to utilize disaccharides, such as lactose or trehalose, particularly for storage at room temperature.

The lyophilized or dehydrated retroviruses of the subject invention may be reconstituted using a variety of substances, but are preferably reconstituted using water. In certain instances, dilute salt solutions which bring the final formulation to isotonicity may also be used. In addition, it may be advantageous to use aqueous solutions containing components known to enhance the activity of the reconstituted retrovirus. Such components include cytokines, such as IL-2, polycations, such as protamine sulfate, or other components which enhance the transduction efficiency of the reconstituted retrovirus. Lyophilized or dehydrated recombinant retrovirus may be reconstituted with any convenient volume of water or the reconstituting agents noted above that allow substantial, and preferably total solubilization of the lyophilized or dehydrated sample.

H. ADMINISTRATION

As noted above, high titer recombinant retroviral particles of the present invention may be administered to a wide variety of locations including, for example, into sites such as the cerebral spinal fluid, bone marrow, joints, arterial endothelial cells, rectum, buccal/sublingual, vagina, the lymph system, to an organ selected from the group consisting of lung, liver, spleen, skin, blood and brain, or to a site selected from the group consisting of tumors and interstitial spaces. Within other embodiments, the recombinant retrovirus may be administered intraocularly, intranasally, sublingually, orally, topically, intravesically, intrathecally, topically, intravenously, intraperitoneally, intracranially, intramuscularly, or subcutaneously. Other representative routes of administration include

gastroscopy, ECRP and colonoscopy, which do not require full operating procedures and hospitalization, but may require the presence of medical personnel.

Considerations for administering the compositions of the present invention include the following:

5 Intravenous (IV) administration can occur under a variety of protocols known to those of skill in the art. For instance, retroviral vector particles can be formulated for IV administration as described above and administered as a single injection. Alternatively, the retroviral vector particles can be delivered in a multiple injection protocol. An example of a multiple injection protocol is administration for three times a day for several
10 consecutive days or on alternate days. The multiple injection schedule can be carried out over a number of days for example a week or 10 days or two weeks. The injection schedule can also be repeated. The total number of vector particles delivered can be dispersed in varying amounts of formulation buffer. Depending on the volume delivered, the retroviral vectors can be delivered as an injection or as an IV formulation such as an IV
15 drip which can be delivered over a longer period of time. Similarly, the rate of administration can vary. Details of the administration protocol such as the single or multiple injection schedule and volume and time of delivery can be determined experimentally by those of skill in the art, and will also vary depending on the particular gene of interest to be delivered. IV administration is a preferred route of administration
20 for retroviral vectors expressing secretory proteins such as Factor VIII and human growth hormone (see e.g. examples 18-21 herein).

Oral administration is easy and convenient, economical (no sterility required), safe (over dosage can be treated in most cases), and permits controlled release of the active ingredient of the composition (the recombinant retrovirus). Conversely, there may be
25 local irritation such as nausea, vomiting or diarrhea, erratic absorption for poorly soluble drugs, and the recombinant retrovirus will be subject to "first pass effect" by hepatic metabolism and gastric acid and enzymatic degradation. Further, there can be slow onset of action, efficient plasma levels may not be reached, a patient's cooperation is required, and food can affect absorption. Preferred embodiments of the present invention include
30 the oral administration of recombinant retroviruses that express genes encoding erythropoietin, insulin, GM-CSF cytokines, various polypeptides or peptide hormones,

their agonists or antagonists, where these hormones can be derived from tissues such as the pituitary, hypothalamus, kidney, endothelial cells, liver, pancreas, bone, hemopoetic marrow, and adrenal. Such polypeptides can be used for induction of growth, regression of tissue, suppression of immune responses, apoptosis, gene expression, blocking receptor-
5 ligand interaction, immune responses and can be treatment for certain anemias, diabetes, infections, high blood pressure, abnormal blood chemistry or chemistries (e.g., elevated blood cholesterol, deficiency of blood clotting factors, elevated LDL with lowered HDL), levels of Alzheimer associated amyloid protein, bone erosion/calcium deposition, and controlling levels of various metabolites such as steroid hormones, purines, and
10 pyrimidines. Preferably, the recombinant retroviruses are first lyophilized, then filled into capsules and administered.

Buccal/sublingual administration is a convenient method of administration that provides rapid onset of action of the active component(s) of the composition, and avoids first pass metabolism. Thus, there is no gastric acid or enzymatic degradation, and the
15 absorption of recombinant retroviruses is feasible. There is high bioavailability, and virtually immediate cessation of treatment is possible. Conversely, such administration is limited to relatively low dosages (typically about 10-15 mg), and there can be no simultaneous eating, drinking or swallowing. Preferred embodiments of the present invention include the buccal/sublingual administration of recombinant retroviruses that
20 contain genes encoding self and/or foreign MHC, or immune modulators, for the treatment of oral cancer; the treatment of Sjogren's syndrome via the buccal/sublingual administration of such recombinant retroviruses that contain IgA or IgE antisense genes; and, the treatment of gingivitis and periodontitis via the buccal/sublingual administration of IgG or cytokine antisense genes.

25 Rectal administration provides a negligible first pass metabolism effect (there is a good blood/lymph vessel supply, and absorbed materials drain directly into the inferior vena cava), and the method is suitable of children, patients with emesis, and the unconscious. The method avoids gastric acid and enzymatic degradation, and the ionization of a composition will not change because the rectal fluid has no buffer capacity
30 (pH 6.8; charged compositions absorb best). Conversely, there may be slow, poor or erratic absorption, irritation, degradation by bacterial flora, and there is a small absorption

surface (about 0.05m^2). Further, lipidophilic and water soluble compounds are preferred for absorption by the rectal mucosa, and absorption enhancers (e.g., salts, EDTA, NSAID) may be necessary. Preferred embodiments of the present invention include the rectal administration of recombinant retroviruses that contain genes encoding colon cancer antigens, self and/or foreign MHC, or immune modulators.

Nasal administration avoids first pass metabolism, and gastric acid and enzymatic degradation, and is convenient. In a preferred embodiment, nasal administration is useful for recombinant retrovirus administration wherein the recombinant retrovirus is capable of expressing a polypeptide with properties as described herein. Conversely, such administration can cause local irritation, and absorption can be dependent upon the state of the nasal mucosa.

Pulmonary administration also avoids first pass metabolism, and gastric acid and enzymatic degradation, and is convenient. Further, pulmonary administration permits localized actions that minimize systemic side effects and the dosage required for effectiveness, and there can be rapid onset of action and self-medication. Conversely, at times only a small portion of the administered composition reaches the bronchioli/alveoli, there can be local irritation, and overdosing is possible. Further, patient cooperation and understanding is preferred, and the propellant for dosing may have toxic effects. Preferred embodiments of the present invention include the pulmonary administration of recombinant retroviruses that express genes encoding IgA or IgE for the treatment of conditions such as asthma, hay fever, allergic alveolitis or fibrosing alveolitis, the CFTR gene for the treatment of cystic fibrosis, and protease and collagenase inhibitors such as α -1-antitrypsin for the treatment of emphysema. Alternatively, many of the same types of polypeptides or peptides listed above for oral administration may be used.

Ophthalmic administration provides local action, and permit prolonged action where the administration is via inserts. Further, avoids first pass metabolism, and gastric acid and enzymatic degradation, and permits self-administration via the use of eye-drops or contact lens-like inserts. Conversely, the administration is not always efficient, because the administration induces tearing. Preferred embodiments of the present invention include the ophthalmic administration of recombinant retroviruses that express genes encoding IgA or IgE for the treatment of hay fever conjunctivitis or vernal and atopic

conjunctivitis; and ophthalmic administration of recombinant retroviruses that contain genes encoding melanoma specific antigens (such as high molecular weight-melanoma associated antigen), self and/or foreign MHC, or immune modulators.

5 Transdermal administration permits rapid cessation of treatment and prolonged action leading to good compliance. Further, local treatment is possible, and avoids first pass metabolism, and gastric acid and enzymatic degradation. Conversely, such administration may cause local irritation, is particularly susceptible to tolerance development, and is typically not preferred for highly potent compositions. Preferred
10 embodiments of the present invention include the transdermal administration of recombinant retroviruses that express genes encoding IgA or IgE for the treatment of conditions such as atopic dermatitis and other skin allergies; and transdermal administration of recombinant retroviruses encoding genes encoding melanoma specific antigens (such as high molecular weight-melanoma associated antigen), self and/or foreign MHC, or immune modulators.

15 Vaginal administration provides local treatment and one preferred route for hormonal administration. Further, such administration avoids first pass metabolism, and gastric acid and enzymatic degradation, and is preferred for administration of compositions wherein the recombinant retroviruses express peptides. Preferred
20 embodiments of the present invention include the vaginal administration of recombinant retroviruses that express genes encoding self and/or foreign MHC, or immune modulators. Other preferred embodiments include the vaginal administration of genes encoding the components of sperm such as histone, flagellin, etc., to promote the production of sperm-specific antibodies and thereby prevent pregnancy. This effect may be reversed, and/or pregnancy in some women may be enhanced, by delivering recombinant retroviruses
25 vectors encoding immunoglobulin antisense genes, which genes interfere with the production of sperm-specific antibodies.

Intravesical administration permits local treatment for urogenital problems, avoiding systemic side effects and avoiding first pass metabolism, and gastric acid and enzymatic degradation. Conversely, the method requires urethral catheterization and
30 requires a highly skilled staff. Preferred embodiments of the present invention include intravesical administration of recombinant retrovirus encoding antitumor genes such as a

prodrug activation gene such thymidine kinase or various immunomodulatory molecules such as cytokines.

Endoscopic retrograde cystopancreatography (ERCP) (goes through the mouth; does not require piercing of the skin) takes advantage of extended gastroscopy, and permits selective access to the biliary tract and the pancreatic duct. Conversely, the method requires a highly skilled staff, and is unpleasant for the patient.

Many of the routes of administration described herein (e.g., into the CSF, into bone marrow, into joints, intravenous, intra-arterial, intracranial intramuscular, subcutaneous, into various organs, intra-tumor, into the interstitial spaces, intra-peritoneal, intralymphatic, or into a capillary bed) may be accomplished simply by direct administration using a needle, catheter or related device. In particular, within certain embodiments of the invention, one or more dosages may be administered directly in the indicated manner: into the cerebral spinal fluid at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; into bone marrow at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; into joint(s) at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; intravenously at dosages greater than or equal to 10^8 , 10^9 , 10^{10} or 10^{11} cfu; intra-arterially at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; intra-cranially at dosages greater than or equal to 10^9 , 10^{10} or 10^{11} cfu; intra-muscularly at dosages greater than or equal to 10^{10} or 10^{11} cfu; intra-ocularly at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; pulmonarily at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; nasally at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; sub-lingually at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; rectally at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; orally at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; topically at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; vaginally at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; sub-cutaneously at dosages greater than or equal to 10^9 , 10^{10} or 10^{11} cfu; inter-vesically at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; into an organ such as the lung, liver, spleen, skin, blood or brain at dosages greater than or equal to 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} or 10^{11} cfu; intra-tumor at dosages greater than or equal to 10^8 , 10^9 , 10^{10} or

10¹¹ cfu; intra-peritoneally at dosages greater than or equal to 10⁸, 10⁹, 10¹⁰ or 10¹¹ cfu; into interstitial spaces at dosages greater than or equal to 10¹⁰ or 10¹¹ cfu; intra-lymphatically at dosages greater than or equal to 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰ or 10¹¹ cfu; into a capillary bed at dosages greater than or equal to 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰ or 10¹¹ cfu; or intrathecally at dosages greater than or equal to 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰ or 10¹¹ cfu.

Recombinant retrovirus may be delivered to the target from outside of the body (as an outpatient procedure) or as a surgical procedure, where the vector is administered as part of a procedure with other purposes, or as a procedure designed expressly to administer the vector. Other routes and methods for administration include the non-parenteral routes as well as administration via multiple sites.

As demonstrated in Example 23 herein, viral vectors and particularly retroviral vectors preferentially infect liver cells and spleen cells in order to effect sustained expression of proteins such as factor VIII and human growth hormone. Furthermore, as described herein expression of proteins in the liver is useful therapeutically, for example, for production of proteins secreted by the liver, and for localized production of therapeutic proteins in the liver which can be used in the treatment of liver diseases.

As described above, the gene delivery vehicles of the invention, including recombinant retroviruses are preferentially administered intravenously, generally in a peripheral vein which is readily accessible. However, the gene delivery vehicles of the invention may also be delivered into the hepatic artery or in the portal vein in order to have more effective delivery to the liver. There are many methods available for placing catheters into the human hepatic artery or portal vein which are known to those of skill in the art. For instance, cannulation of the portal vein can be accomplished by a simple dissection of the umbilical vein, thereby eliminating a laparotomy (Storer *et al.*, 1966, *Am J. Surg* 111:56-68, and Weigand *et al.*, 1983, *Rec Res Cancer Res* 86:90-92). For example, the ligamentum teres is cut 4 to 5 cm above the umbilicus and a polyethylene catheter is threaded into the umbilical vein until reaching the junction with the left branch of the portal vein. Following the exertion of firm pressure on the catheter to break through the vessel wall, a brisk return of blood through the catheter indicates the proper entry into the portal system.

As an additional example, an alternative procedure is described by Beart *et al.*, 1990, *Arch Surg* 125:897-901. In this procedure, a 5F catheter is placed through a hole in the abdominal wall which then extends through a mesenteric vein and into the portal vein. The catheter is flushed with saline and fixed to the exterior of the abdominal wall. These
5 and other procedures may be used to deliver the gene delivery vehicles of the invention to the liver.

In addition, the gene delivery vehicles of the invention can be delivered by direct injection into the liver using standard medical procedures.

I. Formulation and Administration of Growth Factors

10 As is described herein, the recombinant viruses of the invention can be administered after induction of cell proliferation by a growth factor, or may be co-administered with a growth factor. The growth factors of the invention are administered by parenteral, topical, oral or by local administration. For example, the growth factors are administered parenterally, eg. intravenously, subcutaneously, intradermally, or
15 intramuscularly. Preferably, the growth factors are administered intravenously. Administration of the therapeutic agent of the invention can be accomplished by, for example, injection, catheterization, laser-created perfusion channels, cannulization, a particle gun, and a pump.

The growth factors of the invention are typically administered with a
20 pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those
25 of ordinary skill in the art. Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like, and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J.
30 1991). Pharmaceutically acceptable carriers in therapeutic compositions may contain

liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or
5 suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier. The term "liposomes" refers to, for example, the liposome compositions described in U.S. Patent No. 5,422,120, WO 95/13796, WO 94/23697, WO 91/14445 and EP 524,968 B1. Liposomes may be pharmaceutical carriers for the polypeptides of the invention.

10 The growth factors of the invention are administered in therapeutically effective amounts. The term "therapeutically effective amount" as used herein and applied to polypeptide growth factors refers to an amount of a growth factor that is capable of stimulating cell division in a target tissue *in vivo*. Stimulation of cell proliferation in a target tissue means that the number of dividing cells in the target tissue is greater than in
15 the absence of treatment. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and particular growth factor that is used. The effective amount for a given situation can be determined by routine experimentation and will vary from growth factor to growth factor. For example, for HGF, a dose of 1 ug/kg to
20 2 mg/kg body weight, and more preferably from 10 ug/kg to 200 ug/kg body weight is used. In the case of KGF, a dose of 100 ug/kg to 5 mg/kg body weight, or more preferably a dose of 1 mg/kg to 50 mg/kg body weight is used. Dose amounts for the other growth factors used in the claimed methods are known to those of skill in the art or can readily be determined experimentally.

25 Clofibrate, or the other proxisome proliferators, can be administered by IP injection (5-500 mg/kg), or orally (5-500 mg/kg). More preferably the dosages are 10-100 mg/kg. A typical dosing schedule is daily administration for 3-10 days. A tapered dosing can alternatively be employed. Following clofibrate dosing, retroviral vectors can be administered, preferably intravenously, at doses ranging from 1E5 to 1E11 cfu per
30 injection. Injection schedules of one to three times daily, for one to ten days, will be

employed. Repeat administrations of retroviral vector with or without repeat clofibrate or growth factor dosing can be performed.

Collagenase can be administered at a dosage of from .05-5 U/kg, more preferably 0.5-2 U/kg (Liu (1994) Hepatology 19:1521). Estrogens with HGF or other growth factors
5 can be administered at a dosage of 0.01-20 ug/g, and more preferably 0.5-2 ug/g. Heparin or other sulfated glycosaminoglycans administered with HGF or other growth factors can be administered at a dose of 100-10,000 U/kg, more preferably 2000-6000 U/kg.

9-cis-retinoic acid is administered at dosages of 10-200 mg/kg, more preferably 60-100 mg/kg. Cyclosporine A is delivered at a dose of 0.1-100 mg/kg, more preferably 10-
10 50 mg/kg. Prostaglandins E1 and/or I1; isoproterenol can be administered at dosages of 0.5-100 ug/kg; more preferably 1-10 ug/kg with or without glucagon at a dose of 0.1-1-10 mg/kg, more preferably 0.5-2 mg/kg. Phosphatidylethanolamine N-methyltransferase inhibitors such as 3-deazaadenosine or other methylation inhibitors are administered at a
15 dose of 1-50 mg/kg, more preferably 5-15 mg/kg. Liver mitogen nafenopin can be administered at a dose of 0.1- 1000 mg/kg, more preferably 50-300 mg/kg. Cyproterone acetate can be administered at a dose of (0.1- 600 mg/kg, more preferably 10-100 mg/kg. Triiodothyronine can be administered at at dose of 0.1-10 mg/kg, more preferably 0.5-5.0 mg/kg.

20 The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLE 1

Preparation of Retroviral Vector Backbones

A. Preparation of Retroviral Backbones KT-1 and KT-3B

25 The Moloney murine leukemia virus (MoMLV) 5' long terminal repeat (LTR) EcoR I-EcoR I fragment, including *gag* sequences, from the N2 vector (Armentano *et al.*, 1987, *J. Vir.* 61:1647-1650; Eglitis *et al.*, 1985, *Science* 230:1395-1398) is ligated into the plasmid SK⁺ (Stratagene, La Jolla, CA). The resulting construct is designated N2R5. The N2R5 construct is mutated by site-directed *in vitro* mutagenesis to change the ATG start

codon to ATT preventing gag expression. This mutagenized fragment is 200 base pairs (bp) in length and flanked by Pst I restriction sites. The Pst I-Pst I mutated fragment is purified from the SK⁺ plasmid and inserted into the Pst I site of N2 MoMLV 5' LTR in plasmid pUC31 to replace the non-mutated 200 bp fragment. The plasmid pUC31 is
 5 derived from pUC19 (Stratagene, La Jolla, CA) in which additional restriction sites Xho I, Bgl II, BssH II and Nco I are inserted between the EcoR I and Sac I sites of the polylinker. This construct is designated pUC31/N2R5gM.

A 1.0 kilobase (Kb) MoMLV 3' LTR EcoR I-EcoR I fragment from N2 is cloned into plasmid SK⁺ resulting in a construct designated N2R3⁺. A 1.0 Kb Cla I-Hind III
 10 fragment is purified from this construct.

The Cla I-Cla I dominant selectable marker gene fragment from pAFVXM retroviral vector (Kriegler *et al.*, 1984, *Cell* 38:483; St. Louis *et al.*, 1988, *PNAS* 85:3150-3154), comprising a SV40 early promoter driving expression of the neomycin (neo) phosphotransferase gene, is cloned into the SK⁺ plasmid. This construct is designated
 15 SK⁺ SV₂-neo. A 1.3 Kb Cla I-BstB I gene fragment is purified from the SK⁺ SV₂-neo plasmid

KT-3B or KT-1 vectors are constructed by a three part ligation in which the Xho I-Cla I fragment containing the gene of interest and the 1.0 Kb MoMLV 3' LTR Cla I-Hind III fragment are inserted into the Xho I-Hind III site of pUC31/N2R5gM plasmid. This
 20 gives a vector designated as having the KT-1 backbone. The 1.3 Kb Cla I-BstB I neo gene fragment from the pAFVXM retroviral vector is then inserted into the Cla I site of this plasmid in the sense orientation to yield a vector designated as having the KT-3B backbone

EXAMPLE 2

25 0.1. ADMINISTRATION OF RECOMBINANT RETROVIRUSES EXPRESSING FACTOR VIII

A. Construction of Full-Length and B Domain Deleted Factor VIII cDNA

RETROVECTOR™

The following is a description of the construction of several retroviral vectors encoding a full-length factor VIII cDNA. Further discussion is also provided in PCT

Patent Publication No. WO 96/21035. Due to the packaging constraints of retroviral vectors and because selection for transduced cells is not a requirement for therapy, a retroviral backbone, e.g., KT-1, lacking a selectable marker gene is employed.

1. Production of Plasmid Vectors Encoding Full-Length Factor VIII

5 A gene encoding full-length factor VIII can be obtained from a variety of sources. One such source is the plasmid pCIS-F8 (see EP 0 260 148), which contains a full-length factor VIII cDNA whose expression is under the control of a CMV major immediate-early (CMV MIE) promoter and enhancer. The factor VIII cDNA contains approximately 80 bp of 5' untranslated sequence from the factor VIII gene and a 3' untranslated region of about 10 500 bp. In addition, between the CMV promoter and the factor VIII sequence lies a CMV intron sequence, or "cis" element. The cis element, spanning about 280 bp, comprises a splice donor site from the CMV major immediate-early promoter about 140 bp upstream of a splice acceptor from an immunoglobulin gene.

More specifically, a plasmid, designated pJW-2, encoding a retroviral vector for 15 expressing full length factor VIII is constructed using the KT-1 backbone from pKT-1. Briefly, in order to facilitate directional cloning of the factor VIII cDNA insert into pKT-1, the unique Xho I site is converted to a Not I site by site directed mutagenesis. The resultant plasmid vector is then opened with Not I and Cla I. pCIS-F8 is digested to completion with Cla I and Eag I, for which there are two sites, to release the fragment 20 encoding full-length factor VIII. This fragment is then ligated into the Not I/Cla I restricted vector to generate a plasmid designated pJW-2.

2. Construction of a Truncated Factor VIII Retrovector (ND-5)

A plasmid vector encoding a truncation of about 80% (approximately 370 bp) of the 3' untranslated region of the factor VIII cDNA, designated pND-5, is constructed in a 25 pKT-1 vector as follows: As described for pJW-2, the pKT-1 vector employed has its Xho I restriction site replaced by that for Not I. The factor VIII insert is generated by digesting pCIS-F8 with Cla I and Xba I, the latter enzyme cutting 5' of the factor VIII stop codon. The approximately 7 kb fragment containing all but the 3' coding region of the factor VIII

gene is then purified. pCIS-F8 is also digested with Xba I and Pst I to release a 121 bp fragment containing the gene's termination codon. This fragment is also purified and then ligated in a three way ligation with the larger fragment encoding the rest of the factor VIII gene and Cla I/Pst I restricted BLUESCRIPT® KS⁺ plasmid (Stratagene, *supra*) to produce a plasmid designated pND-2.

The unique Sma I site in pND-2 is then changed to a Cla I site by ligating Cla I linkers (New England Biolabs, Beverly, MA) under dilute conditions to the blunt ends created by a Sma I digest. After recircularization and ligation, plasmids containing two Cla I sites are identified and designated pND-3.

The factor VIII sequence in pND-3, bounded by Cla I sites and containing the full length gene with a truncation of much of the 3' untranslated region, is cloned as follows into a plasmid backbone derived from a Not I/Cla I digest of pKT-1 (a pKT-1 derivative by cutting at the Xho I site, blunting with Klenow, and inserting a Not I linker (New England Biolabs)), which yields a 5.2 kb Not I/Cla I fragment. pCIS-F8 is cleaved with Eag I and Eco RV and the resulting fragment of about 4.2 kb, encoding the 5' portion of the full-length factor VIII gene, is isolated. pND-3 is digested with Eco RV and Cla I and a 3.1 kb fragment is isolated. The two fragments containing portions of the factor VIII gene are then ligated into the Not I/Cla I digested vector backbone to produce a plasmid designated pND-5.

3. Construction of the B-Domain Deleted Vector

The precursor DNA for the B-deleted FVIII is obtained from Miles Laboratory. This expression vector is designated p25D and has the exact backbone as pCISF8 above. The Hpa I site at the 3' of the FVIII8 cDNA in p25D is modified to Cla-I by oligolinkers. An Acc I to Cla I fragment is clipped out from the modified p25D plasmid. This fragment spans the B-domain deletion and includes the entire 3' two-thirds of the cDNA. An Acc I to Cla I fragment is removed from the Retrovector™ JW-2 above, and replaced with the modified B-domain deleted fragment just described. This is designated B-del-1.

B. Assay for Factor VIII Expression

1. Assay of KT-ND5 Vector Expression by Transient Packaging and Transduction of Murine Cells

Cell lines, L33, (Dennert, USC Comprehensive Cancer Center, Los Angeles, CA, Patek, *et al.*, 1979, *Int. J. of Cancer* 24:624-628) BC10ME (Patek *et al.*, 1982, *Cell Immuno* 72:113, ATCC# TIB85) L33env, and BCenv (L33env and BCenv express HIV-1 IIIBenv, Warner *et al.*, 1991, *AIDS Res. and Human Retrovirus* 7:645), transduced with the KT-ND5 vector, carrying the amphotropic or VSVG envelope protein are examined for the expression of factor VIII. Non-transduced cells are also analyzed for factor VIII expression and compared with KT-ND5 transduced cells to determine the effect of transduction on protein expression.

Murine cell lines, L33-KT-ND5, L33env-KT-ND5, L33env, L33, BC10ME, BC10ME-KT-ND5, BCenv, and BCenv-KT-ND5, are tested for expression of the KT-ND5 molecule. Cells are grown to subconfluent density and the supernatant is removed following centrifugation at 200 xg. The samples are diluted and assayed by the Coamatic® Factor VIII assay (KabiVitrum Diagnostica, Molndal, Sweden).

The assay is performed as follows: 100 µl of culture media are mixed with 200 µl of 1x working buffer diluted according to the manufacturer's instructions. Fifty µl of the mixture are prewarmed at 37°C for 3-4 minutes in wells of a microtiter plate. The 50 µl of factor reagent from the kit, prewarmed to 37°C are added, and the mixture incubated at 37°C for 4 min., after which 50 µl of chromogenic substrate (7.7mg S2765 plus 0.2 mg of thrombin inhibitor I2581 in a mannitol carrier, diluted to a total of 6.0 ml with sterile water) are added. After a 10 minute incubation at 37°C, 50 µl of 20% acetic acid are added to stop the reaction. Absorbance at 405 nm is determined against buffer. A standard curve using dilutions of pooled normal human plasma (1.0 IU factor VIII/ml) is used. Serum levels of factor VIII in non-hemophilic patients are in the range of 200 ng/mL.

When this assay is used for patient samples, 9 volumes of blood are mixed with one volume of 0.1 M sodium citrate, at a neutral pH, and centrifuged at 2,000 x g for 5 - 20 min. at 20 - 25°C to pellet cells. Due to heat lability of factor VIII, plasma samples

should be tested within 30 min. of isolation or stored immediately at -70°C , although as much as 20% of factor VIII activity may be lost during freezing and thawing.

2. Assay of KT-ND5 Vector Expression by Transient Packaging and Transduction of Human Cells

5 Cell lines transduced with KT-ND5 are examined for expression of factor VIII. Non-transduced cells are analyzed to compare with KT-ND5 transduced cells and determine the effect that transduction has on expression.

Two human cell lines, JY and JY-KT-ND5 are tested for expression of KT-ND5. Suspension cells grown to 10^6 cells/ml are removed from culture flasks by pipet and
10 pelleted by centrifugation at 200 xg. The supernatant is removed, diluted, and assayed by the Coamatic^R Factor VIII assay as described above in Example 2B1.

C. Transient Transfection and Transduction of Packaging Cell Lines HX and DA with the Vector Construct KT-ND5

15 1. Plasmid DNA Transfection

The packaging cell line, HX (WO92/05266), are seeded at 5.0×10^5 cells on a 10 cm tissue culture dish on day 1 with Dulbecco's Modified Eagle Medium (DMEM) and 10% fetal bovine serum (FBS). On day 2, the media is replaced with 5.0 ml fresh media 4 hours prior to transfection. A standard calcium phosphate-DNA co-precipitation
20 is performed by mixing 40.0 μl 2.5 M CaCl_2 , 10 μg plasmid DNA, and deionized H_2O to a total volume of 400 μl . Four hundred microliters of the DNA- CaCl_2 solution is added dropwise with constant agitation to 400 μl precipitation buffer (50 mM HEPES- NaOH , pH 7.1; 0.25 M NaCl and 1.5 mM $\text{Na}_2\text{HPO}_4\text{-NaH}_2\text{PO}_4$). This mixture is incubated at room temperature for 10 minutes. The resultant fine precipitate is added to a culture dish of
25 cells. The cells are incubated with the DNA precipitate overnight at 37°C . On day 3, the media is aspirated and fresh media is added. The supernatant is removed on day 4, passed through a 0.45 μl filter, and stored at -80°C .

Alternatively, 29 2 3 cells (WO 92/05266) (these are 293 cells expressing gag and pol) are transfected with the vector DNA and the plasmid pMLP-VSVG (or other

VSVG encoding plasmids) to yield VSVG pseudotyped vector particles that are harvested and stored as described above.

2. Packaging Cell Line Transduction

DA (an amphotropic cell line derived from a D17 cell line ATCC No. 183, WO 92/05266) cells are seeded at 5.0×10^5 cells/10 cm tissue culture dish in 10 ml DMEM and 10% FBS, 4 $\mu\text{g/ml}$ polybrene (Sigma, St. Louis, MO) on day 1. On day 2, 3.0 ml, 1.0 ml and 0.2 ml of the freshly collected virus-containing HX media is added to the cells. The cells are incubated with the virus overnight at 37°C. On day 3, the media is removed and 1.0 ml DMEM, 10% FBS with 800 $\mu\text{g/ml}$ G418 is added to the plate. Only cells that have been transduced with the vector and contain the neomycin selectable marker will survive. A G418 resistant pool is generated over a period of a week. The pool of cells is dilution cloned by removing the cells from the plate and counting the cell suspension, diluting the cells suspension down to 10 cells/ml and adding 0.1 ml to each well (1 cell/well) of a 96 well plate (Corning, Corning, NY). Cells are incubated for 14 days at 37°C, 10% CO₂. Twenty-four clones are selected and expanded up to 24 well plates, 6 well plates then 10 cm plates at which time the clones are assayed for expression and the supernatants are collected and assayed for viral titer.

The titer of the individual clones is determined by infection of HT1080 cells, (ATCC No. CCL 121). On day 1, 5.0×10^5 HT1080 cells are plated on each well of a 6 well microtiter plate in 3.0 ml DMEM, 10% FBS and 4 $\mu\text{g/ml}$ polybrene. On day 2, the supernatant from each clone is serially diluted 10 fold and used to infect the HT1080 cells in 1.0 ml aliquots. The media is replaced with fresh DMEM, 10% FBS media, and the cells incubated with the vector overnight at 37°C, 10% CO₂. On day 3, selection of transduced cells is performed by replacing the media with fresh DMEM, 10% FBS media containing 800 $\mu\text{g/ml}$ G418. Cells are incubated at 37°C, 10% CO₂ for 14 days at which time G418 resistant colonies are scored at each dilution to determine the viral titer of each clone as colony forming units(cfu)/ml.

Using these procedures, cell lines are derived that produce greater than or equal to 10^6 cfu/ml in culture.

The packaging cell line HX is transduced with vector generated from the DA vector producing cell line in the same manner as described for transduction of the DA cells from HX supernatant.

5 Transduction of the DA or HX cells with vectors lacking a *neo* selectable marker (Example 1) was performed as described above. However, instead of adding G418 to the cells on day 3, the cells are cloned by limiting dilution. Titer is analyzed as described above.

3. Generation of Producer Cell Line via One Packaging Cell Line

10 In some situations it may be desirable to avoid using more than one cell line in the process of generating producer lines. In this case, DA cells are seeded at 5.0×10^5 cells on a 10 cm tissue culture dish on day 1 with DMEM and 10% irradiated (2.5 megarads minimum) FBS. On day 2, the media is replaced with 5.0 ml fresh media 4 hours prior to transfection. A standard calcium phosphate-DNA coprecipitation is performed by mixing 60 μ l 2.0 M CaCl_2 , 10 μ g MLP-G plasmid, 10 μ g KT-ND5 retroviral vector plasmid, and 15 deionized water to a volume of 400 μ l. Four hundred microliters of the DNA- CaCl_2 solution is added dropwise with constant agitation to 400 μ l 2X precipitation buffer (50 mM HEPES-NaOH, pH 7.1, 0.25 M NaCl and 1.5 mM $\text{Na}_2\text{HPO}_4\text{-NaH}_2\text{PO}_4$). This mixture is incubated at room temperature for 10 minutes. The resultant fine precipitate is added to a culture dish of DA cells plated the previous day. The cells are incubated with 20 the DNA precipitate overnight at 37°C. On day 3, the medium is removed and fresh medium is added. The supernatant containing G-pseudotyped virus is removed on day 4, passed through a 0.45 μ l filter and used to infect the DA packaging cell.

DA cells are seeded at 5.0×10^5 cells on a 10 cm tissue culture dish in 10 ml DMEM and 10% FBS, 4 mg/ml polybrene (Sigma, St. Louis, MO) on day 1. On day 2, 25 2.0 ml, 1.0 ml or 0.5 ml of the freshly collected and filtered G-pseudotyped virus containing supernatant is added to the cells. The cells are incubated with the virus overnight at 37°C. On day 3 the medium is removed and 10 ml DMEM, 10% irradiated FBS with 800 μ g/ml G418 is added to the plate. Only cells that have been transduced with the vector and contain the *neo* selectable marker will survive. A G418 resistant pool is 30 generated over the period of 1-2 weeks. The pool is tested for expression and then dilution

cloned by removing the cells from the plate, counting the cell suspension, diluting the cell suspension down to 10 cells/ml and adding 0.1 ml to each well (1 cell/well) of a 96-well plate. Cells are incubated for 2 weeks at 37°C, 10% CO₂. Twenty-four clones are selected and expanded up to 24-well plates, then 6-well plates, and finally 10 cm plates, at which time the clones are assayed for expression and the supernatants are collected and assayed for viral titer as described above.

D. Detection of Replication Competent Retroviruses (RCR)

1. The Extended S⁺L⁻ Assay

The extended S⁺L⁻ assay determines whether replication competent, infectious virus is present in the supernatant of the cell line of interest. The assay is based on the empirical observation that infectious retroviruses generate foci on the indicator cell line MiCl₁ (ATCC No. CCL 64.1). The MiCl₁ cell line is derived from the Mv1Lu mink cell line (ATCC No. CCL 64) by transduction with Murine Sarcoma Virus (MSV). It is a non-producer, non-transformed, revertant clone containing a replication defective murine sarcoma provirus, S⁺, but not a replication competent murine leukemia provirus, L⁻. Infection of MiCl₁ cells with replication competent retrovirus "activates" the MSV genome to trigger "transformation" which results in foci formation.

Supernatant is removed from the cell line to be tested for presence of replication competent retrovirus and passed through a 0.45 µ filter to remove any cells. On day 1, Mv1Lu cells are seeded at 1.0 x 10⁵ cells per well (one well per sample to be tested) of a 6 well plate in 2 ml DMEM, 10% FBS and 8 µg/ml polybrene. Mv1Lu cells are plated in the same manner for positive and negative controls on separate 6 well plates. The cells are incubated overnight at 37°C, 10% CO₂. On day 2, 1.0 ml of test supernatant is added to the Mv1Lu cells. The negative control plates are incubated with 1.0 ml of media. The positive control consists of three dilutions (200 focus forming units (ffu), 20 ffu and 2 ffu each in 1.0 ml media) of MA virus (referred to as pAM in Miller *et al.*, *Molec. and Cell Biol.* 5:431, 1985) which is added to the cells in the positive control wells. The cells are incubated overnight. On day 3, the media is aspirated and 3.0 ml of fresh DMEM and 10% FBS is added to the cells. The cells are allowed to grow to confluency and are split

1:10 on day 6 and day 10, amplifying any replication competent retrovirus. On day 13, the media on the Mv1Lu cells is aspirated and 2.0 ml DMEM and 10% FBS is added to the cells. In addition, the MiCl₁ cells are seeded at 1.0×10^5 cells per well in 2.0 ml DMEM, 10% FBS and 8 µg/ml polybrene. On day 14, the supernatant from the Mv1Lu cells is transferred to the corresponding well of the MiCl₁ cells and incubated overnight at 37°C, 10% CO₂. On day 15, the media is aspirated and 3.0 ml of fresh DMEM and 10% FBS is added to the cells. On day 21, the cells are examined for focus formation (appearing as clustered, refractile cells that overgrow the monolayer and remain attached) on the monolayer of cells. The test article is determined to be contaminated with replication competent retrovirus if foci appear on the MiCl₁ cells. Using these procedures, it can be shown that the HBV core producer cell lines are not contaminated with replication competent retroviruses.

2. Cocultivation of Producer Lines and MdH Marker Rescue Assay

As an alternate method to test for the presence of RCR in a vector-producing cell line, producer cells are cocultivated with an equivalent number of *Mus dunni* (NIH NIAID Bethesda, MD) cells. Small scale cocultivations are performed by mixing of 5.0×10^5 *Mus dunni* cells with 5.0×10^5 producer cells and seeding the mixture into 10 cm plates (10 ml standard culture media/plate, 4 µg/ml polybrene) at day 0. Every 3-4 days the cultures are split at a 1:10 ratio and 5.0×10^5 *Mus dunni* cells are added to each culture plate to effectively dilute out the producer cell line and provide maximum amplification of RCR. On day 14, culture supernatants are harvested, passed through a 0.45 µ cellulose-acetate filter, and tested in the MdH marker rescue assay. Large scale cocultivations are performed by seeding a mixture of 1.0×10^8 *Mus dunni* cells and 1.0×10^8 producer cells into a total of twenty T-150 flasks (30 ml standard culture media/flask, 4 µg/ml polybrene). Cultures are split at a ratio of 1:10 on days 3, 6, and 13 and at a ratio of 1:20 on day 9. On day 15, the final supernatants are harvested, filtered and a portion of each is tested in the MdH marker rescue assay.

The MdH marker rescue cell line is cloned from a pool of *Mus dunni* cells transduced with LHL, a retroviral vector encoding the hygromycin B resistance gene (Palmer *et al.*, 1987, *PNAS* 84: 1055-1059). The retroviral vector can be rescued from

MdH cells upon infection of the cells with RCR. One ml of test sample is added to a well of a 6-well plate containing 10^5 MdH cells in 2 ml standard culture medium (DMEM with 10% FBS, 1% 200 mM L-glutamine, 1% non-essential amino acids) containing 4 $\mu\text{g/ml}$ polybrene. Media is replaced after 24 hours with standard culture medium without polybrene. Two days later, the entire volume of MdH culture supernatant is passed through a 0.45 μ cellulose-acetate filter and transferred to a well of a 6-well plate containing 5.0×10^4 *Mus dunni* target cells in 2 ml standard culture medium containing polybrene. After 24 hours, supernatants are replaced with standard culture media containing 250 $\mu\text{g/ml}$ of hygromycin B and subsequently replaced on days 2 and 5 with media containing 200 $\mu\text{g/ml}$ of hygromycin B. Colonies resistant to hygromycin B appear and are visualized on day 9 post-selection, by staining with 0.2% Coomassie blue.

F. Transduction of Human Cells with KT-ND5 Vector Construct

On day one, HT1080 cells are set up at 2×10^4 cells per well in six well tissue culture plates containing 2 mls standard growth media (DME + 10% FBS). On day two, ND-5 FVIII retroviral vector particles from a confluent vector producing cell line are harvested as a HX-ND-5 clone. They are filtered through .45 μm syringe filters prior to testing the supernatants. (Alternatively the filtered media supernatants may be frozen at 80 in aliquots for later use.) Polybrene is added to each well such that the final concentration is 8 μg per ml. Thirty minutes later, either diluted or undiluted retroviral vector supernatant is added to duplicate wells. Typical volumes and dilutions are 0.5 ml per well and four or more 1:3 serial dilutions in growth media. As a control, two wells are transduced with the same volume of growth media only. On day three, the wells are refeed with 2mls of fresh media and the cells allowed to reach confluence, which may typically be about day four or five. On this day, the cells are again refeed with one ml per well fresh growth media. Twenty four hours later the media is harvested and filtered as above.

G. Expression of Transduced Vector for FVIII

The expression of vector transduced human cells for FVIII is detected by the Coamatic^R assay as described above in Example 2B1. Activity is assayed relative to

supernatant from the control wells by counting the cells per well from the two control wells and normalizing FVIII expression data per 1×10^6 cells per 24 hours.

H. Administration of Vector Construct

1. Animal Administration Protocol

5 The intestinal epithelium is an attractive site for gene delivery due to its rapidly proliferating tissue mass and the known location of stem cells in the crypts of Lieberkuhn. The deep location of the stem cells in the crypts and the protective role of the mucus gel layer, makes the retrovirus relatively inaccessible to the tissue cells. However, the accessibility of the retroviral vector to these stem cells can be improved in animal models
10 by the *in vivo* mucus removal method of Sandberg *et al.*, 1994, *Human Gene Therapy* 5:3232-329.

Male Sprague-Dawley rats obtained from Charles River Breeding Laboratories (Portage, MD.) are anesthetized and the cecum is identified upon opening the peritoneal cavity. A 3 cm ileal segment is isolated from the last Peyer's patch in the terminal ileum
15 and ligated at each end. A plastic catheter attached to a syringe is inserted into the segment and two milliliters of the mucolytic agents dithiothreitol and N-acetyl-cysteine is instilled under mild pressure for two minutes, then removed. This procedure is repeated once again before filling the segment with 0.2 to 2.0 ml of retroviral vector particles at 10^6 to 10^{10} cfu/ml. The ligatures are removed 1 to 4 hours later and the abdominal cavity
20 is sutured. Control animals are instilled with formulation buffer only.

Blood is collected from the tail vein and assayed for factor VIII production by a sandwich ELISA specific for human factor VIII (according to the modified procedure of Zatloukal, K., *et al.*, *PNAS* 91:5148-5152, 1994). The ELISA is based on two
25 Diagnostica). ESH 4 (25 μ g/ml in 1.0 M NaHCO_3 /0.5 M NaCl, pH 9.0) is coupled to the ELISA plates overnight at 4°C, washed with 0.1% Tween 20 in PBS, and blocked with 1% BSA in PBS. The samples are applied in 0.05 M Tris-HCl/1 M NaCl/2% BSA, pH 7.5, over 4 hr at room temperature, the plates are washed, and ESH 8 (2.5 μ g/ml in 0.05 M Tris-HCl/1 M NaCl/2% BSA, pH 7.5,) which has been biotinylated with N-hydroxysuccinimidobiotin (Pierce, Rockford, IL.) is added for 2 hr at room temperature.

The color reaction is performed with peroxidase-conjugated streptavidin (Boehringer Mannheim, Indianapolis, IN.) and o-phenylenediamine dihydrochloride as substrate. The human factor VIII:c standard (from the National Institute for Biological Standards and Control, Hertfordshire, U.K.) and normal rat plasma are used as references.

5 2. Human Administration Protocol

Lyophilized recombinant retrovirus containing the gene for Factor VIII expression is formulated into an enteric coated tablet or gel capsule according to known methods in the art. These are described in the following patents: US 4,853,230, EP 225,189, AU 9,224,296, AU 9,230,801, and WO 92144,52.

10 The capsule is administered orally to be targeted to the jejunum. At 1 to 4 days following oral administration of the recombinant retrovirus, expression of Factor VIII is measured in the plasma and blood by the Coamatic[®] Factor VIII assay as described in Example 2B1.

EXAMPLE 3

15 INTRAVENOUS ADMINISTRATION OF RECOMBINANT RETROVIRUSES EXPRESSING TK

A. Construction of TK Vector Constructs

1 Construction of plasmids containing vector LTR sequences

All of the following retroviral vectors are based on the N2 vector (Keller et al., *Nature* 318:149-154, 1985). Briefly, 5' and 3' Eco RI LTR fragments (2.8 and 1.0 Kb, respectively) (Armentano, *J. Vir.* 61:1647, 1987; Eglitis, *Science* 230:1395, 1985) are initially subcloned into the Eco RI site of plasmids SK⁺ (Stratagene, San Diego, CA) and pUC31. pUC31 is a modification of pUC19 (Stratagene, San Diego, CA) carrying additional restriction sites (Xho I, Bgl II, BssH II, and Nco I) between the Eco RI and Sac I sites of the polylinker. Plasmid N2R3+/- is thereby created from ligation of the SK⁺ plasmid with the 1.0 Kb 3' LTR fragment. The plasmids p31N2R5+/- and p31N2R3+/- are constructed from the ligation of pUC31 with the 2.8 Kb 5' LTR and packaging signal (Y) or the 1.0 Kb 3' LTR fragment, respectively. In each case N2 refers to the vector source. R refers to the fact that the fragment is an Eco RI fragment, 5 and 3 refer to 5' or 3'

25

LTRs, and + or - refers to the orientation of the insert (see Figures 1-6 for examples of LTR subclones).

In one case, a 1.2 Kb Cla I/Eco RI 5' LTR and W fragment from N2 is subcloned into the same sites of an SK⁺ vector. This vector is designated pN2CR5. In another case, the 5' LTR containing a 6 bp deletion of the splice donor sequence (Yee *et al.*, Cold Spring Harbor, Quantitative Biology, 51:1021, 1986) is subcloned as a 1.8 Kb Eco RI fragment into pUC31. This vector is designated p31N25D[+], Figure 6.

2. Construction of plasmids containing HSVTK

The coding region and transcriptional termination signals of HSV-1 thymidine kinase gene (HSVTK) are isolated as a 1.8 Kb Bgl II/Pvu II fragment from plasmid 322TK (3.5 kb Bam HI fragment of HSV-1 (McKnight *et al.*) cloned into Bam HI of pBR322 (ATCC No. 31344)) and cloned into Bgl II/Sma I-digested pUC31. This construct is designated pUCTK. For constructs which require deletion of the terminator signals, pUCTK is digested with Sma I and Bam HI and the 0.3 Kb fragment containing the (A)_n signal is removed. The remaining coding sequences and sticky-end Bam HI overhang are reconstituted with a double-stranded oligonucleotide made from the following oligomers:

5' GAG AGA TGG GGG AGG CTA ACT GAG 3' (SEQUENCE ID. NO. 1)

5' GAT CCT CAG TTA GCC TCC CCC ATC TCT C 3' (SEQUENCE ID. NO. 2)

The resulting construct is designated pTKD A, Figure 7.

For diagnostic purposes, the oligonucleotides are designed to destroy the Sma I site while maintaining the Ava I site without changing the translated protein.

The plasmid pPrTKDA (Figure 8), which contains the HSVTK promoter and coding sequence (lacking an (A)_n signal), is constructed as follows.

1. pTKD A is linearized with Bgl II treated with alkaline phosphatase, and gel purified.
2. A 0.8 Kb fragment contained the HSVTK transcriptional promoter is isolated as a Bam HI/Bgl II fragment from p322TK.
3. Products from (1) and (2) are ligated, transformed into bacteria, and positive clones are screened for the proper orientation of the promoter region. A resultant clone is designated pPrTKDA (Figure 8).

3. Construction of retroviral provectors expressing HSVTK from a constitutive promoter

The retroviral provectors pTK-1 and pTK-3 are constructed essentially as described below.

1. The 5 Kb Xho I/Hind III 5' LTR and plasmid sequences are isolated from p31N2R5(+) (Figure 1).

2. HSVTK coding sequences lacking transcriptional termination sequences are isolated as a 1.2 Kb Xho I/Bam HI fragment from pTKDA (Figure 2).

3. 3' LTR sequences are isolated as a 1.0 Kb Bam HI/Hind III fragment from pN2R3(-) (Figure 2).

4. The fragments from steps 1-3 are mixed, ligated, transformed into bacteria, and individual clones identified by restriction enzyme analysis. The construct is designated TK-1 (Figure 9).

5. pTK-3 is constructed by linearizing TK-1 with Bam HI, filling in the 5' overhang and blunt-end ligating a 5'-filled Cla I/Cla I fragment containing the bacterial lac UV5 promoter, SV40 early promoter, plus Tn5 neo^r gene obtained from pAFVXM retroviral vector (Krieger *et al.*, 1984, *Cell* 39:483; St. Louis *et al.*, 1988, *PNAS* 85:3150). Kanamycin-resistant clones are isolated and individual clones are screened for the proper orientation by restriction enzyme analysis (Figure 9).

These constructs were used to generate infectious recombinant vector particles in conjunction with a packaging cell line, such as DA as described above.

B. Determination of the Effect of Ganciclovir on Mouse Colon Carcinoma Cells With or Without TK-3 Vector

An experiment was performed to determine whether or not ganciclovir had an effect on CT26 cells (colon tumor 26, Brattain, Baylor College of Medicine, Houston, TX) that were transduced with DA/TK-3. CT26 cells are transduced with G-pseudotyped TK-3 vector. Twenty-four hours after adding the viral supernatant, the CT26 cells are placed under G-418 selection (450 lg/ml). After 10 days incubation, a G-418 selected pool is

obtained and designated CT26TK Neo. CT26 TK Neo cells were seeded into six 10 cm² plates at a density of 2.5×10^6 per plate. As controls, each of two other cell types, CT26 and CT26 beta-gal (this cell line was transduced with a retroviral vector carrying the reporter gene β -galactosidase from *E. coli.*), were also seeded into six 10 cm² plates as controls. Five plates of each cell type were treated twice per day for four consecutive days with medium containing ganciclovir concentrations of 100 μ g/ml, 50 μ g/ml, 25 μ g/ml, 12.5 μ g/ml and 6.25 μ g/ml. One plate of each cell type was left untreated. Afterwards, the cells were removed from each dish using trypsin-EDTA, resuspended in DMEM with 10% FBS and counted. The data in Figure 10 shows that even the lowest dose of ganciclovir had a dramatic cytotoxic effect on the CT26 TKneo cells. This dose of ganciclovir (6.25 μ g/ml) or even the next higher dose (12.5 μ g/ml) did not have an effect on either the CT26 or CT26 beta-gal cells. However, beginning at a ganciclovir dose of 25 μ g/ml, a dose-dependent decrease in cell growth could be seen, although CT26 TK Neo cells were always more sensitive to the drug.

C. Determination of a Ganciclovir Dose For the Treatment of Mice Injected with CT26 TK Neo Cells

In order to test whether *in vivo* transduction of a murine tumor could be used to treat the disease, an experiment was performed to determine the optimal concentration of ganciclovir necessary to eliminate a tumor that was transduced and selected *in vitro* to assure 100% transduction. Twelve groups of 3 mice each are injected with 2×10^5 CT26TK Neo cells. Six groups of mice are injected with these cells intraperitoneally (I.P.) and six groups of mice are injected subcutaneously (S.C.). Two other groups of 3 mice each are injected with 2×10^5 unmodified CT26 cells (as a control) either I.P. or S.C..

Ten days after the injection of the CT26 or CT26TK Neo cells into these groups of mice, several concentrations of ganciclovir treatment are initiated. Each dose regimen consists of 2 daily AM and PM I.P. injections of ganciclovir. The experiment is summarized in Table A below.

TABLE A

Group	Innoculum	Injection Route	Concentration of Ganciclovir (Mg/Kg)
1	CT26 I.P.	0	
2	CT26 TKneo	I.P.	0
3	CT26 TKneo	I.P.	15.63
4	CT26 TKneo	I.P.	31.25
5	CT26 TKneo	I.P.	62.5
6	CT26 TKneo	I.P.	125.0
7	CT26 TKneo	I.P.	250.0
8	CT26 TKneo	I.P.	500.0
9	CT26 Subq.	0	
10	CT26 TKneo	Subq.	0
11	CT26 TKneo	Subq.	15.63
12	CT26 TKneo	Subq.	31.25
13	CT26 TKneo	Subq.	62.5
14	CT26 TKneo	Subq.	125.0
15	CT26 TKneo	Subq.	250.0
16	CT26 TKneo	Subq.	500.0

After 5 days, all of the mice in the 125 mg/Kg, 250 mg/Kg and 500 mg/Kg treated groups were dead due to the toxic effects of ganciclovir. Mice in the 15.63 mg/Kg, 31.25 mg/Kg and 62.5 mg/Kg treated groups were treated for an additional 7 days and were able to tolerate the treatment. Tumor measurements were made for 23 days Figure 11).

CT26TK Neo grew only slightly slower than unmodified CT26 in the absence of ganciclovir. Complete tumor regression was seen in the groups of mice treated with the 62.5 mg/Kg regimen. Partial tumor regression was seen in the 31.25 mg/Kg treated groups. Little or no effect was seen in the 15.63 mg/Kg treated groups as compared to the 2 untreated control groups. Even though there was some toxicity observed in the 62.5 mg/Kg groups, it was not life threatening and reversible upon the discontinuation of the

treatments so this concentration was used for future studies (Figure 11). After 24 days, the I.P. injected animals were sacrificed and evaluated. The optimal concentration for anti-tumor effect was similar whether the tumor was grown I.P. or S.C.

D. Comparison of Cytotoxicity on CT26 and CT26TK Neo In Vivo Tumor Growth

5 In order to determine whether ganciclovir has an effect on the growth of unmodified CT26 tumor cells *in vivo*, 2 groups of 7 mice are injected S.C. with 2×10^5 unmodified CT26 cells and 2 groups of 7 mice are injected S.C. with 2×10^5 CT26TK Neo cells. Seven days after tumor implantation, one group of CT26 injected mice and one group of CT26TK Neo injected mice are placed on a twice daily (AM and PM) regimen
10 of I.P. ganciclovir at 62.5 mg/Kg. These mice are treated for 12 days or until the CT26TK Neo injected animals have no detectable tumor burden. Tumor growth is monitored over a three week period. Mice injected with CT26 and treated with ganciclovir had tumors that were somewhat smaller than untreated mice injected with CT26, indicating a small HSVTK-independent inhibition of tumor growth (Figure 12). However,
15 a dramatic decrease in tumor burden was observed if, and only if, CT26 TKneo containing mice were treated with ganciclovir (Figure 12).

E. Determination of the Effect of Ganciclovir on AY-27 Rat Carcinoma Cells With or Without the TK-3 Vector

20 An experiment is performed to determine whether or not ganciclovir has an effect on AY-27 cells that are transduced with DA/TK-3. AY-27 cells are rat carcinoma cells which have been induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (Selman *et al.*, 1986, *J. Urol* 136:141, 1986). The AY-27 cells are transduced with G-pseudotyped TK-3 vector. Twenty-four hours after adding the viral supernatant, the AY-27 cells are placed under G-418 selection (450 μ g/ml). After 10 days incubation, a G-418 selected pool is
25 obtained and designated AY-27TK Neo. AY-27TK Neo cells are seeded into six 10 cm² plates at a density of 2.5×10^6 per plate. As controls, each of two other cell types, AY-27 and AY-27beta-gal (this cell line is transduced with a virus carrying the reporter gene β -galactosidase from *E. coli.*), are also seeded into six 10 cm² plates as controls. Five plates

of each cell type are treated twice per day for four consecutive days with medium containing ganciclovir concentrations of 100 µg/ml, 50 µg/ml, 25 µg/ml, 12.5 µg/ml and 6.25 µg/ml. One plate of each cell type is left untreated. Afterwards, the cells are removed from each dish using trypsin-EDTA, resuspended in DMEM with 10% FBS and counted. The data generated can be used to determine the concentration which has the most cytotoxic effect on the AY-27, AY-27 beta-gal, or AY-27 TK Neo cells.

F. Determination of a Ganciclovir Dose For the Treatment of Rats Injected with AY-27 TK Neo Cells

In order to test whether *in vivo* transduction of a murine tumor could be used to treat the disease, an experiment was performed to determine the optimal concentration of ganciclovir necessary to eliminate a tumor that was transduced and selected *in vitro* to assure 100% transduction. Twelve groups of 3 rats each are injected with 2×10^5 AY-27TK Neo cells. Six groups of rats are injected with these cells intravesically. Six other groups of 3 rats each are injected intravesically with 2×10^5 unmodified AY-27 cells (as a control).

Ten days after the injection of the AY-27 or AY-27TK Neo cells into these groups of rats, several concentrations of ganciclovir treatment are initiated. Each dose regimen consists of 2 daily AM and PM I.P. injections of ganciclovir. The experiment is summarized in Table B below.

TABLE B

Group	Innoculum	Injection Route	Concentration of Ganciclovir (Mg/Kg)
1	AY-27		0
2	AY-27 TKneo	intravesically	0
3	AY-27 TKneo	intravesically	15.63
4	AY-27 TKneo	intravesically	31.25
5	AY-27 TKneo	intravesically	62.5
6	AY-27 TKneo	intravesically	125.0
7	AY-27 TKneo	intravesically	250.0
8	AY-27 TKneo	intravesically	500.0

Rats are treated for 12 days, eliminating those that die due to the higher concentrations of ganciclovir. Tumor measurements are made for 20 days, assessing tumor regression in order to determine an optimal ganciclovir concentration.

G. Administration Protocol

5 1. Rat Administration Protocol

AY-27 rat bladder carcinoma cells are transplanted into the bladders of 20 male Fischer 344 rats (Charles River Breeding Laboratories, Portage, MD). One to fourteen days following transplantation, tumor-bearing rats weighing between 200 to 300 grams are anesthetized, their bladders are surgically exteriorized and evacuated of urine with a 27-
10 gauge needle. Viral vector particles are instilled into the bladders of 5 rats at 10^6 to 10^{10} in cfu 200 to 2,000 μ l of formulation buffer. The addition of 4 to 8 μ g/ml of polybrene increases the efficiency of transduction. In order to prevent leakage, the cystotomy is repaired with 7-zero nonabsorbable suture. The virus is allowed to incubate in the presence of the tumor cells for 0.5 to 1.0 hour by keeping the animal anesthetized and
15 thereby preventing voiding. Ten control rats receive 500 μ l of formulation buffer only.

Alternatively, 200 to 2,000 μ l of vector can be instilled directly into the bladder by catheterization through the urethra following urine evacuation and rinsing with saline.

At 24 to 72 hours after vector treatment, the rats are placed on twice daily (AM and PM) injections of I.P. ganciclovir at the previously determined optimum dose (e.g. 62.5 mg/Kg body weight) for 4 to 12 days. Finally, the rats receive a single daily dose of ganciclovir until the end of the experiment (1 to 10 weeks). Whole bladders are removed and tumor growth is measured.

2. Human Administration Protocol

A urinary (Foley) catheter is inserted through the urethra into the bladder and secured in place. The bladder is evacuated of urine and washed with 100 to 500 mls of sterile saline. Recombinant retroviruses containing the gene for thymidine kinase expression are instilled through the catheter into the bladder at 10^5 to 10^{11} cfu in 10 to 500 ml of formulation buffer preferably containing 4 to 8 μ g/ml of polybrene, or other enhancing excipients. The viral particles are allowed to incubate for 0.25 to 12 hours prior to removal of the catheter. After 1 to 7 days, ganciclovir is administered at 1 to 5mg/Kg I.V. (at a constant rate over 1 hour) every 12 hours for 2 to 21 days. The vector can be readministered multiple times (2 to 20), followed by ganciclovir administration. Due to the frequency of granulocytopenia and thrombocytopenia in patients receiving ganciclovir, it is recommended that neutrophil and platelet counts be performed every two days during the dosing of the drug. Tumor regression is monitored by x-ray and/or biopsy and the treatment repeated if required.

EXAMPLE 4

Pulmonary Administration of Recombinant Retroviruses Expressing Factor VIII

A. Construction of Full-Length and B Domain Deleted Factor VIII cDNA Retrovector™

The construction of the full-length and B domain deleted Factor VIII retrovectors are described in Example 2A.

B. Aerosolization of Recombinant Retroviruses Expressing Factor VIII

The KT-ND5 viral supernatant in formulation buffer, with 4 to 8 µg/ml of polybrene or other transduction enhancing excipient, is nebulized using a DeVilbiss #15 Atomizer (DeVilbiss Health Care Division, Somerset, PA) designed to produce 0.3 to 0.5 µm particles (Rousculp, 1992, *Human Gene Therapy* 3:471-477). The aerosol produced by this nebulizer uses compressed air in a laminar flow hood. The mist is directed into a polypropylene tube, and the condensed vapor, as well as the control viral supernatant, is resterilized by 0.22 µm filtration. Retroviral particles pass through this filter without any significant loss of functional activity.

C. Administration of Vector Construct

1. Rat Administration Protocol

Rats are anesthetized and the trachea is exposed by anterior midline incision. Recombinant retroviral particles expressing the factor VIII gene product are diluted in 300 µl of formulation buffer, with or without 4 to 8 µg/ml of polybrene or other transduction enhancing excipient, at 10^5 to 10^{10} cfu/ml and instilled into the trachea through a small gauge needle. Control animals are administered 300 µl of formulation buffer only. The incision is sutured and the rats are allowed to recover. Two to fourteen days following viral instillation, blood is drawn from the tail vein and examined for factor VIII production as described in Example 2Hi.

2. Human Administration Protocol

The recombinant retrovirus is administered using a DeVilbiss #15 Atomizer (as described above) for 2 to 60 minutes. Two to fourteen days following administration of the recombinant retroviruses, expression of Factor VIII is measured in the blood and plasma by the Coamatic[®] Factor VIII assay (as described in Example 2B1).

EXAMPLE 5

Transdermal Administration of Recombinant Retroviruses

A. Construction of TK-3 Vector Construct

Construction and verification of the TK-3 vector construct and recombinant
5 retroviruses are described in Examples 3A through 3F.

B. Administration of Vector Construct

1. Animal Administration Protocol

Cottontail rabbit papillomavirus (CRPV) provides an animal model for the highly
10 oncogenic human papillomavirus (HPV). Papillomas can be induced in the cottontail
rabbit and virus infection leads to three different outcomes in the rabbit (Lin, Y. et al., *J Virol* 67:382, 1993). First, papillomas appear and persist for the lifetime of the rabbit;
second, papillomas spontaneously regress 2 to 3 months after infection; and third,
papillomas progress to carcinomas after 8 to 15 months.

15 In this experiment, twelve cottontail rabbits (E. Johnson, Rago, KA) are
injected with the B strain of CRPV (Stevens, J. et al., *J Virol* 30:891, 1979) by intradermal
injection as described by Stevens, J., et al., (*J Virol* 30:891, 1979). Four to six months
after infection, when papillomas form, the animals are divided into two groups. In the first
group, papillomas of 6 animals are injected with 25 to 100 μ l of formulation buffer, with
20 or without 4 to 8 μ g/ml of polybrene or other transduction enhancing excipient, at 10^5 to
 10^{10} cfu/ml through a small gauge needle. In the second group, control animals are
administered 25 to 100 μ l of formulation buffer only. At 24 to 72 hours after vector
treatment, the rabbits are placed on twice daily (AM and PM) injections of I.P. ganciclovir
at the previously determined optimum dose (e.g. 62.5 mg/Kg body weight) for 4 to 12
25 days. Finally, the rabbits receive a single daily dose of ganciclovir until the end of the
experiment (1 to 10 weeks). Papilloma regression is visually monitored for 2 to 14 days.

2. Human Administration Protocol

The clinical cutaneous lesions that result from the human papillomavirus (HPV)
30 include common warts, filiform warts, plantar warts, and anogenital warts (reviewed in

Cobb *et al.*, 1990, *J. Am. Acad. Derm.* 22:547). In this experiment, patients are divided into two groups. In the first group, 100 to 500 μ l of recombinant retrovirus particles at a concentration of 10^9 cfu/ml in a formulated ointment, preferably containing 4 to 8 μ g/ml of polybrene or other enhancing excipients, are applied to the warts using a transdermal delivery system (TDS).

Transdermal delivery systems (TDS) are capable of delivering a drug through intact skin so that it reaches the systemic circulation in sufficient quantity to be therapeutically beneficial. TDS provides a variety of advantages including elimination of gastrointestinal absorption problems and hepatic first pass effect, reduction of dosage and dose intervals, and improved patient compliance. The major components of TDS are a controlled release device composed of polymers, the drug to be administered, excipients, and enhancers, and a fastening system to fix the device to the skin. A number of polymers have been described which include gelatin, gum arabic, paraffin waxes, and cellulose acetate phthalate (Sogibayasi, K., *et al.*, *J. Controlled Release*, 29:177-185, 1994).

The second group receives 100 to 500 μ l of vector particle in formulation buffer only. The areas are covered and the viral particles are allowed to incubate for 0.25 to 12 hours prior to removal of the TDS. After 1 to 7 days, ganciclovir is administered at 1 to 5mg/Kg I.V., preferably at a constant rate over 1 hour) every 12 hours for 2 to 21 days. The vector can be readministered multiple times (2 to 20), followed by ganciclovir administration. Due to the frequency of granulocytopenia and thrombocytopenia in patients receiving ganciclovir, it is recommended that neutrophil and platelet counts be performed every two days during the dosing of the drug. The regression of the wart is visually monitored for 2 to 14 days.

EXAMPLE 6

Ocular Administration of Recombinant Retroviruses for E3/19K

A. Cloning of E3/19K Gene into KT-3B

5 1. Isolation and Purification of Adenovirus

The isolation and purification of adenovirus is described by Green *et al.* (*Methods in Enzymology* 58: 425, 1979). Specifically, five liters of Hela cells ($3-6.0 \times 10^5$ cells/ml) are infected with 100-500 plaque forming units (pfu) per ml of adenovirus type 2 (Ad2) virions (ATCC No. VR-846). After incubation at 37°C for 30-40 hours, the cells are
10 placed on ice, harvested by centrifugation at 230 xg for 20 minutes at 4°C, and resuspended in Tris-HCl buffer (pH 8.1). The pellets are mechanically disrupted by sonication and homogenized in trichlorotrifluoroethane prior to centrifugation at 1,000 xg for 10 min. The upper aqueous layer is removed and layered over 10 mls of CsCl (1.43 g/cm^3) and centrifuged in a SW27 rotor for 1 hour at 20,000 rpm. The opalescent viral
15 band is removed and adjusted to 1.34 g/cm^3 with CsCl and further centrifuged in a Ti 50 rotor for 16-20 hours at 30,000 rpm. The visible viral band in the middle of the gradient is removed and stored at 4°C until purification of adenoviral DNA.

2. Isolation and Purification of Adenovirus DNA

20 The adenovirus band is incubated with protease for 1 hour at 37°C to digest proteins. After centrifugation at 7,800 xg for 10 minutes at 4°C, the particles are solubilized in 5% SDS at room temperature for 30 minutes before being extracted with equal volumes of phenol. The upper aqueous phase is removed, re-extracted with phenol, extracted three times with ether, and dialyzed in Tris buffer for 24 hours. The viral Ad2
25 DNA is precipitated in ethanol, washed in ethanol, and resuspended in Tris-EDTA buffer (pH 8.0). Approximately 0.5 mg of viral Ad2 DNA is isolated from virus produced in 1.0 L of cells.

3. Isolation of E3/19K Gene

The viral Ad2 DNA is digested with EcoR I and separated by electrophoresis on a 1% agarose gel. The resulting 2.7 Kb Ad2 EcoR I D fragments, located in the Ad2 coordinate region 75.9 to 83.4, containing the E3/19K gene (Herisse *et al.*, *Nucleic Acids Research* 8:2173, 1980, Cladaras *et al.*, *Virology* 140:28, 1985) are eluted by electrophoresis, phenol extracted, ethanol precipitated, and dissolved in Tris-EDTA (pH 8.1).

4. Cloning of E3/19K Gene into KT-3B

The E3/19K gene is cloned into the EcoR I site of PUC1813. PUC1813 is prepared as essentially described by Kay *et al.* (*Nucleic Acids Research* 15:2778, 1987) and Gray *et al.* (*PNAS* 80:5842, 1983). The E3/19K is retrieved by EcoR I digestion and the isolated fragment is cloned into the EcoR I site of phosphatase-treated pSP73 plasmid. This construct is designated SP-E3/19K. The orientation of the SP-E3/19K cDNA is verified by using appropriate restriction enzyme digestion and DNA sequencing. In the sense orientation, the 5' end of the cDNA is adjacent to the Xho I site of the pSP73 polylinker and the 3' end adjacent to the Cla I site. The Xho I-Cla I fragment containing the E3/19K cDNA in either sense or antisense orientation is retrieved from the SP-E3/19K construct and cloned into the Xho I-Cla I site of the KT-3BB retroviral. This construct is designated KT-3B/E3/19K.

B. Cloning of PCR Amplified E3/19K Gene into KT-3B

1. PCR Amplification of E3/19K Gene

The Ad2 DNA E3/19K gene, including the amino terminal signal sequence, followed by the intraluminal domain and carboxy terminal cytoplasmic tail which allow the E3/19K protein to embed itself in the endoplasmic reticulum (ER), is located between viral nucleotides 28,812 and 29,288. Isolation of the Ad2 E3/19K gene from the viral genomic DNA is accomplished by PCR amplification, with the primer pair shown below:

The forward primer corresponds to the Ad2 nucleotide sequences 28,812 to 28,835.

(Seq ID No. 3) 5'-TATATCTCCAGATGAGGTACATGATTTTAGGCTTG-3'

The reverse primer corresponds to the Ad2 nucleotide sequences 29,241 to 29,213.

(Seq ID No. 4) 5'-TATATATCGATTCAAGGCATTTTCTTTTCATCAATAAAAC-3'

5

In addition to the Ad2 complementary sequences, both primers contain a five nucleotide "buffer sequence" at their 5' ends for efficient enzyme digestion of the PCT amplicon products. This sequence in the forward primer is followed by the Xho I recognition site and by the Cla I recognition site in the reverse primer. Thus, in the 5' to 3' direction, the E3/19K gene is flanked by Xho I and Cla I recognition sites. Amplification of the E3/19K gene from Ad2 DNA is accomplished with the following PCR cycle protocol:

10

Temperature°C	Time (min)	No. Cycles
94	2.0	1
94	0.5	
55	0.17	5
72	3.5	
94	0.5	30
70	3.5	
72	10.0	10

2. Ligation of PCR Amplified E3/19K Gene into KT-3B

15

The E3/19K gene from the SP-E3/19K construct, approximately 780 bp in length, is removed and isolated by 1% agarose/TBE gel electrophoresis. The Xho I-Cla I E3/19K fragment is then ligated into the KT-3B retroviral backbone. This construct is designated KT-3B/E3/19K. It is amplified by transforming *E. coli*, DH5 alpha bacterial strain (Bethesda Research Labs, Gaithersburg, Maryland) with the KT-3B/E3/19K construct.

20

Specifically, the bacteria is transformed with 1-100 ng of ligation reaction mixture DNA. The transformed bacterial cells are plated on LB plates containing ampicillin. The plates

are incubated overnight at 37°C, bacterial colonies are selected and DNA prepared from them. The DNA is digested with Xho I and Cla I. The expected endonuclease restriction cleavage fragment sizes for plasmids containing the E3/19K gene are 780 and 1,300 bp.

5 C. Transduction of Packaging Cell Line DA with the Recombinant Retroviral Vector KT-3B/E3/19K

1. Plasmid DNA Transfection

293 2-3 cells (a cell line derived from 293 cells ATCC No. CRL 1573, (WO 92/05266) 5.0×10^5 cells are seeded at approximately 50% confluence on a 6 cm tissue culture dish. The following day, the media is replaced with 4 ml fresh media 4 hours prior to transfection. A standard calcium phosphate-DNA coprecipitation is performed by mixing 10.0 µg of KT-3B/E3/19K plasmid and 10.0 µg MLP G plasmid with a 2M CaCl₂ solution, adding a 1x HEPES buffered saline solution, pH 6.9, and incubating for 15 minutes at room temperature. The calcium phosphate-DNA coprecipitate is transferred to the 293 2-3 cells, which are then incubated overnight at 37°C, 5% CO₂. The following morning, the cells are rinsed three times in 1x PBS, pH 7.0. Fresh media is added to the cells, followed by overnight incubation at 37°C, 10% CO₂. The following day, the media is collected off the cells and passed through a 0.45 µ filter. This supernatant is used to transduce packaging and tumor cell lines. Transient vector supernatant for other vectors are generated in a similar fashion.

2. Packaging Cell Line Transduction

Packaging cell line transduction is performed as described in Example 2C.

3. Production Of Replication Competent Retroviruses

Production of replication competent retroviruses is performed as described in Example 2D.

D. Transduction of Cell Lines with the Recombinant Retroviral Vector KT-3B/E3/19K

The following adherent human and murine cell lines are seeded at 5×10^5 cells/10 cm dish with 4 μ g/ml polybrene: HT 1080, Hela, and BC10ME. The following day, 1.0 ml of filtered supernatant from the DA E3/19K pool is added to each of the cell culture plates. The following day, 800 μ g/ml G418 is added to the media of all cell cultures. The cultures are maintained until selection is complete and sufficient cell numbers are generated to test for gene expression. The transduced cell lines are designated HT 1080-E3/19K, Hela-E3/19K and BC10ME-E3/19K, respectively.

EBV transformed cell lines (BLCL), and other suspension cell lines, are transduced by co-cultivation with irradiated producer cell line, such as DA-E3/19K. Specifically, irradiated (10,000 rads) producer line cells are plated at 5.0×10^5 cells/6 cm dish in growth media containing 4 μ g/ml polybrene. After the cells have been allowed to attach for 2-24 hours, 10^6 suspension cells are added. After 2-3 days, the suspension cells are removed, pelleted by centrifugation, resuspended in growth media containing 1mg/ml G418, and seeded in 10 wells of a round bottom 96 well plate. The cultures were expanded to 24 well plates, then to T-25 flasks.

E. Expression of E3/19K in the Recombinant Retroviral Vector Construct KT3B-E3/19K

1. Western Blot Analysis

Radio-immuno precipitation assay (RIPA) lysates are made from selected cultures for analysis of E3/19K expression. RIPA lysates are prepared from confluent plates of cells. Specifically, the media is first aspirated off the cells. Depending upon the size of the culture plate containing the cells, a volume of 100 to 500 ml ice cold RIPA lysis buffer (10 mM Tris, pH 7.4; 1% Nonidet P40; 0.1% SDS; 150 mM NaCl) is added to the cells. Cells are removed from plates using a micropipet and the mixture is transferred to a microfuge tube. The tube is centrifuged for 5 minutes to precipitate cellular debris and the supernatant is transferred to another tube. The supernatants are electrophoresed on a 10% SDS-polyacrylamide gel and the protein bands are transferred to an Immobilon membrane

in CAPS buffer (10 mM CAPS (Aldrich, Milwaukee, WI) pH 11.0; 10% methanol) at 10 to 60 volts for 2 to 18 hours. The membrane is transferred from the CAPS buffer to 5% Blotto (5% nonfat dry milk; 50 mM Tris, pH 7.4; 150 mM NaCl; 0.02% Na azide, and 0.05% Tween 20) and probed with a mouse monoclonal antibody to E3/19K (Severinsson *et al.*, 1985, *J. Cell. Biol.* 101:540-547). Antibody binding to the membrane is detected by the use of ^{125}I -Protein A.

2. FACS Analysis of KT3B-E3/19k-Vector Transduced Cells to Demonstrate Decreased Levels of Class I Expression Compared to Non-Transduced Cells.

Cell lines transduced with the KT3b-E3/19K-vector are examined for MHC class I molecule expression by FACS analysis. Non-transduced cells are also analyzed for MHC class I molecule expression and compared with E3/19K transduced cells to determine the effect of transduction on MHC class I molecule expression.

Murine cell lines, BC10ME, BC10ME-E3/19K, P815 (ATCC No. TIB 64), and P815-E3/19K, are tested for expression of the H-2D^d molecule on the cell surface. Cells grown to subconfluent density are removed from culture dishes by treatment with Versene and washed two times with cold (4°C) PBS plus 1% BSA and 0.02% Na-azide (wash buffer) by centrifugation at 200g. Two million cells are placed in microfuge tubes and pelleted in a microfuge at 200g before removing the supernatant. Cell pellets are resuspended with the H-2D^d-specific Mab 34-2-12s (50 ml of a 1:100 dilution of purified antibody, ATCC No. HB 87) and incubated for 30 min at 4°C with occasional mixing. Antibody labeled cells are washed two times with 1 ml of wash buffer (4°C) prior to removing the supernatant. Cells are resuspended with a biotinylated goat anti-mouse kappa light chain Mab (50 ml, of a 1:100 dilution of purified antibody) (Amersham, Arlington Height, IL) and incubated for 30 min at 4°C. Cells are washed, resuspended with 50ml of avidin conjugated FITC (Pierce, Rockford, IL), and incubated for 30 min at 4°C. The cells are washed once more, resuspended in 1 ml of wash buffer, and held on ice prior to analysis on a FACStar Analyzer (Becton Dickinson, Los Angeles, CA). The mean fluorescence intensity of transduced cells is compared with that of non-transduced cells to determine the effect E3/19K protein has on surface MHC class I molecule expression.

F. Administration of Vector Construct

1. Rat Administration Protocol

Rats are anesthetized and one eye is instilled with 5 to 100 μ l of recombinant retroviral particles at a concentration of 10^5 to 10^{10} cfu/ml in formulation buffer, with or without 4 to 8 μ g/ml of polybrene or other transduction enhancing excipient. Five to one hundred μ l of solution containing formulation buffer only is added to the other eye to be used as a control. The solution is allowed to incubate for 1 hour before each eye is rinsed 3 times with 100 μ l of saline. Two to seven days following the treatment, the rat is sacrificed, the cornea is removed, and homogenized in 2 ml ice cold RIPA lysis buffer. Expression of E3/19K is detected by Western blot analysis as described in Example 6E1.

2. Human Administration Protocol

Although the rate of corneal transplant rejection is relatively low, the current therapy for those with rejection requires continuous treatment of steroid compounds. This eventually leads to cataract formation, requiring surgery. Therefore, the introduction of a recombinant retrovirus expressing the E3/19K would prevent the need for such a steroid regimen. Ten to five hundred μ l of recombinant retroviruses at a concentration of 10^5 to 10^{10} cfu/ml in formulation buffer, with or without 4 to 8 μ g/ml of polybrene or other transduction enhancing excipient in formulation buffer, are administered to the eye of a patient lying in a prone position. The solution is allowed to incubate for 15 to 30 minutes before being washed with saline.

Alternatively, the cornea may be incubated for 1 hour in 1 ml of retroviral vector particles at a concentration of 10^5 to 10^{10} cfu/ml in formulation buffer, with or without 4 to 8 μ g/ml of polybrene or other transduction enhancing excipient, just prior to surgical attachment. In either of the above cases, the progress of the transplant is monitored by visually observing tissue viability.

EXAMPLE 7

Intranasal Administration of Recombinant Retroviruses Expressing Factor VIII

A. Construction of Full-Length and B Domain Deleted Factor VIII cDNA Retrovector™

The construction of the full-length and B domain deleted Factor VIII retrovectors are described in Example 2A

5 B. Administration of Vector Construct

1. Rat Administration Protocol

The nasal route has been shown to be effective for the administration of a number of molecules due to the extensive network of capillaries located under the nasal mucosa. This facilitates effective systemic absorption and when the drug is administered with
10 absorption promoters, absorption occurs rapidly with high bioavailability (review in Gizurarson *et al.*, 1990, *Acta Pharm* 2:105).

One group of six Fischer-344 rats are used for nasal administration of the retroviral vector particles for Factor VIII. One to fifty μ l of retroviral vector particles at 10^9 cfu/ml in formulation buffer, with or without 4 to 8 μ g/ml of polybrene or other transduction
15 enhancing excipients are applied with a pipette inserted about 3 to 5 mm into each nostril. Another group is administered formulation buffer without vector in the same manner. Blood samples are collected from the jugular or tail vein 1 to 14 days later and assayed for factor VIII production as described in Example 2Hi.

2. Human Administration Protocol

20 Several types of drug delivery devices for the nasal cavity exists (reviewed in Chien *et al.*, 1987, *Crit Rev Therap Drug Carr Sys* 4:67). These systems include nasal spray, nose drops, saturated cotton pledget, aerosol spray, and insufflator. The metered-dose nebulizer can deliver a predetermined volume of the formulation to the nasal cavity.

Two groups of patients are used in this study. One group of patients receives 100
25 to 500 μ l of retroviral vector particles at 10^9 cfu/ml in formulation buffer, with or without 4 to 8 μ g/ml of polybrene or other transduction enhancing excipients, applied to each nostril via nasal spray or nasal drops. Another group receives formulation buffer only

applied in the same manner. Blood samples are collected 1 to 14 days later and assayed for factor VIII production as described in Example 2B1.

EXAMPLE 8

5 PREPARATION OF RECOMBINANT RETROVIRUS FOR DELIVERY OF HUMAN GROWTH HORMONE

A. Preparation of hGH containing vectors

Vector pDHF828 containing the full-length human growth hormone gene is constructed essentially as follows. Briefly, plasmid pDHF811, was constructed by removing the XhoI- ClaI fragment of the KT-1 retroviral vector described above, and inserting the following oligonucleotide linkers by ligation of the cohesive ends:

Linker sequences:

(SEQUENCE ID# 5) 5' TCGAGGATCC GCCCGGGCGG CCGCATCGAT
15 GTCGACG 3'
(SEQUENCE ID# 6) 5' CGCGTCGA CATCGATGCG GCCGCCCGGG CGGATCC 3'

In particular, the linkers were annealed at 65°C for 20 minutes, 42°C for 20 minutes, 37°C for 20 minutes, and room temperature for 2 hours. The concentrations of both oligonucleotides was 18mM and the salt concentration was 100 mM NaCl. After annealing, 50ml of 1.8 mM annealed linker was digested with ClaI overnight to generate ClaI ends. For ligation, 3nM of KT-1 XhoI - ClaI fragment was mixed with 90nM of linker, and the resultant mixture incubated at 15°C for 3 hours. The ligated DNA sample was transformed into DH-5α competent cells, followed by screening of transformants.

25 Plasmid chGH 800 containing the full length cDNA of the hGH gene (Martial *et al.*, 1979, *Science* 205:602) was digested with Hind III, blunt-ended with the Klenow fragment enzyme, and cloned into the SrfI site of pDHF811. The resultant plasmid was designated pDHF828.

B. Preparation of hGH expressing recombinant retrovirus

The pDHF828 plasmid was then introduced into the HX packaging cell, using standard procedures and assayed using the HGH Chemiluminescence Kit (HGH 100T) (Nichols Institute, San Juan Capistrano, CA.), according to a preferred modification of the kit protocol. On day 1, the kit components were warmed to room temperature and gently mixed by inversion before opening any vials. Test samples were centrifuged for 5' at top speed in a microfuge before using them in order to remove fibrin and other debris. All samples were measured in quadruplicate, including the standards. The incubations are performed in 12 x17 polypropylene tubes that have been stored in the dark. One hundred fifty ul of sample or standard were aliquoted into each tube and ul of antibody is added and the samples were mixed gently. One bead was added to each well using the forceps provided in the kit. The tubes were capped, covered with foil, and shaken on an orbital shaker for 24 hr at room temperature. Standards contain 530 pg/ml (STD D), and serial dilutions were made in zero standard of Std D of 250, 100, 50, 25, 10, 5, and 2.5 pg/ml.

After 24 hours, the tubes were uncapped and 0.5 ml of wash buffer were added. These wash solution was added with enough force to make the bead bounce up off the bottom of the tube. The samples were washed three times with 2.0 ml nanopure water, and aspirated completely each time. The luminometer determinations were done in 12x75 polycarbonate (clear plastic) tubes stored in the dark. The luminometer was pretested with performance control standards.

Using this assay, HX/HGH retrovector producing cell lines were generated with titers of 4.8×10^6 cfu/ml. Introduction of the plasmid into DX packaging cells resulted in production of clonal producer cells with a titer of 1.6×10^7 cfu/ml.

EXAMPLE 9

Preservation of a Recombinant Retrovirus

A. Lactose Formulation of a Recombinant Retrovirus

Crude recombinant retrovirus is obtained from a Celligan bioreactor (New Brunswick, New Brunswick, NJ) containing DA cells transformed with the recombinant retrovirus bound to the beads of the bioreactor matrix. The cells release the recombinant

retrovirus into the growth media that is passed over the cells in a continuous flow process. The media exiting the bioreactor is collected and passed initially through a 0.8 micron filter then through a 0.65 micron filter to clarify the crude recombinant retrovirus. The filtrate is concentrated utilizing a cross flow concentrating system (Filtron, Boston, MA).

5 Approximately 50 Units of DNase (Intergen, New York, NY) per ml of concentrate is added to digest exogenous DNA. The digest is diafiltrated using the same cross flow system to 150 mM NaCl, 25 mM tromethamine, pH 7.2. The diafiltrate is loaded onto a Sephadex S-500 gel column (Pharmacia, Piscataway, NJ), equilibrated in 50 mM NaCl, 25 mM tromethamine, pH 7.4. The purified recombinant retrovirus is eluted from the
10 Sephadex S-500 gel column in 50 mM NaCl, 25 mM tromethamine, pH 7.4.

The formulation buffer containing lactose was prepared at a 2X concentrated stock solution. The formulation buffer contains 25 mM tromethamine, 70 mM NaCl, 2 mg/ml arginine, 10 mg/ml HSA, and 100 mg/ml lactose in a final volume of 100 mls at a pH 7.4.

The purified recombinant retrovirus is formulated by adding one part 2X lactose
15 formulation buffer to one part S-500 purified recombinant retrovirus. The formulated recombinant retrovirus can be stored at -70°C to -80°C or dried.

The formulated retrovirus is lyophilized in an Edwards Refrigerated Chamber (3 Shelf RC3S unit) attached to a Supermodulyo 12K freeze dryer (Edwards High Vacuum, Tonawanda, NY). When the freeze drying cycle is completed, the vials are
20 stoppered under a vacuum following a slight nitrogen gas bleeding. Upon removal, vials are crimped with aluminum seals.

In the given lactose study, formulated liquid product was stored at both -80°C and at -20°C cycling freezer. In Figure 13 viral infectivity of these samples were compared to the viral infectivity of lyophilized samples. The lyophilized samples were stored at -20°C,
25 refrigerator temperature and room temperature. Activity of the samples upon reconstitution are determined by titer assay.

The lyophilized recombinant retrovirus is reconstituted with 1.0 ml water. The infectivity of the reconstituted recombinant retrovirus is determined by a titer activity assay. The assay is conducted on HT 1080 fibroblasts or 3T3 mouse fibroblast cell line
30 (ATCC No. CCL 163). Specifically, 1×10^5 cells are plated onto 6 cm plates and incubated overnight at 37°C, 10% CO₂. Ten microliters of a dilution series of

reconstituted recombinant retroviruses are added to the cells in the presence of 4 mg/mL polybrene (Sigma, St. Louis, MO) and incubated overnight at 37°C, 10% CO₂. Following incubation, cells are selected for neomycin resistance in G418 containing media and incubated for 5 days at 37°C, 10% CO₂. Following initial selection, the cells are re-fed
5 with fresh media containing G418 and incubated for 5-6 days. After final selection, the cells are stained with Commassie blue for colony detection. The titer of the sample is determined from the number of colonies, the dilution, and the volume used.

Figure 13 demonstrates that storage in lyophilized form at -20°C to refrigerator temperatures retains similar viral activity as a recombinant retrovirus stored in liquid at -80
10 to -20°C permitting less stringent temperature control during storage.

B. Mannitol Formulation of a Recombinant Retrovirus

The recombinant retrovirus utilized in this example was purified as described in Example 9A.

The formulation buffer containing mannitol was prepared as a 2X concentrated
15 stock solution. The formulation buffer contains 25 mM tromethamine, 35 mM NaCl, 2 mg/ml arginine, 10 mg/ml HSA and 80 mg/ml mannitol at a final volume of 100 mls at a pH 7.4.

The purified recombinant retrovirus is formulated by adding one part mannitol formulation buffer to one part S-500 purified recombinant retrovirus. The formulated
20 recombinant retrovirus can be stored at this stage at -70°C to -80°C or dried.

The formulated retrovirus is dried in an Edwards Refrigerated Chamber (3 Shelf RC3S unit) attached to a Supermodulyo 12K freeze dryer. When the freeze drying cycle is completed, the vials are stoppered under a vacuum following nitrogen gas bleeding to 700 mbar. Upon removal, vials are crimped with aluminum seals.

25 In the given mannitol study, formulated liquid product was stored at both -80°C and at -20°C in cycling freezers. The viral infectivity of these samples were compared to the viral infectivity of lyophilized samples, Figure 14. The lyophilized samples were stored at -20°C, refrigerator temperature and room temperature. Activity of the samples upon reconstitution are determined using the titer assay described in Example 9A.

Figure 14 demonstrates that storage in lyophilized form at -20°C to refrigerator temperature retains significant viral activity as compared to recombinant retrovirus stored in liquid at -80°C or -20°C, permitting less stringent temperature control during storage.

5 C. Trehalose Formulation of a Recombinant Retrovirus

The recombinant retrovirus utilized in this example was purified as described in Example 9A.

The formulation buffer containing trehalose was prepared as a 2X concentrated stock solution. The formulation buffer contains 25 mM tromethamine, 70 mM NaCl,
10 2.0 mg/ml arginine, 10.0 mg/ml HSA and 100 mg/ml trehalose at a final volume of 100 ml at a pH 7.2.

The purified recombinant retrovirus is formulated by adding one part trehalose formulation buffer to one part S-500 purified recombinant retrovirus. The formulated recombinant retrovirus can be stored at this stage at -70°C to -80°C or dried.

15 The formulated retrovirus is dried in an Edwards Refrigerated Chamber (3 Shelf RC3S unit) attached to a Supermodulyo 12K freeze dryer. When the freeze drying cycle is completed, the vials are stoppered under a vacuum following nitrogen gas bleeding to 700 mbar. Upon removal, vials are crimped with aluminum seals.

In the given trehalose study, formulated liquid product was stored at both -80°C
20 and at -20°C in cycling freezers. The viral infectivity of these samples was compared to the viral infectivity of lyophilized samples, Figure 15. The lyophilized samples were stored at -20°C, refrigerator temperature and room temperature. Activity of the samples upon reconstitution are determined using the titer assay as described in Example 9A.

Figure 15 demonstrates that storage in lyophilized form at -20°C to refrigerator
25 temperature retains similar viral activity as compared to recombinant retrovirus stored in liquid at -80°C to -20°C permitting less stringent temperature control during storage.

Viral infectivity of liquid formulated recombinant retrovirus samples stored at -80°C was compared to viral infectivity of lyophilized formulated recombinant retrovirus stored at -20°C. Initially, a bulk of recombinant retrovirus was received and formulated in
30 four different ways as shown below. The formulated recombinant retrovirus was then frozen in bulk for 1.5 months subsequent to being quick thawed and freeze dried. Positive

controls were stored at -80°C for comparison with lyophilized samples which were stored at -20°C after freeze-drying. The formulations are listed below:

Formulation	Sugar Concentration (mg/ml)	Buffer		Arginine Concentration (mg/ml)	Human Serum Albumin Concentration (mg/ml)
		Concentration (mM tromethamine)	Salt Concentration (mM NaCl)		
Mannitol	40	25	25	1	5
Lactose	40	25	75	1	5
Sucrose	50	25	60	1	5
Trehalose	50	25	60	1	5

In the graphs of Figure 16, the y-axis on each of the 4 graphs (A, B, C, D) represent the normalized titer. At an initial time point after lyophilization, $t = 0$, a titer value was established for both the -80°C liquid sample and the -20°C lyophilized sample. At each time point of the stability study, the titer obtained was divided by the zero time point titer value and the % of original entered onto the graph.

The data demonstrates that post-lyophilization activity is maintained in the lyophilized sample (stored at -20°C) relative to the liquid sample (stored at -80°C). The formulated lyophilized recombinant retrovirus was stored in a -20°C freezer (a frost-free cycling freezer). Comparison to the formulated liquid recombinant retrovirus stored at -80°C indicates the lyophilized form permits less stringent control of storage conditions.

EXAMPLE 10

Analysis of Crude and Purified Recombinant Retrovirus

Crude and purified solutions of recombinant retrovirus particles may be separated on gradient polyacrylamide gels utilizing, for example, the PHASTGEL system (Pharmacia Biotech). Briefly, samples are placed on 4-15% polyacrylamide gels without pretreatment and electrophoresed for 35 minutes at 250V. The gels are then removed and stained with coomassie blue in order to detect virus and other protein components. The

gels are then scanned by laser densitometry in order to determine the content of virus and other components.

Virus bands may be identified by their relative molecular weight and by reverse transcriptase activity (RT). The purpose of this assay is to quantify the activity of reverse transcriptase (RT), an enzyme exclusively associated with all retroviruses. The relative amount of retrovirus in a sample can be determined by measuring the activity of this enzyme in a given preparation.

Briefly, moloney murine leukemia virus reverse transcriptase (Pharmacia, Newark, NJ) is diluted to a concentration of 1 µg/ml by addition of 1x Tris/EDTA buffer solution containing 10 mM Tris-HCl and 1mM EDTA, pH 8.0. One hundred microliters of this solution is added 6.84 ml of sterile dH₂O, 500 µl of 1M Tris HCl pH 8.0, 10 µl of 0.1M MnCl₂, 200 µl of 1M dithiothreitol, 50 µl of 10% Nonidet P40 (NP40), 2 µl of 100 µM dNTP (Pharmacia, Newark, NJ, dNTP Ultrapure KitTM), and 300 µl Methyl - ³H Thymidine 5' - Triphosphate (30-50 Ci/mmol). This mixture is incubated for 1 hour at 37°C in a water bath. Following incubation the sample is placed on ice. Approximately 1.0 ml of 2N HCl is added to the cooled sample. The precipitated radiolabeled DNA fragments are vacuum filtered onto glass fiber filters using a Millipore sampling manifold (Millipore, Philadelphia, PA). The filters are washed, dried, placed in scintillation cocktail, and counted in a Beckman LS5000TD scintillation counter (Beckman, Dallas, TX).

EXAMPLE 11

Analysis of Complement Resistance in Various Packaging Cell Lines

A. Packaging Cell Line Preparation and Transduction

Four different packaging cell lines were used to package pCBβ-gal into infectious virions. Two cell lines were derived from D17 dog cells ("D") (ATCC CCL 183), and two were derived from the human embryonic kidney cell line 293 ("2") (ATCC CRL 1573). In the case of both dog and human packaging cells, one cell line expressed the amphotropic envelope from the 4070A virus (*i.e.*, DA and 2A, respectively) and the other expressed the xenotropic envelope from the NZB9-1 virus (*i.e.*, DX and 2X, respectively). All packaging cells were grown in DMEM media (Irvine Scientific, Santa Ana, CA)

supplemented with 10% heat inactivated fetal bovine serum (Hyclone, Salt Lake City, UT).

Each of the four packaging cell lines was transduced with a G-pseudotyped pCB β -gal (see Burns et al., 1993, *Proc. Nat'l. Acad. Sci. USA* 90:8033-8037, for a pseudotyping procedure). After G418 selection, the selected cell pools were dilution cloned (except for the amphotropic vector producing human cell line which was maintained as a non-clonal pool). Vector producing cell lines producing the highest titer on HT1080 cells (ATCC No. CCL 121) were selected. Titers were determined approximately 2 days after transduction by G418 colony forming units or by X-gal staining of the monolayers. (See *Current Protocols in Molecular Biology*, Ed. Ausubel et al., for more details on the titering assays.)

Retrovirus containing supernatants were collected from each of the confluent monolayers of the individual amphotropic envelope (DA and 2A) or xenotropic envelope (DX or 2X) vector producing cell lines and filtered through a 0.45 μ m filter prior to aliquoting and storage at -70°C.

15 B. Serum Inactivation Assay

Serum inactivation titer assays were performed as follows: Serum was drawn from at least two different human volunteers, chimpanzees, baboons, and macaque monkeys. Approximately 20-70 mL of blood was collected from each donor into serum separating tubes (Becton Dickinson, Los Angeles, CA). Blood was allowed to clot for 20-30 minutes at room temperature, after which time the samples were centrifuged at 2000 x g for 10 minutes at 4°C. Serum was frozen in approximately 1.1 mL aliquots and stored at -80°C. Vials from each batch were tested for total classical complement activity (Quantiplate, Kallestad Labs, Inc., Chaska, MN), and only batches with "normal" levels of complement activity were used. 1 mL aliquots of fresh, 100% serum were used for each inactivation assay. Complement inactivated controls of each serum were prepared by heat inactivation for 30 minutes at 56°C. Undiluted and diluted preparations of supernatants containing recombinant retroviral particles (BCFU greater than or equal to 10³ per mL sera) were mixed 1:10 with medium control, sera, or heat inactivated sera. These mixtures were then incubated at 37°C for 30 minutes. Treated vector particles were then titered by a standard blue colony forming unit assay (*Current Protocols in Molecular Biology*, *supra*).

The results of this experiment are presented below in Table 1 as BCFU/ml.

Table 1

Packaging Cell Line

Serum source	DA	DX	2A	2X
HUMAN				
control	19,000	110,000	5,700	6,700
100% sera	400	0	6,100	7,600
H.I. sera	18,000	100,000	10,500	8,800
CHIMP				
control	16,200	31,600	27,800	22,400
100% sera	900	1,700	21,500	18,300
H.I. sera	28,300	47,000	42,700	48,500
BABOON				
control	16,000	13,000	8,000	7,200
100% sera	0	0	1,800	1,000
H.I. sera	24,000	9,600	15,000	9,400
MACAQUE				
control	170,000	13,000	2,500	2,300
100% sera	0	0	0	10
H.I. sera	270,000	12,000	3,000	2,200

H.I. = heat inactivated

5 control = DMEM + 10% H.I. fetal bovine serum + Sodium pyruvate

Note: zero's indicate that no blue colonies were detected in 0.1 or 0.2 ml undiluted volumes, therefore indicating that titers were conservatively less than 20-40 BCFU/ml.

Briefly, these results demonstrate that recombinant retroviruses which are made in human packaging cell lines exhibit no detectable sensitivity to inactivation by a heat labile component of human serum, presumably complement, in *in vitro* assays. In contrast, they show partial sensitivity to inactivation by chimp, and then increasing sensitivity to baboon and macaque serum, in order of increasing phylogenetic distance from man. In addition, these *in vitro* results demonstrate that recombinant retroviruses produced in D17 derived packaging cell lines exhibit near total sensitivity to inactivation by a heat labile component, presumably complement, of human, chimp, baboon and macaque serum.

Other experiments which were conducted employing another recombinant retroviral genome packaged in either of two of the above-described cell lines (dog cell line DA, and human cell line 2A), as well as a different human cell line (HX, a HT1080-derived packaging cell line; confirm that the conclusions drawn from the above results are not vector dependent. Moreover, human producer cell lines derived from 293 and HT1080 generated equally complement resistant vector.

Additional experimental data which was generated using recombinant retroviral particles made in human HT1080-derived packaging cells expressing a different murine envelope tropism, poly, similarly showed insensitivity to heat labile human serum components, further confirming the conclusions above.

EXAMPLE 12

Recombinant Retrovirus Production from Hollow Fiber Cultures

A. Culture Initiation

To initiate a hollow fiber culture, first condition the hollow fiber bioreactor (HFB) for 48 hours prior to seeding by simulating a run condition with 100-200 mL of complete growth media at 37°C. The growth media should be what ever the cell line has been adapted to. All liquids in the HFB when originally shipped should be aspirated and replaced with the complete growth media. When seeding the bioreactor, the cells should not have been split more than 48 hours earlier and should be in log growth phase at the time of harvest for the seeding of the HFB. The cells are harvested by trypsinization and pelleted by centrifugation. The cell pellet is then resuspended in 4 mL of 25% pre-

conditioned media and delivered to the extra-capillary space by syringe using the side syringe ports found on the HFB. After seeding the HFB, allow the cells to adhere for 20 to 30 minutes before starting the circulation pump. During this time replace the media used to condition the HFB with 100-200 ml using 25% pre-conditioned media. The circulation
5 feed pump is initiated with the starting flow rate set at 25 mL/min. (setting 5 with 2 long pump pins). After 1 hour from the time of switching the pump on, a one mL sample of media is collected in order to record the initial levels of lactate and ammonia. On a daily schedule, 1 ml samples are collected every 24 hours to assay for the daily production of lactate and ammonia. The initial 100-200 ml of old is exchanged media with fresh media
10 when lactate levels begin to reach 2.0 g/l (or the equivalent to 22 mM/L) The same volume of media is replaced until the culture approaches daily levels of 20 mmol/L. When daily levels of lactate reach 20 mmol/L increase your reservoir bottle size to a 500 mL bottle containing 500 mL of fresh media. The flow feed rate is then increased to 50 mL/min. when the culture begins to produce 2.2 mmol/day of lactate. When daily 500 mL volumes
15 reach 20 mmol/L of lactate, the original Cellco supplied reservoir feeding cap is exchanged for the larger reservoir cap (Unisyn-vender part #240820) adapted for the Cellco system with the addition of tubing and male luer lock fittings. This reservoir cap will accommodate the large 2 Liter Corning bottles. (To avoid the exchange of the reservoir caps during a culture run, initiate the culture run with the larger reservoir cap
20 which can also support smaller bottle sizes.) When daily lactate readings are assayed and recorded, one can calculate the daily levels of lactate production of the culture in order to determine when the culture reaches maximum cell density when the rate of lactate decreases and levels off.

B. Seeding density for the 2X- β -gal

25 In order to establish specific seeding requirements, two hollow fiber runs are established. One run is seeded with a low number of cells and one with a high number of cells. Progress of the culture is tracked by analyzing the daily glucose consumption and lactate production levels. Figure 20 is a representative graph of data generated over a two week period of the vector producer cell line 2X- β -GAL₁₇₋₁₄.

In this experiment, one HFB was seeded with 1.3×10^7 cells (to represent the low seed culture) the other seeded with 1.6×10^8 cells. In this experiment, the cell line (2x- β -GAL₁₇₋₁₄) was able to initiate a good hollow fiber run under low and high seeding conditions. Being able to incubate the HFB with fewer cells, is only convenient for reducing the effort required for generating the number of cells required to start a culture. However a low seed start also extends the time it takes to reach optimal cell densities which usually yield the highest titers. In this experiment, the cell line used, adapted very well to hollow fiber cultures which eventually required daily media changes of 500 ml per day.

10 C. Cell Culture Health and Maximum Cell Densities:

In the original Cellco design, it was observed that the original media reservoir cap was not suited to fit larger bottles other than the standard 100 and 500 ml media bottles. This is a problem when aggressive growth cultures require greater than 500 ml daily exchanges of media. Daily multiple changes of media increases the likelihood of culture contamination by increasing the daily handling time of the system. If one does not opt to perform multiple daily exchanges of media then one exposes the culture to daily toxic levels of waste products which can affect the cell expansion of the system along with the length at which the culture run will survive. Figure 20-B demonstrates lactate concentrations of a culture which required daily 500 mL exchanges of fresh media after reaching day 7 of culture. Figure 20-D is one indication of the health of the culture by tracking the amount of lactate being produced on a daily basis. The graphs indicate that the culture was no longer allowed to expand based on the plateauing of daily production of lactate. Another indicator of the health of the cell culture was the drop in peak titer production which also correlated with the daily exposure of high levels of lactate (See Figure 21). These findings would indicate that optimal titers can be correlated with the maximum cell densities and the relative health of the culture.

D. Optimal Titer Concentrations, Frequency of Harvests and Total Harvest Amounts

β -gal titers for the above experiment were determined from frozen samples and were titered on 293 cells assayed 48 or 72 hours after transduction. The transduced cells were stained for β GAL activity and individual cells counted on a hemocytometer giving a titer based on the number of blue cells /mL (BCT/mL). As shown in Figure 21, optimum titers were obtained on day 7 of the high seed culture at 1.8×10^8 BCT/mL from a 72 hour blue cell titer on 293 cells. The duplicate culture initially seeded with a 10 fold lower seeding density, peaked at 5.2×10^7 BCT/mL from a 48 hour blue cell titer. Previous flat stock cultures of 2X b-GAL₁₇₋₁₄ cultures have been titered using 48 hour blue cell titers on HT1080 cells and have been calculated to be 5×10^6 BCT/mL. If one uses the values obtained from 48 hour blue cell titers, the increase in titer by using hollow fiber systems is ten fold higher than crude supernatants obtained from tissue culture dishes or flasks. These maximum titers were reached prior to hitting the daily 20 mmol/L toxic levels lactate which appeared to reduce the titer produced the following week. Crude supernatants can be harvested every 9 hours with out any loss of titer (See Figure 2). It is predicted that 3 harvests per day can be achieved with minimum loss of titers. In addition, continuous hollow fiber cultures can be maintained for several weeks. When titers were compared between the low and the high seed culture, there was little differences by day 11 between the two seed cultures averaging 4×10^7 BCT/mL.

EXAMPLE 13

Two-Phase Purification of Recombinant Retroviruses

A. Concentration of DA/ND-7 recombinant particles

Five milliliters of formulated DX/ND-7 recombinant retroviral particles at a titer of 3.5×10^8 cfu/ml (total of 1.75×10^9 cfu) is diluted in 1400 ml of media (DMEM containing 5% Fetal Bovine Serum). Three hundred milliliters of two-phase partitioning components (PEG-8000 (autoclaved), dextran-sulfate, and NaCl) are added to a final concentration of 6.5% PEG, 0.4% dextran-sulphate, and 0.3 M NaCl. The resultant solution is placed into a two-liter separatory funnel, and left in a cold room for 24 hours (including two mixing steps approximately 6 to 16 hours apart).

Following the 24 hour period, the bottom layer (approximately 20 mL) is carefully eluted, and the interphase (approximately 1 mL) is collected in a 15 mL conical FALCON tube. The interphase containing vector is diluted to 10 mL by addition of PBS, and incubated at 37°C in order to bring the solution to room temperature and destabilize the micelles.

To one-half of the diluted interphase, KCl is added to a final concentration 0.4 M, and mixed well. The tube is then placed on ice for ten minutes, and spun for 2 minutes at 2,000 rpm in a bench-top centrifuge. The supernatant is removed and filtered through a 0.45 um syringe filter.

The other half of the interphase containing vector is separated by S-500 Sephadex chromatography in 1X PBS.

The results of these concentration processes, as determined in a BCFU assay, are shown below in Table 1:

TABLE 1

<u>PHASE</u>	<u>CONCENTRATION</u>
Crude	1.1×10^9 bcfu
Separation: Top phase	1.4×10^8 bcfu
Separation: Interphase	$7(+/-3) \times 10^8$ bcfu
Separation: Bottom phase	2×10^6 bcfu
Final step: KCl separation	$*6(+/-3) \times 10^8$ bcfu
Final step: S-500 separation	$*1.8(+/-0.3) \times 10^8$ bcfu

* Note that since the sample was split into two halves, that these numbers were doubled in order to represent the level of purification that would be expected if the entire 1 mL interphase was separated as indicated.

In summary, 1.4 liters of crude research grade supernatant containing recombinant retroviral particles may be reduced to a 10 ml volume, with approximately 50% (+/-20%) being recovered when KCl separation is utilized as the final step. When S-500

chromatography is utilized as the final step, only about 10% of the initial recombinant retroviral particles are recovered in a 14 ml.

In order to complete concentration of the retroviral vector particles, the vector-containing solution may be further subjected to concentration utilizing an MY-membrane
5 Amicon filter, thereby reducing the volume from 10 to 14 mL, down to less than 1 mL.

EXAMPLE 14

Production of Vector From DX/ND7 β gal Clone 87 Utilizing a Cell Factory

DX/ND7 β gal clone 87, an expression vector, was grown in cell factories. Cells were grown in DMEM supplemented with Fetal Bovine Serum in roller bottles until
5 enough cells to seed 20 10-layer cell factories (NUNC) at a 1:3 dilution were obtained. Each 10-layer cell factory is seeded with approximately 0.8 liters of cell medium.

Cells were seeded into the cell factory by pouring media containing cells into the factory so that the suspensions evenly fill the 10 layers. The factory is then carefully tilted away from the port side to prevent the suspension from redistribution in the common tube.
10 Finally, the cell factory is rotated into its final upright position. A hepa vent filter is attached to each port. The factory was then placed in a CO₂ incubator.

In three days, and for each of the next three days, supernatant containing vector was harvested. The cell factory is placed in a tissue culture hood. One filter is removed and sterile transfer tubing is connected to the open port. The factory is lifted so that
15 supernatant drains into the tubing. Approximately 2 liters of supernatant is harvested from each factory. Fresh DMEM/FBS is used to replenish the lost medium. The transfer tubing is removed and the factory replaced in the incubator. From 20 cell factories, approximately 90 liters of crude vector containing supernatant were obtained.

Verification of the vector was performed by transduction of HT1080 cells. These
20 cells were harvested 2 days later and stained for β -gal protein. The titer of the supernatant was determined to be 2×10^7 /ml.

EXAMPLE 15

Concentration of Recombinant Retroviruses by Low-Speed Centrifugation

A. Retrovector Supernatant Preparation

25 Producer cell lines DA/ β gal and HX/DN-7 were cultured in a culture flask and a roller bottle, respectively, containing Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum plus 1 mM L-Glutamine, Sodium pyruvate, non-essential amino acids and antibiotics. Viral supernatant was harvested from the flask and roller bottle, and were filtered through a 0.45 μ m syringe filter. The filtered
30 supernatants were stored either at 4°C (HX/ND7), or frozen at -70°C (DA β -gal).

B. Virus Concentration

Viral supernatant was aliquoted into 50 ml sterile OAKRIDGE screw cap tubes, and placed into an SS34 rotor for use in a Sorvall centrifuge. The tubes were spun for 1 hour at 16,000 rpm (25,000g-force) at 4°C. Upon completion of the spin, the tubes were removed, the supernatant decanted and a small opaque pellet resuspended in the DMEM media described above.

C. Virus Titration

Concentrated virus was titered on HT1080 cells plated 24 hours earlier at a cell density of 2×10^5 cells per well in a six well plate + 4 ug/ml polybrene. Briefly, virus preps were diluted from 1/10 to 1/10,000 and 50 ul of each dilution was used to infect one well from the six well plate. Plates were incubated overnight at 37°C. Forty-eight hours later, cells were fixed and stained with X-gal. The results are set forth below in Table 1.

Table 1. Virus Concentration through Low Speed Centrifugation

Parameter Description	Experiment number				
	1	2		3	
Virus source	DAB-gal	DAB-gal	HX/ND7	DAB-gal	HX/ND7
Titer of normal harvest	4.4×10^6	2.1×10^6	3.2×10^5	5×10^6	5×10^5
Titer of virus concentrate	6×10^8	7.4×10^7	3.2×10^7	2.9×10^8	3.9×10^7
Starting volume	80 ml	.39 ml	39 ml	118ml	40ml
Final volume	.5 ml	.36 ml	.36 ml	.78ml	.28ml
Fold concentration	136X	34X	100X	58X	78X
Virus recovery	87%	30%	91%	50%	99%

As is evident from Table 1, virus recovery ranged from 30% to 99%, with the best recovery being obtained from human producer cells (HX/ND7; recovery ranged from 91%

EXAMPLE 16

Concentration of Recombinant Retroviruses by Ultrafiltration

S-500 purified supernatant containing the β -gal expressing recombinant retrovirus DX/CB- β gal and partially concentrated supernatant containing the same virus were each
5 filtered through a 0.45 μ m filter, and loaded into a CENTRIPREP-100 filter (product #4308, Amicon, MA). The supernatants were kept at a temperature of 4 °C throughout this procedure, including during centrifugation. The CENTRIPREP filters were spun three times each for 45 to 60 minutes at 500 x G. Between each spin the filtrate was decanted. The retentate was thus sequentially reduced, such that the initial 15 ml (or 10 ml) volume
10 was reduced to approximately 0.6 mL per unit.

The resultant titer was determined by assaying HT1080 target cells set up at a concentration of 1×10^5 cells per well 24 hours prior to transduction of the viral sample. Cells were transduced in the presence of 8 μ g/ml polybrene and 2 mL growth media (DMEM plus 10% FBS) per well. As shown in Table 1 below, approximately one
15 hundred percent of the virus was recovered utilizing this procedure (note that titers are in BCFU/ml).

Table 1

	<i>Pre-centriprep titer/volume.</i>	<i>Final titer/volume</i>
S-500	$4 \times 10^7/15$ ml	$1.3 \times 10^9/0.6$ ml
part. conc.	$3 \times 10^8/10$ ml	$1 \times 10^{10}/0.6$ ml

EXAMPLE 17Preparation of Recombinant Retrovirus in a BioreactorA. Freezing protocol

5 Producer cells are frozen in DMEM media containing 10% to 20% FBS, and 5 to 15% DMSO, at a concentration of 1×10^7 cells/ml/vial. Cells are frozen in a controlled rate freezer (Series PC, Controlled Rate Freezing System, Custom Biogenic Systems, Warren MI) at a rate of from 1 to 10 °C per minute. Frozen cells are stored in liquid nitrogen.

B. Bioreactor protocol

10 Cells are thawed from frozen vials at 37°C, washed once with media to remove DMSO, and expanded into 850 cm² "FALCON" roller bottles (Corning, Corning, N.Y.) Expanded cell culture is used to inoculate a "CELLIGEN PLUS" bioreactor (5 liter working volume; New Brunswick, Edison, N.J.). The cells are grown on microcarriers (i.e., Cytodex 1 or Cytodex 2; Pharmacia, Piscataway, N.J.) at a concentration of 3 to 15 g/L microcarrier. Initial inoculation densities are from 4 to 9 cells/bead at half to full volume for 2 to 24 hours. The media constituents for virus production are DMEM-high glucose (Irvine Scientific, Santa Ana, CA.) basal media supplemented with FBS (10 to 20%), Glutamine (8 to 15mM), glucose (4.5 to 6.5 g/L), Nonessential amino acids (1X), RPMI 1640 amino acids (0.2 to 9.6X), 10 mM HEPES, RPMI 1640 Vitamins (0.2 to 5X).

20 During culture, pH (6.9 to 7.6) and dissolved oxygen ("DO" 5 to 90%) are controlled by the use of a four gas system which includes air, oxygen, nitrogen, and carbon dioxide. After several days of batch growth the culture is then continuously perfused with fresh media with concurrent continuous harvesting in an escalating perfusion rate of 0.5 to 2.5 volumes/day. Cell retention is the result of differential sedimentation of cell covered beads in a decanting column.

25 During operation the bioreactor is monitored for viable cells, titer, glucose, lactate, ammonia levels, and lack of contamination. Viable cells and titer range from 1×10^5 cells/ml to 1×10^7 cells/ml. Glucose ranges from 6 to 0.25 g/L, Lactate from 1 to 25 mM, and Ammonia ranges from 0.5 to 30 mM. Cells are incubated in the bioreactor for 5 to 25 days.

EXAMPLE 18

Long Term Expression of Human Factor VIII in Rabbits Following Intravenous Expression of Vector

Recombinant retroviral vector expressing B domain deleted factor VIII was
5 constructed, packaged, and expressed as described in Example 2 herein. Large scale
production was carried out in Cell Factories as described for DX/ND7 in Example 14. The
retroviral vector was then lactose formulated as described in Example 9 herein. High titer
formulated retroviral vector was injected into 500 g juvenile rabbits according to the
following schedule: 1.5×10^8 vector particles were injected into the ear vein at 2.5 hr
10 intervals, three times per day for three days (Day 0, 1, and 2). On days 3, 4, 5, 6, 7, 56,
and every 7 days subsequently, citrated plasma was obtained by venipuncture of the ear
vein and analyzed for human factor VIII antigen as follows.

Day 1: Coat Immulon IV plates (Dynatech, Chantilly, VA, USA). Plate 1 was coated with
200 μ l anti-factor VIII light chain monoclonal ESH8 (American Diagnostica, Greenwich,
15 CT, USA) at 3 μ g/ml in coating buffer (0.1M bicarbonate, pH 9.2) at 4 degrees overnight.
Plate 2 and 3 were coated with 300 μ l Sigma fractionated ascites anti-beta galactosidase
(Sigma #G4644, Sigma Chemical Company, St. Louis, MO, USA) at 8 μ g/ml. These are
the "absorption" plates.

Day 2: Plates were washed once with buffer DB2 (1000 ml = 7.8 g Tris HCl/ 58.4
20 g NaCl/20 g BSA/1 ml Tween 20, pH 7.5), then blocked with 300 μ l DB2, covered with
parafilm, and incubated at room temperature for at least 90 min. on an orbital shaker at 80
rpm. Plates were then washed in DB2. 200 μ l samples in duplicate were diluted in DB2
(plasma samples were diluted at least 1:3), centrifuged for 5' at room temperature at
14,000 rpm in an Eppendorf microfuge, and added to plate 1. Plate 1 was covered with
25 parafilm and incubated two hours at room temperature shaking at 80 rpm.

100 μ l of polyclonal anti-FVIII:C at 20 μ g/ml in buffer DB2 (Enzyme Research
Lab - South Bend, Indiana, USA) was placed on absorption plate 2, covered with
parafilm, and incubated at room temperature shaking at 80 rpm. Likewise, 300 μ l donkey
anti-sheep IgG conjugated to alkaline phosphatase (Sigma Chemical Company, St Louis
30 Mo., USA) was absorbed on absorption plate 3 at 1:30,000 in DB2, covered and incubated
at room temperature shaking at 80 rpm.

After two hours at room temperature, plate 1 was washed and 200 ul of absorbed sheep anti-VIII:C was transferred from plate 2 to plate 1. Plate 1 was covered with parafilm and incubated at room temperature for 1-2 hrs, shaking at 80 rpm.

After 2 hr, plate 1 was washed and 200 ul absorbed donkey anti-sheep conjugate was transferred from plate 3 to plate 1. Plate 1 was covered and incubated 1 hr at room temperature shaking at 80 rpm.

Plate 1 was washed, and freshly prepared Attophos substrate (JBL Scientific, Huntingdon, England, UK) prepared as recommended by the manufacturer was added at 200 ul per well. the plate was read at 2 min intervals (30 cycles) on Cytofluor II fluorometer, excitation 450, emission 580 filters; mix=1; gain = 65.

Readings were compared to a standard curve using duplicate dilutions of NHP (pooled normal plasma, George King, Overland Park, Kansas, USA) as a factor VIII source diluted in 1:3 rabbit plasma at 3-fold dilutions starting at 1:10 NHP.

Data from Day 0 (prebleeds) to day 261 from 7 experimental and two control rabbits are shown in Figure 22. Levels remained low during the first 7 days, with no significant differences being seen between the experimental and control groups ($p > 0.25$). On Day 56 and subsequent days, two rabbits displayed 30-50 ng/ml human factor VIII antigen in their plasmas. These levels, with slight fluctuations, were maintained at least until Day 261 (8 months later), the last time point tested. The experimental group as a whole over the entire time course was significantly different from the controls ($p < 0.03$). Therefore, rabbits injected via ear vein with high titer formulated retroviral vectors displayed high level systemic expression of factor VIII following a lag phase of 7-56 days.

Figure 23 shows the data in this experiment extended through Day 429. The two high-expressing rabbits described above maintain their expression levels through day 429. Medium-level expressing rabbits do as well, while the control rabbits remain negative. Thus, expression is observed at least from Day 56-429, indicating >373 days of expression from a single course of vector administration.

Example 19High Level Expression of Human Growth Hormone With a Lag Phase in Rabbits
Following Intravenous Injection of Retroviral Vector

Human growth hormone-expressing retroviral vectors were produced as described in Example 8 herein. Large scale production in Cell Factories was performed as described for DX/ND7 in Example 14 herein. The retroviral vector was lactose formulated as described in Example 9 herein. The titer was $8E8$. Vector was diluted 5-fold in formulation buffer, and 1 ml injections were given to 500 g juvenile rabbits 3 time per day for three days as described in Example 18 for factor VIII vector. Serum was collected on days 0 (prebleed), 7, 14, and every 7 days thereafter. Serum was analyzed for human growth hormone content using a commercial ELISA kit (Boehringer Mannheim Biochemicals, Indianapolis, Indiana, USA) according to the directions of the manufacturer. The results are shown in Figure 24. A modest degree of expression (100 pg/ml) was observed in rabbit #861 at Day 7. Several other rabbits displayed smaller initial expression. Expression in all rabbits declined, to zero except for rabbit #861, by Day 14. Unexpectedly, expression in several rabbits (#861, 863, 858, 866) began to rise between Day 21 and Day 36. Two rabbits (#863 and 861) displayed peak expression levels at Day 36 of 200-350 pg/ml. Expression in all rabbits subsequently declined to zero at Day 56. A periodic small rise and decline was seen thereafter, reaching a low steady state of approximately 50 pg/ml in one rabbit (#863) after Day 84. Therefore, rabbits injected via ear vein with high titer formulated retroviral vector displayed a high level systemic expression of human growth hormone with a lag phase of 20-36 days.

Example 20High Level Expression of Human Growth Hormone with a Lag Phase in Mice Following
Intravenous Injection of Retroviral Vector

Human growth hormone-expressing retroviral vectors were produced as described in Example 8, herein. Large scale production in Cell Factories was performed as described for DX/ND7 in Example 14, herein. The retroviral vector was then lactose formulated as described in Example 9, herein. The titer was $8E8$. Three week old mice were given a single injection of 200 ul vector via the tail vein. Human growth hormone was analyzed in

mouse serum using a commercial ELISA kit (Boehringer Mannheim Biochemicals) according to the instructions of the manufacturer. The results are shown in Figure 25. Due to the low serum volumes that could be obtained from young mice relative to the volumes required for ELISA analysis, pooled test mice were tested on Day 14, and therefore the results shown on this date represent the average value for the indicated animals. All three pools (two test, one control) yielded values of < 50 pg/ml on Day 14. By Day 28, animals had grown sufficiently that individual animals could be tested. Animals 2 and 3 displayed hGH levels of approximately 300 pg/ml on Day 28; animal 9 showed a level of 200 pg/ml. All other mice were <100 pg/ml. The two controls, Animals #11 and 12, were 0 throughout the test period. By day 48, all 10 test animals displayed increasing levels of hGH, and all were clearly above 100 pg/ml, with animals #1, 2, 3, 4, 5, and 10 showing levels of 300-600 pg/ml. Therefore, mice injected a single time with high-titer formulated retroviral vector expressed human growth hormone at high levels for at least 20 days following a lag phase of 14-48 days.

Example 21

High Level Expression of Human Growth Hormone in Adult Mice

Human growth hormone-expressing retroviral vectors were produced as described in Example 8 herein. Large scale production was carried out in Cell Factories as described for DX/ND7 in Example 14 herein. The retroviral vectors were then lactose formulated as described in Example 9, herein. The titer was 8×10^8 . Adult mice were given a single injection of 100 μ l vector via the tail vein. One group of mice also received 600 μ g cyclosporin A once daily i.m. starting 1 day prior to injection of vector and continuing through Day 13. Human growth hormone was analyzed in mouse serum using a commercial ELISA kit (Boehringer Mannheim Biochemicals) according to the instructions of the manufacturer. The results are shown in Figure 26. "Positive control" refers to mice that received no cyclosporin. High level (400-1200 pg/ml) human growth hormone was observed on Day 3, declining to zero by Day 14. Negative controls (formulation buffer-injected) expressed no human growth hormone. The injection of cyclosporin A using the above schedule neither augmented nor diminished the growth hormone response.

Therefore, intravenous injection of high titer formulated retroviral vectors induces high level expression of growth hormone in adult animals with no lag phase.

Example 22

Use of Peroxisome Proliferators to Induce Liver Mitosis and Retroviral Transduction In Vivo

Balb/C mice were treated IP (500 μ l) or via gavage (200 μ l) with the peroxisome proliferator WY 14643 (Chem Syn, Lenexa, Kansas, USA) (15 mg/ml) once per day for 4 days. On day 4, 200 μ l beta galactosidase retrovector (1E9 cfu/ml, DA-Bgal) was injected via tail vein. On day 7, the mice were sacrificed, tissues were fixed in 2% formaldehyde/PBS for 24 hr, and blocked into slices of 2-5 mm. Sections were rinsed in PBS and stained in fresh XGAL solution (5 mM potassium ferricyanide/5 mM potassium ferrocyanide/ 2 mM MgCl₂/ 0.5mg/ml XGAL in DMF (Gold Scientific)/1X PBS). Tissue was embedded in paraffin (-50 degrees), sectioned at 5 microns (PML, San Diego), and counterstained with Hematoxylin/Eosin. Sections were compared from both periportal and peripheral regions from normal liver (XGAL stain only), control liver (no WY16463, with vector), WY control liver (WY16463 only, no vector), liver from group I (IP WY16463 plus vector), liver from group II (gavage WY16463 plus vector), and spleen from Group I. Numerous blue cells were observed in both treatment groups, both periportal and on the liver periphery. Very rare blue cells were observed in the control liver (without mitogen). No blue cells were seen in the normal liver (no mitogen or vector) or the WY liver (mitogen, no vector). The results indicate that the mitogen, administered either IP or by gavage, promoted liver transduction by beta-galactosidase-expressing vector, while no background staining was induced by mitogen in the absence of vector.

Example 23

Biolocalization of Intravenously Administered Retroviral Vector Following Long-Term Expression of Gene of Interest

Rabbits which had received intravenous administration retroviral vector resulting in > 373 days of expression of human factor VIII (See Example 18, herein) were sacrificed on day 511. Brain, spleen, and liver samples were collected using a fresh set of sterilized

instruments for each organ in each animal. DNA was isolated using lysis buffer (8M urea, 2% SDS, 0.35M NaCl, 10 mM Tris, pH 8.0) followed by phenol/chloroform extraction. DNA was quantitated by fluorometry and diluted to 500 ng/25 ul.. Integrity of each genomic DNA samples was verified by 0.6% agarose gel electrophoresis. PCR was

5 performed on each sample (0.5 uM primer LTR 492S (CCC TGT GCC TTA TTT GAA CTA ACC) (Seq ID No. 12), 0.55 uM primer LTR 1072AS (CCC ACC ACA ACC ACA TAT CCC TCC) (Seq ID No.13), 1X PCR Buffer, 2.5 mM MgCl₂, 200 uM dNTPs, 2.5 U Taq in a total volume of 50 ul (Perkin-Elmer)). The reactions are incubated 10 min at 94o, then subjected to 32 cycles of 94o x 30 sec, 68o x 30 sec, 72o x 30 sec. The amplicon

10 consisted of a 580 bp region spanning the LTR/Psi region of the vector backbone (see Example 1). Each sample was subjected to four replicate reactions. Two other replicate reactions were spiked with 5 copies of positive control DNA (DA6A3 HBV-IT VCL genomic DNA; see Townsend *et al.*, 1997, *J. Virol.* 71:3365, to control for interference with PCR amplification. Ten microliters of each amplification reaction were dot-blotted

15 onto a nylon membrane (Zeta Probe). The membrane was prehybridized in buffer (6X SSPE, 30% formamide, 5X Denhardt's Solution, 0.5% SDS, 1.5 mg/ml herring sperm DNA) at 42o for 60 min, the hybridized at 42o for 4 hr in the same buffer to a 32P-end labeled probe (LTR-P - CCA GTC CTC CGA TTG ACT G [Seq ID No. 14]) corresponding to a sequence internal to the LTR-Psi amplicon. The blot was washed (at

20 room temperature in 2x SSPE/1% SDS, then 3x 10 min at 42o in 2x SSPE/1% SDS) and exposed to film. The film was inspected for number of positive blots per total number of reactions. Tissue samples from Rabbit #82, which expressed high levels of human factor VIII protein, and from Rabbit #95, a control animal that had received no vector, are shown in Figure 27. The spiked reactions from all tissues were positive, indicating that negatives

25 are not due to PCR inhibiting substances from the tested tissues. Liver samples from 10 locations, a spleen sample, and samples from two brains locations were all negative in the control rabbit. The brain sample was negative in the expressing rabbit, while spleen and all 10 liver samples were positive in the expressing rabbit. The results suggest that liver and spleen have been transduced in the vector-treated rabbit, that marked cells are still

30 present after 511 days, and that these are candidate organs for the source of the circulating factor VIII.

Juvenile mice were treated with DA/beta-gal vector as in Example 20 herein. Expressing mice were sacrificed at Day 59 or 105. Brain, liver, kidney, lung, and spleen were analyzed for vector sequences by quantitative PCR. Quantitative PCR is performed as described above, except that 1 μ l of alpha-32P-dCTP is included in the PCR buffer, and a standard curve is prepared from the same positive control DNA in 3-fold dilutions from 1000 copies/sample down to 1.4 copies/sample, maintaining a constant concentration of 500 ng DNA/reaction by adding human PBMC DNA to each dilution. Five μ l of each reaction is blotted onto Whatman DE81 Ion Exchange Chromatography paper, dried at 420 x 5 min, washed 3x (40 ml 5M NaCl, 21 ml 1M monobasic sodium phosphate, 29 ml 1 M dibasic sodium phosphate, qs to 1 liter), and quantitated relative to the standard curve on the PhosphoImager (Molecular Dynamics). Liver was positive in all four animals tested, spleen in 3/4, and kidney in 1/4. Lung and brain were negative in all four, and ovary was negative in the two animals tested (See Figure 28). Tissue lysates were also prepared from several animals. One third to 1/2 of each tissue was placed in homogenization buffer (Dianon PCNA ELISA kit) and stored on ice, until all of the samples were collected. Samples were liquefied in dounce homogenizers. The lysates were transferred to 1.5 ml microfuge tubes, and centrifuged at 14,000 rpm, 4°C, for 15 minutes. The aqueous layer between the lipid and cell debris layers was aspirated by syringe and stored at -80°C. Samples were thawed at 37°C, diluted 1:3 and 1:10, and tested in duplicate for hGH by ELISA (BMB kit). Protein in each sample was determined in a Bradford protein assay, and results are expressed relative to total protein levels. Growth hormone antigen was found in liver in 4/4 animals tested, in spleen in 2/4, and kidney in 1/4. Brain was negative in 2/2 animals tested (See Figure 29). These data are consistent with the proposal that liver and spleen are the major sites of transduction and synthesis of genes of interest when retroviral vectors are introduced intravenously.

Example 24

Long Term Expression of Human Factor VIII in Normal Dogs Following Intravenous Expression of Vector

Recombinant retroviral vector expressing B domain deleted factor VIII was constructed, packaged, and expressed as described in Example 2 herein. Large scale

production was carried out in Cell Factories as described for DX/ND7 in Example 14 herein. The retroviral vector was then lactose formulated as described in Example 9 herein. High titer formulated retroviral vector was injected into 8 week old normal juvenile dogs according to the following schedule: 4E8 vector particles were injected into the cephalic vein at 2.5 hr intervals, three times per day for three days (Day 0, 1, and 2). On days 4, 7, 10, 13, 20 and every 7 days subsequently, citrated plasma was obtained by venipuncture of the cephalic vein and analyzed for human factor VIII antigen as in Example 18, except that the diluent was 1:3 citrated dog plasma (Harlan).

Data from Day 0 (prebleeds) to day 279 from 2 experimental and one control dog are shown in Figure 30. Levels remained undetectable through Day 7, with no significant differences being seen between the experimental and control groups ($p > 0.25$). On Day 7 and 10, low levels (3-10 ng/ml) of factor VIII were observed in all three dogs. On day 13 and subsequent days until day 90, Control Dog 39 and Experimental Dog 47 ("nonresponder") displayed 0-8 ng/ml human factor VIII antigen in their plasmas. In contrast, Experimental Dog 55 ("responder") displayed levels of 40-110 ng/ml factor VIII. Levels of factor VIII in Dog 55 peaked around Day 160, gradually declining until Day 279, the last date tested. On day 90, 91, and 92, the nonresponder dog #47 was boosted with dosage schedule recapitulating that used on day 0, 1, and 2. On Day 95, dog 47 displayed 95 ng/ml, comparable to the 77 ng/ml found in the unboosted responder dog 55 on that date. Unlike Dog 55, boosted Dog 47 did not maintain these levels, which declined to barely detectable levels by Day 125.

Example 25

Transduction of Splenocytes and Possible Stem Cell Transduction by Intravenous

Administration of Retroviral Vector

Data in Example 24 herein show transduction of spleen and liver in long-term expressing animals treated with retroviral vector intravenously. To test for expression of hGH by splenocytes, an adoptive transfer experiment was carried out. Fragments of spleens (1/4 to 1/3 spleen) were collected from BALB/c mice which had received 1E7 cfu DA-827 51 days earlier via tail vein injection as described in Example 20 herein. Spleens were processed individually. Single-cell suspensions were prepared in sterile Hank's

balanced salt solution (HBSS; Irvine Scientific) by passing tissue fragments through a 70 mm nylon mesh strainer (Becton Dickenson #2350). After pelleting, cells from each spleen were resuspended in 0.8 ml HBSS; 0.3 ml of this suspension was injected intravenously into lethally irradiated (900 R) recipient BALB/c mice. An estimated 6 - 7 x 10⁶ cells were transferred to each recipient. Serum levels of hGH were monitored every two weeks in recipients as in Example 20. levels of hGH expression in recipients roughly corresponded to the levels that had been present in the original donors (See Figure 31), suggesting that these levels correlated with transduced cell number. Peak expression was observed 56 days following spleen cell transfer, with a decrease by day 70. The increase of expression with time as the animals reconstituted indicates that stem cells have been transduced.

Example 26

Expression of Human Factor VIII in Hemophiliac Dogs Following

Intravenous Expression of Vector

Two factor VIII-deficient hemophiliac dogs (8 weeks old) were obtained from the closed colony at U. North Carolina, Chapel Hill. Two normal littermates were also obtained and used without further treatment to provide baseline values for assays. The two test dogs were injected with retroviral vector as in Example 24, herein, except that the injection dates were Days 1,2, and 3. Blood samples were obtained on Days 4,7,10, 14, and every 7 days subsequently. Citrated samples were used for measurements of whole blood clotting time (See Figure 32). On day -4, samples from the hemophiliac dogs were incoagulable (WBCT > 60 min), whereas the normal littermates had WBCT of 6-8 minutes. The WBCT of the normal littermates were maintained throughout the experiment. On day 4-10, the WBCT of the injected hemophiliac dogs dropped to 12-16 minutes. This represents expression of pg levels of factor VIII (Dr. Tim Nichols, UNC-Chapel Hill, personal communication). On day 14-28, the hemophiliac dog WBCT was again incoagulable (>50 min). Starting at day 35, the clotting time was again reduced, reaching 17 minutes for one dog and 16 minutes for the second, indicating a second peak of factor VIII clotting activity. This data demonstrates the successful expression of

biologically active factor VIII in dogs by intravenous administration of a retroviral vector expressing a B-domain deleted factor VIII protein.

5

Example 27

Construction of pBA-5a, pBA-5b, and pBA-5c, PBA-9b and pBA-8bL1 Retroviral Vector Backbones

This example describes several modifications of the retroviral vector pKT1 resulting in decreased sequence homology to the retroviral gag/pol and envelope expression constructs. pKT-1 is described in Example 1 herein and is shown schematically in Figure 33. (The construction of the pKT-1 starting material used in the present example is further described in detail in PCT WO 95/30763 and in co-owned U.S. Serial No. 08/721,327, both of which are hereby incorporated by reference in their entirety. In addition, two stop codons were introduced in the DNA sequence of the packaging signal sequence in order to increase the safety of these vectors. All modifications are summarized in Fig. 36 and the resulting retroviral backbones are called pBA-5a, pBA-5b, and pBA-5c. Further details on the construction of pBA-5a, pBA-5b, and pBA-5c are provided in co-owned U.S. Serial No. 08/721,327 and co-owned application, attorney docket 1147.004, filed May 5, 1997, entitled "Crossless Retroviral Vectors" and which is also hereby incorporated by reference.

A. Substitution of Nonsense Codons in the Extended Packaging Sequence

(Ψ^+)

This example describes modification of the extended packaging signal (Ψ^+) by PCR on the template KT-1 using primers that introduce two stop codons in the extended packaging signal sequence. In particular, the template pKT-1 contains the modification ATT at the normal ATG start site of gag (position 621-623 of SEQ ID NO: 15). Here the start site was further modified to the stop codon, TAA, and an additional stop codon TGA was added to replace the codon TTA at position 645-647 of SEQ ID NO: 15.

Briefly, two sets of PCR reactions were carried out on pKT1, each introducing one stop codon. The primers for the PCR were designed such that the two PCR products had

overlapping regions and a splice-overlap extension PCR (SOE-PCR) was carried out with the two PCR products in order to combine the two introduced stop codons on one strand. The first set of oligonucleotides introducing the change from ATT to TAA were 5'-GGG-AGT-GGT-AAC-AGT-CTG-GCC-TTA-ATT-CTC-AG (SEQ ID NO: 16) and 5'-CGG-TCG-ACC-TCG-AGA-ATT-AAT-TC (SEQ ID NO: 17) and the second set of oligonucleotides introducing the change from TTA to TGA were 5'-CTG-GGA-GAC-GTC-CCA-GGG-ACT-TC (SEQ ID NO: 18) and 5'-GGC-CAG-ACT-GTT-ACC-ACT-CCC-TGA-AGT-TTG-AC (SEQ ID NO: 19). The flanking primers of the final 708 base pair PCR product introduced the *Aat*II and the *Xho*I sites, at the 5' and 3', respectively.

The ends of the 708 base pair product were blunted and phosphorylated and the product introduced into the *Sma*I and *Eco*RV digested vector pBluescript SK- (Stratagene, San Diego, Calif.). The resulting plasmid was designated pBA-2, and is shown diagrammatically in Figure 34.

B. Removal of Retroviral Sequences Upstream and Downstream from the 3' LTR and Upstream and within the 5' LTR

Retroviral envelope sequence was removed upstream of the 3' LTR between the *Cla*I site and the TAG stop codon of the envelope coding sequence. The DNA sequence was modified by PCR such that the TAG stop codon was replaced by a *Cla*I site and the 97 nucleotides upstream from this new *Cla*I site to the original *Cla*I site were deleted, as well as the 212 base pairs of retroviral sequence downstream of the 3' LTR.

Briefly, the following two oligonucleotides were used for the PCR: 5'-CATCGATAAA ATAAAAGATT TTATTTAGTC (SEQ ID NO: 20) and 5'-CAAATGAAAG ACCCCCGCTG AC (SEQ ID NO: 21) and the template was pKT1.

The PCR product was cloned into pPCRII (Invitrogen, San Diego, Calif.) using the TA cloning kit (Invitrogen, San Diego, Calif.) and called pBA-1.

Subsequently, pBA-2 (described in section A above) was digested with *Xba*I and *Aat*II which deleted a part of the multiple cloning site and into this linearized vector the 780 base pair fragment from *Nhe*I to *Aat*II from pKT1 was cloned, resulting in the plasmid pBA-3. This plasmid pBA-3 combined the shortened 5' LTR with the above described packaging region including the two introduced stop codons.

Subsequently, pBA-1 was digested with *ClaI* and *ApaI* resulting in a 640 base pair fragment that was cloned into the *ClaI* and *ApaI* digested pBA-3 resulting in the plasmid pBA-4. This plasmid combines the above described 5' LTR and the packaging signal with the 3' LTR.

5 Subsequently, pBA-4 was digested with *ApaI* and *EcoRI*, ends blunted and religated in order to remove extraneous 3' polylinker sites, resulting in plasmid pBA-5a.

Subsequently, pBA-5a was cut with *NotI* (blunted) and *EcoRI* and introduced into *SmaI* and *EcoRI* digested pUC18 (GIBCO/BRL, Gaithersburg, MD) resulting in pBA-5b. This construct moved the retroviral vector from a pBluescript into an alternate pUC18
10 vector.

pBA-5c is constructed as identical to pUC-18 derived pBA-5b except for the *XhoI/ClaI* multicloning site was introduced into pUC-19.

This example further describes several modifications of the retroviral vector pBA-5b which result in a vector with multiple unique restriction enzyme sites for convenient
15 cloning. In order to prepare the pBA-9b vector, the herpes simplex virus thymidine kinase (HSVTK) gene was retrieved by digesting pBH-1 with *XhoI* and *EcoRI* resulting in a 1.2kb fragment. (pBH-1 was prepared as described in WO 91/02805 entitled "Recombinant Retroviruses Delivering Vector Constructs to Target Cells" which is hereby incorporated by reference.) The neomycin gene driven by the SV40 promoter was
20 retrieved by digesting pKT-1 with *EcoRI* and *BstBI* resulting in a 1.3 kb fragment. Both fragments were cloned into a *XhoI* and *ClaI* digested pBA-5b resulting in the retroviral vector pMO-TK.

The TK gene from the retroviral vector pMO-TK was isolated as a *XhoI-ClaI* fragment and inserted into the *XhoI-ClaI* digested pBA-5b, resulting in the plasmid pBA-
25 5bTK. In order to delete the restriction enzyme sites *HindIII*, *SphI*, *PstI*, *Sall* and *HincII* upstream of the 5' LTR, pBA-5bTK was digested with *HindIII* and *HincII*, overhanging ends removed using T4 polymerase and blunt ends ligated using the T4 DNA ligase, resulting in plasmid pTJBA-5bTK with 16 bases (TGC ATG CCT GCA GGT C) removed from upstream of the 5' LTR. The plasmid pTJBA-5bTK has a *BamHI* upstream of the
30 5' LTR. It is desirable to remove this *BamHI* site since it is a common site used for cloning. In order to destroy the *BamHI* site upstream of the 5' LTR, the *BamHI*-containing

TK gene in pTJBA-5bTK was replaced by the IL-2 gene via XhoI-ClaI digest, resulting in plasmid pTJBA-5bIL-2. The plasmid pTJBA-5bIL-2 was digested with BamHI, the ends filled in with the Klenow fragment and the ends religated, resulting in pTJBA-5bIL-2 (BamIII del.).

5 In order to produce the plasmid pBA-9b, the IL-2 gene from pTJBA-5bIL-2 (BamIII del.) is deleted via XhoI-ClaI digest and replaced with an linker that introduces a multiple cloning site (MCS) and codes for the restriction enzyme sites 5' -XhoI-ApaI-BglII-NotI-NruI-SalI-HindIII-BamHI-ClaI- 3'. The sequence of the two primers that is used to produce the linker are as follows: 5' - TCG AGG GGC CCA GAT CTG CGG
10 CCG CTC GCG AGT CGA CAA GCT TGG ATC CAT - 3' (Seq ID No. 26) as the primer for the + strand and 5' -CGA TGG ATC CAA GCT TGT CGA CTC GCG AGC GGC CGC AGA TCT GGG CCC C - 3' (Seq ID No. 27) as the primer for the - strand.

This example describes several modifications of the retroviral vector pBA-5b which result in a vector coding for the human placental alkaline phosphatase gene (PLAP),
15 driven by the SV40 promoter.

The plasmid pBA-8bL1 was constructed in a three-way ligation using the following three fragments: The NdeI-ClaI fragment from pBA-5b (described above) containing the 3'LTR and the pUC18 backbone, the ClaI-HindIII fragment from pCI-PLAP coding for PLAP and the HindIII-NdeI fragment from pBA-6bL1 containing the
20 5'LTR and the SV40 promoter. Plasmid pBA-6bL1 is based on pBA-6b (described above) where the HIV env/rev coding region was deleted via XhoI-ClaI digest and replaced with the 11 linker coding for several restriction enzyme sites including XhoI at the 5'end and ClaI at the 3'end.

Example 28

Construction Of pBA-5a, pBA-5b, and pBA-5c Retroviral Vectors Expressing B-Domain Deleted Factor VIII

A B domain deleted factor VIII cDNA fragment thus constructed was obtained by XhoI-NdeI digestion, as described below. A retroviral vector (pMBF8) expressing B-domain deleted factor VIII is constructed from the expression plasmid pSVF8-200 which
30 is prepared as described in Truett, 1985, *DNA* 4:333) and in U.S. Patent No. 5,045,455,

and which was deposited with the ATCC on July 17, 1985, and which has been assigned ATCC number 40190.

5 A DNA fragment encoding the β -domain deleted Factor VIII molecule was obtained from pSVF8-302, which has a nine base pair deletion in the 5' non-coding region after the poly G tail. Plasmid SVF8-302 was constructed in a similar manner as pSVF8-200, which is described in detail in Truett and in U.S. Patent No. 5,045,455. Construction of pSVF8-302 is also described in U.S. Patent No. 5,595,886.

10 The procedure outlined below describes the construction of retroviral vectors expressing a β -domain deleted Factor VIII protein obtained from pSVF8-302. However, alternatively, the same procedure can be used to construct such retroviral vectors from pSVF8-200.

15 The full-length cDNA sequence of the factor III is shown in Seq ID No. 44 and the full-length amino acid sequence is shown in Seq ID No. 45. The cDNA sequence of the B-domain deleted SQN deletion is shown in Seq ID No. 46 and the SQN deletion amino acid sequence is shown in Seq. ID No. 47.

20 Fragment 1, encompassing nt 5500-6248 of pSVF8-200 (see Figure 8 of Truett), was obtained by VENT-PCR using factor VIII primers encoding a PF1M1 site at the 3' end and the 5' SQN sequence plus a HindIII site at the 5' end. The 5' primer encompasses the region 2446-2460 of the 5' SQN and the region 5144-5167 just downstream of the 3' SQN sequence. Thus, this fragment spans the sequence between the two SQN sites within the B domain (positions 2461 and 5142). The particular primer sequences used were:

1. 5' GAAGCTTCTCCCAGAACCCACCAGTCTTGAAACGCCATC (Seq ID No. 22)
2. 5' GTACCAGCTTTTGGTCTCATCAAAG (Seq ID No. 23).

25 Fragment 1 was blunt-end cloned into vector SK- that had been cut with SmaI and dephosphorylated, forming pSK-Pfl. Fragment 2, encompassing nt 1190 and 2448 was isolated following HindIII digestion and cloned into the HindIII site of SK-Pfl to form SK-Pfl-Hind. The orientation of the insert was determined using *AccI* and *PstI* digests. pSVF8-200 was digested with *HpaI* and religated to remove two small *HpaI* fragments 3' to the factor VIII cDNA insert, forming pF8-300-del-Hpa. The remaining *HpaI* site was
30 converted to a NotI site using NotI phosphorylated linkers, forming F8-300-Hpa/Not. Fragment 3, encompassing nt 5885-7604, was isolated following PflMI and NotI digestion

and cloned into SK-Pfl-Hind following PflMI and NotI digestion of the latter to form pF8:213. Fragment 4 (encompassing nt 104-133 to 1204) was obtained following VENT-PCR of PSV7dF8-300 with primers containing 5' *Xho*I and 3' *Acc*I sites respectively. The 5' primer encompasses nt 104-133 and the 3' primer encompasses nt 1200-1224. pF8:213 was digested sequentially with *Xho*I followed by *Acc*I and ligated to Fragment 4 which was digested with *Xho*I and *Acc*I, pF8:4213. The primer sequences for the 5' UT and *Xho*I primers were:

3. 5' CTCCTCGAGCTAAAGATATTTTAGAGAAGAATTAAC (Seq ID No. 24)

4. 5' TTCCTCTGGACAGCTGTCTACTTTG (Seq ID No. 25)

The crossless backbones pBA-9b, pBA-5a, pBA-5b and pBA-5c were modified by linearizing with *Cl*aI, blunt ending and religating in the presence of NotI phosphorylated linkers. The modified cDNA fragment was cloned into the *Xho*I/NotI linearized vectors. Similarly, the modified cDNA described above is cloned into the backbone pMBA backbone described above which has been digested with *Xho*I and NotI

Example 29

Construction of Recombinant Adeno-Associated Virus (rAAV) Vectors that Express the Heavy and Light Chains of Human Factor VIII

We constructed two rAAV vectors, one expressed the light chain, and the other expressed the heavy chain. Both chains contain the Factor VIII leader sequence and a variable amount of the B domain.

To clone the heavy chain, a region of the Factor VIII gene from 174 bp 5' of the ATG to amino acid 745 was amplified by PCR. This fragment includes the entire heavy chain and first five amino acids of the B domain. The oligos used were: forward, 5'-CACCGTCGTCGACTTATGCT-3' (Seq ID No. 28), and reverse, 5'-GACCGTCGACTCAATTCTGGGAGAAGCTTCTTGG-3' (Seq ID No. 29). The plasmid used as a template in the PCR reaction was pCMVKmHSTB, a B deleted factor VIII expression construct. The amplified fragment was digested with *Sal* I, and cloned into a CMV expression vector, pCMVKmLINK digested with *Sal* I and *Xho* I. This plasmid was called pCMVKm90H. pCMVKmLINK is an expression vector containing the CMV promoter/intron, a polylinker for cloning genes of interest, and a bovine growth

homone polyadenylation signal. To make a rAAV vector expressing the heavy chain, pCMVKm90H was digested with Sal I and Bam HI, the Bam HI site was filled in with T4 DNA polymerase, and this fragment was cloned into the rAAV vector pKm201CMV-CI digested with Sal I and Eco RV. pKm201CMV-CI contains the inverted terminal repeats of AAV, the CMV promoter, the chimeric intron from pCI (Promega, Madison, WI), and the bovine growth hormone polyadenylation signal. The final AAV vector was called pKm201-90H.

To clone the light chain, we first amplified the factor VIII 5' untranslated and leader region using the following primers: forward, 5'-CACCGTCGTCGACTTATGCT-3' (Seq ID No. 30), and reverse, 5'-CAACGCTCGAGAAGCAGAATCGCAAAAGGC-3' (Seq ID No. 31). Again, pCMVKmHSTB was used as a template in the PCR reaction. The amplified region includes sequences from 174 bp upstream of the ATG to amino acid 19 of factor VIII. This fragment was digested with Xho I and Sal I and cloned into pCMVKmLINK digested with Xho I and Sal I. This plasmid was called pCMVKmF8L (for factor VIII leader). To amplify the light chain, the following primers were used: forward, 5'-TCGGCTCGAGGCATCAACGGGAAATAACTCGT-3' (Seq ID No. 32), and reverse, 5'-CCGACTCGAGTCAGTAGAGGTCCTGTGCCTC-3' (Seq ID No. 33). Again, pCMVKmHSTB served as the template for the PCR. The amplified fragment included sequences from amino acid 1645 of factor VIII to the STOP codon after amino acid 2332. This included the last four amino acids of the B domain and the complete light chain. This fragment was digested with Xho I and cloned into the Xho I site of pCMVKmF8L. This resulted in a light chain construct containing the factor VIII leader which was called pCMVKm80L. pCMVKm80L was digested with Sal I and Bam HI to remove the light chain construct, and this fragment was cloned into pKm201CMV-CI digested with Sal I and Bam HI to generate pKm201-80L. See Figures 35 and 36 for diagrams pKm201-80L and pKm201-90H, respectively.

Example 30

Co-Infection of Cells with rAAV Vectors Expressing the Heavy and Light Chains of Factor VIII Results in the Production of Biologically Active Factor VIII

The heavy and light chain constructs, pKm201-80L and pKm201-90H, were packaged following standard procedures for the production of rAAV (Zhou *et al.*, 1994, *J. Exp. Med.* 179:1867-1875). rAAV was purified as described (Wang *et al.*, 1995, *Proc. Natl. Acad. Sci. USA* 92:12416-12420) and used to infect 293 cells plated in 6-well plates. Supernatants of infected cells were collected at 48 h after infection and assayed for biologically active factor VIII by Coamatic Factor VIII (KabiVitrum, Stockholm) following manufacturer's instructions. Normal human plasma (George King Bio-Medical, Inc., Overland Park, Kansas) was used to generate a standard curve. Cells were infected at a multiplicity of infection (MOI) of 6000 rAAV particles per cell. The experiment was done both with and without the addition of etoposide (0.3 M) to the medium. Etoposide has been shown to increase the transduction efficiency of rAAV vectors (Russell *et al.*, 1995, *Proc. Natl. Acad. Sci. USA* 92:51719-51723). As shown in Table 5 below, co-infection of rAAV-80L and rAAV-90H resulted in the production of biologically active factor VIII. The amount of factor VIII was increased in the presence of etoposide.

Table 5: Co-infection of rAAV-80L and rAAV-90H results in the production of biologically active factor VIII.

Virus	Factor VIII (ng/ml)	
	- etoposide	+ etoposide
80L	0	0
90H	0	0
80L + 90H	1.4	6.1

Example 31

Construction Of A Retroviral Vector Expressing Human LDL Receptor

The human LDL-receptor expression plasmid pLDLR17 was obtained from Bev Davidson, Univ of Iowa. Alternatively, the expression plasmid can be prepared as described in JBC 264, 21682-88(1989)). The 5' fragment was reconstructed using VENT-PCR. The 3' primer contained a XhoI site and the 3' primer encompasses the unique

EcoRI site within the LDLR cDNA. The EcoRI digested 5' fragment was subcloned into Bluescript SK- and cut with SmaI and EcoRI. The SmaI site at the 3' end of LDLR cDNA in LDLR17 was modified using Not I linker to yield pLDLR17-S/N. The two fragments (The 5' fragment: XhoI to EcoRI and the 3' fragment: EcoRI to NotI) were ligated to pBA-6b (see Example 27, herein) which was digested with XhoI and NotI. The sequence of the PCR primers used was:

1. 5' GCGACTCGAGCATGGGGCCCTGGGGC (Seq ID No. 34)

2. 5' GCACTGGAATTCGTCAGGGCG (Seq ID No. 35)

The resulting vector was named p6b-LDLR.

A high titer DA producer clone for p6b-LDLR was selected under G418. The G418 vector titer in the supernatant was around 2×10^7 cfu/ml. Expression in target cells in vitro was demonstrated to be comparable to normal levels using either a Western blot or a functional assay.

Example 32

Human Alpha 1 Antitrypsin Retroviral Vectors for the Treatment of Antitrypsin Deficiency

The human alpha-1 antitrypsin cDNA clone was obtained from ATCC (Clone #256976). The plasmid was digested with EcoRI and blunted using T4 DNA polymerase large fragment (Klenow). The fragment containing the cDNA is cloned into the *SrfI* linearized pBA-9 vector (see Example 27 herein) to produce the provector pBA9-AAT. An oxidation resistant cDNA clone prepared as described in U.S. Patent 4,732,973 was digested with restriction enzymes and ligated to pBA-5b (described above).

Example 33

Construction of the Retroviral Vector Encoding Interferon- α 2a, α 2b and α 2c

(a) Preparation of Interferon -alpha Sequences Utilizing PCR

Construction of the Retroviral Vector Encoding Interferon- α 2a, α 2b, α 2c, α 54, and α 76

DNA clones of interferon- α 2a, α 2b, α 2c α 54, and α 76 are prepared utilizing PCR. The interferon- α 2a DNA is obtained from a cDNA library as described by Goeddel *et al*, 1980, *Nature* 287:411-416. The interferon- α 2b DNA is obtained from a cDNA library

described by Streuli *et al.*, 1980, *Science* 209:1343-1347, and the interferon- α 2c DNA is obtained as described by Saveliev *et al.*, 1986, *Antibiot. Med. Biotechnol.* 3:592-596.

DNA clones of interferon- α 54 and α 76 are prepared utilizing PCR. Both the interferon- α 54 DNA and the interferon- α 76 DNA are obtained as described in U.S. Patent No. 4,975,276 and U.S. Patent No. 5,098,703.

A reaction mixture is then prepared according to procedures specified by New England Biolabs (Beverly, MA). More specifically, a reaction mixture is prepared containing 1 ug purified plasmid, 10 ul of 10X ThermoPol reaction buffer, 2 ul 2.5 mM of each dATP, dCTP, dGTP and dTTP, 0.5 ul of 2 units/100 ul Vent polymerase, 1 - 3 ul of 100mM MgSO₄, and 0.5-1.0 ug of the primers specified below (Mattila *et al.*, 1991, *Nucleic Acids Research* 19:4967-4973, Eckert, K.A. and Kunkel, T. A., PCR Methods and Applications 1, 17-24, 1991).

a. Interferon- α 2a and α 2b

For interferon- α 2a and α 2b, the coding region is identical except for AAA codon at position 23 for interferon- α 2a and AGA codon at position 23 for interferon- α 2b. The sense primer for both interferon- α 2a and α 2b is from the 5' region of the coding sequence, 6 bp upstream from the ATG start codon until 25 bp downstream from the start codon. The 5' end of the primer contains the Xho I restriction site.

(Seq ID No. 36) 5'-3': CGCG CCG CTC GAG TCT ACA ATG GCC TTG ACC TTT GCT TTA CTG G

For interferon- α 2a and α 2b, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Cla I restriction site.

(Seq ID No. 37) 5'-3': GCG CCC ATC GAT TCA TTC CTT ACT TCT TAA ACT TTC TTG CAA G

b. Interferon- α 2c

For interferon- α 2c, the sense primer is from the 5' region of the coding sequence, 7 bp upstream from the ATG start codon until 28 bp downstream from the start codon. The 5' end of the primer contains the Xho I restriction site.

(Seq ID No. 38) 5'-3': CGCG CCG CTC GAG CAT CCA ATG GCC CTG TCC TTT TCT TTA CTT ATG G

For interferon- α 2c, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Cla I restriction site.

(Seq ID No. 39) 5'-3': CC ATC GAT TCA ATC CTT CCT CCT TAA TCT TTT TTG CAA G

5 c. Interferon- α 54

The sense primer is from the 5' region of the coding sequence, 6 bp upstream from the ATG start codon until 24 bp downstream from the start codon. The 5' end of the primer contains the Xho I restriction site.

(Seq ID No. 53) 5'-3': CGCG CCG CTC GAG TCT ACA ATG GCT TTG CCT TTT GCT TTA CTG

- 10 The second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Cla I restriction site.

(Seq ID No. 54) 5'-3': GCG CCC ATC GAT TTA TTC CTT CCT CCT TAA CCT TTC TTG CAA G

 d. Interferon- α 76

- 15 For interferon-76, the sense primer is from the 5' region of the coding sequence, 7 bp upstream from the ATG start codon until 28 bp downstream from the start codon. The 5' end of the primer contains the Xho I restriction site.

(Seq ID No. 55) 5'-3': CGCG CCG CTC GAG CAT CCC AAT GGC CCT GTC CTT TTC TTT ACT GAT GG

- 20 The second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Cla I restriction site.

(Seq ID No. 56) 5'-3': CC ATC GAT TCA ATC CTT CCT CCT TAA TCT TTT TTG CAA G

- 25 The reaction mixture is brought up to 100 μ l with DI H₂O, and each tube is placed into a thermocycler (Gene Amp PCR System 9600, Perkin-Elmer, Cetus, Calif.). The PCR program regulates the temperature of the reaction vessel first at 94°C for 10 minutes to hot

start reactions. Vent polymerase is added next and the cycle begins with 94°C for 2 minutes, next at 56°C for 30 - 60 seconds, and 72°C for 30 - 60 seconds. This cycle is repeated 35 times. After the 35th cycle, product ends are sealed by the reactions at 72°C for 3 - 5 minutes. Reactions are held at 4°C. If necessary, PCR amplification can be
5 optimized using touchdown or stepdown PCR protocol (White, B. A., PCR Cloning Protocols 67, 39-45, 1997).

The PCR product from the reaction yields the interferon- α 2a, α 2b and α 2c gene. Following the PCR reaction, the solution is transferred to a fresh 1.5 ml microfuge tube. Fifty microliters of 3 M sodium acetate is added to this solution followed by 500 μ l of
10 chloroform:isoamyl alcohol (24:1). The mixture is vortexed and then centrifuged at 14,000 rpm for 5 minutes. The aqueous phase is transferred to a fresh microfuge tube and 1.0 ml 100% EtOH is added. This solution is incubated at -20°C for 4.5 hours, and then centrifuged at 10,000 rpm for 20 minutes. The supernatant is decanted, and the pellet rinsed with 500 μ l of 70% EtOH. The pellet is dried by centrifugation at 10,000 rpm
15 under vacuum and then resuspended in 10 μ l deionized H₂O. One microliter of the PCR product is analyzed by electrophoresis in a 1.0% agarose gel.

These PCR products, approximately 570 bp in length, are digested with Xho I and Cla I restriction endonucleases, electrophoresed through a 1.0% agarose gel and the DNA is purified from the gel slice by GeneClean II (Bio 101, Vista, California). These Xho I-
20 Cla I PCR products are subcloned into the respective sites of pBluescript KSII+ (Stratagene, La Jolla, California). These constructs are designated KSII+ Xho-Cla IFN- α 2a, α 2b, α 2c, α 54 and α 76 respectively, and are verified by DNA sequencing.

(b) Insertion of interferon-alpha sequences into retroviral vectors

1. Retroviral Vector Backbone - pBA6bL1

25 The pBA6bL1 retroviral vector backbone is described above. Two fragments are purified for the construction of the interferon α 2a, α 2b, α 2c, α 54 and α 76 pBA6bL1 retroviral vector. First, pBA6bL1 is digested with Xho I and Cla I and the 6.2 kb fragment containing the retroviral vector backbone is isolated. Second, from KSII+ Xho-Cla IFN- α 2a, α 2b, α 2c, α 54 and α 76, the 570 Xho I-Cla I bp fragment containing the interferon-
30 α 2a, α 2b, α 2c, α 54 and α 76 gene is isolated and inserted into the Xho I-Cla I sites of

pBA6b11. The vector constructs are designated pBA6b-IFN α 2a, pBA6b-IFN α 2b, pBA6b-IFN α 2c, pBA6b-IFN α 54 and pBA6b-IFN α 76, respectively.

2. Retroviral Vector Backbone - pLXSN

The retroviral vector backbone, pLXSN is available by Clontech (Palo, Alto, Calif.). Two fragments are purified for the construction of the LXSN retroviral vector encoding interferon- α 2a, α 2b, α 2c, α 54 and α 76. First, pLXSN is digested with Xho I and Bam HI and the 5.9 kb fragment containing the retroviral vector backbone is isolated. Second, from KSII+ Xh-Cla IFN- α 2a, α 2b, α 2c, α 54 and α 76, the 570 bp Xho-Bam HI fragment containing either the interferon- α 2a, α 2b, α 2c, α 54 or α 76 gene is isolated and inserted into the respective sites of pLXSN. This vector construct is designated pLXSN-IFN α 2a, pLXSN-IFN α 2b, pLXSN-IFN α 2c, pLXSN-IFN α 54 and pLXSN-IFN α 76.

3. Lentiviral Backbone

An HIV retroviral vector backbone is made, similar to V653RSN as described by Parolin *et al.* (*J Virol.* 68:3888-3895, 1994). From KSII+ Xho-Cla IFN- α 2a, α 2b, α 2c, α 54 and α 76, the 570 bp Xho I-Xba I fragment containing the interferon- α 2a, α 2b, α 2c, α 54 and α 76 is isolated and inserted into the Xho I-Xba I sites of a CMV expression vector, pCI (Promega, Madison, WI) and is designated pCI-IFN α 2a, IFN α 2b, IFN α 2c, IFN α 54 and IFN α 76, respectively. From pCI-IFN α 2a, IFN α 2b, IFN α 2c, IFN α 54 and IFN α 76, the Bgl II-Bam HI fragment is isolated and inserted into the Bam HI sites of V653RSN where the SL3NEO sequences have been removed. To determine the orientation of the interferon α insert, vector constructs are sequenced. These vector constructs are designated V653-IFN α 2a, V653-IFN α 2b, V653-IFN α 2c, V653-IFN α 54 and V653-IFN α 76, respectively.

4. Retroviral Vector Backbone - pBA8bL1

The pBA8bL1 retroviral vector backbone has been described before in Example 27.

a. Interferon- α 2a and α 2b

In a separate set of PCR reactions, the sense primer for both interferon- α 2a and α 2b is from the 5' region of the coding sequence, 6 bp upstream from the ATG start codon until 25 bp downstream from the start codon. The 5' end of the primer contains the Bam HI restriction site.

5 (Seq ID No. 40) 5'-3': CC GGA TCC TCT ACA ATG GCC TTG ACC TTT GCT TTA CTG G

For interferon- α 2a and α 2b, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Not I restriction site.

(Seq ID No. 41) 5'-3': CGCG CCG GCG GCC GC TCA TTC CTT ACT TCT TAA ACT TTC TTG CAA G

10 b. Interferon- α 2c

For interferon- α 2c, the sense primer is from the 5' region of the coding sequence, 7 bp upstream from the ATG start codon until 28 bp downstream from the start codon. The 5' end of the primer contains the Bam HI restriction site.

(Seq ID No. 42) 5'-3': CC GGA TCC CAT CCA ATG GCC CTG TCC TTT TCT TTA CTT ATG G

15 For interferon- α 2c, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Not I restriction site.

(Seq ID No. 43) 5'-3': CGCG CCG GCG GCC GC TCA ATC CTT CCT CCT TAA TCT TTT TTG CAA G

c. Interferon- α 54

20 In a separate set of PCR reactions, the sense primer for both interferon- α 54 is from the 5' region of the coding sequence, 6 bp upstream from the ATG start codon until 25 bp downstream from the start codon. The 5' end of the primer contains the Bam HI restriction site.

(Seq ID No. 57) 5'-3': CC GGA TCC TCT ACA ATG GCT TTG CCT TTT GCT TTA CTG

25 For interferon- α 54, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Not I restriction site.

(Seq ID No. 58) 5'-3': CGCG CCG GCG GCC GC TTA TTC CTT CCT CCT TAA CCT TTC TTG CAA G

d. Interferon- α 76

For interferon- α 76, the sense primer is from the 5' region of the coding sequence, 7 bp upstream from the ATG start codon until 28 bp downstream from the start codon. The 5' end of the primer contains the Bam HI restriction site.

(Seq ID No. 59) 5'-3': CC GGA TCC CAT CCC AAT GGC CCT GTC CTT TTC TTT ACT GAT GG

For interferon- α 76, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Not I restriction site.

(Seq ID No. 60) 5'-3': CGCG CCG GCG GCC GC TCA ATC CTT CCT CCT TAA TCT TTT TTG CAA G

These PCR products, approximately 570 bp in length, are digested with Bam HI and Not I restriction endonucleases, electrophoresed through a 1.0% agarose gel and the DNA is purified from the gel slice by GeneClean II (Bio 101, Vista, California). This Bam HI-Not I PCR product is subcloned into the respective sites of pBluescript KSII+ (Stratagene, La Jolla, California). These constructs, designated KSII+ Bam-Not IFN- α 2a, α 2b, α 2c, α 54, and α 76 are verified by DNA sequencing.

Two fragments are purified for the construction of the interferon α 2a, α 2b, α 2c, α 54 and α 76 pBA8bL1 retroviral vector. First, pBA8bL1 is digested with Not I and Srf I and the 6.1 kb fragment containing the retroviral vector backbone is isolated. Second, from KSII+ Bam-Not IFN α 2a, α 2b, α 2c, α 54 and α 76, the 570 bp Sma I-Not I fragments containing the interferon- α 2a, α 2b, α 2c, α 54 or α 76 are isolated and inserted into the Srf I-Not I sites of pBA8bL1. These vector constructs are designated pBA8b-IFN- α 2a, pBA8b-IFN- α 2b, pBA8b- α 2c, pBA8b-IFN- α 54 and pBA8b-IFN α 76.

5. Retroviral Vector Backbone - pBA6bL1/TK

The herpes simplex virus (HSV) thymidine kinase (TK) cDNA is excised from pTJBA-5bTK retroviral vector by Xho I/Cla I double digestion as described before in Example 27B and inserted into the Sal I/Cla I sites of pSP72 plasmid (Promega, Madison,

WI) and designated pSP72-TK. The human interleukin-2 (IL-2) cDNA is excised from KT3-IL-2 (described in PCT Patent Publication Nos. WO 94/21792 and WO 96/21015) and inserted into the Xho I/Cla I sites of pBluescript SK- and designated pBSSK-IL2. The Hind III/Sma I double digest of pSP72-TK excises TK cDNA and this fragment is inserted
 5 into the Hind III/Sma I sites of pBSSK-IL2. This construct has the following: Xho I-IL2 cDNA-Cla I-Hind III-TK cDNA-Sma I sequence and is designated pBSSK-IL2/TK.

From KSII+ Xho-Cla IFN- α 2a, α 2b, α 2c, α 54 or α 76, the 570 Xho I-Cla I bp fragment containing the interferon- α 2a, α 2b, α 2c, α 54 or α 76 gene is isolated. From pBSSK-IL2/TK, the IL2 fragment is excised by Xho I/Cla I double digestion, and replaced
 10 with Xho/Cla I fragments containing the interferon- α 2a, α 2b, α 2c, α 54 or α 76 genes. The vector constructs are designated pBSSK-IFN α 2a /TK, pBSSK-IFN α 2b /TK, pBSSK-IFN α 2c /TK, pBSSK-IFN α 54/TK and pBSSK-IFN α 76/TK, respectively. The Xho I/Not I fragments from pBSSK-IFN α 2a /TK, pBSSK-IFN α 2b /TK, pBSSK-IFN α 2c /TK, pBSSK-IFN α 54 /TK and pBSSK-IFN α 76 /TK are excised and inserted into the Xho I-Not I
 15 sites of pBA6bL1. These di-cistronic retroviral vectors encoding IFN α 2a, α 2b, α 2c α 54 and α 76 are designated pBA6bL1 IFN α 2a/TK, pBA6bL1 IFN α 2b/TK, pBA6bL1 IFN α 2c /TK, pBA6bL1 IFN α 54/TK and pBA6bL1 IFN α 76/TK.

6 Retroviral Vector Backbone with a Liver-specific promoter

The ApoE enhancer-alpha 1-antitrypsin promoter yields high levels of expression
 20 from liver cells (Okuyama *et al.*, 1996, *Hum Gene Ther* 7:637-645). The retroviral vector encoding the liver-specific promoter is constructed as follows.

a ApoE enhancer cassette

The apolipoprotein E (Apo E) enhancer sequence has been identified as a 154 bp fragment by Shachter *et al.*, 1993, *J. Lipid Res* 34:1699-1707. The ApoE enhancer
 25 cassette was generated by sets of four oligonucleotides that span the entire sequence. For the first reaction, four oligonucleotides were synthesized that were phosphorylated at the 5' end. The first oligonucleotide is the sense strand and contains Hind III restriction site at the 5' end.

(Seq ID No. 61) 5'-3': AG CTT GCT GTT TGT GTG CTG CCT CTG AAG TCC ACA CTG AAC AAA
CTT CAG CCT ACT CAT GTC CCT AAA ATG GGC AAA CAT TGC AAG CAG C

The second oligonucleotide is the sense strand, spanning the second half of the Apo E enhancer and contains the Hind III restriction site at the 3' end.

5

(Seq ID No. 62) 5'-3': AAA CAG CAA ACA CAC AGC CCT CCC TGC CTG CTG ACC TTG GAG
CTG GGG CAG AGG TCA GAG ACC TCT CTG A

The third oligonucleotide is the antisense strand of the second half of the Apo E enhancer and contains the Hind III site at the 5' end.

10

(Seq ID No. 63) 5'-3': AG CTT CAG AGA GGT CTC TGA CCT CTG CCC CAG CTC CAA GGT CAG
CAG GCA GGG AGG GCT GTG TGT TTG CTG TTT GCT GCT TG

The fourth oligonucleotide is the antisense strand of the first half of the Apo E enhancer and contains the Hind III site at the 3' end.

15

(Seq ID No. 64) 5'-3': CAA TGT TTG CCC ATT TTA GGG ACA TGA GTA GGC TGA AGT TTG TTC
AGT GTG GAC TTC AGA GGC AGC ACA CAA ACA GC A

This set of four oligonucleotides of approximately 80 bases in length are annealed, and ligated into the dephosphorylated Hind III sites of pBluescript KSII+ (Stratagene, La Jolla, California) following standard molecular cloning protocols. Recombinants are selected and sequenced. Correct monomer Apo E enhancer elements are excised by Hind III, electrophoresed through a polyacrylamide gel and the DNA is purified following procedures described by Asubel et al., *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (1987). The monomer enhancer element is ligated into the dephosphorylated Hind III sites of pBluescript KSII+ at an insert:vector ratio of 10:1 in order to generate recombinants containing dimers. Recombinant plasmids were assessed by DNA sequencing to select clones which carried both enhancer fragments in the same orientation with the 5' end closer to the Eco RV site and the 3' end closer to

20

25

the Cla I site within the multi-cloning site of pBluescript. This construct is designated KSII+ Hind III ApoE(x2)

For the second reaction, another set of four oligonucleotides were synthesized that were phosphorylated at the 5' end. The first oligonucleotide is the sense strand and
5 contains Eco RI restriction site at the 5' end.

(Seq ID No. 65) 5'-3': AAT TC GCT GTT TGT GTG CTG CCT CTG AAG TCC ACA CTG AAC AAA
CTT CAG CCT ACT CAT GTC CCT AAA ATG GGC AAA CAT TGC AAG CAG C

The second oligonucleotide is the sense strand, spanning the second half of the
10 APO E enhancer and contains the Eco RI restriction site at the 3' end.

(Seq ID No. 66) 5'-3': AAA CAG CAA ACA CAC AGC CCT CCC TGC CTG CTG ACC TTG GAG CTG
GGG CAG AGG TCA GAG ACC TCT CTG G

The third oligonucleotide is the antisense strand of the second half of the Apo E
15 enhancer and contains the Eco RI site at the 5' end.

(Seq ID No. 67) 5'-3': AA TTC CAG AGA GGT CTC TGA CCT CTG CCC CAG CTC CAA GGT CAG
CAG GCA GGG AGG GCT GTG TGT TTG CTG TTT GCT GCT TG

The fourth oligonucleotide is the antisense strand of the first half of the Apo E
20 enhancer and contains the Eco RI site at the 3' end.

(Seq ID No. 68) 5'-3': CAA TGT TTG CCC ATT TTA GGG ACA TGA GTA GGC TGA AGT TTG
TTC AGT GTG GAC TTC AGA GGC AGC ACA CAA ACA GC G

In a second reaction, this set of four oligonucleotides of approximately 80 bases in
25 length are annealed, and ligated into the dephosphorylated Eco RI sites of pBluescript
KSII+ (Stratagene, La Jolla, California). Recombinants are selected and sequenced.
Correct monomer Apo E enhancer elements are excised by Eco RI, electrophoresed
through a polyacrylamide gel and the DNA is purified following standard procedures. The
monomer enhancer element is ligated into the dephosphorylated Eco RI sites of

pBluescript KSII+ at an insert:vector ratio of 10:1 in order to generate a second set of recombinants containing dimers. Recombinant plasmids were assessed by DNA sequencing to select clones which carried both enhancer fragments in the same orientation with the 5' end closer to the Pst I site and the 3' end closer to the Eco RV site. This construct is designated KSII+ Eco RI ApoE(x2).

The 300 base pair Pst I/Eco RV fragment from KSII+ Eco RI ApoE(x2) is inserted into the Pst I and Eco RV sites within the multi-cloning sites of KSII+ Hind III ApoE(x2). This construct is designated KSII+ ApoE(x4), and contains 4 copies of the 154 base pair Apo E enhancer.

10 b. Human alpha 1-antitrypsin promoter

The human alpha 1-antitrypsin (hAAT) promoter has been identified as a 400 base pair region by Shen *et al.*, 1989, *DNA* 8:101-108. The hAAT promoter DNA is obtained from a genomic library as was done by Long *et al.*, 1984, *Biochem* 23:4828-4837, or can be obtained from ATCC (ATCC No. 61596).

15 A PCR reaction is conducted in order to isolate the hAAT promoter. The 5' end of the primer contains the Sma I restriction site.

(Seq ID No. 69) 5'-3': CGCG CCG CCC GGG GTA GAT CTT GCT ACC AGT GG

20 The second primer corresponding to the anti-sense nucleotide sequence contains the Not I restriction site.

(Seq ID No. 70) 5'-3': GCG CCC GCG GCC GC CAC TGT CCC AGG TCA GTG GTG GTG CC

25 This PCR product, approximately 400 bp in length, is digested with Sma I and Not I and is cloned into the Sma I and Not I sites within the multi-cloning sites of KSII+ ApoE(x4). This construct is confirmed by sequencing and is designated KSII+ ApoE/hAAT.

c. Construction of the retroviral vector pBA6 ApoE/hAAT-IFN α 2a and pBA6 ApoE/hAAT-IFN α 2b

1. Interferon- α 2a and α 2b

The sense primer for both interferon- α 2a and α 2b is from the 5' region of the coding sequence, 6 bp upstream from the ATG start codon until 25 bp downstream from the start codon. The 5' end of the primer contains the Not I restriction site.

5

(Seq ID No. 71) 5'-3': CGCG CCG GCGG CCGC TCT ACA ATG GCC TTG ACC TTT GCT TTA CTG G

For interferon- α 2a and α 2b, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Cla I restriction site.

10

(Seq ID No. 72) 5'-3': GCG CCC ATC GAT TCA TTC CTT ACT TCT TAA ACT TTC TTG CAA G

The product of this PCR reaction is digested with Not I and Cla I and purified. KSII+ ApoE/hAAT is digested with Not I and Cla I and the 1 kb fragment containing the Apo E enhancer and the hAAT promoter is isolated. From pBA6bL1, the 6.1 kb Xho/Cla I retroviral vector backbone is isolated. In a three part ligation (a) the Xho I/Not I fragment containing the Apo E enhancer and the hAAT promoter, (b) the Not I/ Cla I fragment encoding the IFN α 2a or α 2b gene and (c) the Xho I/Cla I fragment encoding the retroviral vector backbone are joined to generate pBA6 ApoE/hAAT-IFN α 2a or α 2b.

15

20

7. Construction of the Marker-less retroviral vector pBA9 ApoE/hAAT-IFN α 2a and

pBA9 ApoE/hAAT-IFN α 2b

25

a. Interferon- α 2a and α 2b

The sense primer for both interferon- α 2a and α 2b is from the 5' region of the coding sequence, 6 bp upstream from the ATG start codon until 25 bp downstream from the start codon. The 5' end of the primer contains the Not I restriction site.

30

(Seq ID No. 73) 5'-3': CGCG CCG GCGG CCGC TCT ACA ATG GCC TTG ACC TTT GCT TTA CTG G

For interferon- α 2a and α 2b, the second primer corresponds to the anti-sense nucleotide sequence, extending 31 bp into the coding sequence from the 3' end of the interferon gene. The 5' end of the primer contains the Cla I restriction site.

5 (Seq ID No. 74) 5'-3': GCG CCC ATC GAT TCA TTC CTT ACT TCT TAA ACT TTC TTG CAA G

The product of this PCR reaction is digested with Not I and Cla I and purified. KSII+ ApoE/hAAT is digested with Not I and Cla I and the 1 kb fragment containing the Apo E enhancer and the hAAT promoter is isolated. From pBA9b, the 4.8 kb Xho/Cla I retroviral vector backbone is isolated. In a three part ligation (a) the Xho I/Not I fragment containing the Apo E enhancer and the hAAT promoter, (b) the Not I/ Cla I fragment encoding the IFN α 2a or α 2b gene and (c) the Xho I/Cla I fragment encoding the pBA9b retroviral vector backbone are joined to generate pBA9 ApoE/hAAT-IFN α 2a or α 2b.

15 8. Construction of the retroviral vector pBA6 TK/ApoE/hAAT-IFN α 2a and pBA6

TK/ApoE/hAAT-IFN α 2b

The thymidine kinase (TK) gene is excised from pTJ5b-TK with Xho/Cla I and inserted into the Xho I/Cla I sites of KSII+ ApoE/hAAT. This construct is designated •
20 KSII+ TK/ApoE/hAAT.

PCR products containing either the IFN α 2a or IFN α 2b genes described in the example above is digested with Not I and Cla I and purified. The Xho/Not fragment containing the TK/ApoE/hAAT sequence is excised from KSII+ TK/ApoE/hAAT. From pBA6bL1, the 6.1 kb Xho/Cla I retroviral vector backbone is isolated.

25 In a three part ligation (a) the Xho I/Not I fragment containing the TK gene and the Apo E enhancer with the hAAT promoter, (b) the Not I/ Cla I fragment encoding the IFN α 2a or α 2b gene and (c) the Xho I/Cla I fragment encoding the retroviral vector backbone are joined to generate pBA6 TK/ApoE/hAAT-IFN α 2a or pBA6 TK/ApoE/hAAT-IFN α 2b.

9. Construction of the Marker-less retroviral vector pBA9 TK/ApoE/hAAT-IFN α 2a

and pBA9 TK/ApoE/hAAT-IFN α 2b

5 The thymidine kinase (TK) gene is excised from pTJ5b-TK with Xho/Cla I and inserted into the Xho I/Cla I sites of KSII+ ApoE/hAAT. This construct is designated KSII+ TK/ApoE/hAAT.

10 PCR products containing either the IFN α 2a or IFN α 2b genes described in the example above is digested with Not I and Cla I and purified. The Xho/Not fragment containing the TK/ApoE/hAAT sequence is excised from KSII+ TK/ApoE/hAAT. From pBA9b, the 4.8 kb Xho/Cla I pBA9 retroviral vector backbone is isolated.

15 In a three part ligation (a) the Xho I/Not I fragment containing the TK gene and the Apo E enhancer with the hAAT promoter, (b) the Not I/ Cla I fragment encoding the IFN α 2a or α 2b gene and (c) the Xho I/Cla I fragment encoding the pBA9 retroviral vector backbone are joined to generate pBA9 TK/ApoE/hAAT-IFN α 2a or pBA9 TK/ApoE/hAAT-IFN α 2b.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Chiron Corporation
- (ii) TITLE OF INVENTION: Methods for Administration of
Recombinant Gene Delivery Vehicles for Treatment of Human Disease
- (iii) NUMBER OF SEQUENCES: 83
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Chiron Corporation
 - (B) STREET: 4560 Horton Street
 - (C) CITY: Emeryville
 - (D) STATE: California
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 94608
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: Unassigned
 - (B) FILING DATE: Even date herewith
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kruse, Norman J.
 - (B) REGISTRATION NUMBER: 35,235
 - (C) REFERENCE/DOCKET NUMBER: 1155.300
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (510) 923-3520
 - (B) TELEFAX: (510) 655-3542

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GAGAGATGGG GGAGGCTAAC TGAG
24

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
GATCCTCAGT TAGCCTCCCC CATCTCTC
28

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TATATCTCCA GATGAGGTAC ATGATTTTAG GCTTG
35

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TATATATCGA TTCAAGGCAT TTTCTTTTCA TCAATAAAAC
40

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCGAGGATCC GCCC GGCGG CCGCATCGAT GTCGACG
37

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGCGTCGACA TCGATGCGGC CGCCGGGCG GATCC
35

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AGTGAATTCG AGCTCGGTAC CCGGGGATCC TCTAGAGTCG ACCTGCAGGC ATGCAAGCTT
60
GGCGTAATCA TGGTCAT
77

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

- (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Ala Arg Glu Met Gly Glu Ala Asn
1 5
- (2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
CCCGAGAGAT GGGGGAGGCT AACTGAG
27
- (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GGGCTCTCTA CCCCCTCCGA TTGACACCTA G
31
- (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Thr Ile Met Thr Met
1 5

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCCTGTGCCT TATTGAACT AACC
24

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CCCACCACAA CCACATATCC CTCC
24

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCAGTCCTCC GATTGACTG
19

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8332 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCGCCAGTCC TCCGATTGAC TGAGTCGCCC GGGTACCCGT GTATCCAATA AACCCCTCTTG
60CAGTTGCATC CGACTTGTGG TCTCGCTGTT CCTTGGGAGG GTCTCCTCTG AGTGATTGAC
120TACCCGTCAG CGGGGGTCTT TCATTGTTGGG GCTCGTCCGG GATCGGGAGA CCCCTGCCCCA
180GGGACCACCG ACCCACCACC GGGAGGTAAG CTGGCCAGCA ACTTATCTGT GTCTGTCCGA
240TTGTCTAGTG TCTATGACTG ATTTTATGCG CCTGCGTCGG TACTAGTTAG CTAAGTAGCT
300CTGTATCTGG CGGACCCGTG GTGGAAGTGA CGAGTTCGGA ACACCCGGCC GCAACCCTGG
360GAGACGTCCC AGGGACTTCG GGGGCCGTTT TTGTGGCCCG ACCTGAGTCC AAAAATCCCG
420

ATCGTTTTGG ACTCTTTGGT GCACCCCCCT TAGAGGAGGG ATATGTGGTT CTGGTAGGAG
480

ACGAGAACCT AAAACAGTTC CCGCCTCCGT CTGAATTTTT GCTTTCGGTT TGGGACCGAA
540

GCCGGGCGGC GCGTCTTGTC TGCTGCAGCA TCGTTCTGTG TTGTCTCTGT CTGACTGTGT
600

TTCTGTATTT GTCTGAGAAT ATGGGCCAGA CTGTTACCAC TCCCTTAAGT TTGACCTTAG
660

GTCAGTGGAA AGATGTCGAG CGGATCGCTC ACAACCAGTC GGTAGATGTC AAGAAGAGAC
720

GTTCGTTTAC CTTCTGCTCT GCAGAATGGC CAACCTTTAA CGTCGGATGG CCGCGAGACG
780

GCAGTTTAA CCGAGACCTC ATCACCAGG TTAAGATCAA GGTCTTTTCA CCTGGCCCCG
840

ATGGAATTT AGACCAGGTC CCCTACATCG TGACCTGGGA AGCCTTGGCT TTTGACCCCC
900

CTCGTTTAT CAAGCCCTTT GTACACCCTA AGCCTCCGCC TCCTCTTCCT CCATCCGCCC
960

CGTCTTTT CTTGAACCT CCTCGTTTGA CCCCAGCTCG ATCCTCCCTT TATCCAGCCC
1020

TCATTTTCT TAGGCGCC AAACCTAAAC CTCAAGTTCT TTCTGACAGT GGGGGGCGC
1080

TCATTTTCT ACTTACAGAA GACCCCCCGC CTTATAGGGA CCAAGACCA CCCCCTTCG
1140

ACAATTTT AAATGGTGGA GAAGCGACCC CTGCGGGAGA GGCACCGGAC CCCTCCCCAA
1200

TGGTTTCT TCTACGTGGG AGACGGGAGC CCCCTGTGGC CGACTCCACT ACCTCGCAGG
1260

CATTTTCT TCGGCAGGA GGAAACGGAC AGCTTCAATA CTGGCCGTTC TCCTCTTCTG
1320

ACCTTTCT TGGAAAAAT AATAACCCTT CTTTTTCTGA AGATCCAGGT AACTGACAG
1380

CTTTTCTC ATCACCATC AGCCACCTG GGACGACTGT CAGCAGCTGT
1440

TTTACCGGA GAAGAAAAAC AACGGGTGCT CTTAGAGGCT AGAAAGGCGG
1500

TTTGGGCGC CCCACTCAAC TGCCCAATGA AGTCGATGCC GCTTTTCCCC
1560

TCCTTGGAT TACACCACCC AGGCAGGTAG GAACCACCTA GTCCACTATC
1620

GCCAATTT TTAGCGGGT CTCCAAAACG CGGGCAGAAG CCCCACCAAT TTGGCCAAGG
1680

TAAAAGGAAT AACACAAGGG CCAATGAGT CTCCTCGGC CTCCTAGAG AGACTTAAGG
1740

AAGCCTATCG CAGGTACACT CCTTATGACC CTGAGGACCC AGGGCAAGAA ACTAATGTGT
1800

CTATGTCTTT CATTTGGCAG TCTGCCCCAG ACATTGGGAG AAAGTTAGAG AGGTTAGAAG
1860

ATTTAAAAA CAAGACGCTT GGAGATTTGG TTAGAGAGGC AGAAAAGATC TTTAATAAAC
1920

GAGAAACCCC GGAAGAAAGA GAGGAACGTA TCAGGAGAGA AACAGAGGAA AAAGAAGAAC
1980

GCCGTAGGAC AGAGGATGAG CAGAAAGAGA AAGAAAGAGA TCGTAGGAGA CATAGAGAGA
2040

TGAGCAAGCT ATTGGCCACT GTCGTTAGTG GACAGAAACA GGATAGACAG GGAGGAGAAC
2100

GAAGGAGGTC CCAACTCGAT CGCGACCAGT GTGCCTACTG CAAAGAAAAG GGGCACTGGG
2160

CTAAAGATTG TCCCAAGAAA CCACGAGGAC CTCGGGGACC AAGACCCAG ACCTCCCTCC
2220

TGACCCTAGA TGA TAGGGA GGT CAGGGT AGGAGCCCC CCCTGAACCC AGGATAACCC
2280

TCAAAGTCGG GGGGCAACCC GTCACCTTCC TGGTAGATAC TGGGGCCCAA CACTCCGTGC
2340

TGACCCAAA TCCTGGACCC CTAAGTGATA AGTCTGCCTG GGTCCAAGGG GCTACTGGAG
2400

GAAAGCGGTA TCGCTGGACC ACGGATCGCA AAGTACATCT AGCTACCGGT AAGGTCACCC
2460

ACTCTTTCCT CCATGTACCA GACTGTCCCT ATCCTCTGTT AGGAAGAGAT TTGCTGACTA
2520

AACTAAAAGC CCAAATCCAC TTTGAGGGAT CAGGAGCTCA GGTTATGGGA CCAATGGGGC
2580

AGCCCCTGCA AGTGTTGACC CTAAATATAG AAGATGAGCA TCGGCTACAT GAGACCTCAA
2640

AAGAGCCAGA TGTTTCTCTA GGGTCCACAT GGCTGTCTGA TTTTCTCAG GCCTGGGCGG
2700

AAACCGGGGG CATGGGACTG GCAGTTCGCC AAGCTCCTCT GATCATACCT CTGAAAGCAA
2760

CCTCTACCCC CGTGTCCATA AAACAATACC CCATGTCACA AGAAGCCAGA CTGGGGATCA
2820

AGCCCCACAT ACAGAGACTG TTGGACCAGG GAATACTGGT ACCCTGCCAG TCCCCCTGGA
2880

ACACGCCCCCT GCTACCCGTT AAGAAACCAG GGAATAATGA TTATAGGCCT GTCCAGGATC
2940

TGAGAGAAGT CAACAAGCGG GTGGAAGACA TCCACCCAC CGTGCCCAAC CTTACAACC
3000

TCTTGAGCGG GCTCCCACCG TCCCACCAGT GGTACACTGT GCTTGATTTA AAGGATGCCT
3060

TTTTCTGCCT GAGACTCCAC CCCACCAGTC AGCCTCTCTT CGCCTTTGAG TGGAGAGATC
3120

CAGAGATGGG AATCTCAGGA CAATTGACCT GGACCAGACT CCCACAGGGT TTCAAAAACA
3180

GTCCCACCCT GTTTGATGAG GCACTGCACA GAGACCTAGC AGACTTCCGG ATCCAGCACC
3240

CAGACTTGAT CCTGCTACAG TACGTGGATG ACTTACTGCT GGCCGCCACT TCTGAGCTAG
3300

ACTGCCAACA AGGTACTCGG GCCCTGTTAC AAACCCTAGG GAACCTCGGG TATCGGGCCT
3360

CGGCCAAGAA AGCCCAAATT TGCCAGAAAC AGGTCAAGTA TCTGGGGTAT CTTCTAAAAG
3420

AGGGTCAGAG ATGGCTGACT GAGGCCAGAA AAGAGACTGT GATGGGGCAG CCTACTCCGA
3480

AGACCCCTCG ACAACTAAGG GAGTTCCTAG GGACGGCAGG CTTCTGTCGC CTCTGGATCC
3540

CTGGGTTTGC AGAAATGGCA GCCCCCTTGT ACCCTCTCAC CAAAACGGGG ACTCTGTTTA
3600

ATTGGGGCCC AGACCAACAA AAGGCCTATC AAGAAATCAA GCAAGCTCTT CTAAGTCCCC
3660

CAGCCCTGGG GTTGCCAGAT TTGACTAAGC CCTTTGAACT CTTTGTCGAC GAGAAGCAGG
3720

GCTACGCCAA AGGTGTCCTA ACGCAAAAAC TGGGACCTTG GCGTCGGCCG GTGGCCTACC
3780

TGTCCAAAAA GCTAGACCCA GTAGCAGCTG GGTGGCCCCC TTGCCTACGG ATGGTAGCAG
3840

CCATTGCCGT ACTGACAAAG GATGCAGGCA AGCTAACCAT GGGACAGCCA CTAGTCATTC
3900

TGGCCCCCA TGCAGTAGAG GCACTAGTCA AACAACCCCC CGACCGCTGG CTTTCCAACG
3960

CCCGGATGAC TCACTATCAG GCCTTGCTTT TGGACACGGA CCGGGTCCAG TTCGGACCGG
4020

TGGTAGCCCT GAACCCGGCT ACGCTGCTCC CACTGCCTGA GGAAGGGCTG CAACACAAC
4080

GCCTTGATAT CCTGGCCGAA GCCCACGGAA CCCGACCCGA CCTAACGGAC CAGCCGCTCC
4140

CAGACGCCGA CCACACCTGG TACACGGATG GAAGCAGTCT CTTACAAGAG GGACAGCGTA
4200

AGGCGGGAGC TGCGGTGACC ACCGAGACCG AGGTAATCTG GGCTAAAGCC CTGCCAGCCG
4260

GGACATCCGC TCAGCGGGCT GAACTGATAG CACTCACCCA GGCCCTAAAG ATGGCAGAAG
4320

GTAAGAAGCT AAATGTTTAT ACTGATAGCC GTTATGCTTT TGCTACTGCC CATATCCATG
4380

GAGAAATATA CAGAAGGCGT GGGTTGCTCA CATCAGAAGG CAAAGAGATC AAAAATAAAG
4440

ACGAGATCTT GGCCCTACTA AAAGCCCTCT TTCTGCCCAA AAGACTTAGC ATAATCCATT
4500

GTCCAGGACA TCAAAAGGGA CACAGCGCCG AGGCTAGAGG CAACCGGATG GCTGACCAAG
4560

CGGCCCCGAAA GGCAGCCATC ACAGAGACTC CAGACACCTC TACCCTCCTC ATAGAAAATT
4620

CATCACCTTA CACCTCAGAA CATTTTCATT ACACAGTGAC TGATATAAAG GACCTAACCA
4680

AGTTGGGGGC CATTTATGAT AAAACAAAGA AGTATTGGGT CTACCAAGGA AAACCTGTGA
4740

TGCCTGACCA GTTTACTTTT GAATTATTAG ACTTCTTCA TCAGCTGACT CACCTCAGCT
4800

TCTCAAAAAT GAAGGCTCTC CTAGAGAGAA GCCACAGTCC CTACTACATG CTGAACCGGG
4860

ATCGAACACT CAAAAATATC ACTGAGACCT GCAAAGCTTG TGCACAAGTC AACGCCAGCA
4920

AGTCTGCCGT TAAACAGGGA ACTAGGGTCC GCGGGCATCG GCCCGGCACT CATTGGGAGA
4980

TCGATTTTAC CGAGATAAAG CCCGGATTGT ATGGCTATAA ATATCTTCTA GTTTTTATAG
5040

ATACCTTTTC TGGCTGGATA GAAGCCTTCC CAACCAAGAA AGAAACCGCC AAGGTCGTAA
5100

CCAAGAAGCT ACTAGAGGAG ATCTTCCCCA GTTCGGCAT GCCTCAGGTA TTGGGAAGTG
5160

ACAATGGGCC TGCCTTCGTC TCCAAGGTGA GTCAGACAGT GGCCGATCTG TTGGGGATTG
5220

ATTGGAAATT ACATTGTGCA TACAGACCCC AAAGCTCAGG CCAGGTAGAA AGAATGAATA
5280

GAACCATCAA GGAGACTTTA ACTAAATTAA CGCTTGCAAC TGGCTCTAGA GACTGGGTGC
5340

TCCTACTCCC CTTAGCCCTG TACCGAGCCC GCAACACGCC GGGCCCCCAT GGCCTCACCC
5400

CATATGAGAT CTTATATGGG GCACCCCCGC CCCTTGTAAG CTTCCCTGAC CCTGACATGA
5460

CAAGAGTTAC TAACAGCCCC TCTCTCCAAG CTCACTTACA GGCTCTCTAC TTAGTCCAGC
5520

ACGAAGTCTG GAGACCTCTG GCGGCAGCCT ACCAAGAACA ACTGGACCGA CCGGTGGTAC
5580

CTCACCCTTA CCGAGTCGGC GACACAGTGT GGGTCCGCCG ACACCAGACT AAGAACCTAG
5640

AACCTCGCTG GAAAGGACCT TACACAGTCC TGCTGACCAC CCCCACCGCC CTCAAAGTAG
5700

ACGGCATCGC AGCTTGGATA CAGCCGCCCC ACGTGAAGGC TGCCGACCCC GGGGGTGGAC
5760

CATCCTCTAG ACTGACATGG CGCGTTCAAC GCTCTCAAAA CCCCTTAAAA ATAAGGTTAA
5820

CCCGCGAGGC CCCCTAATCC CCTTAATTCT TCTGATGCTC AGAGGGGTCA GTACTGCTTC
5880

GCCCGGCTCC AGTCCTCATC AAGTCTATAA TATCACCTGG GAGGTAACCA ATGGAGATCG
5940

GGAGACGGTA TGGGCAACTT CTGGCAACCA CCCTCTGTGG ACCTGGTGGC CTGACCTTAC
6000

CCCAGATTTA TGTATGTTAG CCCACCATGG ACCATCTTAT TGGGGGCTAG AATATCAATC
6060

CCCTTTTTCT TCTCCCCCGG GGCCCCCTTG TTGCTCAGGG GGCAGCAGCC CAGGCTGTTC
6120

CAGAGACTGC GAAGAACCTT TAACCTCCCT CACCCCTCGG TGCAAACTG CCTGGAACAG
6180

ACTCAAGCTA GACCAGACAA CTCATAAATC AAATGAGGGA TTTTATGTTT GCCCCGGGCC
6240

CCACCGCCCC CGAGAATCCA AGTCATGTGG GGGTCCAGAC TCCTTCTACT GTGCCTATTG
6300

GGGCTGTGAG ACAACCGGTA GAGCTTACTG GAAGCCCTCC TCATCATGGG ATTTTCATCAC
6360

AGTAAACAAC AATCTCACCT CTGACCAGGC TGTCCAGGTA TGCAAAGATA ATAAGTGGTG
6420

CAACCCCTTA GTTATTCGGT TTACAGACGC CGGGAGACGG GTTACTTCCT GGACCACAGG
6480

ACATTACTGG GGCTTACGTT TGTATGTCTC CGGACAAGAT CCAGGGCTTA CATTTGGGAT
6540

CCGACTCAGA TACCAAATC TAGGACCCCG CGTCCAATA GGGCCAAACC CCGTTCTGGC
6600

AGACCAACAG CCACTCTCCA AGCCCAAACC TGTTAAGTCG CCTTCAGTCA CCAAACCACC
6660

CAGTGGGACT CCTCTCTCCC CTACCCAACT TCCACCGGCG GGAACGGAAA ATAGGCTGCT
6720

AAACTTAGTA GACGGAGCCT ACCAAGCCCT CAACCTCACC AGTCCTGACA AAACCCAAGA
6780

GTGCTGGTTG TGTCTAGTAG CGGGACCCCC CTACTACGAA GGGGTGCGG TCCTGGGTAC
6840

CTACTCCAAC CATACTCTG CTCCAGCCAA CTGCTCCGTG GCCTCCCAAC ACAAGTTGAC
6900

CCTGTCCGAA GTGACCGGAC AGGGACTCTG CATAGGAGCA GTTCCCAAAA CACATCAGGC
6960

CCTATGTAAT ACCACCCAGA CAAGCAGTCG AGGGTCCTAT TATCTAGTTG CCCCTACAGG
7020

TACCATGTGG GCTTGTAGTA CCGGGCTTAC TCCATGCATC TCCACCACCA TACTGAACCT
7080

TACCACTGAT TATTGTGTTT TTGTCGAACT CTGGCCAAGA GTCACCTATC ATTCCCCCAG
7140

CTATGTTTAC GGCCTGTTTG AGAGATCCAA CCGACACAAA AGAGAACCGG TGTCGTTAAC
7200

CCTGGCCCTA TTATTGGGTG GACTAACCAT GGGGGGAATT GCCGCTGGAA TAGGAACAGG
7260

GACTACTGCT CTAATGGCCA CTCAGCAATT CCAGCAGCTC CAAGCCGCAG TACAGGATGA
7320

TCTCAGGGAG GTTGAAAAAT CAATCTCTAA CCTAGAAAAG TCTCTCACTT CCCTGTCTGA
7380

AGTTGTCCTA CAGAATCGAA GGGGCCTAGA CTTGTTATTT CTAAAAGAAG GAGGGCTGTG
7440

TGCTGCTCTA AAAGAAGAAT GTTGCTTCTA TGCGGACCAC ACAGGACTAG TGAGAGACAG
7500

CATGGCCAAA TTGAGAGAGA GGCTTAATCA GAGACAGAAA CTGTTTGAGT CAACTCAAGG
7560

ATGGTTTGAG GGAAGTTTA ACAGATCCCC TTGGTTTACC ACCTTGATAT CTACCATTAT
7620

GGGACCCCTC ATTGTACTCC TAATGATTTT GCTCTTCGGA CCCTGCATTC TTAATCGATT
7680

AGTCCAATTT GTTAAAGACA GGATATCAGT GGTCCAGGCT CTAGTTTGA CTCAACAATA
7740

TCACCAGCTG AAGCCTATAG AGTACGAGCC ATAGATAAAA TAAAAGATT TATTTAGTCT
7800

CCAGAAAAAG GGGGGAATGA AAGACCCAC CTGTAGGTTT GGCAAGCTAG CTTAAGTAAC
7860

GCCATTTTGC AAGGCATGGA AAAATACATA ACTGAGAATA GAGAAGTTCA GATCAAGGTC
7920

AGGAACAGAT GGAACAGCTG AATATGGGCC AAACAGGATA TCTGTGGTAA GCAGTTCCTG
7980

CCCCGGCTCA GGGCCAAGAA CAGATGGAAC AGCTGAATAT GGGCCAAACA GGATATCTGT
8040

GGTAAGCAGT TCCTGCCCCG GCTCAGGGCC AAGAACAGAT GGTCCCCAGA TCGGTCCAG
8100

CCCTCAGCAG TTTCTAGAGA ACCATCAGAT GTTCCAGGG TCCCCAAGG ACCTGAAATG
8160

ACCCTGTGCC TTATTTGAAC TAACCAATCA GTTCGCTTCT CGCTTCTGTT CGCGCGCTTC
8220

TGCTCCCCGA GCTCAATAAA AGAGCCCACA ACCCCTCACT CGGGGCGCCA GTCCTCCGAT
8280

TGACTGAGTC GCCCGGTAC CCGTGATCC AATAAACCT CTTGCAGTTG CA
8332

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGGAGTGGTA ACAGTCTGGC CTTAATTCTC AG
32

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGGTCGACCT CGAGAATTAA TTC
23

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CTGGGAGACG TCCCAGGGAC TTC
23

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGCCAGACTG TTACCACTCC CTGAAGTTTG AC
32

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
CATCGATAAA ATAAAAGATT TTATTTAGTC
30
- (2) INFORMATION FOR SEQ ID NO:21:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
CAAATGAAAG ACCCCCCTG AC
22
- (2) INFORMATION FOR SEQ ID NO:22:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GAAGCTTCTC CCAGAACCCA CCAGTCTTGA AACGCCATC
39
- (2) INFORMATION FOR SEQ ID NO:23:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
GTACCAGCTT TTGGTCTCAT CAAAG
25
- (2) INFORMATION FOR SEQ ID NO:24:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
CTCCTCGAGC TAAAGATATT TTAGAGAAGA ATTAAC
36
- (2) INFORMATION FOR SEQ ID NO:25:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TTCCTCTGGA CAGCTGTCTA CTTTG
25

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TCGAGGGGCC CAGATCTGCG GCCGCTCGCG AGTCGACAAG CTTGGATCCA T
51

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 49 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CGATGGATCC AAGCTTGTCTG ACTCGCGAGC GGCCGCAGAT CTGGGCCCC
49

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CACCGTCGTC GACTTATGCT
20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GACCGTCGAC TCAATTCTGG GAGAAGCTTC TTGG
34

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CACCGTCGTC GACTTATGCT
20

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
CAACGCTCGA GAAGCAGAAT CGCAAAAGGC
30
- (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
TCGGCTCGAG GCATCAACGG GAAATAACTC GT
32
- (2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
CCGACTCGAG TCAGTAGAGG TCCTGTGCCT C
31
- (2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
GCGACTCGAG CATGGGGCCC TGGGGC
26
- (2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
GCACTGGAAT TCGTCAGGGC G
21
- (2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
CGCGCCGCTC GAGTCTACAA TGGCCTTGAC CTTTGCTTTA CTGG
44

- (2) INFORMATION FOR SEQ ID NO:37:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 43 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
GCGCCCATCG ATTCATTCCT TACTTCTTAA ACTTTCTTGC AAG
43
- (2) INFORMATION FOR SEQ ID NO:38:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 47 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
CGCGCCGCTC GAGCATCCAA TGGCCCTGTC CTTTCTTTA CTTATGG
47
- (2) INFORMATION FOR SEQ ID NO:39:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
CCATCGATTG AATCCTTCCT CCTTAATCTT TTTTGCAAG
39
- (2) INFORMATION FOR SEQ ID NO:40:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
CCGGATCCTC TACAATGGCC TTGACCTTG CTTTACTGG
39
- (2) INFORMATION FOR SEQ ID NO:41:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 46 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
CGCGCCGGCG GCCGCTCATT CTTACTTCT TAACTTTCT TGCAAG
46
- (2) INFORMATION FOR SEQ ID NO:42:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 42 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
CCGGATCCCA TCCAATGGCC CTGTCCTTTT CTTTACTTAT GG
42

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
CGCGCCGGCG GCCGCTCAAT CCTTCCTCCT TAATCTTTT TGCAAG
46

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9080 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GGGGGGGGGG GGGGGGGGGG GGGTGAGCAC ATCCAGTGGG TAAAGTTCCT TAAAATGCTC
60
TGCAAAGAAA TTGGGACTTT TCATTAAATC AGAAATTTTA CTTTTTTCCC CTCCTGGGAG
120
CTAAAGATAT TTTAGAGAAG AATTAACCTT TTGCTTCTCC AGTTGAACAT TTGTAGCAAT
180
AAGTCATGCA AATAGAGCTC TCCACCTGCT TCTTTCTGTG CCTTTTGCGA TTCTGCTTTA
240
GTGCCACCAG AAGATACTAC CTGGGTGCAG TGGAAGTATC ATGGGACTAT ATGCAAAGTG
300
ATCTCGGTGA GCTGCCTGTG GACGCAAGAT TTCCTCCTAG AGTGCCAAAA TCTTTTCCAT
360
TCAACACCTC AGTCGTGTAC AAAAAGACTC TGTTTGTAGA ATTCACGGAT CACCTTTTCA
420
ACATCGCTAA GCCAAGGCCA CCCTGGATGG GTCTGCTAGG TCCTACCATC CAGGCTGAGG
480
TTTATGATAC AGTGGTCATT ACACTTAAGA ACATGGCTTC CCATCCTGTC AGTCTTCATG
540
CTGTTGGTGT ATCCTACTGG AAAGCTTCTG AGGGAGCTGA ATATGATGAT CAGACCAGTC
600
AAAGGGAGAA AGAAGATGAT AAAGTCTTCC CTGGTGGAAG CCATACATAT GTCTGGCAGG
660
TCCTGAAAGA GAATGGTCCA ATGGCCTCTG ACCCACTGTG CCTTACCTAC TCATATCTTT
720
CTCATGTGGA CCTGGTAAAA GACTTGAATT CAGGCCTCAT TGGAGCCCTA CTAGTATGTA
780
GAGAAGGGAG TCTGGCCAAG GAAAAGACAC AGACCTTGCA CAAATTTATA CTACTTTTTG
840
CTGTATTTGA TGAAGGAAA AGTTGGCACT CAGAAACAAA GAACCTCTTG ATGCAGGATA
900
GGGATGCTGC ATCTGCTCGG GCCTGGCCTA AAATGCACAC AGTCAATGGT TATGTAAACA
960
GGTCTCTGCC AGGTCTGATT GGATGCCACA GGAAATCAGT CTATTGGCAT GTGATTGGAA
1020
TGGGCACCAC TCCTGAAGTG CACTCAATAT TCCTCGAAGG TCACACATTT CTTGTGAGGA
1080
ACCATCGCCA GCGTCCTTG GAAATCTCGC CAATAACTTT CCTTACTGCT CAAACACTCT
1140
TGATGGACCT TGGACAGTTT CTACTGTTTT GTCATATCTC TTCCACCAA CATGATGGCA
1200

TGGAAGCTTA TGTCAAAGTA GACAGCTGTC CAGAGGAACC CCAACTACGA ATGAAAAATA
1260
ATGAAGAAGC GGAAGACTAT GATGATGATC TTAAGTATTC TGAAATGGAT GTGGTCAGGT
1320
TTGATGATGA CAACTCTCCT TCCTTTATCC AAATTCGCTC AGTTGCCAAG AAGCATCCTA
1380
AACTTGGGT ACATTACATT GCTGCTGAAG AGGAGGACTG GGACTATGCT CCCTTAGTCC
1440
TCGCCCCCGA TGACAGAAGT TATAAAAGTC AATATTTGAA CAATGGCCCT CAGCGGATTG
1500
GTAGGAAGTA CAAAAAGTC CGATTTATGG CATAACAGA TGAAACCTTT AAGACTCGTG
1560
AAGCTATTCA GCATGAATCA GGAATCTTGG GACCTTTACT TTATGGGGAA GTTGAGACA
1620
CACTGTTGAT TATATTTAAG AATCAAGCAA GCAGACCATA TAACATCTAC CCTCAGGAA
1680
TCACTGATGT CCGTCCTTTG TATTCAAGGA GATTACCAA AGGTGTAAAA CATTTGAAGG
1740
ATTTTCAAT TCTGCCAGGA GAAATATTCA AATATAAATG GACAGTGACT GTAGAAGATG
1800
GGCCATTAA ATCAGATCCT CGGTGCCTGA CCCGCTATTA CTCTAGTTTC GTTAATATGG
1860
AGAGATATGT AGCTTCAGGA CTCATTGGCC CTCTCCTCAT CTGCTACAAA GAATCTGTAG
1920
ATCAAAATA AAACCAGATA ATGTCAGACA AGAGGAATGT CATCCTGTTT TCTGTATTTG
1980
ATTAAGATTA AAGCTGGTAC CTCACAGAGA ATATACAACG CTTTCTCCCC AATCCAGCTG
2040
GAGTAAATTA AGAGGATCCA GAGTTCCAAG CCTCCAACAT CATGCACAGC ATCAATGGCT
2100
ATGTTTATTA TAGTTTGCAG TTGTCAGTTT GTTTCATGA GGTGGCATACT TGGTACATTC
2160
TAAATATTA AGCAGAGACT GACTTCCTTT CTGTCTTCTT CTCTGGATAT ACCTTCAAAC
2220
ACAAATATTA CTATGAAGAC AACTCACCC TATTCCTATT CTCAGGAGAA ACTGTCTTCA
2280
TCTATATTA AAACCCAGGT CTATGGATTC TGGGGTGCCA CAACTCAGAC TTTCGGAACA
2340
GATATATTA GGCCTTACTG AAGGTTTCTA GTTGTGACAA GAACACTGGT GATTATTACG
2400
AGATATATTA TGAAGATATT TCAGCATACT TGCTGAGTAA AAACAATGCC ATTGAACCAA
2460
GAAATATTA TCAGAATTCA AGACACCCTA GCACTAGGCA AAAGCAATTT AATGCCACCA
2520
CAATATATTA AATGACATA GAGAAGACTG ACCCTTGGTT TGCACACAGA ACACCTATGC
2580
CTATATATTA AATGTCTCC TCTAGTGATT TGTTGATGCT CTTGCGACAG AGTCCTACTC
2640
CAATATATTA TCTTTATCT GATCTCCAAG AAGCCAAATA TGAGACTTTT TCTGATGATC
2700
CAATATATTA AATAGAC AGTAATAACA GCCTGTCTGA AATGACACAC TTCAGGCCAC
2760
AATATATTA ATGGGGAC ATGGTATTTA CCCCTGAGTC AGGCCTCCAA TTAAGATTAA
2820
ATATATATTA AGACAACT GCAGCAACAG AGTTGAAGAA ACTTGATTTC AAAGTTTCTA
2880
GTATATATTA AATCTGATT TCAACAATTC CATCAGACAA TTTGGCAGCA GGTACTGATA
2940
ATAATATTA TTAGGACCC CCAAGTATGC CAGTTCATTA TGATAGTCAA TTAGATACCA
3000
CTATATATTA TAAAAGTCA TCTCCCCTTA CTGAGTCTGG TGGACCTCTG AGCTTGAGTG
3060

AAGAAAATAA TGATTCAAAG TTGTTAGAAT CAGGTTTAAT GAATAGCCAA GAAAGTTCAT
3120
GGGGAAAAAA TGTATCGTCA ACAGAGAGTG GTAGGTTATT TAAAGGGAAA AGAGCTCATG
3180
GACCTGCTTT GTTGACTAAA GATAATGCCT TATTCAAAGT TAGCATCTCT TTGTTAAAGA
3240
CAAACAAAAC TTCCAATAAT TCAGCAACTA ATAGAAAGAC TCACATTGAT GGCCCATCAT
3300
TATTAATTGA GAATAGTCCA TCAGTCTGGC AAAATATATT AGAAAGTGAC ACTGAGTTTA
3360
AAAAAGTGAC ACCTTTGATT CATGACAGAA TGCTTATGGA CAAAATGCT ACAGCTTTGA
3420
GGCTAAATCA TATGTCAAAT AAACTACTT CATCAAAAAA CATGGAAATG GTCCAACAGA
3480
AAAAAGAGGG CCCCATTCCA CCAGATGCAC AAAATCCAGA TATGTCGTTT TTTAAGATGC
3540
TATTCTTGCC AGAATCAGCA AGGTGGATAC AAAGGACTCA TGGAAAGAAC TCTCTGAACT
3600
CTGGGCAAGG CCCCAGTCCA AAGCAATTAG TATCCTTAGG ACCAGAAAAA TCTGTGGAAG
3660
GTCAGAATTT CTTGTCTGAG AAAAACAAAG TGGTAGTAGG AAAGGGTGAA TTTACAAAGG
3720
ACGTAGGACT CAAAGAGATG GTTTTTCCAA GCAGCAGAAA CCTATTTCTT ACTAACTTGG
3780
ATAATTTACA TGAAAATAAT ACACACAATC AAGAAAAAAA AATTCAGGAA GAAATAGAAA
3840
AGAAGGAAAC ATTAATCCAA GAGAATGTAG TTTTGCCTCA GATACATACA GTGACTGGCA
3900
CTAAGAATTT CATGAAGAAC CTTTTCTTAC TGAGCACTAG GCAAATGTA GAAGGTTTCAT
3960
ATGACGGGGC ATATGCTCCA GTACTTCAAG ATTTTAGGTC ATTAAATGAT TCAACAAATA
4020
GAACAAAGAA ACACACAGCT CATTTCTCAA AAAAAGGGGA GGAAGAAAAC TTGGAAGGCT
4080
TGGGAAATCA AACCAGCAA ATTGTAGAGA AATATGCATG CACCACAAGG ATATCTCCTA
4140
ATACAAGCCA GCAGAATTTT GTCACGCAAC GTAGTAAGAG AGCTTTGAAA CAATTCAGAC
4200
TCCCCTAGA AGAAACAGAA CTTGAAAAAA GGATAATTGT GGATGACACC TCAACCCAGT
4260
GGTCCAAAAA CATGAAACAT TTGACCCCGA GCACCCCTAC ACAGATAGAC TACAATGAGA
4320
AGGAGAAAGG GGCCATTACT CAGTCTCCCT TATCAGATTG CCTTACGAGG AGTCATAGCA
4380
TCCCTCAAGC AAATAGATCT CCATTACCCA TTGCAAAGGT ATCATCATTT CCATCTATTA
4440
GACCTATATA TCTGACCAGG GTCCTATTCC AAGACAACCT TTCTCATCTT CCAGCAGCAT
4500
CTTATAGAAA GAAAGATTCT GGGGTCCAAG AAAGCAGTCA TTTCTTACAA GGAGCCAAAA
4560
AAAATAACCT TTCTTTAGCC ATTCTAACCT TGGAGATGAC TGGTGATCAA AGAGAGGTTG
4620
GCTCCCTGGG GACAAGTGCC ACAAATTCAG TCACATACAA GAAAGTTGAG AACACTGTTC
4680
TCCCGAAACC AGACTTGCCC AAAACATCTG GCAAAGTTGA ATTGCTTCCA AAAGTTCACA
4740
TTTATCAGAA GGACCTATTC CCTACGGAAA CTAGCAATGG GTCTCCTGGC CATCTGGATC
4800
TCGTGGAAGG GAGCCTTCTT CAGGGAACAG AGGGAGCGAT TAAGTGGAAT GAAGCAAACA
4860
GACCTGAAA AGTTCCCTTT CTGAGAGTAG CAACAGAAAG CTCTGCAAAG ACTCCCTCCA
4920

AGCTATTGGA TCCTCTTGCT TGGGATAACC ACTATGGTAC TCAGATACCA AAAGAAGAGT
4980
GGAAATCCCA AGAGAAGTCA CCAGAAAAAA CAGCTTTTAA GAAAAAGGAT ACCATTTTGT
5040
CCCTGAACGC TTGTGAAAGC AATCATGCAA TAGCAGCAAT AAATGAGGGA CAAAATAAGC
5100
CCGAAATAGA AGTCACCTGG GCAAAGCAAG GTAGGACTGA AAGGCTGTGC TCTCAAAACC
5160
CACCAGTCTT GAAACGCCAT CAACGGGAAA TAACTCGTAC TACTCTTCAG TCAGATCAAG
5220
AGGAAATTGA CTATGATGAT ACCATATCAG TTGAAATGAA GAAGGAAGAT TTTGACATTT
5280
ATGATGAGGA TGAAAATCAG AGCCCCGCA GCTTTCAAAA GAAAACACGA CACTATTTTA
5340
TTGCTGCAGT GGAGAGGCTC TGGGATTATG GGATGAGTAG CTCCCCACAT GTTCTAAGAA
5400
ACAGGGCTCA GAGTGGCAGT GTCCCTCAGT TCAAGAAAGT TGTTTTCCAG GAATTTACTG
5460
ATGGCTCCTT TACTCAGCCC TTATACCGTG GAGAACTAAA TGAACATTTG GGACTCCTGG
5520
GGCCATATAT AAGAGCAGAA GTTGAAGATA ATATCATGGT AACTTTCAGA AATCAGGCCT
5580
CTCGTCCCTA TTCCTTCTAT TCTAGCCTTA TTTCTTATGA GGAAGATCAG AGGCAAGGAG
5640
CAGAACCTAG AAAAACTTT GTCAAGCCTA ATGAAACCAA AACTTACTTT TGGAAAGTGC
5700
AACATCATAT GGCACCCACT AAAGATGAGT TTGACTGCAA AGCCTGGGCT TATTTCTCTG
5760
ATGTTGACCT GGAAAAAGAT GTGCACTCAG GCCTGATTGG ACCCCTTCTG GTCTGCCACA
5820
CTAACACACT GAACCCTGCT CATGGGAGAC AAGTGACAGT ACAGGAATTT GCTCTGTTTT
5880
TCACCATCTT TGATGAGACC AAAAGCTGGT ACTTCACTGA AAATATGGAA AGAACTGCA
5940
GGGCTCCCTG CAATATCCAG ATGGAAGATC CCACTTTTAA AGAGAATTAT CGCTTCCATG
6000
CAATCAATGG CTACATAATG GATACACTAC CTGGCTTAGT AATGGCTCAG GATCAAAGGA
6060
TTCGATGGTA TCTGCTCAGC ATGGGCAGCA ATGAAAACAT CCATTCTATT CATTTCAGTG
6120
GACATGTGTT CACTGTACGA AAAAAAGAGG AGTATAAAAT GGCACGTAC AATCTCTATC
6180
CAGGTGTTTT TGAGACAGTG GAAATGTTAC CATCCAAAGC TGGAATTTGG CGGGTGAAT
6240
GCCTTATTGG CGAGCATCTA CATGCTGGGA TGAGCACACT TTTTCTGGTG TACAGCAATA
6300
AGTGTGAGAC TCCCCTGGGA ATGGCTTCTG GACACATTAG AGATTTTCAG ATTACAGCTT
6360
CAGGACAATA TGGACAGTGG GCCCCAAAGC TGGCCAGACT TCATTATTCC GGATCAATCA
6420
ATGCCTGGAG CACCAAGGAG CCCTTTTCTT GGATCAAGGT GGATCTGTTG GCACCAATGA
6480
TTATTACGG CATCAAGACC CAGGGTGCCC GTCAGAAGTT CTCCAGCCTC TACATCTCTC
6540
AGTTTATCAT CATGTATAGT CTTGATGGGA AGAAGTGGCA GACTTATCGA GGAAATTCCA
6600
CTGGAACCTT AATGGTCTTC TTTGGCAATG TGGATTCATC TGGGATAAAA CACAATATTT
6660
TTAACCTCC AATTATTGCT CGATACATCC GTTTGCACCC AACTCATTAT AGCATTCGCA
6720
GCACTCTTCG CATGGAGTTG ATGGGCTGTG ATTTAAATAG TTGCAGCATG CCATTGGGAA
6780

TGGAGAGTAA AGCAATATCA GATGCACAGA TTAGTGCTTC ATCCTACTTT ACCAATATGT
6840
TTGCCACCTG GTCTCCTTCA AAAGCTCGAC TTCACCTCCA AGGGAGGAGT AATGCCTGGA
6900
GACCTCAGGT GAATAATCCA AAAGAGTGGC TGCAAGTGA CTTCCAGAAG ACAATGAAAG
6960
TCACAGGAST AACTACTCAG GGAGTAAAAT CTCTGCTTAC CAGCATGTAT GTGAAGGAGT
7020
TCCTCATCTC CAGCAGTCAA GATGGCCATC AGTGGACTCT CTTTTTTCAG AATGGCAAAG
7080
TAAAGGTTTT TCAGGGAAAT CAAGACTCCT TCACACCTGT GGTGAACTCT CTAGACCCAC
7140
CGTTACTGAC TCGCTACCTT CGAATTCACC CCCAGAGTTG GGTGCACCAG ATTGCCCTGA
7200
GGATGGAGGT TCTGGGCTGC GAGGCACAGG ACCTCTACTG AGGGTGGCCA CTGCAGCACC
7260
TGCCACTGCC GTCACCTCTC CCTCCTCAGC TCCAGGGCAG TGTCCCTCCC TGGCTTGCCT
7320
TCTACCTTTG TGCTAAATCC TAGCAGACAC TGCCTTGAAG CCTCCTGAAT TAACTATCAT
7380
CAGTCTCTCA TTTCTTTGGT GGGGGGCCAG GAGGGTGCAT CCAATTTAAC TTAACCTTA
7440
CCTATTTTTT GCAGCTGCTC CCAGATTACT CCTTCCTTCC AATATAACTA GGCAAAAAGA
7500
AGTGAGGAGA AACCTGCATG AAAGCATTCT TCCCTGAAAA GTTAGGCCTC TCAGAGTCAC
7560
CACTTCTCTT GTTGTAGAAA AACTATGTGA TGAAACTTTG AAAAAGATAT TTATGATGTT
7620
AACATTTA GTTAAGCCTC ATACGTTTAA AATAAACTC TCAGTTGTTT ATTATCCTGA
7680
TCAATATCTC AACAAAGCAT GTTTCAGGAT CAGATCAATA CAATCTTGGA GTCAAAAGGC
7740
AAATATTTT GACAATCTGC AAAATGGAGA GAATACAATA ACTACTACAG TAAAGTCTGT
7800
TTCTTTT TACACATAG ATATAATTAT GTTATTTAGT CATTATGAGG GGCACATTCT
7860
TATTTTAAA ACTAGCATTC TTAACTGAG AATTATAGAT GGGGTTCAG AATCCCTAAG
7920
TCCCTTAAA TTATATAAGG CATTCTGTAT AAATGCAAAT GTGCATTTTT CTGACGAGTG
7980
TCAATAAAT TAAAGCCATT TGGTCTTAAT TCTGACCAAT AAAAAAATAA GTCAGGAGGA
8040
TGGTATTTT TAAAGCTTTG AAATAAAATA ACAATGTCTT CTTGAAATTT GTGATGGCCA
8100
AGATTTTAT TATGATGAC ATTAGGCTTC TAAAGGACAT ACATTTAATA TTTCTGTGGA
8160
AATTTTAT TATCCATGG TTATCTGAGA TAGGAGATAC AACTTTGTA ATTCTAATAA
8220
TGTATTTT TACTCTCTC CCTCTACTAA TTTCTGCTG AAAATAACAC AACAAAAATG
8280
TATTTTAT TATATATAC CGTGAAGTAA AACTAGAGTC CTACTTACAT AGTTGAAATA
8340
TGTATTTT TAAAGAAAA TTGGACTGGT GAAACAGAA AAAACACTCC AGTCTGCCAT
8400
ATTTTAT TATAGGATCC CCCTTCTTGC CCTCCACCCC CATAAGATTG TGAAGGGTTT
8460
ACTTTTAT TATCTGCCT GACCCCTTCA CTATGACTAC ACAGAATCTC CTGATAGTAA
8520
AGTTTAT TATGCAAGGAT AAGTTATAGA GCAGTTGGAG GAAGCATCCA AAGATTGCAA
8580
CCCTTTAT TATGGAACA GAGATCCTA ATATGAAAGA AAAATGGATC CCAATCTGAG
8640

AAAAGGCAAA AGAATGGCTA CTTTTTCTA TGCTGGAGTA TTTTCTAATA ATCCTGCTTG
 8700
 ACCCTTATCT GACCTCTTTG GAAACTATAA CATAGCTGTC ACAGTATAGT CACAATCCAC
 8760
 AAATGATGCA GGTGCAAATG GTTTATAGCC CTGTGAAGTT CTAAAGTTT AGAGGCTAAC
 8820
 TTACAGAAAT GAATAAGTTG TTTTGTTTTA TAGCCCGGTA GAGGAGTTAA CCCCAGAGGT
 8880
 GATATGGTTT TATTTCTGT TATGTTTAACT TTAATAATCT TATTTTGGCA TTCTTTTCCC
 8940
 ATTGACTATA TACATCTCTA TTTCTCAAAT GTTCATGGAA CTAGCTCTTT TATTTTCTGT
 9000
 CTGGTTTCTT CAGTAATGAG TTAAATAAAA CATTGACACA TACAAAAAAA AAAAAAAA
 9060
 AAAAAAAA AAAAAAAA
 9080

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2351 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Met	Gln	Ile	Glu	Leu	Ser	Thr	Cys	Phe	Phe	Leu	Cys	Leu	Leu	Arg	Phe	1	5	10	15
Cys	Phe	Ser	Ala	Thr	Arg	Arg	Tyr	Tyr	Leu	Gly	Ala	Val	Glu	Leu	Ser	20	25	30	
Trp	Asp	Tyr	Met	Gln	Ser	Asp	Leu	Gly	Glu	Leu	Pro	Val	Asp	Ala	Arg	35	40	45	
Phe	Pro	Pro	Arg	Val	Pro	Lys	Ser	Phe	Pro	Phe	Asn	Thr	Ser	Val	Val	50	55	60	
Tyr	Lys	Lys	Thr	Leu	Phe	Val	Glu	Phe	Thr	Asp	His	Leu	Phe	Asn	Ile	65	70	75	80
Ala	Lys	Pro	Arg	Pro	Pro	Trp	Met	Gly	Leu	Leu	Gly	Pro	Thr	Ile	Gln	85	90	95	
Ala	Glu	Val	Tyr	Asp	Thr	Val	Val	Ile	Thr	Leu	Lys	Asn	Met	Ala	Ser	100	105	110	
His	Pro	Val	Ser	Leu	His	Ala	Val	Gly	Val	Ser	Tyr	Trp	Lys	Ala	Ser	115	120	125	
Glu	Gly	Ala	Glu	Tyr	Asp	Asp	Gln	Thr	Ser	Gln	Arg	Glu	Lys	Glu	Asp	130	135	140	
Asp	Lys	Val	Phe	Pro	Gly	Gly	Ser	His	Thr	Tyr	Val	Trp	Gln	Val	Leu	145	150	155	160
Lys	Glu	Asn	Gly	Pro	Met	Ala	Ser	Asp	Pro	Leu	Cys	Leu	Thr	Tyr	Ser	165	170	175	
Tyr	Leu	Ser	His	Val	Asp	Leu	Val	Lys	Asp	Leu	Asn	Ser	Gly	Leu	Ile	180	185	190	
Gly	Ala	Leu	Leu	Val	Cys	Arg	Glu	Gly	Ser	Leu	Ala	Lys	Glu	Lys	Thr				

195	200	205
Gln Thr Leu His Lys Phe Ile	Leu Leu Phe Ala Val	Phe Asp Glu Gly
210	215	220
Lys Ser Trp His Ser Glu Thr	Lys Asn Ser Leu Met	Gln Asp Arg Asp
225	230	235
Ala Ala Ser Ala Arg Ala Trp	Pro Lys Met His Thr	Val Asn Gly Tyr
245	250	255
Val Asn Arg Ser Leu Pro Gly	Leu Ile Gly Cys His Arg	Lys Ser Val
260	265	270
Tyr Trp His Val Ile Gly Met	Gly Thr Thr Pro Glu	Val His Ser Ile
275	280	285
Phe Leu Glu Gly His Thr Phe	Leu Val Arg Asn His	Arg Gln Ala Ser
290	295	300
Leu Glu Ile Ser Pro Ile Thr	Phe Leu Thr Ala Gln	Thr Leu Leu Met
305	310	315
Asp Leu Gly Gln Phe Leu Leu	Phe Cys His Ile Ser	Ser His Gln His
325	330	335
Asp Gly Met Glu Ala Tyr Val	Lys Val Asp Ser Cys	Pro Glu Glu Pro
340	345	350
Gln Leu Arg Met Lys Asn Asn	Glu Glu Ala Glu Asp	Tyr Asp Asp Asp
355	360	365
Leu Thr Asp Ser Glu Met Asp	Val Val Arg Phe Asp	Asp Asp Asn Ser
370	375	380
Pro Ser Phe Ile Gln Ile Arg	Ser Val Ala Lys Lys	His Pro Lys Thr
385	390	395
Trp Val His Tyr Ile Ala Ala	Glu Glu Glu Asp Trp	Asp Tyr Ala Pro
405	410	415
Leu Val Leu Ala Pro Asp Asp	Arg Ser Tyr Lys Ser	Gln Tyr Leu Asn
420	425	430
Asn Gly Pro Gln Arg Ile Gly	Arg Lys Tyr Lys Lys	Val Arg Phe Met
435	440	445
Ala Tyr Thr Asp Glu Thr Phe	Lys Thr Arg Glu Ala	Ile Gln His Glu
450	455	460
Ser Gly Ile Leu Gly Pro Leu	Leu Tyr Gly Glu Val	Gly Asp Thr Leu
465	470	475
Leu Ile Ile Phe Lys Asn Gln	Ala Ser Arg Pro Tyr	Asn Ile Tyr Pro
485	490	495
His Gly Ile Thr Asp Val Arg	Pro Leu Tyr Ser Arg	Arg Leu Pro Lys
500	505	510
Gly Val Lys His Leu Lys Asp	Phe Pro Ile Leu Pro	Gly Glu Ile Phe
515	520	525
Lys Tyr Lys Trp Thr Val Thr	Val Glu Asp Gly Pro	Thr Lys Ser Asp

530					535					540					
Pro 545	Arg	Cys	Leu	Thr	Arg 550	Tyr	Tyr	Ser	Ser	Phe 555	Val	Asn	Met	Glu 560	Arg
Asp	Leu	Ala	Ser	Gly 565	Leu	Ile	Gly	Pro	Leu 570	Leu	Ile	Cys	Tyr	Lys 575	Glu
Ser	Val	Asp	Gln 580	Arg	Gly	Asn	Gln	Ile 585	Met	Ser	Asp	Lys	Arg 590	Asn	Val
Ile	Leu	Phe 595	Ser	Val	Phe	Asp	Glu 600	Asn	Arg	Ser	Trp	Tyr 605	Leu	Thr	Glu
Asn 610	Ile	Gln	Arg	Phe	Leu	Pro 615	Asn	Pro	Ala	Gly	Val 620	Gln	Leu	Glu	Asp
Pro 625	Glu	Phe	Gln	Ala	Ser 630	Asn	Ile	Met	His 635	Ser	Ile	Asn	Gly	Tyr	Val 640
Phe	Asp	Ser	Leu	Gln 645	Leu	Ser	Val	Cys 650	Leu	His	Glu	Val	Ala	Tyr 655	Trp
Tyr	Ile	Leu	Ser 660	Ile	Gly	Ala	Gln	Thr 665	Asp	Phe	Leu	Ser	Val 670	Phe	Phe
Ser	Gly	Tyr 675	Thr	Phe	Lys	His 680	Lys	Met	Val	Tyr	Glu	Asp 685	Thr	Leu	Thr
Leu 690	Phe	Pro	Phe	Ser	Gly	Glu 695	Thr	Val	Phe	Met	Ser 700	Met	Glu	Asn	Pro
Gly 705	Leu	Trp	Ile	Leu	Gly 710	Cys	His	Asn	Ser 715	Asp	Phe	Arg	Asn	Arg	Gly 720
Met	Thr	Ala	Leu	Leu 725	Lys	Val	Ser	Ser 730	Cys	Asp	Lys	Asn	Thr	Gly 735	Asp
Tyr	Tyr	Glu	Asp 740	Ser	Tyr	Glu	Asp	Ile 745	Ser	Ala	Tyr	Leu	Leu 750	Ser	Lys
Asn	Asn	Ala 755	Ile	Glu	Pro	Arg 760	Ser	Phe	Ser	Gln	Asn 765	Ser	Arg	His	Pro
Ser 770	Thr	Arg	Gln	Lys	Gln	Phe 775	Asn	Ala	Thr	Thr	Ile 780	Pro	Glu	Asn	Asp
Ile 785	Glu	Lys	Thr	Asp 790	Pro	Trp	Phe	Ala	His 795	Arg	Thr	Pro	Met	Pro	Lys 800
Ile	Gln	Asn	Val	Ser 805	Ser	Ser	Asp	Leu	Leu 810	Met	Leu	Leu	Arg	Gln 815	Ser
Pro	Thr	Pro	His 820	Gly	Leu	Ser	Leu	Ser 825	Asp	Leu	Gln	Glu	Ala 830	Lys	Tyr
Glu	Thr	Phe 835	Ser	Asp	Asp	Pro	Ser 840	Pro	Gly	Ala	Ile	Asp 845	Ser	Asn	Asn
Ser 850	Leu	Ser	Glu	Met	Thr	His 855	Phe	Arg	Pro	Gln	Leu	His	His	Ser	Gly
Asp	Met	Val	Phe	Thr	Pro	Glu	Ser	Gly	Leu	Gln	Leu	Arg	Leu	Asn	Glu

1205					1210					1215						
Ile	Glu	Lys	Lys	Glu	Thr	Leu	Ile	Gln	Glu	Asn	Val	Val	Leu	Pro	Gln	
1220					1225					1230						
Ile	His	Thr	Val	Thr	Gly	Thr	Lys	Asn	Phe	Met	Lys	Asn	Leu	Phe	Leu	
1235					1240					1245						
Leu	Ser	Thr	Arg	Gln	Asn	Val	Glu	Gly	Ser	Tyr	Asp	Gly	Ala	Tyr	Ala	
1250					1255					1260						
Pro	Val	Leu	Gln	Asp	Phe	Arg	Ser	Leu	Asn	Asp	Ser	Thr	Asn	Arg	Thr	
1265					1270					1275					1280	
Lys	Lys	His	Thr	Ala	His	Phe	Ser	Lys	Lys	Gly	Glu	Glu	Glu	Asn	Leu	
1285					1290					1295						
Glu	Gly	Leu	Gly	Asn	Gln	Thr	Lys	Gln	Ile	Val	Glu	Lys	Tyr	Ala	Cys	
1300					1305					1310						
Thr	Thr	Arg	Ile	Ser	Pro	Asn	Thr	Ser	Gln	Gln	Asn	Phe	Val	Thr	Gln	
1315					1320					1325						
Arg	Ser	Lys	Arg	Ala	Leu	Lys	Gln	Phe	Arg	Leu	Pro	Leu	Glu	Glu	Thr	
1330					1335					1340						
Glu	Leu	Glu	Lys	Arg	Ile	Ile	Val	Asp	Asp	Thr	Ser	Thr	Gln	Trp	Ser	
1345					1350					1355					1360	
Lys	Asn	Met	Lys	His	Leu	Thr	Pro	Ser	Thr	Leu	Thr	Gln	Ile	Asp	Tyr	
1365					1370					1375						
Asn	Glu	Lys	Glu	Lys	Gly	Ala	Ile	Thr	Gln	Ser	Pro	Leu	Ser	Asp	Cys	
1380					1385					1390						
Leu	Thr	Arg	Ser	His	Ser	Ile	Pro	Gln	Ala	Asn	Arg	Ser	Pro	Leu	Pro	
1395					1400					1405						
Ile	Ala	Lys	Val	Ser	Ser	Phe	Pro	Ser	Ile	Arg	Pro	Ile	Tyr	Leu	Thr	
1410					1415					1420						
Arg	Val	Leu	Phe	Gln	Asp	Asn	Ser	Ser	His	Leu	Pro	Ala	Ala	Ser	Tyr	
1425					1430					1435					1440	
Arg	Lys	Lys	Asp	Ser	Gly	Val	Gln	Glu	Ser	Ser	His	Phe	Leu	Gln	Gly	
1445					1450					1455						
Ala	Lys	Lys	Asn	Asn	Leu	Ser	Leu	Ala	Ile	Leu	Thr	Leu	Glu	Met	Thr	
1460					1465					1470						
Gly	Asp	Gln	Arg	Glu	Val	Gly	Ser	Leu	Gly	Thr	Ser	Ala	Thr	Asn	Ser	
1475					1480					1485						
Val	Thr	Tyr	Lys	Lys	Val	Glu	Asn	Thr	Val	Leu	Pro	Lys	Pro	Asp	Leu	
1490					1495					1500						
Pro	Lys	Thr	Ser	Gly	Lys	Val	Glu	Leu	Leu	Pro	Lys	Val	His	Ile	Tyr	
1505					1510					1515					1520	
Gln	Lys	Asp	Leu	Phe	Pro	Thr	Glu	Thr	Ser	Asn	Gly	Ser	Pro	Gly	His	
1525					1530					1535						
Leu	Asp	Leu	Val	Glu	Gly	Ser	Leu	Leu	Gln	Gly	Thr	Glu	Gly	Ala	Ile	

1540	1545	1550
Lys Trp Asn Glu Ala Asn Arg Pro Gly Lys Val Pro Phe Leu Arg Val 1555	1560	1565
Ala Thr Glu Ser Ser Ala Lys Thr Pro Ser Lys Leu Leu Asp Pro Leu 1570	1575	1580
Ala Trp Asp Asn His Tyr Gly Thr Gln Ile Pro Lys Glu Glu Trp Lys 1585	1590	1595
Ser Gln Glu Lys Ser Pro Glu Lys Thr Ala Phe Lys Lys Lys Asp Thr 1605	1610	1615
Ile Leu Ser Leu Asn Ala Cys Glu Ser Asn His Ala Ile Ala Ala Ile 1620	1625	1630
Asn Glu Gly Gln Asn Lys Pro Glu Ile Glu Val Thr Trp Ala Lys Gln 1635	1640	1645
Gly Arg Thr Glu Arg Leu Cys Ser Gln Asn Pro Pro Val Leu Lys Arg 1650	1655	1660
His Gln Arg Glu Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln Glu Glu 1665	1670	1675
Ile Asp Tyr Asp Asp Thr Ile Ser Val Glu Met Lys Lys Glu Asp Phe 1685	1690	1695
Asp Ile Tyr Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe Gln Lys 1700	1705	1710
Lys Thr Arg His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp Asp Tyr 1715	1720	1725
Gly Met Ser Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln Ser Gly 1730	1735	1740
Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr Asp Gly 1745	1750	1755
Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu His Leu Gly 1765	1770	1775
Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile Met Val 1780	1785	1790
Thr Phe Arg Asn Gln Ala Ser Arg Pro Tyr Ser Phe Tyr Ser Ser Leu 1795	1800	1805
Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly Ala Glu Pro Arg Lys Asn 1810	1815	1820
Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr Phe Trp Lys Val Gln His 1825	1830	1835
His Met Ala Pro Thr Lys Asp Glu Phe Asp Cys Lys Ala Trp Ala Tyr 1845	1850	1855
Phe Ser Asp Val Asp Leu Glu Lys Asp Val His Ser Gly Leu Ile Gly 1860	1865	1870
Pro Leu Leu Val Cys His Thr Asn Thr Leu Asn Pro Ala His Gly Arg		

1875	1880	1885
Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe Thr Ile Phe Asp Glu 1890 1895 1900		
Thr Lys Ser Trp Tyr Phe Thr Glu Asn Met Glu Arg Asn Cys Arg Ala 1905 1910 1915 1920		
Pro Cys Asn Ile Gln Met Glu Asp Pro Thr Phe Lys Glu Asn Tyr Arg 1925 1930 1935		
Phe His Ala Ile Asn Gly Tyr Ile Met Asp Thr Leu Pro Gly Leu Val 1940 1945 1950		
Met Ala Gln Asp Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met Gly Ser 1955 1960 1965		
Asn Glu Asn Ile His Ser Ile His Phe Ser Gly His Val Phe Thr Val 1970 1975 1980		
Arg Lys Lys Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr Pro Gly 1985 1990 1995 2000		
Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys Ala Gly Ile Trp Arg 2005 2010 2015		
Val Glu Cys Leu Ile Gly Glu His Leu His Ala Gly Met Ser Thr Leu 2020 2025 2030		
Phe Leu Val Tyr Ser Asn Lys Cys Gln Thr Pro Leu Gly Met Ala Ser 2035 2040 2045		
Gly His Ile Arg Asp Phe Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln 2050 2055 2060		
Trp Ala Pro Lys Leu Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala 2065 2070 2075 2080		
Trp Ser Thr Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu Ala 2085 2090 2095		
Pro Met Ile Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe 2100 2105 2110		
Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly 2115 2120 2125		
Lys Lys Trp Gln Thr Tyr Arg Gly Asn Ser Thr Gly Thr Leu Met Val 2130 2135 2140		
Phe Phe Gly Asn Val Asp Ser Ser Gly Ile Lys His Asn Ile Phe Asn 2145 2150 2155 2160		
Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu His Pro Thr His Tyr Ser 2165 2170 2175		
Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly Cys Asp Leu Asn Ser 2180 2185 2190		
Cys Ser Met Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln 2195 2200 2205		
Ile Thr Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro		

2210	2215	2220
Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Pro		
2225	2230	2235 2240
Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val Asp Phe Gln Lys Thr		
	2245	2250 2255
Met Lys Val Thr Gly Val Thr Thr Gln Gly Val Lys Ser Leu Leu Thr		
	2260	2265 2270
Ser Met Tyr Val Lys Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His		
	2275	2280 2285
Gln Trp Thr Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly		
	2290	2295 2300
Asn Gln Asp Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu		
	2305	2310 2315 2320
Leu Thr Arg Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile		
	2325	2330 2335
Ala Leu Arg Met Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr		
	2340	2345 2350

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4832 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

CTCGAGCTAA AGATATTTTA GAGAAGAATT AACCTTTTGC TTCTCCAGTT GAACATTTGT
60
AGCAATAAGT CATGCAAATA GAGCTCTCCA CCTGCTTCTT TCTGTGCCTT TTGCGATTCT
120
GCTTTAGTGC CACCAGAAGA TACTACCTGG GTGCAGTGGG ACTGTCATGG GACTATATGC
180
AAAGTGATCT CGGTGAGCTG CCTGTGGACG CAAGATTTCC TCCTAGAGTG CCAAAATCTT
240
TTCCATTCAA CACCTCAGTC GTGTACAAAA AGACTCTGTT TGTAAGAATTC ACGGATCACC
300
TTTTCAACAT CGCTAAGCCA AGGCCACCCT GGATGGGTCT GCTAGGTCCT ACCATCCAGG
360
CTGAGGTTTA TGATACAGTG GTCATTACAC TTAAGAACAT GGCTTCCCAT CCTGTCAGTC
420
TTCATGCTGT TGGTGTATCC TACTGGAAAG CTTCTGAGGG AGCTGAATAT GATGATCAGA
480
CCAGTCAAAG GGAGAAAGAA GATGATAAAG TCTTCCCTGG TGGAAGCCAT ACATATGTCT
540
GGCAGGTCCT GAAAGAGAAT GGTCCAATGG CCTCTGACCC ACTGTGCCTT ACCTACTCAT
600
ATCTTTCTCA TGTGGACCTG GTAAAAGACT TGAATTCAGG CCTCATTGGA GCCCTACTAG
660
TATGTAGAGA AGGGAGTCTG GCCAAGGAAA AGACACAGAC CTGCACAAA TTTATACTAC
720
TTTTTGCTGT ATTTGATGAA GGGAAAAGTT GGCATCAGA AACAAAGAAC TCCTTGATGC
780
AGGATAGGGA TGCTGCATCT GCTCGGGCCT GGCCTAAAAT GCACACAGTC AATGGTTATG
840

TAAACAGGTC TCTGCCAGGT CTGATTGGAT GCCACAGGAA ATCAGTCTAT TGGCATGTGA
900
TTGGAATGGG CACCACTCCT GAAGTGCACT CAATATTCCT CGAAGGTCAC ACATTTCTTG
960
TGAGGAACCA TCGCCAGGCG TCCTTGAAA TCTCGCCAAT AACTTTCCTT ACTGCTCAAA
1020
CACTCTIGAT GGACCTTGGA CAGTTTCTAC TGTTTTGTCA TATCTCTTCC CACCAACATG
1080
ATGGCATGGA AGCTTATGTC AAAGTAGACA GCTGTCCAGA GGAACCCCAA CTACGAATGA
1140
AAATAATGA AGAAGCGGAA GACTATGATG ATGATCTTAC TGATTCTGAA ATGGATGTGG
1200
TCAGGTTTGA TGATGACAAC TCTCCTTCCT TTATCCAAAT TCGCTCAGTT GCCAAGAAGC
1260
ATCCTAATAA TTGGGTACAT TACATTGCTG CTGAAGAGGA GGACTGGGAC TATGCTCCCT
1320
TAGTCTTAA CCCCAGTGAC AGAAGTTATA AAAGTCAATA TTTGAACAAT GGCCCTCAGC
1380
GGATIGTAA GAAGTACAAA AAAGTCCGAT TTATGGCATA CACAGATGAA ACCTTTAAGA
1440
CTCCTGAAGC TATTCAGCAT GAATCAGGAA TCTTGGGACC TTTACTTTAT GGGGAAGTTG
1500
GAGAATAAT CTTGATTATA TTTAAGAATC AAGCAAGCAG ACCATATAAC ATCTACCCTC
1560
ACGGAATAT TGATGTCCGT CCTTTGTATT CAAGGAGATT ACCAAAAGGT GTAAAACATT
1620
TGAAATAAT TCAATTCTG CCAGGAGAAA TATTCAAATA TAAATGGACA GTGACTGTAG
1680
AAGATATAT AACTAAATCA GATCCTCGGT GCCTGACCCG CTATTACTCT AGTTTCGTTA
1740
ATATATAT AGATCTAGCT TCAGGACTCA TTGGCCCTCT CCTCATCTGC TACAAAGAAT
1800
CTGATATAT AAGAGGAAAC CAGATAATGT CAGACAAGAG GAATGTCATC CTGTTTTCTG
1860
TATTTATAT AACCGAAGC TGGTACCTCA CAGAGAATAT ACAACGCTTT CTCCCCAATC
1920
CAGATATAT TAGCTTGAG GATCCAGAGT TCCAAGCCTC CAACATCATG CACAGCATCA
1980
ATGATATAT TTTTGATAGT TTGCAGTTGT CAGTTTGTTT GCATGAGGTG GCATACTGGT
2040
ACATATAT ATTGGAGCA CAGACTGACT TCCTTTCTGT CTTCTTCTCT GGATATACCT
2100
TCAGATAT AATGGTCTAT GAAGACACAC TCACCCTATT CCCATTCTCA GGAGAAACTG
2160
TCTATATAT ATGGAAAAC CCAGGTCTAT GGATTCTGGG GTGCCACAAC TCAGACTTTC
2220
GGATATAT TGGACCGCC TTAGTGAAGG TTTCTAGTTG TGACAAGAAC ACTGGTGATT
2280
ATTATATAT TTTATGAA GATATTTAG CATACTTGCT GAGTAAAAAC AATGCCATTG
2340
ATATATAT TTTCCAG AACCCACCAG TCTTGAAACG CCATCAACGG GAAATAACTC
2400
GTATATAT ATTCAGAT CAAGAGGAAA TTGACTATGA TGATACCATA TCAGTTGAAA
2460
TGATATAT ATTTTGAC ATTTATGATG AGGATGAAAA TCAGAGCCCC CGCAGCTTTC
2520
AATATATAT TTAACACTAT TTTATTGCTG CAGTGGAGAG GCTCTGGGAT TATGGGATGA
2580
GTATATAT ATATGTTCTA AGAAACAGGG CTCAGAGTGG CAGTGTCCCT CAGTTCAAGA
2640
AATATATAT TAGGAATTT ACTGATGGCT CCTTTACTCA GCCCTTATAC CGTGGAGAAC
2700

TAAATGAACA TTTGGGACTC CTGGGGCCAT ATATAAGAGC AGAAGTTGAA GATAATATCA
 2760
 TGGTAACTTT CAGAAATCAG GCCTCTCGTC CCTATTCTTT CTATTCTAGC CTTATTTCTT
 2820
 ATGAGGAAGA TCAGAGGCAA GGAGCAGAAC CTAGAAAAAA CTTTGTCAAG CCTAATGAAA
 2880
 CCAAACTTA CTTTGGAAA GTGCAACATC ATATGGCACC CACTAAAGAT GAGTTTGGCT
 2940
 GCAAAGCCTG GGCTTATTTT TCTGATGTTG ACCTGGAAAA AGATGTGCAC TCAGGCCTGA
 3000
 TTGGACCCCT TCTGGTCTGC CACACTAACA CACTGAACCC TGCTCATGGG AGACAAGTGA
 3060
 CAGTACAGGA ATTTGCTCTG TTTTTCACCA TCTTTGATGA GACCAAAAGC TGGTACTTCA
 3120
 CTGAAAATAT GGAAAGAAAC TGCAGGGCTC CCTGCAATAT CCAGATGGAA GATCCCACTT
 3180
 TTAAAGAGAA TTATCGCTTC CATGCAATCA ATGGCTACAT AATGGATACA CTACCTGGCT
 3240
 TAGTAATGGC TCAGGATCAA AGGATTCGAT GGTATCTGCT CAGCATGGGC AGCAATGAAA
 3300
 ACATCCATTC TATTCATTTT AGTGGACATG TGTTCACTGT ACGAAAAAAA GAGGAGTATA
 3360
 AAATGGCACT GTACAATCTC TATCCAGGTG TTTTGGAGAC AGTGGAAATG TTACCATCCA
 3420
 AAGCTGGAAT TTGGCGGGTG GAATGCCTTA TTGGCGAGCA TCTACATGCT GGGATGAGCA
 3480
 CACTTTTCTT GGTGTACAGC AATAAGTGTC AGACTCCCCT GGGAATGGCT TCTGGACACA
 3540
 TTAGAGATTT TCAGATTACA GCTTCAGGAC AATATGGACA GTGGGCCCCA AAGCTGGCCA
 3600
 GACTTCATTA TTCCGGATCA ATCAATGCCT GGAGCACCAA GGAGCCCTTT TCTTGGATCA
 3660
 AGGTGGATCT GTTGGCACCA ATGATTATTC ACGGCATCAA GACCCAGGGT GCGCGTCAGA
 3720
 AGTTCTCCAG CCTCTACATC TCTCAGTTTA TCATCATGTA TAGTCTTGAT GGAAGAAGT
 3780
 GGCAGACTTA TCGAGGAAAT TCCACTGGAA CCTTAATGGT CTTCTTTGGC AATGTGGATT
 3840
 CATCTGGGAT AAAACACAAT ATTTTAAACC CTCCAATTAT TGCTCGATAC ATCCGTTTGC
 3900
 ACCCAACTCA TTATAGCATT CGCAGCACTC TTCGCATGGA GTTGATGGGC TGTGATTAA
 3960
 ATAGTTGCAG CATGCCATTG GGAATGGAGA GTAAAGCAAT ATCAGATGCA CAGATTACTG
 4020
 CTTTCATCCTA CTTTACCAAT ATGTTTGCCA CTGGTCTCC TTCAAAAGCT CGACTTCACC
 4080
 TCCAAGGGAG GAGTAATGCC TGGAGACCTC AGGTGAATAA TCCAAAAGAG TGGCTGCAAG
 4140
 TGGACTTCCA GAAGACAATG AAAGTCACAG GAGTAACTAC TCAGGGAGTA AAATCTCTGC
 4200
 TTACCAGCAT GTATGTGAAG GAGTTCCTCA TCTCCAGCAG TCAAGATGGC CATCAGTGGA
 4260
 CTCTCTTTTT TCAGAATGGC AAAGTAAAGG TTTTTCAGGG AAATCAAGAC TCCTTCACAC
 4320
 CTGTGGTGAA CTCTCTAGAC CCACCGTTAC TGAATCGCTA CCTTCGAATT CACCCCCAGA
 4380
 GTTGGGTGCA CCAGATTGCC CTGAGGATGG AGGTTCTGGG CTGCGAGGCA CAGGACCTCT
 4440
 ACTGAGGGTG GCCACTGCAG CACCTGCCAC TGCCGTCACC TCTCCCTCCT CAGCTCCAGG
 4500
 GCAGTGTCCC TCCCTGGCTT GCCTTCTACC TTTGTGCTAA ATCCTAGCAG AACTGCCTT
 4560

GAAGCCTCCT GAATTAAC TAATCAGTCC TGCATTTCTT TGGTGGGGGG CCAGGAGGGT
 4620
 GCATCCAATT TAACTTAAC CTTACCTATT TTCTGCAGCT GCTCCCAGAT TACTCCTTCC
 4680
 TTCCAATATA ACTAGGCAAA AAGAAGTGAG GAGAAACCTG CATGAAAGCA TTCTTCCCTG
 4740
 AAAAGTTAGG CCTCTCAGAG TCACCACTTC CTCTGTTGTA GAAAACTAT GTGATGAAAC
 4800
 TTTGAAAAAG ATATTTATGA TGTTCGCGCC GC
 4832

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1457 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Met	Gln	Ile	Glu	Leu	Ser	Thr	Cys	Phe	Phe	Leu	Cys	Leu	Leu	Arg	Phe	1	5	10	15
Cys	Phe	Ser	Ala	Thr	Arg	Arg	Tyr	Tyr	Leu	Gly	Ala	Val	Glu	Leu	Ser	20	25	30	
Trp	Asp	Tyr	Met	Gln	Ser	Asp	Leu	Gly	Glu	Leu	Pro	Val	Asp	Ala	Arg	35	40	45	
Phe	Pro	Pro	Arg	Val	Pro	Lys	Ser	Phe	Pro	Phe	Asn	Thr	Ser	Val	Val	50	55	60	
Tyr	Lys	Lys	Thr	Leu	Phe	Val	Glu	Phe	Thr	Asp	His	Leu	Phe	Asn	Ile	65	70	75	80
Ala	Lys	Pro	Arg	Pro	Pro	Trp	Met	Gly	Leu	Leu	Gly	Pro	Thr	Ile	Gln	85	90	95	
Ala	Glu	Val	Tyr	Asp	Thr	Val	Val	Ile	Thr	Leu	Lys	Asn	Met	Ala	Ser	100	105	110	
His	Pro	Val	Ser	Leu	His	Ala	Val	Gly	Val	Ser	Tyr	Trp	Lys	Ala	Ser	115	120	125	
Glu	Gly	Ala	Glu	Tyr	Asp	Asp	Gln	Thr	Ser	Gln	Arg	Glu	Lys	Glu	Asp	130	135	140	
Asp	Lys	Val	Phe	Pro	Gly	Gly	Ser	His	Thr	Tyr	Val	Trp	Gln	Val	Leu	145	150	155	160
Lys	Glu	Asn	Gly	Pro	Met	Ala	Ser	Asp	Pro	Leu	Cys	Leu	Thr	Tyr	Ser	165	170	175	
Tyr	Leu	Ser	His	Val	Asp	Leu	Val	Lys	Asp	Leu	Asn	Ser	Gly	Leu	Ile	180	185	190	
Gly	Ala	Leu	Leu	Val	Cys	Arg	Glu	Gly	Ser	Leu	Ala	Lys	Glu	Lys	Thr	195	200	205	
Gln	Thr	Leu	His	Lys	Phe	Ile	Leu	Leu	Phe	Ala	Val	Phe	Asp	Glu	Gly	210	215	220	
Lys	Ser	Trp	His	Ser	Glu	Thr	Lys	Asn	Ser	Leu	Met	Gln	Asp	Arg	Asp				

225 230 235 240
 Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr
 245 250 255
 Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val
 260 265 270
 Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile
 275 280 285
 Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser
 290 295 300
 Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met
 305 310 315 320
 Arg Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His
 325 330 335
 Arg Gly Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro
 340 345 350
 Gln Leu Arg Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp
 355 360 365
 Leu Thr Asp Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser
 370 375 380
 Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr
 390 395 400
 His Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro
 405 410 415
 Leu Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn
 420 425 430
 Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met
 435 440 445
 Thr Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu
 455 460
 Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu
 470 475 480
 Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro
 485 490 495
 Ile Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys
 500 505 510
 Lys His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe
 515 520 525
 Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp
 535 540
 Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg
 550 555 560
 Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu

565					570					575					
Ser	Val	Asp	Gln	Arg	Gly	Asn	Gln	Ile	Met	Ser	Asp	Lys	Arg	Asn	Val
			580					585					590		
Ile	Leu	Phe	Ser	Val	Phe	Asp	Glu	Asn	Arg	Ser	Trp	Tyr	Leu	Thr	Glu
		595					600					605			
Asn	Ile	Gln	Arg	Phe	Leu	Pro	Asn	Pro	Ala	Gly	Val	Gln	Leu	Glu	Asp
	610					615					620				
Pro	Glu	Phe	Gln	Ala	Ser	Asn	Ile	Met	His	Ser	Ile	Asn	Gly	Tyr	Val
	625					630					635				640
Phe	Asp	Ser	Leu	Gln	Leu	Ser	Val	Cys	Leu	His	Glu	Val	Ala	Tyr	Trp
				645					650					655	
Tyr	Ile	Leu	Ser	Ile	Gly	Ala	Gln	Thr	Asp	Phe	Leu	Ser	Val	Phe	Phe
			660					665					670		
Ser	Gly	Tyr	Thr	Phe	Lys	His	Lys	Met	Val	Tyr	Glu	Asp	Thr	Leu	Thr
		675					680					685			
Leu	Phe	Pro	Phe	Ser	Gly	Glu	Thr	Val	Phe	Met	Ser	Met	Glu	Asn	Pro
						695					700				
Gly	Leu	Trp	Ile	Leu	Gly	Cys	His	Asn	Ser	Asp	Phe	Arg	Asn	Arg	Gly
	705					710					715				720
Met	Thr	Ala	Leu	Leu	Lys	Val	Ser	Ser	Cys	Asp	Lys	Asn	Thr	Gly	Asp
				725					730					735	
Tyr	Tyr	Glu	Asp	Ser	Tyr	Glu	Asp	Ile	Ser	Ala	Tyr	Leu	Leu	Ser	Lys
			740					745					750		
Asn	Asn	Ala	Ile	Glu	Pro	Arg	Ser	Phe	Ser	Gln	Asn	Pro	Pro	Val	Leu
		755					760					765			
Lys	Arg	His	Gln	Arg	Glu	Ile	Thr	Arg	Thr	Thr	Leu	Gln	Ser	Asp	Gln
	770					775					780				
Glu	Glu	Ile	Asp	Tyr	Asp	Asp	Thr	Ile	Ser	Val	Glu	Met	Lys	Lys	Glu
	785					790					795				800
Asp	Phe	Asp	Ile	Tyr	Asp	Glu	Asp	Glu	Asn	Gln	Ser	Pro	Arg	Ser	Phe
			805						810					815	
Gln	Lys	Lys	Thr	Arg	His	Tyr	Phe	Ile	Ala	Ala	Val	Glu	Arg	Leu	Trp
			820					825					830		
Asp	Tyr	Gly	Met	Ser	Ser	Ser	Pro	His	Val	Leu	Arg	Asn	Arg	Ala	Gln
		835					840					845			
Ser	Gly	Ser	Val	Pro	Gln	Phe	Lys	Lys	Val	Val	Phe	Gln	Glu	Phe	Thr
	850					855					860				
Asp	Gly	Ser	Phe	Thr	Gln	Pro	Leu	Tyr	Arg	Gly	Glu	Leu	Asn	Glu	His
	865					870					875				880
Leu	Gly	Leu	Leu	Gly	Pro	Tyr	Ile	Arg	Ala	Glu	Val	Glu	Asp	Asn	Ile
				885					890					895	
Met	Val	Thr	Phe	Arg	Asn	Gln	Ala	Ser	Arg	Pro	Tyr	Ser	Phe	Tyr	Ser

	900						905						910							
Ser Leu Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly Ala Glu Pro Arg 915 920 925	Lys Asn Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr Phe Trp Lys Val 930 935 940	Gln His His Met Ala Pro Thr Lys Asp Glu Phe Asp Cys Lys Ala Trp 945 950 955	Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His Ser Gly Leu 965 970 975	Ile Gly Pro Leu Leu Val Cys His Thr Asn Thr Leu Asn Pro Ala His 980 985 990	Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe Thr Ile Phe 995 1000 1005	Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Met Glu Arg Asn Cys 1010 1015 1020	Arg Ala Pro Cys Asn Ile Gln Met Glu Asp Pro Thr Phe Lys Glu Asn 1025 1030 1035 1040	Tyr Arg Phe His Ala Ile Asn Gly Tyr Ile Met Asp Thr Leu Pro Gly 1045 1050 1055	Leu Val Met Ala Gln Asp Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met 1060 1065 1070	Gly Ser Asn Glu Asn Ile His Ser Ile His Phe Ser Gly His Val Phe 1075 1080 1085	Thr Val Arg Lys Lys Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr 1090 1095 1100	Pro Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys Ala Gly Ile 1105 1110 1115 1120	Trp Arg Val Glu Cys Leu Ile Gly Glu His Leu His Ala Gly Met Ser 1125 1130 1135	Thr Leu Phe Leu Val Tyr Ser Asn Lys Cys Gln Thr Pro Leu Gly Met 1140 1145 1150	Ala Ser Gly His Ile Arg Asp Phe Gln Ile Thr Ala Ser Gly Gln Tyr 1155 1160 1165	Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr Ser Gly Ser Ile 1170 1175 1180	Asn Ala Trp Ser Thr Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu 1185 1190 1195 1200	Leu Ala Pro Met Ile Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln 1205 1210 1215	Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser Leu 1220 1225 1230	Asp Gly Lys Lys Trp Gln Thr Tyr Arg Gly Asn Ser Thr Gly Thr Leu

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 100 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Arg Gly Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr
1 5 10 15

Gly Asp Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu
 20 25 30
 Ser Lys Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg
 35 40 45
 His Pro Ser Thr Arg Gln Lys Gln Phe Asn Ala Thr Pro Pro Thr Pro
 50 55 60
 Pro Thr Pro Pro Val Leu Lys Arg His Gln Arg Glu Ile Thr Arg Thr
 65 70 75 80
 Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr Asp Asp Thr Ile Ser
 85 90 95
 Val Glu Met Lys
 100

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 300 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

AGAGGCATGA CCGCCTTACT GAAGGTTTCT AGTTGTGACA AGAACACTGG TGATTATTAC
 60
 GAGGACAGTT ATGAAGATAT TTCAGCATAC TTGCTGAGTA AAAACAATGC CATTGAACCA
 120
 AGAAGCTTCT CCCAGAATTC TAGACACCTT AGCACTAGGC AAAAGCAATT TAATGCCACC
 180
 CCTCCTACAC CACCAACCCC ACCAGTACTG AAACGCCATC AACGGGAAAT AACTCGTACT
 240
 ACTCTTCAGT CTGATCAAGA GGAAATTGAC TATGATGATA CCATATCAGT TGAAATGAAG
 300

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Ser Arg His Pro Ser Thr Arg Gln Lys Gln Phe Asn Ala Thr Pro Pro
 1 5 10 15
 Val Leu Lys Arg His Gln Arg Glu Ile Thr Arg
 20 25

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

TCGCGACACC CTAGCACTAG GCAAAAGCAA TTTAATGCCA CCCACCACT CCTGAAACGC
60
CATCAACGGG AAATAACGCG T
81

(2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
ACTACTCTTC AATCTGATCA AGAGGAA
27

(2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 43 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
CGCGCCGCTC GAGTCTACAA TGGCTTTGCC TTTTGCTTA CTG
43

(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 43 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
GCGCCCATCG ATTTATTCCT TCCTCCTTAA CCTTTCTTGC AAG
43

(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 48 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:
CGCGCCGCTC GAGCATCCCA ATGGCCCTGT CCTTTTCTTT ACTGATGG
48

(2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
CCATCGATTC AATCCTTCCT CCTTAATCTT TTTTGCAAG
39

(2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
CCGGATCCTC TACAATGGCT TTGCCTTTG CTTTACTG
38
- (2) INFORMATION FOR SEQ ID NO:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
CCGCCCGCG GCCGCTTATT CCTTCCTCCT TAACCTTTCT TGCAAG
46
- (2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
CCGGATCCCA TCCCAATGGC CCTGTCCTTT TCTTTACTGA TGG
43
- (2) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:
CCGCCCGCG GCCGCTCAAT CCTTCCTCCT TAATCTTTTT TGCAAG
46
- (2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 90 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
AGCTTGCTGT TTGTGTGCTG CCTCTGAAGT CCACACTGAA CAAACTTCAG CCTACTCATG
60
TCCCTAAAAT GGGCAAACAT TGCAAGCAGC
90
- (2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

AAACAGCAAA CACACAGCCC TCCCTGCCTG CTGACCTTGG AGCTGGGGCA GAGGTCAGAG
60
ACCTCTCTGA
70

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 82 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

AGCTTCAGAG AGGTCTCTGA CCTCTGCCCC AGCTCCAAGG TCAGCAGGCA GGGAGGGCTG
60
TGTGTTTGCT GTTGCTGCT TG
82

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 78 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

CAATGTTTGC CCATTTTAGG GACATGAGTA GGCTGAAGTT TGTTCAAGTGT GGAATTCAGA
60
GGCAGCACAC AAACAGCA
78

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 90 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

AATTCGCTGT TTGTGTGCTG CCTCTGAAGT CCACACTGAA CAACTTCAG CCTACTCATG
60
TCCCTAAAAT GGGCAAACAT TGCAAGCAGC
90

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

AAACAGCAAA CACACAGCCC TCCCTGCCTG CTGACCTTGG AGCTGGGGCA GAGGTCAGAG
60
ACCTCTCTGG
70

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 82 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:
AATTCCAGAG AGGTCTCTGA CCTCTGCCCC AGCTCCAAGG TCAGCAGGCA GGGAGGGCTG
60
TGTGTTTGCT GTTTGCTGCT TG
82

(2) INFORMATION FOR SEQ ID NO:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
CAATGTTTGC CCATTTTAGG GACATGAGTA GGCTGAAGTT TGTTCAAGTGT GGAAGTCAGA
60
GGCAGCACAC AAACAGCG
78

(2) INFORMATION FOR SEQ ID NO:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:
CGCGCCGCCC GGGGTAGATC TTGCTACCAG TGG
33

(2) INFORMATION FOR SEQ ID NO:70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:
GCGCCCGCGG CCGCCACTGT CCCAGGTCAG TGGTGGTGCC
40

(2) INFORMATION FOR SEQ ID NO:71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:
CGCGCCGCGG GCCGCTCTAC AATGGCCTTG ACCTTTGCTT TACTGG
46

(2) INFORMATION FOR SEQ ID NO:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:
GCGCCCATCG ATTCATTCCT TACTTCTTAA ACTTTCTTGC AAG
43

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:
CGCGGCTCTAC AATGGCCTTG ACCTTTGCTT TACTGG
46

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:
GCGGCTCTAC ATTCATTCCT TACTTCTTAA ACTTTCTTGC AAG
43

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Arg His Pro Ser

5

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Pro Pro Val Leu Lys Arg His Gln Arg Glu Ile Thr

5

10

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:
ACCTAGC

18

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:
CAAAACCCAC CAGTCTTGAA ACGCCATCAA CGGGAAATAA CG
42
- (2) INFORMATION FOR SEQ ID NO:79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:
GCGCTGTGGG ATCGGTTTTG GGTGGTCAGA AC
32
- (2) INFORMATION FOR SEQ ID NO:80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:
TTTGCGGTAG TTGCCCTTA TTGC
24
- (2) INFORMATION FOR SEQ ID NO:81:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:
Arg Thr Leu Gln Ser Asp
1 5
- (2) INFORMATION FOR SEQ ID NO:82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:
CGTACTCTTC AGTCT
15
- (2) INFORMATION FOR SEQ ID NO:83:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:
GCATGAGAAG TCAGACTAG
19

Claims

WHAT IS CLAIMED

1. A preparation of replication defective recombinant retrovirus expressing a therapeutic protein, wherein said recombinant retrovirus preparation is resistant to degradation by human complement and is capable of inducing long term systemic expression of said therapeutic protein when administered intravenously to a human, wherein said long term systemic expression results in a measurable level said therapeutic protein being produced in the blood of said human for a period of at least 30 days after the administration of said recombinant retroviral vector preparation.
2. The recombinant retrovirus preparation of claim 1, wherein said recombinant retrovirus preparation has a titer on HT1080 cells of greater than 10^6 cfu/ml.
3. The recombinant retrovirus preparation of claim 2 wherein said retrovirus preparation has a titer on HT1080 cells of greater than 10^7 cfu/ml.
4. The recombinant retrovirus preparation of claim 1 wherein said therapeutic protein is a human clotting factor selected from the group consisting of factor V, antithrombin III, protein C, prothrombin, and thrombomodulin.
5. The recombinant retrovirus preparation of claim 1 wherein said therapeutic protein is an interferon-alpha.
6. The recombinant retrovirus preparation of claim 5 wherein said interferon-alpha is selected from the group consisting of interferon- $\alpha 2a$, interferon- $\alpha 2b$, and interferon- $\alpha 2c$.
7. The recombinant retrovirus preparation of claim 1 wherein said therapeutic protein is the LDL receptor.

8. The recombinant retrovirus preparation of claim 1 wherein said therapeutic protein is human growth hormone.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a replication defective recombinant retrovirus expressing a therapeutic protein, wherein said recombinant retrovirus preparation is resistant to degradation by human complement and is capable of inducing long term systemic expression of said therapeutic protein when administered intravenously to a human, wherein said long term systemic expression results in a measurable level said therapeutic protein being produced in the blood of said human for a period of at least 30 days after the administration of said recombinant retroviral vector preparation.

10. The pharmaceutical composition of claim 9, wherein said recombinant retrovirus preparation has a titer on HT1080 cells of greater than 10^6 cfu/ml.

11. The pharmaceutical composition of claim 10 wherein said retrovirus preparation has a titer on HT1080 cells of greater than 10^7 cfu/ml.

12. The pharmaceutical composition of claim 9 wherein said therapeutic protein is a human clotting factor selected from the group consisting of factor V, antithrombin III, protein C, prothrombin, and thrombomodulin.

13. The pharmaceutical composition of claim 10 wherein said therapeutic protein is an interferon-alpha.

14. The pharmaceutical composition of claim 13 wherein said interferon-alpha is selected from the group consisting of interferon- α 2a, interferon- α 2b, and interferon- α 2c.

15. The pharmaceutical composition of claim 9 wherein said therapeutic protein is the EGF receptor.

16. The pharmaceutical composition of claim 9 wherein said therapeutic protein is human growth hormone.

17. A method of administering a preparation of replication defective recombinant retrovirus expressing a therapeutic protein to a human patient comprising injecting said preparation of recombinant retrovirus into a blood vessel of said patient, wherein said recombinant retrovirus preparation is resistant to human complement and expresses the therapeutic protein in said patient resulting in a measurable level of human factor IX protein being produced in said patient for a period of at least 30 days after the injection of said recombinant retrovirus preparation.

18. The method of claim 17 wherein said recombinant retrovirus preparation has a titer on HT1080 cells of greater than 10^6 cfu/ml.

19. The method of claim 18 wherein said retrovirus preparation has a titer on HT1080 cells of greater than 10^7 cfu/ml.

20. The method of claim 17 wherein said therapeutic protein is a human clotting factor selected from the group consisting of factor V, antithrombin III, protein C, prothrombin, and thrombomodulin.

21. The method of claim 17 wherein said therapeutic protein is an interferon- α .

22. The method of claim 21 wherein said interferon- α is selected from the group consisting of interferon- $\alpha 2a$, interferon- $\alpha 2b$, and interferon- $\alpha 2c$.

23. The method of claim 17 wherein said therapeutic protein is the LDL receptor.

24. The method of claim 17 wherein said therapeutic protein is human growth hormone.

25. A method of increasing the efficiency of infecting a mammalian cell with a recombinant retrovirus comprising:

- a) contacting said cell with a growth factor capable of stimulating division of said cell; and
- b) infecting said cell with a recombinant retrovirus.

26. The method of claim 25 wherein said growth factor is KGF.

1 / 41





FIG. 1

2 / 41




FIG. 2

3/41






FIG. 3

4 / 41

**FIG. 4**

5 / 41




FIG. 5

6 / 41





FIG. 6

7 / 41





FIG. 7

8 / 41

**FIG. 8**

9 / 41




FIG. 9

10/41




FIG. 10

11 / 41




FIG. II

12 / 41






FIG. 12


13 / 41

**Formulation:**

25mM Tris pH 7.2
60mM NaCl
1 mg/ml Arginine
5 mg/ml HSA
50 mg/ml Lactose


**FIG. 13**

14 / 41



.FIG. 14

15 / 41

**Formulation:**

25mM Tris pH 7.2
60mM NaCl
1mg/ml Arginine
5mg/ml HSA
50mg/ml Trehalose

—■— -80°C Liquid

- - - -20°C Liquid

- - ◆ - -20°C Lyoph

- - ● - -Refrig. Lyoph

- - ▲ - -R.T. Lyoph

FIG. 15

16 / 41




FIG. 16A




FIG. 16B

17 / 41




FIG. 16C




FIG. 16D

18 / 41




FIG. 17

19/41





FIG. 18

20 / 41

**FIG. 19**

21 / 41




FIG. 20B




FIG. 20A

22/41




FIG. 20D




FIG. 20C

23 / 41





FIG. 21

24/41



25/41




FIG. 23




FIG. 24

27 / 41





FIG. 25



28/41




FIG. 27

29/41





FIG. 28



30/41




FIG. 30

31/41




FIG. 31

32/41




FIG. 32

33 / 41





FIG. 33

34 / 41



CROSS-LESS RETROVIRAL BACKBONE: pBA-5




FIG. 34

35 / 41




FIG. 35

36 / 41




FIG. 36

37 / 41




FIG. 37

38 / 41

		Seq ID No. 48	Seq ID No. 49
2341	ArgGlyMetThrAlaLeuLeuLysValSerSerCysAspLysAsnThrGlyAspTyrTyr AGAGGCATGACCGCCTTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTAC TCTCCGTACTGGCGGAATGACTTCCAAAGATCAACACTGTTCTTGTGACCACTAATAATG		
2401	GluAspSerTyrGluAspIleSerAlaTyrLeuLeuSerLysAsnAsnAlaIleGluPro GAGGACAGTTATGAAGATATTTGAGCATACTTGCTGAGTAAACAAATGCCATTGAACCA CTCCCTGTCAATACTTCTATAAAGTCGTATGAACGACTCATTTTGTACGGTAACCTTGGT		
2461	<-----N-terminus of beta domain-----> ArgSerPheSerGlnAsnSerArgHisProSerThrArgGlnLysGlnPheAsnAlaThr AGAAGCCTTCTCCAGAAATCTAGACACCCCTAGCCTAGGCAAAAGCAATTTAATGCCACC TCTTCGAAGAGGGTCTTAAGATCTGTGGGATCGTGATCCGTTTTCGTTAAATTACGGTGG 2463 HIND3, 2475 ECOR1, 2479 XBAI, <-- IgA hinge ----><-- C-term. beta domain --> ProProThrProThrProProValLeuLysArgHisGlnArgGluIleThrArgThr CCTCCTACACCAACCCACCCAGTACTGAAACGCCATCAACGGGAAATAACTCGTACT GGAGGATGTGGTGGTTGGGGTGGTTCATGACTTTGGGGTAGTTGCCCTTTATTGAGCATGA 2544 SCAI, ThrLeuGlnSerAspGlnGluGluIleAspTyrAspAspThrIleSerValGluMetLys ACTCTTCAGTCTGATCAAGAGGAAATTGACTATGATGATACCATATCAGTTGAAATGAAG TGAGAAGTCAGACTAGTTCCTTTAACTGATACTACTATGGTATAGTCACTTTACTTC 2592 BCL1,		

FIG: 38

40/41




FIG. 40A




FIG. 40B

41/41

Linkers for pSVF8-500B

end 92 19aa C terminal
to thrombin cleavage at 740

SerArgHisProSerThrArgGlnLysGlnPheAsnAlaThrProProValLeuLysArg Seq ID No. 50
TCGCGACACCCCTAGCACTAGGCAAAAGCAATTAAATGCCACCCACCCAGTCCTGAAACGC Seq ID No. 51
AGCGCTGTGGGATCGTGATCCGTTTTCGTTAAATTACGGTGGGGTGGTCAATGACTTTGCG
(TT)
NRU1

mutant
wild type

Start 80K
HisGlnArgGluIleThrArg
CATCAACGGGAAATAACGCGT
GTAGTTGCCCTTTATTGCGCA

MLU1
9aa N terminal to 80K

FIG. 4I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/11784

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/15 C12N15/18 C12N15/20 C12N15/57
 C12N15/86 C12N7/01 C12N9/64 C07K14/56 C07K14/61
 C07K14/705 C07K14/745 C07K14/755 C07K14/81 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	COSSET F -L ET AL: "HIGH-TITER PACKAGING CELLS PRODUCING RECOMBINANT RETROVIRUSES RESISTANT TO HUMAN SERUM" JOURNAL OF VIROLOGY, vol. 69, no. 12, 1 December 1995, pages 7430-7436, XP000569527 see the whole document ---	1-3, 9-11, 17-19
Y	WO 96 04934 A (GENETIC THERAPY INC ;CANCER RES INST ROYAL (GB)) 22 February 1996 see the whole document ---	1-3, 9-11, 17-19
A	WO 95 03834 A (US HEALTH) 9 February 1995 see the whole document ---	1-26

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

12 January 1998

Date of mailing of the international search report

03.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/11784

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/21 A61K38/27 A61K38/36 A61K38/55 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 25698 A (US GOV AS REPRESENTED BY THE) 23 December 1993 see the whole document ---	1-26
A	WO 95 16784 A (TRANSGENE SA ;MEHTALI MAJID (FR); LEISSNER PHILIPPE (FR)) 22 June 1995 see the whole document ---	1-26
A	TAKEUCHI Y ET AL: "TYPE C RETROVIRUS INACTIVATION BY HUMAN COMPLEMENT IS DETERMINED BY BOTH THE VIRAL GENOME AND THE PRODUCER CELL" JOURNAL OF VIROLOGY, vol. 68, no. 12, 1 December 1994, pages 8001-8007, XP000569528 see the whole document ---	1-26

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 January 1998

Date of mailing of the international search report

03.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Authorized officer

Hannig U

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 97/11784

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DEPOLO N ET AL: "Differential sensitivity of retrovectors to human serum inactivation." KEYSTONE SYMPOSIUM ON GENE THERAPY AND MOLECULAR MEDICINE, STEAMBOAT SPRINGS, COLORADO, USA, MARCH 26-APRIL 1, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21A). 1995. 404. ISSN: 0733-1959, 10 March 1995 - 4 April 1995, XP002051678 Abstract no.C6-407 see abstract	1-26
A	--- K. CORNETTA ET AL.: "Safety issues related to retroviral-mediated gene transfer in humans" HUMAN GENE THERAPY, vol. 2, no. 1, 1991, MARY ANN LIEBERT, INC. PUBLISHERS, NEW YORK, US, pages 5-14, XP002051679 cited in the application see the whole document	1-26
A	--- K. CORNETTA ET AL.: "Amphotropic murine leukemia retrovirus is not an acute pathogen for primates" HUMAN GENE THERAPY, vol. 1, no. 1, 1990, MARY ANN LIEBERT, INC. PUBLISHERS, NEW YORK, US, pages 15-30, XP002051680 cited in the application see the whole document	1-26
A	--- BANAPOUR B ET AL: "THE AIDS-ASSOCIATED RETROVIRUS IS NOT SENSITIVE TO LYSIS OR INACTIVATION BY HUMAN SERUM" VIROLOGY, vol. 152, no. 1, 15 July 1986, pages 268-271, XP000613450 cited in the application see the whole document	1-26
A	--- WO 91 02805 A (VIAGENE INC) 7 March 1991 cited in the application see the whole document	1-26
P,X	--- WO 96 21014 A (VIAGENE INC) 11 July 1996 see page 3, line 8 - line 14 see page 3, line 17 - page 4, line 29; claims 2-19 see page 15, line 6 - page 36, line 19 --- -/--	1-3, 9-11, 17-19

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/11784

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>GREENGARD J S ET AL: "Sustained high level factor VIII antigen expression in immune-competent rabbits following peripheral intravenous injection of retroviral vector."</p> <p>THIRTY-EIGHTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, ORLANDO, FLORIDA, USA, DECEMBER 6-10, 1996. BLOOD 88 (10 SUPPL. 1 PART 1-2). 1996. 273A. ISSN: 0006-4971, XP002051681</p> <p>Abstract no. 1080</p> <p>see abstract</p> <p style="text-align: center;">---</p>	<p>1-3, 9-11, 17-19</p>
P,X	<p>WO 96 21035 A (VIAGENE INC) 11 July 1996</p> <p>see page 20, line 32 - page 21, line 5</p> <p>see page 29, line 18 - line 25</p> <p style="text-align: center;">---</p>	<p>1-3, 9-11, 17-19</p>
P,X	<p>WO 97 08330 A (CANCER RES CAMPAIGN TECH ;COLLINS MARY KATHARINE LEVINGE (GB); WEI) 6 March 1997</p> <p>see page 8, line 28 - line 34</p> <p>see page 9, line 28 - page 10, line 7</p> <p style="text-align: center;">-----</p>	<p>1-3, 9-11, 17-19</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/11784

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/11784

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 17-24 and claims 25,26 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

information on patent family members

Intern. Patent Application No

PCT/US 97/11784

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9604934 A	22-02-96	CA 2196208 A EP 0769968 A	22-02-96 02-05-97
WO 9503834 A	09-02-95	AU 7516594 A	28-02-95
WO 9325698 A	23-12-93	CA 2137361 A EP 0644946 A JP 9507741 T	23-12-93 29-03-95 12-08-97
WO 9516784 A	22-06-95	FR 2713657 A AU 1275195 A CA 2155568 A EP 0682712 A JP 8506970 T	16-06-95 03-07-95 22-06-95 22-11-95 30-07-96
WO 9102805 A	07-03-91	AU 5915394 A AU 648261 B AU 6185390 A AU 7058496 A CA 2066053 A EP 0487587 A JP 4507196 T US 5662896 A US 5591624 A US 5691177 A	16-06-94 21-04-94 03-04-91 16-01-97 19-02-91 03-06-92 17-12-92 02-09-97 07-01-97 25-11-97
WO 9621014 A	11-07-96	AU 4608096 A EP 0796331 A	24-07-96 24-09-97
WO 9621035 A	11-07-96	US 5681746 A AU 4602596 A EP 0795021 A	28-10-97 24-07-96 17-09-97
WO 9708330 A	06-03-97	AU 6827896 A	19-03-97